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Summary   
This thesis consisted of experiments designed to explore the construct of attention and 
investigate the disruptive effects of psychotomimetics, with a specific focus on NMDA 
antagonists.  Phencyclidine (PCP) was administered through a variety of treatment regimens 
in order to to determine the ability of inducing cognitive-specific disruptions in attentional 
functioning.  The hypothesis that sub-chronic exposure to PCP would result in persistent 
attentional impairment was tested, using the 5-choice serial reaction time task (5-CSRTT).  
The 5-CSRTT assesses not only visuospatial attention, but also components of impulsivity, 
compulsivity, speed of processing and motivation. It was determined that an additional task-
related intervention that increased the attentional load was required to elucidate attentional 
impairment following sub-chronic PCP treatment. 
 
The ability of rats to perform the modified version of the 5-CSRTT, known as the 5-choice 
continuous performance test (5C-CPT), was investigated.  The 5C-CPT was implemented to 
provide a task that may have greater analogy to the human CPT, than the original 5-CSRTT.  
The consequence of dopaminergic D1 system activation was investigated.  It was revealed 
that D1 partial agonism improved attentional performance in a baseline-dependent manner.   
 
Following successful acquisition of the task, it was shown that repeated PCP treatment 
induced cognitive disruption that was cognitive-specific, and not confounded by generalised 
response disruption.  Furthermore, a partial attenuation of the PCP-induced performance 
disruption was achieved following administration of the D1 partial agonist, SKF 38393.  
Moreover, sub-chronic PCP treatment was shown to impair 5C-CPT performance in the drug-
free state.  However, an additional challenge that further increased the attentional load was 
needed to elucidate a performance deficit.  This highlighted that sustained 
attention/vigilance is sensitive to persistent impairment following sub-chronic PCP 
administration in a manner consistent with deficits observed in schizophrenia patients. 
 
This prompted the investigation that tested the hypothesis that sub-chronic PCP treatment 
could induce enduring structural deficits in regions associated with attentional performance.  
Magnetic resonance imaging (MRI) was conducted, in conjunction with 5-CSRTT and pre-
pulse inhibition (PPI).  It was revealed that sub-chronic PCP treatment resulted in 
morphological brain abnormalities in brain regions associated with 5-CSRTT performance. 
This was coupled with deficits in sustained attentional performance following an increase in 
attentional load, yet PPI was unaffected.  Taken together, these findings suggested sub-
chronic PCP treatment impairs attentional functionality, an effect that dissociates between 
effortful and passive attentional processes. 
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1.1 Schizophrenia 
Schizophrenia has been described as one of the worst psychiatric disorders to afflict mankind 
(Tandon et al. 2008).  Schizophrenia has been described as such due to the progressive 
course, social and occupational implications and the tendency to present symptomatology 
during late adolescence, the time when young adults are forging a life for themselves.  
Schizophrenia affects approximately 1% of the general population, irrespective of gender or 
race, however the disease usually presents itself clinically earlier in males (late teens – early 
twenties) compared to females, where symptoms tend to present in their late twenties.  A 
public misconception is that schizophrenia is a disease that results in split personalities, 
although the term schizophrenia literally means split (schizein) mind (phren), it was first 
coined by Bleuler (1908) to describe the patients detachment from reality (Fusar-Poli and 
Politi, 2008). 
Schizophrenia consists of two main symptom domains; positive and negative (van Os and 
Kapur 2009). Positive symptoms refer to symptoms that are in excess of normal behaviours.  
These include perceptual disturbances, namely hallucinations (usually auditory but can 
include visual, taste or tactile hallucinations) bizarre delusions (commonly persecutory or 
abusive in nature) and thought disturbances that tend to result in disorganized speech 
(Feldman et al. 1997).  The second group of symptoms are known as negative symptoms, 
referring to the absence of behaviours that are normally present in people of the general 
population.  These include social withdrawal, poverty of speech, blunted affect, reduced 
motor activity, catatonia or stereotyped behaviour (Feldman et al. 1997).  In addition to the 
positive and negative symptoms, schizophrenia also results in dysfunction in several areas of 
cognition, which is central to the disorder (Sullivan et al. 1994; Kuperberg and Heckers, 
2000).  Emil Kraepelin (1921) initially referred to the disorder as dementia praecox due to 
impairment of cognitive function occurring at such a young age (Meltzer et al. 1999), 
however due to discrepancies in Kraepelin’s initial description, Bleuler described the 
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condition as schizophrenia (Fusar-Poli and Politi 2008) and is a term now used to describe the 
condition.  Cognitive tests such as the Wisconsin Card Sorting Test, Stroop Colour Word 
Interference Test and the continuous performance test (CPT) have shown that patients with 
schizophrenia have deficits across many different domains of cognition, including, working 
memory, verbal learning, executive function, attention and abstraction (Siever and Davis 
2004).  It is generally accepted that schizophrenic patients perform, on average, 1.0 – 1.75 
standard deviations below healthy people in a wide variety of cognitive tests (Gold 2004) and 
its been suggested that the severity of the cognitive dysfunction is closely correlated with the 
functional outcome of the patient (McGurk and Meltzer 2000; Green et al. 2004).  Cognitive 
dysfunction is largely left untreated by current antipsychotic medication and therefore poses 
a great unmet clinical need (Marder and Fenton 2004). 
Schizophrenia has a strong genetic component and although the worldwide prevalence of 
the disorder is approximately 1%, the prevalence increases to roughly 10% in first-degree 
relatives of schizophrenia patients.  In dizygotic twins, the increase in risk rises to 
approximately 20%, whereas in monozygotic twins the probability of one twin developing the 
illness is around 50% if the other twin has the disorder (Gottesman and Wolfgram 1991).  
There are currently around 43 candidate genes, mutations in which are associated with an 
increased risk for the development of schizophrenia (Need et al. 2009; Insel, 2010).  For 
example, Harrison and Owen (2003) published a review highlighting several genes that may 
increase the susceptibility of schizophrenia.  In this review they described how the gene 
coding for neuregulin 1 (NRG1) had a significant association with increased risk for 
schizophrenia.  NRG1 is expressed throughout the central nervous system (CNS) and is 
involved in the expression and activation of neurotransmitter receptors, including the 
glutamate receptor (Stefansson et al. 2002).  Several other genes have been implicated in the 
development of the disorder, genes such as DISC 1 (a protein involved with cell growth, 
axonal development and neural positioning) (Ozeki et al. 2003), COMT (encodes for a protein 
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responsible for catecholamine degradation) (Williams et al. 2007) and DTNBP1 (encodes for 
dysbindin and is suggested to be involved in neuronal plasticity) (Kendler 2004); however, a 
definitive gene relating to schizophrenia development has yet to be identified.  Although it is 
evident that schizophrenia has a strong genetic component, faulty genes cannot fully explain 
the disorder as the concordance rates in monozygotic twins is only 50% (Gottesman and 
Wolfgram 1991).  If schizophrenia were a complete genetic disorder, one would expect the 
concordance rates in monozygotic twins to be 100%.  The fact it is not therefore indicates 
that a combination of both genetic and environmental factors play an important role in the 
aetiology of the disorder. 
The National Institute of Mental Health (NIMH), in combination with educational institutions, 
implemented an initiative called the Measurement and Treatment Research to Improve 
Cognition in Schizophrenia (MATRICS.ucla.edu) (Green et al. 2008; Kern et al. 2008; 
Nuechterlein et al. 2008).  The MATRICS initiative was formed in an attempt to accurately 
identify areas of cognition that are afflicted in schizophrenia, furthering the development of 
new treatment strategies to improve the cognitive and social dysfunction evident in the 
disorder.  The primary aim of the MATRICS initiative was to identify a series of clinical and 
preclinical test batteries which addressed the cognitive disturbances in terms of specific 
domains that are affected, rather than cognitive dysfunction as a whole (Marder and Fenton 
2004).  The MATRICS initiative implemented a series of clinical tests that identified seven 
separate areas of cognition that are affected to some degree in schizophrenia.  These include 
speed of processing, attention/vigilance, working memory, verbal learning and memory, 
visual learning and memory, reasoning and problem solving, and social cognition 
(Nuechterlein el al. 2004; Floresco et al. 2005).  Thus, the MATRICS initiative introduced an 
element of standardisation to cognitive assessment when determining the severity of 
cognitive deficits in schizophrenia, enabling meaningful comparisons to be made between 
studies conducted within different laboratories and attempting to enhance the translation 
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from animals to humans.  The separation of cognitive dysfunction into distinct categories 
enables researchers to develop pre-clinical tests that address the specific cognitive domain 
with greater ease then before, and will eventually lead to the development of reliable animal 
models that can be used to assess drug efficacy in alleviating cognitive dysfunction.   
 
1.2 Attention 
Attention is an area of cognition that is defined as a system that allows an individual to 
detect, select and process relevant sensory information, while simultaneously filtering out 
any irrelevant stimuli from the environment, enabling an individual to attend appropriately 
to certain situational demands (Maunsell and Treue, 2006).  Attention is not a single entity 
(Muir 1996), but more of a functional system that is comprised of several different cognitive 
constituents that operate in conjunction with one another to form a functioning attentional 
system.  The attentional system is comprised of several specific forms of attention, which 
include sustained, selective and divided attention (Robbins 2002; Chudasama and Robbins 
2004).  Sustained attention allows the individual to maintain attention and attend to a 
specific task over a prolonged period.  This form of attention ensures that attentional goals 
are upheld over a period of time (Parasuraman 1998; Sturm and Willmes 2001).  Although 
sustained attention is sometimes also referred to as vigilance, subtle differences exist 
between the two constructs (Robbins, 1998) (described in more detail in chapter 4).  The 
ability to sustain one’s attention in a vigilant manner enables an individual to focus 
attentional processing to a specific task for a prolonged duration, facilitating the detection of 
relevant or salient signals from the surrounding environment that may be of importance.  
Parasuraman et al. (1987) stated that the difference in protocols of vigilance tasks between 
laboratories impose fundamental differences in how the construct is measured.  Therefore, a 
task classification system was developed investigating the effects of four experimental 
dimensions and the effect they have on assessing vigilance.  Signal discrimination type, event 
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rate, modality and source complexity were all considered (Parasuraman et al. 1987; Muir 
1996) and it has been determined that the most effective method of assessing vigilance 
involves a task that presents successive signal and non-signal events, high event-rates, the 
use of low level salient signals and event asynchrony, thus producing a task assessing 
vigilance with a high level of power and reproducibility (McGaughy and Sarter 1993).   
Selective attention enables sensory information to be given informational priority by limiting 
the number of sensory channels available (Muir 1996).  Informational priority is important 
due to the finite computational capacity of the brain; therefore, selective attention is a 
means by which important sensory information is processed, whilst also acting as an 
‘attentional filter’ ensuring irrelevant information is ignored facilitating the resistance of 
informational distraction (Muir 1996; Parasuraman 1998).  A classic example demonstrating 
selective attention is known as the ‘cocktail party effect’, facilitating the focus of attentional 
processing to a specific conversation, whist simultaneously and selectively filtering out the 
background ‘noise’ of irrelevant conversations proposed by Broadbent (1958).  However, 
Broadbent’s model of attentional selectivity cannot account for hearing someone mention 
your name across the room in this scenario, as according to the model, incoming irrelevant 
sensory information is filtered before being processed, thus it would be impossible to 
determine if your name had been mentioned.  An adaptation of the Broadbent selective filter 
was proposed and suggested unintentional sensory information is held in a temporary buffer 
zone before being processed or discarded, therefore facilitating the selective filtering of 
irrelevant stimuli but also enabling the detection of unexpected sensory cues, providing a 
model that can account for the ‘cocktail party’ effect (Treisman 1964).   
Divided attention enables the individual to divide attentional capabilities across several 
temporal or spatial channels, allowing the performance of several tasks at once.  This allows 
the individual to allocate attentional processing power to various tasks at the same time, 
despite the limited attentional capacity of the individual (Broadbent 1958; Parasruaman 
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1998; Robbins 2002).  Impairments in tasks assessing divided attentional capabilities may 
result from exhaustion of this capability due to simultaneous fractionation of processing 
power (parallel processing) or exhaustion from continuous shifts between multiple 
attentional activities (serial processing - Muir 1996).  Musicians routinely utilise divided 
attentional capacities, focusing on reading sheet music, playing the instrument along with 
listening to the musical output.  Focus must be divided to play the instrument to an 
appropriate standard, but also in synchrony with other musicians, with attention being 
allocated to the conductor.  Taken together, these three forms of attention function 
collectively forming an operational attentional system, enabling the individual to select and 
attend to various tasks and ignore irrelevant stimuli.  This facilitates the detection and 
appropriate response to salient information from the surrounding environment, while at the 
same time providing the underlying substrate for several higher order cognitive processes 
including learning, memory and executive functioning (Chudasama and Robbins 2004; Riedel 
et al. 2006). 
 
1.3 Neuroanatomy of Attention in Humans  
A number of studies have been designed in order to elucidate regions of the human brain 
that are involved in attentional processes with various attentional models being proposed. 
Despite the many and varied models of the attentional system, many cortical (frontal, 
prefrontal, parietal) and sub-cortical regions (limbic system, basal ganglia, reticular activating 
system), along with connectivity between regions are consistently suggested to be involved 
with attentional processing (Riccio et al. 2002).  
In order to elucidate this, many studies subject volunteers to attentional tasks and measure 
brain activity by a variety of imaging techniques, including single photon emission 
tomography (SPECT), positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI), allowing insight into the neuroanatomy of the attentional network 
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in vivo (Hager et al. 1998).  Ojeda et al (2002) highlighted that previous investigations in this 
area showed specific prefrontal regions and the cingular gyrus are involved in attentional 
tasks, as well as being intricately involved in other cognitive processes such as working 
memory (Grady et al. 1997; Halpern and Zatorre 1999).  Ojeda et al. (2002) utilised an 
auditory adaptation of the continuous performance test (CPT – described in detail below), 
measuring relative cerebral blood flow by utilising PET and radiolabelled water molecules in 
order to demonstrate possible regions of interest involved in sustained attention in humans.  
Results indicated that the dorsal lateral prefrontal cortex (DLPFC) is involved in the effective 
performance of tasks that require not only attentional processes but also elements of 
working memory.  Additionally, it was reported that schizophrenia resulted in a failure of 
activation of the parietal cortex, which is in agreement with the posterior attentional model 
proposed by Posner and Peterson (1990).  Ojeda et al. (2002) however reported 
inconsistencies in data collected by previous groups concerning the involvement of the 
cingulate region in attentional tasks.  It appears that the cingulate region’s involvement in 
attention is determined by the type of attention assessed (e.g. selective, sustained etc.) or 
the sensory modality being processed.  The group concluded that the anterior cingulate 
cortex is indeed involved in attentional processing, indicating involvement of the structure in 
some but not all of the cognitive elements involved in attention, specifically the regions 
involvement in divided attention.  An fMRI study was conducted encompassing a simple task 
that involved the assessment of sustained attention (Lewin et al. 1996).  The group assessed 
visual sustained attention by asking volunteers to concentrate on a small dim central dot 
centred on a black background.  During the session, the dot dimmed repeatedly and the 
subjects were asked to maintain their attention on the dot and count the number of times 
the dot dimmed over the course of the session.  Inclusion of the element of maintenance 
over a prolonged session increases the attentional load and is therefore a valid means of 
measuring sustained attention.  This investigation indicated that the right middle frontal 
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gyrus and parietal lobe were activated in human volunteers when asked to perform a task 
that imposed demands on sustained attention.  These data were in agreement with the 
findings demonstrated by Pardo and colleagues (1991), in which they conducted a similar 
study using the PET technique, which identified the previously mentioned regions of the 
brain and the involvement in sustained attention.  Other laboratories have conducted studies 
that have also implicated several subcortical structures such as the thalamus and basal 
ganglia in the modulation and maintenance of attentional processes and arousal (Buchsbaum 
and Haiger 1987; Hager et al. 1998).  Further imaging studies (Hager et al. 1998) 
demonstrated using fMRI, that the mediodorsal and anterior nuclei of both hemispheres of 
the thalamus have increased activity in test subjects when the attentional load is increased.  
The group then go on to suggest that the thalamus may act as a relay station, providing 
afferent input to the DLPFC and anterior cingulate cortex, areas that are also implicated in 
the attentional system.  Considering the extensive reciprocal connections with various 
cortical brain regions (Kamishina et al. 2009), the suggestion that thalamic nuclei serve as a 
relay centre in attentional processes is a likely situation.  Lawrence et al. (2003) has 
demonstrated that a network of multiple neuronal regions, including frontal and parietal 
cortices and thalamic and caudate nuclei, are involved in attention.  The regions of the brain 
involved in the attention system proposed by Lawrence and colleagues (2003) are in 
agreement with those suggested by Wigen et al. (2008), who conducted a pharmaco-fMRI 
study.  These findings suggested that an extensive sub-cortical network is involved, along 
with frontal and parietal cortices (Poser and Peterson 1990), in several of the cognitive 
elements that are directly involved with attentional processing. 
 
1.4 Attentional Impairment and Schizophrenia 
Attentional impairment is evident in a number of psychiatric disorders and has been 
identified as a core component of schizophrenia symptomatology ever since the disease was 
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first scientifically recognised at the turn of the 20th century (Kraepelin 1921; Bleuler 1951).  
Attentional impairments may be core to the disorder, may precede the presentation of 
psychotic symptoms, outlast psychotic symptoms, may be a useful indicator of the 
susceptibility to the disorder and indicate functional outcome.  Additionally, impaired 
attentional performance is often present in non-symptomatic relatives of schizophrenia 
patients (Cornblatt and Keilp 1994; Jones et al. 1994; Green 1997; Parasuraman 1998; an der 
Heiden and Hafner 2000; Chen and Faraone 2000; Wang et al. 2007).  Attentional 
impairments in schizophrenia typically result in the inability to select and interpret incoming 
sensory information, and as a result can lead to inappropriate responding in various 
situations (Nestor and O’Donnell 1998).  As the attentional system is intimately linked to the 
function of several higher-order cognitive processes (Riedel et al. 2006), impairment of the 
attentional system can also lead to a number of subsequent consequences, including 
increased distractibility, memory impairment, learning impairment, confusion, perseveration 
(compulsive behaviour) or behavioural disinhibition (increased impulsivity).  These symptoms 
are regularly seen to some degree in schizophrenia patients (American Psychiatric 
Association 1989, p 1217; Nestor and O’Donnell 1998), as well as in a variety of other 
psychiatric conditions.  One clinical test that can be used to measure an important aspect of 
attention, namely attention/vigilance, is the continuous performance test (CPT).  The CPT 
was developed in the late 1950’s by Rosvold and colleagues (1956) and the original task 
involves the patient reporting the rare occurrence of a single target letter that is visually 
presented amongst a number of irrelevant letters over a prolonged duration of 
approximately ten minutes.  A correct response to the target stimulus generates a hit, 
whereas an omission is recorded as a miss.  Conversely, an incorrect response to the 
presentation of a non-target stimulus is deemed a false alarm, with the contrary measure 
being a correct rejection and represents the individual correctly inhibiting a response to the 
non-target stimulus. 
Chapter 1                                                                                                                 General Introduction 
11 
The term ‘continuous performance test’ is actually a generalised term used to describe a 
group of tests assessing attentional functioning.  A number of variants of the basic task exist, 
varying what constitutes a target stimulus, potentially tapping into different constructs of the 
attentional system depending on the basic protocols of the task.  For example, during the AX-
CPT (Cornblatt and Keilp 1994) the target letter (X) is only correct when it is immediately 
preceded by the letter A, and therefore recruits an element of working memory in addition 
to the attentional component of the task.  As such, the difficulty of the task can be further 
increased by ‘priming’ for errors; presentation of ‘AY’ stimuli probe for deficits in inhibitory 
control, whereas ‘BX’ stimuli generally tax working memory capabilities of the individual.  
Similarly, within the CPT-identical pairs (CPT-IP, Green et al. 2004; Holmen et al. 2010), a 
correct target stimulus consists of the second identical letter presented in succession and 
errors can be probed by presenting ‘XY’ stimuli instead of ‘XX’, for example.  Alternatively, 
Conners CPT (Egeland et al. 2009) presents large numbers of target trials within the session 
and the non-target trials constitute the rare and unpredictable element of the task, in 
contrast to other CPTs that generally have a greater bias towards the non-target trial being 
presented throughout the session.   
Schizophrenia patients perform poorly in all variants of the CPT (Straube et al. 2002).  The 
MATRICS initiative included the CPT-IP in their cognitive battery in order to assess 
attention/vigilance in the clinical population, with schizophrenia patients demonstrating 
impaired performance (Cornblatt and Malhorta 2001; Groom et al. 2008).  Impairment in 
attentional capabilities may result in increased omissions, which will result in a reduction in 
choice accuracy.  Along with the increase in omissions, attentional impairment (or 
behavioural disinhibition) may also result in an increase in the number of ‘false alarms’, 
whereby the subject incorrectly reports the detection of the stimulus when the non-target 
stimulus was presented (Cornblatt and Keilp 1994).  Due to the ability of the CPT to generate 
and record false alarms, investigators find it advantageous to use signal detection theory 
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(SDT) to give an indication of signal discrimination (Rutschmann et al. 1977), while at the 
same time giving insight into the strategy of responding (i.e. liberal or conservative 
responding).  Signal detection analysis (described in greater detail in Chapter 4) typically 
provides two additional indices, D prime (d’) and , where d’ is a measure of the subjects’ 
ability to detect the target stimulus from background noise and  is the measure of strategy 
of responding.  Impaired CPT performance, exhibited by schizophrenia patients typically 
consists of a reduction in accuracy and an increased frequency of false alarm responding.  
Patients consequentially produce d’ values that are ~2.5 – 2.8 standard deviations below the 
population mean, suggesting schizophrenia impairs the ability to discriminate between the 
target signal from background noise presented in the CPTs (Liu et al. 2002).  Along with 
schizophrenia patients performing poorly in CPTs, the many variants of the task can also give 
indications of vulnerability to schizophrenia to those at risk in the population, as non-
symptomatic relatives of patients with schizophrenia often have a reduction in task 
performance compared to healthy volunteers (Cornblatt and Keilp 1994; Chen and Faraone 
2000; Cornblatt and Malhotra 2001).   
Another aspect of the attentional domain, selective attention, can be assessed using the 
Stroop task developed by Stroop (1935), in which schizophrenia patients demonstrate 
impaired performance (Barch et al. 2009).  The task consists of words spelling various 
colours, printed in different coloured ink (e.g. Yellow, Blue, Red etc.).  Either the participant 
has to name the word written or the colour of the ink the word is printed in.  Reading of the 
word is governed by a pre-potent response, requiring minimal cognitive control.  To read the 
colour of the ink, however, requires higher levels of ‘top-down’ cognitive control involving 
the recruitment of the PFC in order to bias responding inhibiting the pre-potent ‘word 
reading’ response enabling the colour of the ink to be named (Lesh et al. 2010), indicative of 
the higher levels of selective attentional capacity necessary (Pardo et al 1990).  Schizophrenia 
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patients demonstrate impairment in the Stroop task, exhibiting longer reaction times 
(Wapner and Krus, 1960; Everitt et al. 1989) and increased error rates (Perlstein et al. 1998) 
compared to healthy controls, suggesting impaired selective attention is associated with the 
disease. 
1.5 Behavioural Inhibition and Inappropriate Responding 
Along with the various attentional processes that are dysfunctional in schizophrenia, the 
disorder also results in impairment in aspects of behavioural inhibition resulting in an 
increase in inappropriate responding (Paine and Carlezon Jr 2009).  One type of task that can 
reveal an increase in behavioural disinhibition includes Go/No-Go tasks as they require the 
participant to respond to certain stimuli (go trial) and withhold a response to a different type 
of stimuli (no-go trials) throughout the task.  Coupled with assessing attentional processing, 
the CPT is a classic example of a task that can incorporate elements of Go/No-Go tasks.  
Previous studies have demonstrated that schizophrenia patients perform poorly in these 
types of task and the impairment may not be mediated solely by the attentional element of 
the task.  The reduction in performance can also be attributed to the inability of the patient 
to withhold from responding when a response is not required, characterised by an elevated 
false alarm rate (Green 1997; Ng 2002).  Weisbrod and colleagues (2000) conducted an 
auditory version of a Go/No-Go task in healthy volunteers and schizophrenia patients, while 
at the same monitoring brain activity using the fMRI technique. In the Go condition, the 
subjects were required to press a button upon hearing an infrequent tone. In the No-Go 
situation, the subjects were to continuously respond when a frequent tone was presented, 
but withhold from responding when the infrequent tone appeared.  The group demonstrated 
that there was no difference in performance between schizophrenia and non-schizophrenia 
subjects in trials requiring a ‘go’ response, but there was a significant reduction in the ability 
of schizophrenia patients to perform the task when instructed to withhold from responding 
in the No-Go trials.  This implied that schizophrenia results in the inability to withhold from 
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inappropriate responding to irrelevant stimuli or discriminate between trial types.  This may 
contribute to impaired performance during CPTs.  Using the fMRI data, Weisbrod and 
colleagues (2000) indicate that the anterior cingulate gyrus, bilateral dorsolateral prefrontal 
cortex and left premotor cortex in healthy volunteers became activated when performing the 
No-Go task.  Previous studies (Pardo et al. 1990; Berman et al. 1992; Petrides et al. 1993; 
D’Esposito et al. 1995; Carter et al. 1997) also implicated that these brain regions are 
involved in executive control and behavioural inhibition.  The study conducted by Weisbrod 
and colleagues (2000) demonstrated a reduction in cerebral activation in schizophrenia 
patients compared to healthy volunteers in these regions when attempting to perform the 
No-Go component of a task, further supporting the previous findings. 
 
Thus, it is evident that schizophrenia patients demonstrate attentional dysregulation, 
disruption that may be pivotal in the development of additional cognitive impairment.  It is 
now pertinent to discuss the potential neurobiological processes that may be implicated in 
the pathophysiology of schizophrenia.  
 
1.6 Dysfunctional Neurotransmitter Systems and Schizophrenia 
Although there is a clear genetic component to the development of schizophrenia (discussed 
previously), highlighted by the increased concordance rate resulting from family history, 
decades of research has attempted to establish causality between abnormal 
neurotransmission and schizophrenia pathology.  Many neurotransmitters have been 
implicated in the development of schizophrenia; however, significant attention has focused 
on the involvement of monoaminergic neurotransmitters or the amino acid 
neurotransmitters, including glutamate and gamma-aminobutyric acid (GABA). 
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1.6.1 Dopamine 
One of the first hypotheses describing a dysfunctional neurotransmitter system and the 
development of schizophrenia involved dopamine, specifically the hyperdopaminergic 
hypothesis of schizophrenia.  Dopamine is an essential monoaminergic neurotransmitter 
within the brain and is thought to be involved in the pathophysiology of a number of 
conditions, including Parkinson’s disease (Brown and Marsden, 1990), drug addiction 
(Jentsch and Taylor, 2003; Dalley et al. 2007), attention-deficit hyperactivity disorder (ADHD) 
(Berridge and Devilbiss, 2010) and also schizophrenia (Howes and Kapur, 2009).  The 
suspected involvement of dopamine in a number of neurological and psychiatric disorders 
demonstrates the key importance of this neurotransmitter system and highlights the impact 
of dysregulation of the dopaminergic system on the functionality of an individual.  The basis 
for the hypothesis emerged from observations that psychostimulant drugs, such as 
amphetamine, which act by facilitating dopaminergic transmission (Ferris et al. 1972), can 
induce episodes of psychosis similar to that seen in the clinical population (Connell 1958; Bell 
1973).  Furthermore, schizophrenia patients given psychostimulant drugs show signs of 
increased psychosis at doses that are sub-psychotogenic in normal controls (Lieberman et al. 
1987).  Moreover, drugs that primarily act as dopamine receptor antagonists (specifically D2 
antagonists) were introduced in the 1950’s as the first class of drugs to be marketed as 
antipsychotics as they showed efficacy in attenuating psychotic symptoms in psychiatric 
patients (Singh and Kay, 1975).  Taken together, these findings suggest that there is a strong 
involvement of an over active dopaminergic system in the pathology of schizophrenia, 
playing a pivotal role in the development of psychotic, positive symptoms.  A number of 
shortfalls exist in the hyperdopaminergic hypothesis, however.  While amphetamine (and 
related psychostimulants) is effective at inducing positive-like symptoms, it is relatively 
ineffective at producing the negative symptomatology and cognitive deficits evident in the 
disorder.  Furthermore, antipsychotic medication (particularly classical antipsychotics) is 
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typically ineffective in attenuating cognitive dysfunction exhibited in the disorder, ruling out 
dopamine D2 involvement in this aspect of the disorder. 
 
1.6.2 Glutamate  
Research into the glutamatergic system and schizophrenia yielded the potential involvement 
of excitatory amino acids in the development of the disorder when it was discovered that 
cerebrospinal fluid (CSF) contained low levels of glutamate in patients with schizophrenia 
(Kim et al. 1980).  However, this theory failed to gain credit for several reasons.  Firstly, the 
findings were difficult to replicate in subsequent studies and at the time of the suggested 
hypothesis, scientific knowledge of the glutamatergic system was limited.  As a result it was 
thought that dysfunction of the glutamate system would result in neurotoxicity and gross 
developmental abnormalities, which are not seen in schizophrenia patients (Luby et al. 1959; 
Moghaddam 2005).  Glutamate is the major excitatory neurotransmitter in the CNS and 
approximately 40% of neurons utilise glutamate.  There are two main classes of glutamate 
receptors; ionotropic and metabotropic.  Ionotropic receptors, when activated, open a 
central channel in the receptor and allow the passage of charged ions across the cell 
membrane (Goff and Coyle 2001).  The ionotropic receptors include kainite, NMDA and 
AMPA subtypes and, due to the fast passage of ions when activated, these are responsible 
for rapid cellular depolarisation (Moghaddam 2005).  Metabotropic receptors on the other 
hand are G-protein coupled receptors (GPCR).  Once glutamate binds to and activates the 
receptor complex, a signal cascade of 2nd messengers is initiated and this has a number of 
cellular effects, depending on the class of glutamatergic metabotropic receptor activated.  
There are several subtypes of metabotropic glutamate receptor and they are classified as 
mGlu1 through to mGlu8 and modulate slower neurotransmission, compared to the 
ionotropic glutamate receptors (Moghaddam 2005). 
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The NMDA subtype of glutamate receptors are (amongst others) responsible for the slow 
excitatory postsynaptic potentials (EPSPs) and long term potentiation/depression (LTP/LTD).  
One of the most important consequences following activation of the NMDA receptor (thus 
generating EPSPs) is long-lasting change in synaptic function, known as synaptic plasticity e.g. 
LTP/LTD (Nestler et al. 2001).  It has been postulated that these processes are intricately 
involved in various complex behaviours, including associative learning, working memory, 
behavioural flexibility and attention (Moghaddam 2005), all of which are affected to some 
degree in schizophrenia.  Since the work of Kim et al. (1980), the scientific community’s 
knowledge of glutamate and the NMDA receptor subtype has vastly increased and evidence 
has accumulated indicating dysfunctional NMDA receptor function in the pathophysiology of 
schizophrenia (Olney and Faber, 1995; Olney et al. 1999). 
Administration of non-competitive NMDA receptor antagonists (phencyclidine, ketamine, 
MK-801) can induce a psychotomimetic state in normal humans (Luby et al. 1959; Allen and 
Young 1978) that resembles characteristics of schizophrenia.  Importantly aspects of the 
negative and cognitive symptomatology of the disorder are also exhibited (Javitt and Zukin 
1991; Krystal et al. 1994; Goff and Coyle 2001), and interestingly symptoms are exacerbated 
in stabilised schizophrenia patients (Lahti et al. 1995).  Following these findings, behavioural 
research into NMDA receptor blockade and the possibility that it can successfully model a 
more complete picture of schizophrenia gained momentum (Javit and Zukin 1991).  This 
resulted in the suggestion that the NMDA receptor is dysfunctional in schizophrenia and led 
to the development of the glutamatergic hypofunction hypothesis of schizophrenia (Abi-Saab 
et al. 1998; Javit and Zukin 1991; Olney and Faber 1995; Tsai and Coyle 2002).  The 
glutamatergic hypofunction hypothesis suggests that dysfunctional NMDA receptor(s) and/or 
abnormal downstream NMDA receptor effects are core to the pathophysiology of the disease 
(Olney et al. 1999; Goff and Coyle 2001), potentially providing a more compelling model than 
the hyperdopaminergic hypothesis of schizophrenia (Coyle 2006).  Therefore, it is thought 
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that blockade of the NMDA receptor system may reliably replicate aspects of schizophrenia 
symptomatology in humans and thus, the condition may reflect a dysfunctional glutamate 
system.  
 
1.6.3 γ-animobutyric acid (GABA) 
Neocortical neurons are organised in layers (layers I – VI), with approximately 70 – 80% 
consisting of excitatory (glutamatergic) pyramidal neurons (DeFeilpe and Farinas 1992), with 
the remaining neocortical neurons consisting mainly of GABAergic inhibitory interneurons 
(Markram et al. 2004).  Gamma-aminobutyric acid (GABA) functions as the principle 
inhibitory amino acid neurotransmitter in cortical interneurons.  The major exception is a 
class of interneuron called the spiny stellate cell (SSC) which is excitatory and contains 
glutamate.  The SSC is only found in a specific cortical region; layer IV of the primary sensory 
area, receiving afferents from thalamic nuclei, with information being relayed to cortical 
layer II/III (Lund 1973; LeVay, 1973; White 1989; Thomson 1997; Feldmeyer et al. 2002). 
Interneurons containing different calcium-immunoreactive proteins have unique 
morphometry (fig 1.1); calbindin (CB)-immunoreactive (ir) neurons are described as a double 
bouquet cell (primates) and provide vertical inhibition to pyramidal cells located within the 
same minicolumn (DeFelipe et al. 1989; Raghanti et al. 2010). Interneurons containing 
calretinin (CR) extend vertically to synapse with pyramidal dendrites located in separate 
cortical layers within a narrow minicolumn, with a morphometry consisting of bipolar, double 
bouquet and Cajal-Retzius cells (DeFelipe 1997; Raghanti et al. 2010). Finally, there are 
interneurons that are immunoreactive for parvalbumin (PV), namely the basket cells and 
chandelier cells.  Both are predominantly multipolar. Basket cells have long-range axons that 
extend horizontally across the cortical layer, terminating with dendrites of pyramidal cells 
located in a different minicolumn (Lund and Lewis 1993; DeFeilpe 1997; Raghanti et al. 2010).  
Chandelier cells also project horizontally through the cortical layer, with a shorter range than 
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the basket cells, but again terminating with dendrites of pyramidal neurons (DeFelipe 1997; 
Raghanti et al. 2010).   
 
 
Fig 1.1 Schematic of the various layers of the neocortex, along with the major interneuron subtypes indicating the 
different cortical layers they populate.  Different calcium-binding proteins are localised in individual interneurons, 
such as calbindin (CB), calretinin (CR) and parvalbumin (PV)-immunoreactive interneurons and each interneuron is 
located in the specific cortical layers, with a unique morphometry and all utilising GABA as an inhibitory 
neurotransmitter. Image taken from Raghanti et al. 2010  
 
There is substantial evidence for dysfunctional GABAergic interneuron function in the 
pathology of schizophrenia, which was first proposed by Roberts in 1972.  Following the 
original suggestion by Roberts (1972) a number of post-mortem studies have confirmed 
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abnormalities relating to GABAergic interneurons in schizophrenia patients (Blum and Mann 
2002), with deficits in PV containing interneurons in the prefrontal cortex (Beasley and 
Reynolds, 1997; Beasley et al. 2002) and the hippocampus (Zhang and Reynolds 2002).  
Coupled with the deficits in GABAergic containing interneurons in schizophrenia patients, 
there is also a consistent reduction in the expression of the mRNA and protein for glutamic 
acid decarboxylase67 (GAD67), a synthesizing enzyme for GABA in the prefrontal cortex of 
schizophrenia patients (Guidotti et al. 2000; Volk et al. 2000; see Neill et al. 2010 for review).  
Furthermore, it has been demonstrated that mRNA expression for GAD67 along with GAT1 
(GABA transporter) is reduced in schizophrenia in PV-ir containing neurons within the PFC 
(Hashimoto et al. 2003).  These findings clearly implicate a dysfunctional GABAergic system in 
the pathogenesis of schizophrenia, and due to their location, deficits that may contribute to 
the development of cognitive dysfunction associated with the disorder (Lewis et al. 2005). 
The primary function of GABAergic interneurons (located within the PFC or hippocampus) is 
to provide local inhibitory control over cortical excitatory pyramidal neurons, regulating their 
activity and excitatory output (Benes and Berretta 2001).  Furthermore, the regulation of the 
GABAergic interneurons is determined by afferents arising from glutamatergic neurons.  
Taken together, there is evidence to suggest that a reciprocal GABAergic – glutamatergic 
interaction in prefrontal and hippocampal regions exist, and this interaction may be 
dysfunctional in schizophrenia patients (Coyle 2004) potentially leading to cognitive 
impairment in patients with schizophrenia (Lewis et al. 2005). 
 
1.7 Animal Models of Schizophrenia Symptomatology 
As the previous section described, schizophrenia is an extremely complex disease with an 
even more complex neuropathology and aetiology.  Attempts to develop animal models of 
schizophrenia have met certain difficulties, due to the complexity of the disorder lending to 
difficulties assessing the validity of the model under scrutiny.  Furthermore, certain aspects 
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of the disorder are inherently human constructs (verbal learning and fluency etc) and thus, 
impossible to assess in experimental animals.  Additionally, aspects such as delusional 
thoughts and auditory hallucinations are equally difficult to quantify in a rodent model.  
However, it is imperative to model aspects of schizophrenia in experimental animals enabling 
the processes behind the neurobiology and symptomatology to be investigated, enhancing 
our overall knowledge of the disease.  Once the understanding of the biological process 
behind the symptomatology is improved, efficacious pharmacotherapy targeting cognitive 
dysfunction and social deficits can be developed more readily. 
 
1.7.1 Neurodevelopmental Models 
Although the precise mechanisms underlying neurobiological features of schizophrenia are 
not completely understood, there is a hypothesis that the disorder may arise as a result of 
“early neurodevelopmental” insults (Pantelis et al. 2005), contributing to atypical brain 
development.  Abnormalities in brain development are seen to begin prenatally and may 
continue throughout childhood, the changes that have been observed during these periods 
must have consequences for development of neuronal circuitry and connectivity (Gourion et 
al. 2004).  It was noted that monkeys reared in isolation demonstrated a number of 
behavioural deficits, including impaired grooming, stereotypic movements and social 
interaction defects in adulthood (Kornetsky and Markowitz 1978).  These observations were 
reminiscent of some of the negative symptomatology presented in schizophrenia (Andreasen 
1982).  Further investigation led to the implementation of the isolation rearing 
neurodevelopmental model of schizophrenia (Paulus et al. 1998; Varty and Geyer 1998). 
Coupled with aspects of negative symptomatology, elements of cognitive impairment are 
also evident, with deficits in prepulse inhibition present in isolation-reared rats (Geyer et al. 
1993; Fone and Porkess 2008).  Additionally, isolation-rearing induced cognitive deficits with 
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animals displaying disrupted performance within a novel object recognition task and 
attentional set-shifting (McLean et al. 2010).    
A number of methods have been used to model the developmental origin of schizophrenia 
symptomatology in animals.  These models attempt to replicate some of the factors that may 
be casual factors to the development of schizophrenia, such as early stressful experience 
(Lehmann et al. 2000).  One developmental model is based on the postulation that 
schizophrenia is the result of a temporary reduction of glutamatergic neurotransmission 
(Goff and Coyle 2001).  Studies have shown that repeated neonatal PCP (10 mg/kg s.c. on 
PND 7, 9 and 11) administration may lead to some behavioural disturbances in adult animals, 
namely, reduction of baseline prepulse inhibition (PPI) of the acoustic startle response and 
retardation of acquisition of spatial alteration task in female and male Sprague-Dawley rats 
(Wang et al. 2001) and delayed spatial learning task (Yuede et al. 2010).  Moreover, a similar 
treatment regime, i.e. PND 7, 9 and 11 resulted in cognitive deficits, impairing performance 
in an attentional set-shifting task (Broberg et al. 2008).  Yet another study showed that 
administering the DNA methylating agent, methylazoxymethanol (MAM), to the pregnant 
dams on gestational day (GD) 17 induced neurodevelopmental deficits (Lodge and Grace 
2007).  Administration of MAM during GD 17 resulted in cortical thinning with increased 
neural packing density in adult rats (Moore et al. 2006), disrupted PPI, increased sensitivity to 
PCP (Flagstad et al. 2004; Moore et al. 2006), executive behavioural impairment (Gourevitch 
et al. 2004), social impairment (Talamini et al. 2000) and impaired rhythmic activity of frontal 
cortical regions (Goto and Grace 2006), all of which have been observed in schizophrenia 
patients to some degree (Lodge and Grace 2007).  Some studies have also shown 
impairments in working memory in adulthood in Sprague-Dawley rats with perinatal sub-
chronic MK-801 administration (0.1 mg/kg for four days beginning from PND 7, twice a day) 
(Stefani and Mogaddam 2005) and disturbances in psychomotor activity (Schiffelholz et al. 
2004). Moreover, postnatal PCP administration has been shown to induce a number of 
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neuropathological abnormalities in brain regions implicated in schizophrenia, including the 
hippocampus and frontal cortex (Ikonomidou et al. 1999; Wang and Johnson 2005).  Also, 
recent neurochemical evidence suggests that blockade of NMDA receptors during brain 
development using MK-801 results in postpubertal emergence of hippocampal brain-derived 
neurotrophic factor (BDNF) upregulation, which is associated with the behavioural 
abnormality in animals, tested using locomotor activity in adolescent Sprague-Dawley rats 
(Guo et al. 2010).  This has been implicated with the development of schizophrenia-like 
behaviour and pathophysiology, thus demonstrating face validity to the development of 
clinical symptomatology in humans in early adulthood. 
 
1.7.2 Pharmacological Models 
The previously described models of schizophrenia symptomatology are neurodevelopmental 
and involve pharmacological or environmental insult either prior to birth or shortly 
afterwards.  A number of pharmacological models exist which involve treating adult animals, 
investigating the potential of drug treatment to mimic aspects of the behavioural and 
neurobiological effects observed in schizophrenia.  Administration of psychostimulant drugs 
(e.g. amphetamine) is an obvious method, based on the hyperdopaminergic hypothesis of 
schizophrenia.  Following several days of continuous amphetamine administration (Gaylord 
and Eison 1983), both monkeys and rats display a number of ‘hallucinatory’ behaviours i.e. 
‘wet-dog’ shakes or parasitotic-like grooming episodes.  Although these measures are an 
indirect assessment of hallucinations (for obvious reasons), they are suggested to serve as a 
means of identifying psychotic-like behaviour arising from amphetamine treatment.  Another 
method of assessing aspects of positive symptomatology is by the quantification of pre-pulse 
inhibition (PPI) of a startle response (described in detail in section 1.13).  It is suggested PPI 
deficits reflect deficits in sensorimotor gating and potentially pivotal in fragmentation of 
thought seen in schizophrenia (McGhie and Chapman 1961), and is evident in schizophrenia 
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patients (Braff et al. 2001).  Drugs such as amphetamine, cocaine, apomorphine, along with a 
variety of other drugs that act by increasing dopaminergic transmission have been shown to 
impair PPI (for review see Geyer et al. 2001).  Furthermore, antipsychotics have been shown 
to attenuate PPI impairment induced by dopaminergic compounds (Mansbach et al. 1988; 
Geyer et al. 2001).  Therefore, utilising this methodology, it is possible to screen novel 
compounds to assess their efficacy in attenuating aspects of positive symptomatology in the 
clinical population.  However, no matter how effective psychostimulant drugs are at inducing 
aspects of the positive symptomatology in animals, they are relatively ineffective in modelling 
the full range of symptoms present in the disorder (i.e. negative and cognitive symptoms – 
previously discussed in detail).  Therefore, the primary aim of this thesis was to investigate 
the ability of PCP treatment in adult rats to model aspects of the cognitive dysfunction 
present in schizophrenia patients.  However, the validity and the treatment regimen used 
must be considered, which is discussed in detail below. 
 
1.8 Modelling Aspects of Schizophrenia Symptomatology 
NMDA receptor antagonists (e.g. PCP, MK-801, ketamine) have been used on a number of 
occasions to investigate aspects of schizophrenia ever since PCP was described as a 
schizophrenomimetic agent by Luby and colleagues (1959).  Different laboratories use a 
variety of treatment regimens to administer NMDA receptor antagonists in order to assess 
the behavioural and/or cognitive effects of the drug.  However, there is debate as to what is 
regarded as the most effective method of drug administration during preclinical testing.  
Which regimen results in impairments, in not only cognition, but also neurochemical and 
morphological changes that are most relevant to those seen in schizophrenia (Jentsch and 
Roth 1999; Morris et al. 2005; Amitai and Markou 2010; Neill et al. 2010)?  Many studies 
make use of acute administration of the drug, whilst others favour sub-chronic or chronic 
dosing schedules and employ a strategy of repeated exposure of the drug before behavioural 
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testing is conducted following a significant wash-out period.  Both regimens can induce 
behavioural symptomatology resembling that presented in schizophrenia (Jentsch and Roth 
1999), but both also appear to have their merits and downfalls, differences that will be 
discussed below. 
 
1.8.1 Acute PCP Treatment 
Acute exposure to PCP can result in a variety of behavioural responses in rodents that are 
indicative of schizophrenia-like symptoms, and are a useful way of inducing dysfunction in 
paradigms used to assess behaviour that attempt to mimic aspects of schizophrenia 
symptomatology (Jentsch and Roth 1999).  These include impairment in motivation, motor 
function, frontal cortex function, temporal cortex function social behaviour and sensorimotor 
gating (Heale and Harley 1990; Hoehn-Saric et al. 1991; Aguardo et al. 1994; Sams-Dodd 
1996; Verma and Moghaddam 1996; Jentsch and Roth 1999).  While acute administration 
can induce cognitive impairment mimicking that observed in schizophrenia, Jentsch and Roth 
(1999) have highlighted the fact that acute administration impairs many faculties that are not 
affected in the disorder.  Administration of PCP has been shown to impair acquisition of 
conditioned emotional response (Hoehn-Saric et al. 1991), conditioned cue preference 
(Stevens et al. 1997) and brightness discrimination (Tang and Franklin 1983), tasks that 
involve sensory processes and associative learning (Jentsch and Roth 1999) and these 
processes remain intact in schizophrenia.  Additionally, following acute NMDA antagonism it 
has been demonstrated that there is a significant increase above basal levels of glutamate, 
dopamine, serotonin and acetylcholine within the PFC (Deutch et al. 1987; Hertel et al. 1996; 
Verma and Moghaddam 1996; Jentsch et al. 1997 a, b; Adams and Moghaddam 1998; 
Abekawa et al. 2006), which may give rise to the behavioural or cognitive disruption 
observed following acute NMDA antagonist exposure.  However, schizophrenia is associated 
with a reduction of frontal cortical dopamine transmission (Weinberger et al. 1988; Daniel et 
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al. 1989; Davis et al. 1991), not an increase.  Additionally, acute administration of PCP 
produces a biphasic response to glucose metabolism, with an increase 3 h after exposure, a 
reduction 24 h following exposure and a return to baseline approximately 48 h after acute 
administration (Gao et al. 1993; Cochran et al. 2003).  In accordance with the discrepancies 
regarding cortical dopamine transmission, the increase in glucose utilisation following acute 
NMDA antagonism is in contrast to that observed in schizophrenia, with patients 
demonstrating ‘hypofrontalitiy’, characterised by a reduction in frontal blood flow and 
glucose utilisation (Weinberger et al. 1986; Weinberger and Berman 1996; Jentsch and Roth 
1999).  Moreover, the behavioural and physiological alterations associated with acute 
exposure to PCP, or other NMDA antagonists, are generally transient and short lived and 
thus, are only apparent as a result of direct exposure to the drug, being present only while 
the drug is still within the system, or for a short duration after metabolism and excretion 
(Jentsch and Roth 1999).  Therefore, acute PCP exposure perhaps only offers a temporary 
method of impairing cognitive performance, but in a manner that is not completely 
analogous to the physiological consequences of the disorder.  Furthermore, and possibly of 
greater consequence to the interpretation of behavioural performance, relates to the effect 
of acute NMDA receptor antagonism and the emergence of generalised behavioural 
disruption – acute administration often results in ataxia, stereotypy and/or sedation 
(Verebey et al. 1981; Melnick et al. 2002).  Locomotor impairments may result in a non-
specific inability to perform the task at hand, obscuring the interpretation of impaired 
performance resulting from cognitive dysfunction.  Additionally, acute NMDA antagonism has 
been suggested to result in motivational impairment (Jentsch and Roth 1999; Paine and 
Carlezon 2009).  Thus, if the animal has a reduced drive to perform a given task, it could 
further confound the behavioural interpretation.  To circumvent these potentially 
confounding consequences of acute NMDA antagonist administration, experimenters often 
assess cognitive function following repeated, sub-chronic or chronic exposure to NMDA 
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receptor antagonists, conducting cognitive testing without the generalised behavioural 
disturbances potentially hindering interpretation. 
 
1.8.2 Sub-chronic PCP Treatment  
The review article published by Jentsch and Roth (1999) stated that long-term, repeated 
exposure to PCP (or other NMDA antagonists) may provide an enhanced model of some of 
the cognitive impairments in animals that resemble those that are seen clinically in 
schizophrenia. Research has suggested that sub-chronic PCP treatment regimens are able to 
induce a more selective set of deficits, including social impairment, locomotor sensitisation 
and specific cognitive impairments indicative of the symptomatology clinically presented in 
the disorder (Jentsch and Roth 1999; Morris et al. 2005; Neill et al. 2010).  Studies have 
shown that rats sub-chronically treated with PCP demonstrate less social interaction and 
actively avoid social contact with unfamiliar rats, in comparison to interaction levels of rats 
treated with saline (Snigdha and Neill 2008a, b).  This is reminiscent of symptoms seen in the 
clinic (Bobes et al. 2010) and one of a few models that demonstrate the ability of PCP (and 
potentially other NMDA receptor antagonists) to induce certain aspects of the negative 
symptomatology of the disorder. 
Sub-chronic PCP treatment has also been shown to selectively disrupt the ability of animals 
to perform in a variety of cognitive tasks following cessation of drug treatment (see Neill et 
al. 2010 for review), disturbances that are of relevance to the cognitive domains putatively 
affected in schizophrenia (Young et al 2009a).  Domains of cognitive function that are 
susceptible to disruption include episodic-like memory (Grayson et al. 2007; Karasawa et al. 
2008), cognitive flexibility (Idris et al. 2005; McLean et al. 2009), and executive functioning 
deficits (Rodefer et al. 2005; Rodefer et al. 2008; McLean et al. 2008; Broberg et al. 2009).  
PCP-induced deficits in these tasks occurred following a substantial washout period (several 
months in some cases).  These findings indicate performance deficits were not due to ‘acute 
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drug effects’ or withdrawal effects, suggesting that long-term exposure to PCP produced 
long-lasting neurobiological changes resulting in an impaired ability to perform in a variety of 
cognitive paradigms.  Furthermore, repeated or sub-chronic exposure to NMDA antagonists 
significantly reduced or completely ameliorated the ataxic or stereotyped behaviour that 
may potentially confound interpretation following acute administration (Podhorna and 
Didriksen 2005; Didriksen et al. 2007; Amitai et al. 2007).  The lack of generalised motoric 
impairment following these treatment regimens suggests a degree of tolerance to the 
generalised behavioural impairment observed following acute NMDA administration, thus 
eliminating this complication when interpreting performance.  Along with the profound 
behavioural and cognitive impairments, sub-chronic PCP treatment also induces various 
neurochemical and neuroanatomical changes that resemble those presented clinically in 
schizophrenia patients.  Mouri and colleagues (2007) described several studies that revealed 
following chronic PCP administration, basal or stress-induced utilisation of dopamine in the 
PFC was decreased for several days after drug treatment in mice, rats and monkeys (Jentsch 
et al. 1997a, b; Noda et al. 2000), mimicking the reduction of frontal dopaminergic 
transmission observed in schizophrenia (Weinberger et al. 1988; Daniel et al. 1989).  
Furthermore, in addition to disrupted PFC dopamine utilisation, Noda et al. (2000) showed 
that following sub-chronic PCP treatment, 5-HT utilisation increased in the PFC under 
stressful conditions.  These data indicate that prolonged blockade of NMDA receptors results 
in disruption of the balance between prefrontal dopaminergic and serotonergic 
neurotransmission (Mouri et al. 2007).  Several reports have also suggested that repeated 
exposure to PCP reduces the density of parvalbumin containing neurons in the hippocampus 
and prefrontal cortex of the rat (Cochran et al. 2003; Reynolds et al. 2004; Abdul-Monim et 
al. 2007; Mouri et al. 2007).  This is consistent with the reduction of GABAergic interneurons 
seen in the hippocampus and frontal cortex of schizophrenia patients (Beasley and Reynolds 
1997; Beasley et al. 2002; Zhang and Reynolds 2002).  In addition to the PCP-induced 
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dysfunctional GABAergic transmission, a dramatic reduction in the number of prefrontal 
dendritic spine synapses (41% reduction) coupled with an increase in astroglial process 
density (59% increase) has also been demonstrated following sub-chronic PCP treatment in 
rats (Hajszan et al. 2006).  This effect is also consistent with the reduction of PFC dendritic 
spine density demonstrated in schizophrenia patients (Glantz and Lewis 2000).  In light of 
these findings, the suggestion that long-term, repeated exposure to NMDA receptor 
antagonists may provide a valid means of pharmacologically inducing cognitive, 
neurochemical and morphological changes in experimental animals, reminiscent to those 
seen in schizophrenia patients, certainly looks promising. 
 
1.9 Dopamine and Cognition 
It has recently become evident that dopamine plays a regulatory role in aspects of the many 
domains of cognition that are compromised in schizophrenia (Sawaguchi and Goldman-Rakic 
1991; Cohen and Servan-Schreiber 1993; Goldman-Rakic et al. 2004), including attention 
(Nieoullon 2002).  Dopaminergic projections arise from the midbrain and project to cortical 
and sub-cortical brain regions.  Fibres arising from the substantia nigra project to areas of the 
brain associated with movement and motor control and are likely the projections that are 
involved in the neurodegenerative disorder, Parkinson’s Disease (Fearnley and Lees 1991).  
Conversely, projections ascending from the ventral tegmental area (VTA) of the midbrain 
project to cortical brain regions (fig 1.2) and are thought to be associated with higher-order 
cognitive processing, in particular those that terminate in the frontal cortical regions (Davis 
et al. 1991).    
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Fig 1.2. Simplified schematic of the circuitry and projections of the mesolimbic dopamine system in the rat brain 
highlighting the major inputs to the nucleus accumbens (NAc) and ventral tegmental area (VTA) (glutamatergic 
projections, blue; dopaminergic projections, red; GABAergic projections, orange; orexinergic projections, green). 
Glutamatergic synapses excite postsynaptic neurons and GABAergic synapses inhibit postsynaptic neurons. 
Dopamine release exerts more complex modulatory effects. AMG, amygdala; BNST, bed nucleus of the stria 
terminalis; LDTg, laterodorsal tegmental nucleus; LH, lateral hypothalamus; PFC, prefrontal cortex; VP, ventral 
pallidum.  Image and figure legend taken from Kauer and Malenka, 2007. 
 
This led to the suggestion that dopamine may have a dual dysfunction in the pathophysiology 
in schizophrenia (Davis et al. 1986).  Dopaminergic over-activation in sub-cortical regions 
gives rise to the positive symptoms of the disease, whilst reduced function of dopaminergic 
innervation of cortical regions (‘hypofrontalitiy’) may contribute to the negative and 
cognitive aspects of the disorder (Davis et al. 1986; Davis et al. 1991; Grace, 1991; Howes and 
Kapur 2009).  This provides a possible explanation to why classical neuroleptic drugs that are 
potent dopamine D2 antagonists, acting on receptors predominantly located in sub-cortical 
regions (Guillin et al. 2007), show efficacy in treating auditory hallucinations and bizarre 
thought (i.e. positive symptoms).  However, these drugs are relatively ineffective in treating 
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the cognitive or negative symptoms of the disease (Scatton and Sanger, 2000; Ibrahim and 
Tamminga, 2010), symptoms which are postulated to be mediated by cortical brain regions. 
Dopamine D1-like receptors are increasingly being implicated in cognitive processing 
(Sawaguchi and Goldman-Rakic 1991; Sawaguchi and Goldman-Rakic 1994; Goldman-Rakic et 
al. 2004).  Dopaminergic D1 receptors are located within the PFC (Sawaguchi and Goldman-
Rakic, 1991; Guillin et al. 2007), a region with extensive reciprocal innveration with various 
sub-cortical structures (Elman et al. 2006) and has been suggested to be associated with the 
functionality of a number of cognitive domains, including working memory (Arnsten et al. 
1994; Sawaguchi and Goldman-Rakic 1994), visual learning and memory (McLean et al. 2009) 
and reasoning and problem solving (Mclean et al. 2009).  Furthermore, D1 dopaminergic 
neurotransmission and the PFC is also suggested to be involved in attentional processing 
(Nieoullon, 2002; Lesh at al. 2010), in particular the involvement of providing ‘top-down’ 
cognitive control to coordinate behaviour (Miller 2000; Miller and Cohen, 2001).  Further 
evidence to implicate dysfunctional dopaminergic D1 receptors within frontal cortical regions 
in schizophrenia comes from PET studies, demonstrating a down-regulation of dopamine D1 
receptors in schizophrenia patients within the PFC (Okubo et al. 1997).  It should also be 
noted that the reduction in D1 receptor expression demonstrated by Okubo et al. (1997) 
occurred in patients naive from drug treatment, eliminating the potential confound of 
altered receptor expression induced by long-term antipsychotic medication. Thus, down 
regulation of frontal cortical dopaminergic receptors is likely to be due to the pathology of 
the disorder, and given their location in a region implicated in cognitive control, may also be 
associated with impaired cognition in the disorder. Consequently, the MATRICS initiative 
identified the dopaminergic D1 system as a promising target for future pharmacological focus 
and prompted the development of several new compounds which may prove efficacious in 
the treatment of schizophrenia (Tamminga 2006). 
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1.10 Preclinical Models of Attentional Processes 
As previously discussed, it has been identified that cognitive dysfunction, including 
attentional impairment, is core to the pathophysiology of the disorder (Cornblatt and Keilp 
1994; Marder et al. 2004; Ibrahim and Tamminga 2010).  Cognitive impairment is suggested 
to be inherently associated with the functional outcome of schizophrenia patients (Green, 
1996), and is one of the driving factors influencing a patients’ inability in successfully 
reintegrating back into society, even once psychotic symptoms have been managed by 
pharmacotherapy.  It is therefore of vital importance that the underlying mechanisms of the 
cognitive processes affected in schizophrenia are properly understood, thus enabling 
elucidation of the dysfunctional processes involved that result in the emergence of cognitive 
deficits exhibited in the disorder.  It is clear that attentional processing is dysfunctional in 
schizophrenia patients.   Furthermore, attention has been described as ‘the gateway to 
cognition’ (Riedel et al. 2006), reflecting the possibility that attention forms the underlying 
substrate for several higher-order cognitive processes.  As a result, several preclinical tasks 
have been developed that assess attentional function in experimental animals, which 
therefore facilitate the investigation of the fundamental neurobiological processes that 
govern the control of the multifaceted construct of attentional processing. 
 
1.10.1 Sustained Attention Task  
McGaughy and Sarter (1995) developed an operant based task to assess attentional abilities 
with focus on the construct of vigilance in rats, known as the sustained attention task (SAT).  
The task consists of two discrete trials (summarised in fig 1.3), one where a signal is 
presented (signified by the presentation of a visual stimulus) and one where the signal is not 
presented (with the absence of a light stimulus).   
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Fig 1.3. Schematic diagram of the two trial types presented in the sustained attention task (SAT).  VI signifies a 
variable interval, following which the signal is presented (or absent), following the signal event and another VI the 
response levers are presented and the animals’ response is recorded.  Correct responses result in food reward 
and incorrect responses are penalised by a 2 s time out period. Image taken from Rezvani et al. 2008. 
 
Following the signal or non-signal and post-stimulus interval, two response levers are 
presented and depending on whether the signal was presented or not, lever presses result in 
hits or misses (signal trial), or correct rejections or false alarms (non-signal trial), with hits 
and correct rejections resulting in the delivery of a food reward.  The signal and non-signal 
trials are presented to the animal in a pseudo-randomised order so that both trial types are 
presented a number of times throughout the whole session.  In the original study, McGaughy 
and Sarter (1995) varied the stimulus duration (SD) of the signal (25, 50 or 500 ms) and the 
session consisted of 27 signal trials (of each SD) and 81 non-signal trials in a session totalling 
162 trials.  As the SAT produces measures similar to that generated by human CPTs (i.e. hits, 
misses, correct rejections and false alarms) depending on what action the animal took when 
presented with each of the two trial types, SDT can be accurately employed.   SDT was used 
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to generate an index of discriminability (termed the vigilance index; VI), facilitating the 
quantification of vigilance levels (McGaughy and Sarter 1995; Sarter at al. 2001).  Antagonism 
of the NMDA receptor system has been demonstrated to impair performance in the SAT, 
following systemic administration of dizocilpine (MK-801) (Rezvani and Levin 2003; Rezvani 
et al. 2008a, b).  Acute drug treatment impaired attentional processing characterised by a 
reduction in hits and a reduction in correct rejections, suggesting an inability to discriminate 
between signal and non-signal events.  The experimental design conducted by Rezvani and 
Levin (2003) grouped the trials from the session into block and it was identified that 
dizocilpine treatment impaired the ability to correctly respond to the target stimulus in only 
the middle and last group of trials.  However, the reduction in correct rejections was evident 
throughout the session, although more pronounced in the latter stages of the session.  In-
vivo microdialysis demonstrated that acetylcholine (ACh) efflux within the mPFC is involved 
in attentional performance, characterised by a 140% increase above basal levels upon 
initiation of the behavioural procedure (Kozak et al. 2006).  Additional evidence to suggest 
that NMDA antagonism disrupts attentional functioning is provided by Kozak et al. (2006).  
These findings demonstrated that bilateral infusion of DL-2-amino-5-phosphonovaleric acid 
(APV) into the basal forebrain (BF) resulted in an impaired ability to perform the SAT, 
exemplified by a reduction in hits (although, in contrast to Rezvani and Levin 2003, APV in 
this case did not induce a reduction in correct rejections).  Moreover, it was demonstrated 
that infusion of APV resulted in increased release of acetylcholine (Ach) efflux in the mPFC.  
This increase was over and above the 140% rise from basal level elicited from the 
behavioural task alone with ACh efflux levels reaching ~200% above baseline (Kozak et al. 
2006), supporting previously demonstrated increases in cortical ACh in response to NMDA 
antagonists (Kim et al. 1999; Nelson et al. 2002).  These findings not only confirm that NMDA 
antagonism disrupts performance of an attentional operant task, but suggests that 
cholinergic innervations of the mPFC, arising from the BF is intrinsically involved in the ability 
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of an individual to engage in the task at hand and suggests its involvement in attentional 
processing, particularly under challenging attentional conditions.  
 
1.10.2 Five-Choice Serial Reaction Time Task 
The 5-choice serial reaction time task (5-CSRTT) is one of the most commonly used tasks of 
attentional function in experimental animals.  The 5-CSRTT is based on Leonard’s five-choice 
serial reaction task (Leonard, 1959; Wilkinson, 1963), and has been said to share many 
features with the human CPT (Bari et al, 2008).  The 5-choice task is conducted in an operant 
chamber that uses light stimuli instead of levers.  The chamber contains five functional 
apertures, which contain incandescent bulbs or LEDs that provide the brief visual stimulus, 
and the rodent must respond to the visual stimulus by nose poking the aperture in which the 
stimulus was presented.  Correct responses result in delivery of a food reward, while 
incorrect responses result in a time out (for a more detailed description of the task see 
chapter 2 and chapter 3).  Although the description of the task makes it appear simplistic in 
nature, optimal performance in the task requires a number of cognitive processes (Robbins, 
2002).  During the inter-trial interval (ITI) the animal must divide and sustain its attention 
across the five spatial locations in order to detect the brief visual stimulus.  In addition, 
during the ITI, the rat must focus its attention and withhold from responding before the 
stimulus is presented as this would result in a premature response (Chudasama and Robbins 
2004a; Bari et al. 2008).  In an adaptation of the basic protocol, the 5-choice task can also 
measure elements of selective attention.  If the task interpolates busts of distracting white 
noise at the time the visual stimulus is presented, or just prior to, the animal must selectively 
filter out the white noise in order to detect presentation of the stimulus.  Therefore the 5-
choice task is capable of measuring the three main components of attention, sustained, 
divided and in certain circumstances, selective attention (Robbins 2002; Chudasama and 
Robbins 2004a).  As there are five apertures for the rat to respond to, following the visual 
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stimulus, the chance performance is therefore ~20% correct response, whereas operant tasks 
using levers (typically two) often have chance performance levels of 50% (Robbins 2002).  
This value gives a useful baseline level of performance, as rats that are highly trained in the 
task will be performing at approximately 70 - 80% correct responding.  
 
1. 11 Possible Neural Circuits Involved in the 5-CSRTT 
Many regions of the rat brain have been implicated in successful performance of the 5-choice 
task and therefore hypothesised to be involved in attentional processing. There are a variety 
of methods that can be used to elucidate regions of the brain and their involvement in 
behavioural processes, whether it is revealing involvement in attentional functionality or 
behavioural inhibition. One methodology includes the use of neurotoxic lesion, in which 
selected regions of the brain or connectivity are disrupted, followed by assessment of 5-
CSRTT performance. 
 
1.11.1 Neurotoxic Lesions and the 5-CSRTT 
Chudasama et al. (2003) conducted extensive work into dissociating and elucidating sub-
regions of the PFC involved in task performance.  The PFC can be divided into specific sub-
regions, depending on sub-cortical efferent projections and involvement of each sub-region 
in specific aspects of 5-choice task performance can be dissociated.  Lesions to the medial 
PFC (mPFC) primarily results in a reduction in choice accuracy, attributed to impaired 
attentional processing.  Medial PFC lesions also increased premature responding, suggesting 
that this region is involved in impulse control.  Neurotoxic lesions of the prelimbic cortex also 
resulted in a reduction in accuracy and an increase in premature responding, whereas 
infralimbic cortex lesion tended to only result in an increase in omissions (Passetti et al. 
2002).  Along with attentional processing and impulse control, frontal cortical regions are 
also implicated in cognitive flexibility, demonstrated by an increase in perseveration 
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following lesion of mPFC and orbitofrontal cortex (Chudasama et al. 2003). Furthermore, 
along with the involvement of frontal cortical regions, it is evident that various sub-cortical 
regions are involved in 5-choice task performance. Lesion of striatal regions have resulted in 
impaired 5-choice performance (Rogers et al. 2001), along with thalamic regions (Chudasama 
and Muir 2001). However, these sub-cortical brain regions have been demonstrated to 
receive substantial afferent input from cortical regions (Divac and Diemer 1980; McGeorge 
and Faull 1989; Sesack et al. 1989; Rogers et al. 2001), and perhaps the impairment in task 
performance following a sub-cortical lesion is due to the reduction in top-down control 
originating from frontal cortical regions and not due to the involvement of the sub-cortical 
region, per se (Miller 2000; Miller and Cohen 2001). 
 
1.12 Psychotomimetics and the 5-CSRTT 
Performance in the 5-choice task can be modified by pharmacological agents.  Of specific 
interest to the work presented in this thesis is the effect of psychotomimetic administration 
on the behaviours measured in the task, and the potential elucidation of their impact on 
attentional processing.  One method involved intracerebral injections of drugs directly into 
specific brain regions suggested to be involved in performance of the task.  Following drug 
administration, performance can then be assessed in the 5-choice task to determine drug 
effects and impact of the specific brain region on task performance. 
Baviera et al. (2008) used the competitive NMDA receptor antagonist 3-(R)-2-
carboxypiperazin-4-propyl-1-phosphonic acid (CPP), injected directly into the medial PFC of 
rats trained in the 5-choice task.  The frontal cortex is densely populated with NMDA 
receptors (Cotman and Iversen 1987; Ulus et al. 1992) and this experiment demonstrated 
that selective blockade of NMDA receptors within this region produced a profound 
impairment in the rat’s ability to perform in the task.  Bilateral injection of CPP (50ng/side) in 
the mPFC region of the rat brain resulted in a reduction in choice accuracy, increased the 
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number of omissions, increased the correct latency and produced behavioural disinhibition in 
the form of increased perseverative and premature responding.  These data clearly implicate 
the mPFC and a functioning NMDA glutamatergic system in successful performance of the 
task.  These data were in agreement with the results produced by Murphy et al. (2005) who 
also demonstrated that bilateral central infusion of CPP into the mPFC produced 
performance deficits in the 5-choice task.  However, Murphy and colleagues (2005) 
investigated the effects of CPP infusion in the prelimbic and the infralimbic cortices, which 
are specific sub-regions of the PFC.  This study demonstrated that blockade of NMDA 
receptors within the PFC produced dissociable effects depending on the region.  Infusions of 
CPP produced a reduction in choice accuracy and an increase in omissions across both 
cortical regions within the medial PFC; however, an increase in premature responding was 
only evident when NMDA receptors contained within the infralimbic cortex, but not the 
prelimbic cortex, were blocked.  Murphy et al. (2005) suggested that these data 
demonstrated a dissociable role for the prefronto-cortical glutamatergic system concerning 
behavioural disinhibition, localised to the ventromedial infralimbic region of the mPFC.  
 
1.13 Sensorimotor Gating 
Sensorimotor gating refers to the pre-attentive abilities of the individual, crucial in the ability 
to filter out irrelevant sensory stimuli and can be construed as a form of passive attention or 
a construct of automatic attentional processing of incoming sensory information (Graham 
1975).  If an individual is exposed to a sudden, unexpected noise (for example, 120db burst of 
white noise) a startle response is generated, in which muscles involuntarily contract, and this 
is conserved across species, and present in all mammals (Braff et al. 2001).  If the startle 
stimulus is preceded by a stimulus that falls below the threshold of that which elicits the 
startle response, there is a diminished reaction when the startling stimulus is presented.  This 
is known as pre-pulse inhibition (PPI) of the startle response and is thought to represent a 
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method of quantifying the process of sensorimotor gating (Braff et al. 2001; Geyer et al. 
2001; Young et al. 2009a).  The startle stimulus and the sub-threshold stimulus needn’t 
always be auditory, as it has been shown that various stimulus modalities can be used to 
elicit a startle response or induce PPI of the startle response (Swerdlow et al. 2002).  
However it is extremely time-dependent with a tight time effect window (50 – 300 ms) 
between the prepulse and startle stimulus onset for startle inhibition to occur (Blumenthal 
and Gescheider 1987; Swerdlow et al. 1999; Young et al. 2009a).  Schizophrenia patients 
demonstrate a deficit in PPI; a startling stimulus elicits a full response even when preceded 
with a pre-pulse of a lower magnitude (Braff et al. 2001).  It has been suggested that 
schizophrenia patients have a deficit in the early stages of information processing and the 
ability to filter and integrate incoming sensory information resulting in downstream 
disorganisation, hypothesised to be involved in the cognitive fragmentation, clinical 
symptomatology and functional impairment seen in the disorder (Venables 1960; Braff and 
Geyer 1990; Braff et al. 2001).  Interestingly, impairments in the PPI of the startle response 
are also seen in humans and animals following treatment with NMDA receptor antagonists 
(Mansbach and Geyer 1989; Geyer et al. 1990; Keith et al. 1991; Johansson et al. 1995; 
Martinez et al. 1999; Jones and Shannon, 2000; Heekeren et al. 2007), thereby highlighting 
the putative face validity of this pharmacological challenge to model passive attentional 
componets of schizophrenia. This suggests an involvement of NMDA receptors in passive 
attentional processing, filtering and organising incoming sensory information and therefore 
implicates NMDA receptor dysfunction in the pathogenesis of schizophrenia.  
 
1.14 Neuroimaging and Schizophrenia 
Along with computerized tomography (CT) and positron emission tomography (PET), 
magnetic resonance imaging (MRI) has revolutionised the medical field by providing a means 
of visualising internal tissue and organs, including neurobiological structures in vivo without 
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the need for invasive surgical procedures. The non-invasive nature of imaging techniques 
enables the comparison of neurobiological structure or function in both healthy and patient 
groups (Feldman et al. 1997), facilitating the identification of key differences in biology that 
may have a mechanistic bearing in the pathophysiology of schizophrenia. 
MRI is a widely used neuroimaging technique which relies on the behaviour of charged atoms 
in a strong magnetic field. In this setting nuclei resonate and emit a radio frequency at 
unique wavelengths. The frequency of this radio wave emission is dependent on what type of 
atom it originates from, as well as what chemical or physical environment the atom is located 
in (Feldman et al. 1997).  Additionally, depending on the atom and its environment (i.e. the 
tissue it’s located in), the relaxation period, which is the time taken for the atom to return to 
its previous state when the magnetic field is removed, differs and is characteristic of the 
atom type and location.  Based on these measures, different tissue types and compositions 
can be deduced and an image of the brain, detailing various structures and functionality, can 
be constructed. 
One MRI technique that can help elucidate the structural composition of the brain is voxel 
based morphometry (VBM), which is a technique that compares different brains on a voxel-
by-voxel basis following a process that has compensated for macroscopic differences which 
occur naturally between samples (Mechelli et al. 2005).  VBM is generally used to identify 
regional differences in grey and white matter and cerebrospinal fluid as opposed to general 
global differences in brain structure; therefore VBM imaging provides greater sensitivity in 
detecting abnormalities in volumetric structure in specific target regions of the brain.  A 
particular advantage of VBM is that it is essentially hypothesis-free and is sensitive to the 
detection of morphometry differences that lie outside a particular region of interest (Job et 
al. 2002).  Structural imaging has identified a number of abnormalities present in the brains 
of schizophrenic patients that are absent from normal controls, and these differences may 
account for the pathology present in the disorder.  In first-episode schizophrenia patients, 
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morphometric analysis demonstrated that patients show reductions in grey matter primarily 
in the left and right caudate nuclei, cingulate gyri, parahippocampal gyri, superior temporal 
gyri, right thalamus and prefrontal cortex (Chua et al. 2007).  Additionally, in this study 
volumetric analysis demonstrated there was an increase in the volume of CSF, particularly in 
the right lateral ventricle (Chua et al. 2007), likely due to an enlargement of the ventricles, 
which is a consistent finding among schizophrenia patients (Van Horn et al. 1992; Pomarol-
Chotet et al. 2010).  Wolf et al. (2008) also demonstrated grey matter deficits in 
schizophrenia, located within the left hippocampal gyrus and the right superior frontal cortex 
utilising VBM. In addition, they showed impaired cognitive abilities were correlated with 
structural abnormalities in a task that assesses divided attention (Wolf et al. 2008).  
Furthermore, it has been demonstrated that alterations in grey matter density observed in 
schizophrenia patients in the left thalamic nucleus, left angular, and supramarginal gyrus and 
left inferior frontal and postcentral gyri are positively correlated to the impaired 
performance of the CPT-IP assessing sustained attentional abilities (Salagado-Pineda et al. 
2003).  Additionally, this study was carried out in treatment-naive patients, ruling out the 
potential confound that attentional impairment or structural abnormalities were the result of 
chronic pharmacotherapy.  Thus, structural disturbances are not only associated with 
schizophrenia pathophysiology, they may play a pivotal role in the cognitive impairment 
demonstrated in the disorder. 
A recent development of MRI is a technique known as diffusion tensor imaging (DTI) and 
rather than determining the structural density or volume of tissue, DTI can reveal 
abnormalities in the connectivity between various regions of the brain (Filler 2009).  The 
methodology behind DTI involves the movement of water molecules through varying 
mediums of brain tissue.  In regions where water molecules can move unrestricted (i.e. the 
ventricles) water diffuses in an isotropic fashion (i.e. in all directions).  However, when water 
molecules are confined within the axons of neurons, movement is restricted by the axonal 
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membranes and so diffusion is anisotropic (i.e. flows along the axis of the axon).  This enables 
the production of a measure of fractional anisotropy (FA); high FA suggests a non-spherical 
tensor in which water is moving in a particular direction (i.e. along an axon), whereas a 
reduced FA indicates more isotropic movement which can be the result of compromised 
white matter (Beaulieu, 2002).  By using the information obtained from DTI (isotropic 
regions, anisotropic regions and flow direction), it is possible to implement a technique 
known as fibre tractography (Kubicki et al. 2005), which visualises the neuronal tracts within 
the brain, thus enabling the comparison between normal and diseased brains to determine if 
the pathology is associated with deficits in white matter connectivity.  Since its 
implementation, DTI has revealed white matter abnormalities in schizophrenia (Kubicki et al. 
2002; Kubicki et al. 2005) that correlate with cognitive impairment (Dwork et al. 2007). 
Consistent findings have demonstrated lower anisotropy in schizophrenia patients, compared 
to controls, indicating white matter abnormalities or a reduction in connectivity in frontal 
and prefrontal regions (Buchsbaum et al. 1998; Lim et al. 1999).  Furthermore, Camchong et 
al. (2009) demonstrated a reduced FA in frontal white matter in non-symptomatic relatives of 
schizophrenia patients, demonstrating the heritability of white matter abnormalities.  
Recently, white matter abnormalities have been demonstrated in the medial frontal cortex of 
schizophrenia patients (Pomarol-Clotet et al. 2010).  Thus, these studies highlight that the 
integrity of myelination of frontal regions of the brain are compromised and may play an 
integral role in the pathophysiology of schizophrenia. 
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1.15 Experimental Aims 
The aim of the work presented within this thesis was firstly to characterise the pre-clinical 
test of attention, the 5-choice serial reaction time task, and to establish the effect of 
psychotomimetic drugs on task performance.  Importantly, the differing effect of treatment 
regimens and task disruption were assessed. 
To further investigate attentional processing, a modified version of the 5-CSRTT was 
implemented, which may have greater analogy to its human counterpart, known as the 5-
choice continuous performance test (5C-CPT).  This task has previously only been validated in 
mice, and therefore it was important to determine if rats can be successfully trained to 
perform this task and necessarily discriminate between target and non-target trials.  
Moreover, the effect of D1 dopamine activation on task performance was assessed, with the 
ability to attenuate impaired performance following a behavioural challenge investigated.   
The primary aim of this thesis was to characterise the attentional-disruptive effect of PCP on 
5C-CPT performance.  Firstly the ability of repeated PCP administration to induce cognitive-
specific deficits in the 5C-CPT was investigated.  Secondly, as a paucity of information 
regarding persistent attentional impairment following NMDA receptor antagonism exists, the 
ability of a sub-chronic PCP treatment regimen to induce 5C-CPT deficits in the drug-free 
state was explored. 
Finally the morphology of the brain was assessed, utilising structural magnetic resonance 
imaging (MRI), to determine if sub-chronic exposure to PCP induced long-term structural 
abnormalities in the brain.  Neuroimaging was conducted in conjunction with the assessment 
of attentional processing investigating the dissociation between sustained and passive 
attentional impairment. 
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The following chapter will describe the general methodology used throughout the 
experimental chapters contained within this thesis.  Detailed methods relating to specific 
aspects of the hypothesis under investigation are described in the relevant experimental 
chapters. The experiments carried out in the two 5-CSRTT chapters (3 and 7) were performed 
at different institutes (University of Bradford and University of Cambridge, respectively) and 
headed as such. 
 
2.1. Subjects 
2.1.1  University of Bradford 
All subjects used in behavioural testing carried out at University of Bradford were female 
Lister-hooded rats (chapters 3, 4, 5, and 6; Charles River; approx 250 + 10 g at the start of 
experiment) were housed in groups of five on a 12 hour reversed light cycle (lights on at 
7:00pm – with the exception of chapter 3 in which animals were house under standard 
lighting; lights on at 7:00am). All animals at University of Bradford were housed in a 
temperature (21 + 2oC) and humidity (55 + 5%) controlled environment.  All experiments took 
place in the dark cycle (except experimental chapter 3), under red lighting, and animals had 
free access to food (Special Diet Services, UK) and water until one week prior to the 
beginning of training, when food restriction reduced animal weight to 90% of their free-
feeding body weight (approximately 14g rat chow/rat/day).  Food restriction continued 
throughout training and testing, however water was available ad libitium whilst in the home 
cage.  All experiments were conducted in accordance with the UK Animals (Scientific 
Procedures) 1986 Act and local University of Bradford ethical guidelines. 
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2.1.2 University of Cambridge 
Male hooded-Lister rats (chapter 7; Charles River, UK; weighing approx 350 + 10 g at the start 
of the experiment) were housed in groups of four on a 12 hour reversed light cycle (lights on 
at 7:00pm) in a temperature (21 + 2oC) and humidity (55 + 10%) controlled environment.  
Behavioural testing took place during the dark cycle, under red lighting.  Animals had free 
access to food (Special Diet Services, UK) and water until one week prior to the beginning of 
training, where food restriction reduced animal weights to 90% of their free-feeding body 
weight (approximately 16 - 18g rat chow/rat/day).  Food restriction continued throughout 
training and testing, however water was available ad libitium whilst in the home cage.  All 
experiments were conducted in accordance with the UK Animals (Scientific Procedures) 1986 
Act and local University of Cambridge ethical guidelines. 
 
2.2 Drugs 
All drugs were administered at a volume of 1ml/kg via the interperitoneal (i.p.) route and 
drug dose is expressed as free-base.  Phencyclidine hydrochloride (PCP, Sigma-Aldrich, UK) 
was dissolved in 0.9% sterile saline (conversion factor, CF, 1.15).  d-Amphetamine sulphate 
(Amphetamine, Sigma-Aldrich, UK) was dissolved in 0.9% saline (CF 1.36).  SKF 38393 (Sigma-
Aldrich, UK) was dissolved in distilled H2O (CF 1.14).  The CF was calculated by the following: 
 
 
Conversion factor = Relative Molecular Weight (RMW) 
                                          (RWM – RWM of the salt) 
 
Information regarding the specific treatment regimen and the dose the animal received can 
be found in the relevant experimental chapters. 
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2.3 Apparatus 
2.3.1 University of Bradford 
The test apparatus (for chapters 3, 4, 5, and 6) consisted of eight 25 cm x 25 cm aluminium 
chambers, each enclosed within a wooden sound attenuating box (fig 2.1 - constructed in-
house for GlaxoSmithKline, GSK Harlow, UK, gifted to the University of Bradford).  The rear 
wall of the testing chamber was concavely curved and contained nine individual apertures, 
four of which were occluded, leaving apertures 1, 3, 5, 7 and 9 free for exploration.  Each 
aperture was 2.5 cm2, 4 cm deep and set 2 cm above floor level.  Located at the rear of each 
aperture was a yellow incandescent bulb (chapter 3) or white LED (chapters 4, 5, and 6), 
which provided the visual stimulus.  An infrared photocell beam fixed vertically, at the 
entrance of each aperture, registered nose-poke responses.  Located on the front wall of the 
test chamber was a food magazine that allowed retrieval of the food reward (45 mg sucrose 
Rodent Pellet, Sandown Scientific).  A hinged panel covered the food magazine and a micro-
switch reported the collection of food rewards (see fig 2.1 and 2.2 for outline of chamber 
layout).  In addition to the sound attenuating box, there was also a low-level fan that not only 
provided ventilation, but also provided a means to mask extraneous background noises. The 
floor of the test chamber consisted of a wire grid, under which was a removable tray that 
was covered with sawdust.  All eight chambers were connected to a PC and data collection 
and initial analysis was controlled by K-Limbic software (Conclusive Solutions) which 
generated an Excel spreadsheet (Microsoft) containing raw data. 
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Fig 2.1.  A 5-choice serial reaction time task chamber at University of Bradford 
 
 
Fig 2.2.  A schematic diagram of the 5-CSRTT chamber indicating the arrangement of the five response apertures 
and the food magazine. Image taken from Bari et al. 2008. 
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2.3.2 University of Cambridge 
The apparatus set-up used in experimental chapter 7 was similar to that described for the 
previous experimental chapters, with the following exceptions: twelve 5-hole boxes were 
used (Med Associates, Saint Albans, Vermont, US) with the visual stimulus being provided by 
a yellow LED.  Reward pellets were delivered to the magazine at the front of the chamber, 
and food collection was reported via infrared photobeam.  All twelve chambers were 
connected to a PC and data collection and initial analysis was controlled by Whisker control 
system v2.5 (Cambridge Cognition, Cambridge, UK). 
 
2.4 Behavioural Procedure – 5-CSRTT 
Rats were trained to detect and report the occurrence of a brief visual stimulus (1 s) (Mirza 
and Stolerman, 1998; Fletcher et al. 2007; Young et al. 2007) presented pseudo-randomly in 
one of the five available apertures following an inter-trial interval (ITI, 5 s), conducted with 
the house light on.  The pseudo-random presentation of the visual stimulus was banked.  
Each bank consisted of a stimulus being presented once in a random order in each of the five 
apertures.  Once the visual stimulus had been presented in each of the five apertures, the 
next bank of stimulus presentations began, therefore ensuring only a maximum of two 
consecutive stimuli presentation in the same aperture was possible throughout the session.  
The alternative would have been a completely random sequence in which large numbers of 
consecutive stimuli presentations in a single aperture could potentially occur.  A summary of 
performance of each trial presented in the 5-CSRTT is described in figure 2.3. 
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Fig 2.3. Schematic diagram of the correct performance of a trial presented to the rat during the 5-CSRTT. Image 
taken from Amitai and Markou 2010 
 
Correct detection of the visual stimulus within the limited hold (LH; time period following the 
stimulus during which animals can make a response, 5 s) was reported via a nose-poke in the 
aperture the stimulus was presented in (correct response), and resulted in a food reward.  
Reward collection immediately initiated the next ITI during which the animal had to attend to 
the array of visual apertures and detect the presentation of the next visual stimulus.  Failure 
to respond to the stimulus (error of omission) or responding to an aperture where the light 
was not presented (incorrect response) resulted in the animal being exposed to a 5 s time 
out (TO) period, whereby the house light was extinguished and no food reward was 
delivered.  A repeat response during the TO period restarted the 5 s TO period.  Failure to 
wait for the stimulus presentation, i.e. a nose-poke during the ITI, was recorded as a 
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premature response and was also followed by a TO period.  Following the TO after a 
premature response, the ITI for the previous trial began automatically.  Animals also received 
a TO period following a single repeat response in any of the apertures (perseverative 
response).  The whole session was completed within 100 trials (20 banks of 5 trials) or 30 
minutes, whichever occurred first.  In previous 5-CSRTT studies, accuracy is also referred to 
as percent correct responses and the terms are used interchangeably.  However, an 
important distinction exists and one that is often overlooked; accuracy is calculated 
independently of omissions (Muir 1996), whereas percent of correct responding is calculated 
from the total number of responses within the session (correct, incorrect and omissions).  
Throughout this thesis, this method of calculating accuracy and percent correct responses 
has been adopted, as previously described by others (Amitai et al. 2007; Amitai and Markou 
2009; Amitai and Markou 2010).  The following table (table 2.1) describes the behavioural 
measures of the 5-CSRTT and how they were calculated: 
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Table 2.1 Description of the behavioural measures used in the 5C-CPT 
Measure & Description 
Accuracy: Correct responses/(correct + incorrect)*100 – a measure of selective attention 
Percent Correct: Correct responses/total number of trials*100 – a measure of overall 
performance 
Percent omission: Omissions/(correct + incorrect + omissions) *100 – a measure of sustained 
attention/motivation 
Correct Latency, CL: Time taken to make a correct response; used to assess psychomotor speed 
Incorrect Latency, IL: Time taken to make an incorrect response to assess general response 
speed 
Magazine Latency, ML: Time taken to collect the food reward to assess motivational state 
Total trials: Number of trials completed within the session 
Premature responses: Inappropriate responses made within the ITI period to assess motor 
impulsivity 
Perseverative responses: Inappropriate repeat response following a correct response 
 
 
2.5 Training Schedule – 5-CSRTT 
 
2.5.1 University of Bradford 
Firstly, rats were habituated to the test boxes for two days prior to training; during which the 
magazine tray and response apertures were lit and baited to encourage exploration.  Each rat 
was assigned to an operant box, which remained constant throughout training and testing.  
Additionally, the time of day the animals were trained, tested and fed remained constant 
throughout the entire experiment.  The training schedule (for chapter 3) started with both 
the stimulus duration (SD) and limited hold (LH) duration lasting for 60 s.  Based on rats’ 
individual performance the SD was progressively reduced (see table 2.2) to the test criteria of 
1 s SD.  Animals were moved up a stage when they reached a stable >80% accuracy and <20% 
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omissions for three consecutive days.  The LH was also progressively reduced as the animal 
acquired the task in the same manner as the SD, with the exception that the LH reduction 
stopped at 5 s therefore giving testing criteria of 1 s SD and 5 s LH.  Throughout the training 
period, the ITI and time out period remained at 5 s.  Rats progressed through the stages of 
training when they had reached the criteria of >80% correct and <20% omissions, which was 
stable over three consecutive days.  Rats were deemed trained when they had reached this 
level of performance utilising the testing conditions (1 s SD, 5 s ITI, 5 s LH) for five 
consecutive days.  When rats had reached criterion, they were only trained 3 days per week, 
enabling the rest of the cohort to reach criterion and avoiding the quicker rats becoming 
over-trained.  The animals were trained Mondays – Fridays and animals took approximately 
16 weeks to acquire the task. 
 
Table 2.2: Description of the 5-CSRTT training schedule 
Training 
Stage 
Stimulus Duration 
(SD) 
Limited Hold  
(LH) 
Inter-trial Interval  
(ITI) 
Time Out 
(TO) 
0 
1 
2 
3 
4 
5 
6 
7 
8 
60 
30 
15 
10 
8 
5 
2.5 
2 
1 
60 
30 
15 
10 
8 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
Summary of the training schedule used in chapter 3.  Animals progressed through training stages once they 
attained the desired performance criterion for three consecutive days.  All durations shown are seconds. 
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2.5.2 University of Cambridge 
Animals used in chapter 7 were habituated to the 5-CSRTT chambers as previously described 
(section 2.5.1).  Following the habituation period, animals were trained (6-days per week) in 
the 5-CSRTT procedure by progressively increasing the task difficulty when animals reached a 
predetermined criterion.  Details of the training schedule can be found in table 2.3.  Animals 
progressed to the next training stage once they reached the desired criterion for each stage 
and were deemed trained once they reached stage 7 and performed consistently for a period 
of 3 days.  Training to criterion took approximately 50 – 60 sessions. 
 
Table 2.3: Description of the 5-CSRTT training schedule 
Training 
Stage 
Stimulus Duration 
(SD) 
Limited Hold (LH) Inter-trial Interval 
(ITI) 
Criterion to move 
to the next stage 
0 
1 
2 
3 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
120 
30 
20 
10 
 
5 
 
 
2.5 
 
 
1.25 
 
 
1 
 
30 
20 
20 
10 
 
5 
 
 
5 
 
 
5 
 
 
5 
 
2 
2 
2 
5 
 
5 
 
 
5 
 
 
5 
 
 
5 
 
> 30 Trials 
> 30 Trials 
> 30 Trials 
> 50 Trials 
> 50 Trials 
>80% Accuracy 
< 20% Omissions 
> 50 Trials 
> 80% Accuracy 
< 20% Omissions 
> 50 Trials 
> 80% Accuracy 
< 20% Omissions 
> 50 Trials 
> 80% Accuracy 
< 20% Omissions 
Summary of 5-CSRTT training schedule used in chapter 7.  All durations shown are measured in seconds. 
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Below is a summary of the response sequence used within the University of Cambridge (fig 
2.4), describing the possible response outcomes of the 5-CSRTT.  Although it is largely similar 
to the previous methods (used in Chapter 3), one important difference exists; following a 
premature response the animal had to initiate the subsequent trial following the TO period 
and therefore a premature response was counted as a trial.  Additionally, while perseverative 
responding was recorded, they did not initiate a 5 s TO period. 
 
Fig 2.4.  A schematic summary of the response sequence used in the 5-CSRTT described in detail above.  Image 
adapted from Bari et al. 2008. 
 
2.6 Five-Choice Continuous Performance Test (5C-CPT) 
2.6.1 Behavioural Procedure 
The 5C-CPT is similar in some aspects to the 5-CSRTT which is described in detail above.  
However, a number of differences in the methodology exist.  Instead of a fixed ITI of 5 s 
described previously, chapters 4, 5, and 6 utilised a variable ITI (4.0, 4.5, 5.5, and 6.0 s) which 
had a mean of 5 s throughout training.  The variable ITI was implemented in order to 
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minimise a temporally mediated strategy being used by the rats’ when responding during the 
session (Spratt et al. 2000).  The 5C-CPT encompasses the measures typically generated by 
the original 5-CSRTT and correct responses result in a reward being delivered, whilst 
incorrect responding initiates a TO.  Responses made during the TO period restarted the 5 s 
TO period and were recorded as time out responses.  
Importantly, the 5C-CPT procedure also included no-go trial stimuli in which lights in all 
apertures are presented, signifying that the animal must inhibit responding (correct 
rejection) in order to obtain a reward (fig 2.5).  An incorrect response made during non-
target trials (either during the stimulus presentation or during the LH period) was recorded 
as a false alarm and resulted in a TO period.  In a similar manner to 5-CSRTT training, 
presentation of target and non-target stimuli was banked and presented in a pseudo-random 
order throughout the session.  Details of the ratio of stimuli presentation can be found below 
(section 2.6.3).  The session consisted of 120 trials, lasting no more than 30 minutes.  Table 
2.4 describes the additional behavioural measures assessed by the 5C-CPT.  
 
Table 2.4 Description of the behavioural measures used in the 5C-CPT 
Measure & Description 
Correct Rejections: Correctly withheld /(correct rejections + false alarms)*100 – a measure of 
correct rejection of no-go trials 
Hit rate, p[HR]: The proportion of target trials correctly detected 
False alarm rate, p[FA]: The proportion of non-target trials incorrectly responded to: to assess 
response disinhibition 
Sensitivity index, SI: Non-parametric measure of the ability to discriminate between target and 
non-target trials – a measure of vigilance 
Responsivity index, RI: Non-parametric measure of the response bias or strategy of the animal 
Summary of additional measures available in the 5C-CPT.   
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Fig 2.5. Schematic diagram of the two trial types presented within the session of the 5C-CPT and the correct 
action required.  Image taken from Young et al 2009b. 
 
2.6.2 Signal Detection Theory 
The following describes the methods used to calculate the non-parametric indices used in 
signal detection theory (SDT) as originally described by Frey and Colliver (1973) and also used 
in the mouse 5C-CPT (Young et al. 2009b).  Human CPTs utilise parametric indices (d’ and β – 
described in detail in chapter 4), however they require assumption to be made regarding 
data distribution and normality.  As a result, non-parametric equivalents of d’ and β (SI and 
RI, respectively) described by Frey and Colliver (1973) have been implemented.  Correct, 
incorrect and omissions refer to possible response outcomes when presented with a target 
trial, FA (false alarm) indicates an incorrect response to non-target trial and CR (correct 
rejection) refers to a correct rejection of non-target trial:     
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Similar to human CPT studies regarding the calculation of d’, if the values for CR or FA were 
equal to zero than the following corrections were used prior to the calculation of SI or RI. 
2.6.2.1 Calculation Correction: 
2
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2.6.3 Training Schedule 
Training was conducted in a similar manner to the original 5-CSRTT (section 2.5.1), with the 
following exceptions.  The modified task included non-target trials, whereby all apertures 
presented a visual stimulus and the reward pellet was dispensed following a correct 
rejection.  Initially, methods followed the same protocol set out in the original mouse version 
of the 5C-CPT (Young et al. 2009b).  As such, the session consisted of 100 target trials and 20 
non-target trials, presented pseudorandomly throughout the session.  However, with this 
parameter configuration rats were unable to differentiate between trial types and responded 
to the majority of non-target trials presented within the session (described in chapter 4).  
Therefore, it was required to place a greater emphasis on the presentation of non-target 
Chapter 2                                                                                                                       General Methods 
59 
trials, therefore the proportion per session was increased (77 target trials and 43 non-target 
trials).  This configuration was used until rats could correctly respond to target trials and 
inhibit a response to non-target trials.  Once rats were able to reliably discriminate between 
trial types (p[HR] > p[FA] – approximately 14 weeks), the proportion of target trials per 
session was increased to 84 and non-target trials reduced to 36, a configuration used 
throughout the remainder of training and testing.  At the beginning of training the SD was 10 
s (for both target and non-target trials) and was progressively reduced (10, 8, 4, and 2 s) for 
individual rats as they reached criterion (>75% accuracy, <25% omission and >65% correct 
rejections of non-target trials, for three consecutive days).  Training was conducted until 
animals achieved a stable performance at the desired testing parameters (chapter 4, SD = 1.5 
s and chapters 5 and 6 SD = 1 s, for all chapters a 5 s TO, variable ITI with mean of 5 s and 2 s 
LH was used unless otherwise stated) over three consecutive days.  Animals took 
approximately 14 weeks to reliably discriminate between trial types, and a further 6 – 10 
weeks to reach stable performance at the desired testing criteria.  The entire training 
procedure took approximately 20 – 24 weeks. 
 
2.7 Data Analysis 
All data are expressed as mean + SEM and graphically displayed using Graphpad Prism (v5).  
Statisitcal analysis was carried out using Statsoft Statistica (v6) with alpha level set to 0.05.  
The distribution of data was checked using normality plots.  Any deviation of normality 
resulted in the transformation of data prior to analysis.  Percentage data underwent arc-sin 
transformation, latencies were log transformed and inappropriate responding data were 
subject to square root transformation, when appropriate (Hahn et al. 2002); however raw 
data were graphically displayed.  Specific information regarding the statistical design and 
approach for each analysis used are described in the methods section of each experimental 
chapter. 
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Chapter 3 
 
Assessment of attentional processing using the 5-Choice Serial Reaction 
Time Task: Disruptive effects of psychotomimetics 
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3.1 Introduction 
As discussed previously, the 5-choice serial reaction time task (5-CSRTT) is a common 
preclinical task assessing attentional processing (Bari et al. 2008), suggested to share many 
features with human attentional tasks, namely the continuous performance test (CPT).  
Construct validity of the 5-CSRTT as a task of attention has been demonstrated (Robbins 
2002).  The 5-CSRTT is a complex paradigm that can record a number of different behavioural 
measures, which may be controlled by a variety of cognitive processes, not just attentional 
processing. 
Response accuracy in this task is largely dependent on the attentiveness of the experimental 
animal, with deficits resulting in the animal being unable to sustain its attention or divide it 
across the spatial apertures.  This may result in the target stimulus not being detected, and 
consequently the animal may respond by ‘guessing’ and perhaps guessing incorrectly, thus 
responding in an incorrect aperture and reducing response accuracy (Young et al. 2009a).  
Spratt and colleges (2000) confirmed this theory.  The group had modified the basic 
configuration of the 5-CSRTT and during discrete trials throughout the session withholding a 
response when no stimulus was presented earned a food reward.  It was revealed that rats 
responded to approximately 90% of no stimulus light conditions.  These findings suggested 
that perhaps the rats were responding based on a temporally mediated response strategy, 
nose-poking even if a visual stimulus had not been detected but following the elapse of the 
ITI.  Another consequence of impairment in attentional function may be an increase in the 
number of error of omissions (Amitai and Markou, 2010).  If the test subject is failing to 
attend to the task and continually misses the visual stimulus presentation and fails to elicit a 
response, the result will be an increase in the number of missed trials, particularly if the 
animal is not adopting the ‘guessing’ strategy.  Coupled with the increase in omissions being 
recorded, a reduction in the number of correct responses being made is likely. 
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Another collection of behavioural measures assessed by the 5-CSRTT includes response 
latencies, consisting of the correct latency (CL), incorrect latency (IL) and magazine latency 
(ML).  The latency measures can be interpreted in a number of ways and depends largely on 
the pattern of response of not only each of the latencies, but also the other behavioural 
measures (Robbins, 2002).  Firstly, response latencies are suggested to provide a measure of 
speed of informational processing.  An increase in the CL may be indicative of a reduced 
ability of the rodent to process information that the visual stimulus has been presented and 
therefore a response must be made.  However, this interpretation (as with others) must be 
made in conjunction with other behavioural measures being taken into account (Robbins, 
2002; Amitai and Markou, 2010), as an increase in CL, caused by pharmacological treatment, 
may be a result of altered motivation to complete the task or motor impairment instead.  
This can usually be determined by observing the ML.  Impairment in motivation or motor 
function is likely to be coupled with an increase in the time taken for the rodent to retrieve 
the food reward, and therefore an increase in magazine latency would be observed (Robbins, 
2002; Chudasama and Robbins, 2004a).  Similarly, it has been suggested that when an 
increase in omissions is accompanied by an increase in magazine latency, the likely reason for 
increased omissions is probably due to some form of motor impairment and not attentional 
impairment as previously discussed (Chudasama and Robbins, 2004a).  However, if the 
increase in the number of omissions is not associated with an increase in the time taken to 
retrieve the food reward, the explanation is more likely due to impairment in attentional 
function (Amitai and Markou 2010).  These considerations demonstrate an important factor 
concerning understanding of 5-CSRTT performance.  Any interpretation of the effects of drug 
treatment or parameter manipulation on the ability to conduct the task must be made when 
all behavioural parameters (and how they are affected) have been taken into consideration, 
and not based on behavioural measures observed in isolation (Robbins, 2002; Chudasama 
and Robbins, 2004a; Amitai and Markou, 2010). 
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Another area of cognition that the 5-choice task can assess is behavioural inhibition and 
inappropriate responding, in the form of premature or perseverative responding, which is 
known as response inhibitory control (Robbins, 2002).  Premature responses are the result of 
a response being made during the ITI, before the visual stimulus has been presented.  
Premature responses occur when the rat is most likely anticipating the presentation of the 
visual stimulus, therefore the number of premature responses increases when there is 
impairment in the animal’s ability to withhold a highly prepotent response and thus it 
responds inappropriately.  As a result, this type of inappropriate responding is suggested to 
be indicative of impulsive behaviour.  Deficits in impulse control are often observed in 
various psychiatric disorders, including schizophrenia (Kiehl et al. 2000; Weibrod et al. 2000; 
Wykes et al. 2000).  Perseverative responses represent another form of inhibitory 
impairment, which manifests itself by the repetitive over-responding of a previously 
rewarded behaviour.  Perseverative responding involves the rat repeatedly nose poking a 
response aperture, even following the delivery of the food reward.  This type of behaviour is 
an inhibitory impairment in the form that the rodent cannot disengage from the behaviour 
once initiated, representative of compulsive behaviour (Robbins, 2002).  Thus, along with the 
obvious attentional component, aspects of impulsivity, compulsivity and speed of 
information processing are also involved in successful task performance, areas of cognition 
that are also suggested to be affected in schizophrenia (American Psychiatric Association 
1989, p 1217; Riedel et al. 2006; Young et al. 2009a). 
Previous work within our laboratory has established several behavioural paradigms that 
measure the ability of rodents to perform cognitive tasks of relevance to schizophrenia (see 
Neill et al. 2010 for review).  They include novel object recognition (Grayson et al. 2007), 
attentional set-shifting (McLean et al. 2009a), reversal learning (McLean et al. 2009b) and 
social cognition, in the form of social interaction (Snigdha and Neill, 2008); all of which reflect 
preclinical paradigms assessing cognitive domains putatively core to the cognitive deficits 
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observed in schizophrenia (Neuctherlein et al. 2004; Young et al. 2009a).  As these paradigms 
have the potential of quantifying aspects of cognitive disruption, they provide a means of 
screening potential pro-cognitive agents.  Therefore, they may assist in the elucidation of 
neurobiological mechanisms involved in cognitive disruption and may direct research 
ultimately leading to the attenuation of cognitive impairment of schizophrenia.  In these 
paradigms, sub-chronic treatment with the NMDA antagonist, PCP, results in cognitive 
deficits and an inability to perform the task compared to control animals, lending further 
support that a dysfunctional glutamatergic system may be involved in the emergence of the 
cognitive impairments present in schizophrenia (Olney and Faber 1995; Olney et al. 1999; 
Goff and Coyle 2001). 
The aim of this experimental chapter was to identify the possibility of establishing the 5-
CSRTT in female rats at the University of Bradford as a model assessing attentional 
processing.  This would enable the suitability of inducing attentional impairments via NMDA 
receptor blockade to be determined, which may have clinical relevance to the cognitive 
impairments seen in schizophrenia.  Previous investigations have been carried out following 
administration of NMDA antagonists and the 5-CSRTT; however, all were conducted using an 
acute or repeated dosing regime in male rats.  Therefore, the primary aim was to establish 
whether female rats can be trained to perform the task to a similar level of performance as 
male subjects.  More importantly the ability to induce persistent impairments in task 
performance following a sub-chronic PCP treatment regime in the drug-free state was to be 
determined.  Finally, the effect of an acute challenge of PCP or amphetamine on task 
performance was assessed. 
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3.2. Methods 
3.2.1 Subjects 
50 female hooded-Lister rats (Charles River; approximately 250g (+ 10g) at the start of 
training were used in the experiments described in this chapter.  Information regarding the 
housing conditions, food restriction and ethical guidelines can be found in chapter 2. 
 
3.2.2 Training and Behavioural Procedure 
Details regarding the 5-CSRTT behavioural procedure and how the animals were trained in 
order to acquire the task are described in the general methods section (Chapter 2). 
 
3.2.3 Drugs 
3.2.3.1 Sub-chronic PCP treatment regime 
Once fully trained in 5-CSRTT, rats were sub-chronically treated with either vehicle (0.9% 
saline, n = 10) or PCP (2 mg/kg, n = 40).  The dosing regimen consisted of one dose in the 
morning (approx 9 am) followed by one dose in the afternoon (approx 5 pm) for 7-days.  The 
7-days twice-daily treatment regimen was followed by a 7-day washout period.  During the 
treatment period animals received no training or testing.  Following the 7-day washout 
period, testing in the 5-CSRTT commenced.   
 
3.2.3.2 Acute Psychotomimetic Challenge 
Acute challenge treatment (described in section 3.2.6) consisted of an acute challenge of 
drug with a 30-minute pre-treatment time.  Behavioural testing commenced immediately 
after the pre-treatment time. 
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3.2.4 Effect of sub-chronic PCP treatment on 5-CSRTT performances 
Following completion of the sub-chronic PCP treatment regimen, 5-CSRTT performance was 
assessed under conditions of standard attentional load.  5-CSRTT testing parameters 
consisted of 1 s SD, 5 s ITI, 5 s TO and 5 s LH. Additionally, performance was assessed when 
attentional load was increased, by reducing the SD to 0.5 s (summarised in table 3.1).  All 
other parameters remained constant.  This was designed to further tax attentional 
performance without altering the basic methodology of the task. 
 
3.2.5 Effects of protocol change on performance in the 5-CSRTT 
Modifications to basic 5-CSRTT protocols were design to further tax attentional performance 
(table 3.1). Challenge sessions consisted of altered ITI (increased or decreased) with a SD of 
0.5 s.  TO and LH durations were 5 s throughout.   Challenge sessions were conducted on 
Wednesdays and Fridays, and interspersed with sessions consisting of standard protocols (1 s 
SD, 5 s ITI, 5 s TO, 5 s LH). 
 
Table 3.1 Summary of behavioural manipulations used to challenge 5-CSRTT performance 
Challenge Effect 
Reducing Stimulus-Duration 
 
 
Reducing Inter-trial Interval 
 
 
Increasing Inter-trial Interval 
Taxes attentional capabilities due to the increased difficulty 
in target stimulus detection 
 
Increases the event-rate and taxes attentional processing 
due to the continuous allocation of attentional resources 
 
Increases the duration between stimulus-onset reducing the 
event-rate, placing demands on attention and impulse 
control 
Description of task interventions used and the effect on performance 
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3.2.6 Effects of acute challenge of psychotomimetics on rat performance in 5-CSRTT 
Effects of acute psychotomimetic challenge were investigated.  Administration of either 
amphetamine or PCP conformed to a Latin square design.  Experiments were conducted 
Monday – Friday over a course of two weeks.  Animas were allocated into two treatment 
groups with all receiving vehicle (0.9% saline, i.p.) on Monday, Wednesday and Friday.  
Depending on treatment group, on Tuesday and Thursday, animals were treated with vehicle 
(0.9% saline, i.p.), PCP (1.5, 2.0, 2.5 mg/kg, i.p) or amphetamine (0.25, 0.5, 0.75 mg/kg, i.p), 
according to the Latin square design.  The doses of PCP and amphetamine were chosen 
based on previous findings in our laboratory in various cognitive tasks (Idris et al. 2005; 
McLean et al. 2010), in which impairment in rodent’s performance was produced using 
similar doses.  The testing parameters on treatment days were 0.25 s SD, 5 s ITI, 5 s TO and 5 
s LH. 
 
3.2.7 Data Analysis 
All data are expressed as mean + S.E.M.  Analysis of the effect of sub-chronic PCP treatment 
on 5-CSRTT performance was conducted by an unpaired Students t-test.  Analysis of acute 
psychotomimetic challenge of 5-CSRTT performance was conducted by a mixed-model 
analysis with Treatment as fixed factor and animal as a random effect, followed by Planned 
Comparisons (Snedecor and Cochran, 1989). This allowed a reduction of variability by 
utilising within-subjects analysis, resulting in an increased statistical power (Simon Bate, 
personal communication).  
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3.3. Results 
3.3.1.1 Effect of sub-chronic PCP treatment on 5-CSRTT performance 
Sub-chronic PCP treatment had no impact on animal baseline animal performance.  Response 
accuracy (t = 1.04, NS), percent correct (t = 0.28, NS) and percent omission (t = 0.98, NS) 
showed no significant difference (fig 3.1A).  Likewise, CL (t = 0.34, NS), IL (t = 1.56, NS), ML (t 
= 1.08, NS) were also unaffected (fig 3.1B).  The number of trials completed was similarly 
unaffected (t = 1.05, NS) as was premature responding (t = 0.39, NS).  A trend towards a PCP-
induced increase in perseverative responding was observed, but the increase lacked 
statistical significance (t=1.68, p = 0.09) (fig 3.1C). 
Fig 3.1 The effect of sub-chronic PCP treatment on baseline behavioural performance.  Data are expressed as 
mean + SEM for vehicle (n = 8) and PCP (n = 8) treated animals.  Measures assessed include attentional 
performance (A), response latencies (B) and response profile (C).  
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3.3.1.2 Reduction of Stimulus Duration 
A reduction of SD from 1 s to 0.5 s impaired 5-CSRTT performance (table 3.2), indicating an 
increase in attentional load.  Accuracy was significantly reduced (t = 3.68, p<0.01), as was 
percent correct responding (t = 4.08, p<0.01).  Omissions was significantly increased (t = 2.24, 
p<0.05).   No effect on CL was observed (t = 0.6, NS), but IL was significantly elevated (t = 
3.29, p<0.01) independent of ML alterations (t = 1.10, NS).  The number of trials was 
unaffected (t = 1.17, NS), in addition to premature (t = 0.76) and perseverative responding (t 
= 0.48, NS). 
 
Table 3.2 Effect of reduced SD in saline treated animals 
Measure 1 s SD            0.5 s SD 
Accuracy (%) 95.62 + 1.56 
 
83.12 + 2.82  ** 
 
Correct (%) 83.00 + 2.29 
 
66.55 + 3.16  ** 
 
Omission (%) 13.16 + 2.15 
 
20.03 +  2.21  * 
 
Correct Latency (s) 0.61 + 0.04 
 
0.57 + 0.03 
 
Incorrect Latency (s) 0.91 + 0.24 
 
1.75 + 0.12  ** 
 
Magazine Latency (s) 3.48 + 0.87 
 
2.51 + 0.32 
 
Trials 100.00 + 0.00 
 
98.1 + 1.31 
 
Perseverative Response 15.33 + 4.06 
 
19.14 + 3.09 
 
Premature Response 22.50 + 3.87 
 
25.85 + 5.61 
 
                   Comparisons between long (1 s) and short (0.5 s) stimulus duration (n = 8) 
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While the reduced SD resulted in performance impairment, a PCP-induced deficit was not 
evident (fig 3.2A).  No differences in accuracy (t = 0.73, NS), percent correct (t = 0.17, NS) and 
percent omissions (t = 0.9, NS) were observed between treatment groups.  Additionally, CL (t 
= 1.16, NS), IL (T = 0.9, NS) and ML (t = 1.12, NS) were also unaffected (fig 3.2B).  
Furthermore, no change in trials completed (t = 1.8, NS), premature responding (t = 0.5, NS) 
or perseverative responding (t = 1.24, NS) was observed (fig 3.2C).   
 
Fig 3.2 The effect of sub-chronic PCP (n = 8) treatment compared to vehicle (n = 8) treatment in the 5-choice task 
when the attentional load was increased by reducing the stimulus duration to 0.5s. Data are expressed as mean + 
SEM.  Measures assessed include attentional performance (A), response latencies (B) and response profile (C). 
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3.3.2 Effects of task interventions on rat performance in 5-CSRTT 
3.3.2.1 Increased Event-Rate 
An increased event-rate revealed a PCP-induced attentional impairment.  Accuracy was 
significantly reduced in PCP-treated animals (t = 2.64, p<0.05) (fig 3.3A).  This occurred 
without an effect on percent responding (t = 1.11, NS) or percent omissions (t = 0.09, NS).  
Furthermore, PCP-treatment had no effect on CL (t = 0.27, NS), IL (t = 0.23, NS) or ML (t = 
0.53, NS) (fig 3.3B).  Likewise, trials competed (t = 0.14, NS), premature (t = 1.03, NS) and 
perseverative responding (t = 0.89, NS) were all insensitive to a PCP-induced alteration 
(fig3.3C).  
 
Fig 3.3A: The effect of sub-chronic PCP treatment (n = 8) compared to vehicle treated animals (n = 8) in the 5-
choice task when challenged by reducing the ITI from 5 seconds to 2 seconds. Data expressed as mean + SEM and 
analysed by unpaired Student’s t-test (* p<0.05 reduction in accuracy when PCP was compared to the Veh group). 
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A repeat of the increased event-rate challenge also demonstrated attentional impairment.  
However, accuracy was unaffected (t = 0.2, NS).  Instead a reduction in correct responding (t 
= 2.45, p<0.05) and an increase in omission (t = 2.45, p<0.05) was observed (fig 3.4A).  
Consistent with the previous exposure to the increased event-rate challenge, no treatment 
effect was observed in CL (t = 0.57, NS), IL (t = 0.41, NS) and ML (t = 0.11, NS) (fig 3.4B).  
Additionally, PCP-treatment had no effect on trials completed (t = 1.61, NS), premature (t = 
1.36, NS) or perseverative responding (t = 0.51, NS) (fig 3.4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.4A: In a repeated experiment where the ITI was again 2 seconds, PCP (n = 8) produced a significant 
difference in percent correct and percent omission compared to vehicle animals (n = 7). Data are expressed as 
mean + SEM and analysed by unpaired Student’s t test.  Percent correct responding was significantly reduced and 
percent omissions was significantly increased (* = p<0.05, PCP compared to the Veh group). 
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3.3.2.2 Reduced Event-Rate 
Sub-chronic PCP treatment had no effect when the event rate was reduced, by increasing the 
ITI.  The lack of effect on accuracy (t = 0.54, NS), percent correct (t = 0.08, NS) and omissions 
(t = 0.72, NS) suggest no PCP-induced attentional impairment (fig 3.5A).  Additionally, no 
effect on CL (t = 0.85, NS), IL (t = 0.34, NS) or ML (t = 0.51, NS) was evident (fig 3.5B).  
Furthermore, there was no treatment effect on trials completed (t = 0.17, NS), premature 
responding (t = 0.32, NS) or perseverative responding (t = 0.29, NS) (fig 3.5C). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.5A, B and C: The effect of sub-chronic PCP treatment (n = 8) and vehicle treatment (n = 7) in the 5-choice 
task when animals were challenged by increasing the ITI from 5 to 6 seconds. Data are expressed as mean + SEM 
and analysed by unpaired Student’s t test. 
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3.3.3 Effects of acute challenge with psychotomimetics on rat performance in 5-CSRTT 
3.3.3.1 Amphetamine 
The following two experiments utilised a Latin square design in which each animal received 
each dose and acted as its own control.  Analysis showed that amphetamine (fig 3.6A) caused 
a significant reduction in accuracy [F(3, 19)=3.74, p<0.05].  Planned Comparisons revealed the 
highest dose (0.75 mg/kg) of amphetamine significantly reduced accuracy (p<0.01).  
Additionally, amphetamine reduced percent correct responding [F(3, 19)=6.02, p<0.01].   
Planned Comparisons demonstrated only the highest dose of amphetamine produced a 
significant reduction of percent correct responding (p<0.01).  Amphetamine also produced a 
significant increase in the number of error of omissions [F(3, 19)=5.46, p<0.01], however 
Planned Comparisons showed that only the lowest dose (0.25mg.kg) of amphetamine 
produced a significant effect (p<0.05).  Amphetamine treatment (fig 3.6B) had no significant 
effect on correct latency [F(3, 19)=1.41, NS].  Initial analysis of incorrect latency resulted in a 
strong trend towards a significant reduction [F(3,, 19)=2.60, p=0.06].  Planned Comparisons 
demonstrated that all amphetamine doses significantly reduced incorrect latency (p<0.05).  
Analysis of the effect of amphetamine on magazine latency (fig 3.6B) revealed a strong trend 
towards a significant effect [F(3, 19)=2.58, p=0.06].  Planned Comparisons showed that 0.5 
mg/kg and 0.75 mg/kg significantly increased magazine latency (p<0.05).  Amphetamine 
treatment produced a significant reduction (fig 3.6C) in the number of trials completed [F(3, 
19)=12.97, p<0.001].  Further analysis revealed that amphetamine (0.5 mg/kg and 0.75 mg/kg) 
resulted in a significant reduction in completed trials (p<0.001).  Amphetamine treatment 
produced a significant increase in the number of premature responses (fig 3.6C) [F(3, 
19)=10.36, p<0.001].  Planned Comparisons revealed that all three doses of amphetamine 
produced a significant increase in premature responding (p<0.001).  Amphetamine also 
produced a significant increase in the level of perseverative responding [F(3, 19)=8.29, 
p<0.001].  Following Planned Comparisons, it was revealed that all three doses of 
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amphetamine produced a significant increase in perseverative responding (p<0.001) (fig 
3.6C). 
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Fig 3.6A Acute amphetamine (n = 20) treatment (0.75 mg/kg i.p.) produced a significant reduction in accuracy and 
percent responding.  The dose of 0.25 mg/kg produced a significant reduction in percent omissions B; 
Amphetamine resulted in a significant reduction in incorrect latency (0.25 – 0.75 mg/kg).  Amphetamine also 
increased magazine latency (0.5 – 0.75 mg/kg). C; Amphetamine reduced the number of trials completed (0.5 – 
0.75 mg/kg) and also significantly increased the number of premature and perseverative responses.  Data 
expressed as mean + SEM.  * = p<0.05, ** = p<0.01, *** = p<0.001 significantly different from Veh group. 
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3.3.3.2 PCP 
Acute PCP treatment produced a significant reduction in accuracy [F(3, 19)=8.89, p<0.001].  
Following Planned Comparisons it was evident that only the two higher doses of PCP resulted 
in a significant reduction in accuracy (p<0.01 and p<0.001, respectively) (fig 3.7A).   PCP also 
produced a highly significant effect on percent correct responding [F(3, 19)=14.61, p<0.001].  As 
with accuracy, Planned Comparisons showed that it was only the two highest doses that 
produced a significant reduction in percent correct responding (p<0.01 and p<0.001, 
respectively) (fig 3.7A).  Acute PCP treatment also produced a significant increase in the 
number of error of omissions [F(3, 19)=12.28, p<0.001].  Planned Comparisons demonstrated 
that only 2.0 mg/kg and 2.5 mg/kg PCP produced significant increases in omissions (p<0.05 
and p<0.001, respectively).  Statistical analysis showed that PCP had a significant effect on 
correct latency [F(3, 19)=6.34, p<0.01].  Only the highest dose of PCP (2.5 mg/kg) produced a 
significant increase in correct latency (p<0.001) (fig 3.7B).  PCP also produced a significant 
effect on incorrect latency [F(3, 19) = 5.22; p<0.01].  Planned Comparisons also indicated PCP 
treatment only produced a significant effect at the highest dose (p<0.01) (fig 3.7B).  Initial 
analysis suggested that PCP treatment did not affect magazine latency [F(3, 19)=1.84, p=0.15].  
However, Planned Comparisons demonstrated that the highest dose of PCP (2.5 mg/kg) 
produced a significant increase in magazine latency (p<0.05) (fig 3.7B).  PCP produced a 
significant reduction in the number of trials completed [F(3, 19) = 13.35, p<0.001].  It was 
demonstrated the two higher doses of PCP caused a significant reduction in trials completed 
(p<0.01 and p<0.001, respectively) (fig 3.7C).  Additionally, a significant increase in premature 
responding was evident [F(3, 19)=5.05, p<0.01].  Planned Comparisons revealed that all three 
doses of PCP produced a significant increase (p<0.05 and p<0.01) (fig 3.7C).   
A strong trend towards an increase in perseverative responding was observed [F(3, 19)=2.44, 
p=0.07].  However, Planned Comparisons showed all three doses of PCP produced a 
significant increase in perseverative responding (p<0.05) (fig 3.7C). 
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Fig 3.7A; Acute PCP (n = 20) treatment (2.0 – 2.5 mg/kg) reduced accuracy, percent correct and increased percent 
missed. B; Data show that acute PCP (2.5 mg/kg i.p.) caused a significant increase in correct latency, incorrect 
latency and magazine latency. C; PCP (2.0 – 2.5 mg/kg i.p.) reduced the number of trials completed. Premature 
and perseverative responding was increased as a result of PCP treatment (1.5 – 2.5 mg/kg). Data expressed as 
mean + SEM.  * = p<0.05, ** = p<0.01, *** = p<0.001 significantly different from Veh group. 
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3.4. Discussion 
The primary aim of this chapter was to establish the 5-choice task serial reaction time task in 
female rats as a method of assessing the multifaceted cognitive construct of attention.  
Secondary to this aim, the effects of sub-chronic PCP treatment were investigated in this 
paradigm for its ability to disrupt successful performance of the task and identify whether 
sub-chronic exposure to PCP disrupted attentional processing.  Finally, the effect of an acute 
challenge of PCP or amphetamine on the ability of the animal to perform the 5-CSRTT was 
investigated. 
 
One of the primary aims of this chapter was to establish and validate the 5-Choice Serial 
Reaction Time Task (5-CSRTT) at University of Bradford.  The first experiment demonstrated 
that female Lister-hooded rats can be trained in the 5-CSRTT to a predetermined criteria 
(>80% correct responding, <20% omissions), which is the general accepted level of training 
suggested by previous experiments (Grottick and Higgins 2000; Higgins et al. 2005; Murphy 
et al. 2005).  This level of performance is well above chance performance of 20% correct 
responding (Robbins, 2002).  The secondary aim of the experiments within this chapter was 
to determine the effects sub-chronic PCP treatment had on the animals’ performance in the 
task.  Data demonstrated that sub-chronic PCP treatment failed to induce a performance 
deficit in the 5-CSRTT, when animals were tested using the same criteria that they were 
trained to.  The lack of PCP-induced impairment was still evident when the attentional load 
of the task was increased by reducing the stimulus duration (SD).  The reduction in SD did 
increase the difficulty of the task, as evidenced by the impaired performance in control 
animals.  However, it is possible that the stimulus duration was not reduced enough, with a 
further reduction potentially revealing a PCP-induced impairment.  Previous studies have 
used either a 1 or 0.5 s SD for standard testing (Mirza and Stolerman, 1998; Grannon et al. 
2000; Dalley et al. 2001; Fletcher et al. 2007; Young et al. 2007).  Therefore, if the SD was 
Chapter 3                             PCP and the 5-CSRTT 
79 
reduced beyond 0.5 s (e.g. 0.25 or 0.125 s), stimulus detection is made more difficult further 
testing the animal’s attentional capacity, with the potential consequence of PCP treated 
animals having an increased inability in target detection compared to control animals.  
Testing under these conditions may have revealed a more robust PCP-induced impairment.  
 
In light of these observations, the next stage was to challenge performance by introducing 
parameter manipulations.  When the ITI was reduced, thus increasing the event rate and 
increasing the attentional load of the task (Parasuraman, 1998), PCP treated rats had a small, 
yet significant impairment in a number of attentional measures.  A reduction in accuracy was 
evident.  This effect is suggestive of an impairment in attentional processing, resulting in a 
reduced ability to detect and correctly report the occurrence of the visual stimulus.  As a 
result, the implementation of a guessing strategy (detailed in the introduction) is possible, 
which increases the likelihood of incorrect responding, reducing the choice accuracy.  When 
the reduced ITI challenge was repeated, to determine the reproducibility of the impairment, 
there was a different outcome.  The reduction in accuracy disappeared, however this was 
replaced by a reduction in percent correct responding and an increase in omission.  The 
interpretation of attentional dysfunction resulting in an increase in omissions (Risbrough et 
al. 2002; Young et al. 2004; Cordova et al. 2006) is supported by the lack of a concomitant 
increase in magazine latency.  If the time to retrieve the food reward was elevated, it is 
suggestive of reduced motivation which would confound interpretation of attentional 
dysfunction.  As these effects occurred without alterations in response latencies they can be 
interpreted as a reduction in attentional capabilities (Amitai and Markou, 2010).   
 
The alteration in effects observed may have been due to the fact animals had been exposed 
to this behavioural challenge once before and thus an element of learning had taken place.  
Animals may have modified their strategy in light of the repeated exposure to the same 
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challenge and so were not simply guessing (and guessing incorrectly) when they failed to 
detect the target stimulus, hence the lack of effect on response accuracy.  However, as their 
attentional capabilities were still compromised following this challenge, this resulted in the 
increased number of trials being omitted (which also reduced the number of correct 
response being made). 
 
When the ITI was increased it was hypothesised that the reduction in event rate would make 
the task sensitive to aspects of behavioural disinhibition and would reveal if PCP treatment 
induced impulse control impairments.  While there was an increase in the baseline level of 
premature responding (a well characterized measure of impulsivity), the elevated level of 
premature responding was not significantly affected by PCP treatment.  This, therefore 
suggests, that the form of impulsivity assessed by premature responses is not sensitive to 
disruption via sub-chronic exposure to NMDA receptor antagonists in the drug-free state. 
Sub-chronic PCP treatment produced significant impairments in performance, albeit only 
subtle deficits, when the parameters were altered that are reminiscent of the results 
produced by some lesion studies.  Carli and colleagues (1983) lesioned the ascending 
noradrenergic fibres arising from the locus coerulus (the dorsal noradrenergic bundle, DNAB) 
using 6-hydroxydopamine (6-OHDA), in rats that were fully trained in the task. Initially there 
was no impairment in the rats’ ability to perform the task.  However, when the ITI was 
reduced, this resulted in a significant reduction in choice accuracy which was not present 
when rats were test under baseline conditions.  Carli and colleagues (1983) also examined 
the effect of interpolating bursts of white noise with the presentation of the stimulus, which 
resulted in a reduction in choice accuracy and an increase in percent omissions, indicating 
attentional impairment in the DNAB lesioned animals.   
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One main limitation of this experiment was the assumption that sub-chronic PCP treatment 
would induce impairment in 5-CSRTT performance.  Task performance relies heavily on PFC 
function, demonstrated by impaired performance following discrete lesion of this region 
(Muir et al. 1996), an area that is densely populated with NMDA receptors (Cotman & 
Iversen, 1987; Ulus et al. 1992).  It has been demonstrated that acute and repeated PCP 
treatment induced deficits in 5-CSRTT performance (Amitai et al. 2007).  In light of this, it was 
therefore hypothesised that performance in the 5-CSRTT would also be sensitive to 
disruption via sub-chronic PCP treatment.  Another task that requires the PFC for successful 
performance is the attentional set-shifting task (Birrell & Brown, 2000), and previous 
investigations have demonstrated that performance within this task is disrupted via sub-
chronic PCP administration (Rodefer et al. 2005; Rodefer et al. 2008; McLean et al. 2008; 
Broberg et al. 2009; McLean et al. 2009).  These findings suggest PCP treatment may induce 
long-term changes that compromise the functioning of the PFC, impairing task performance 
in paradigms associated with this brain region. 
 
When animals were exposed to acute doses of psychotomimetic drugs, there was a 
pronounced effect on task performance.  When rats received an acute dose of PCP (1.5 – 2.5 
mg/kg) there was a significant impairment in performance, demonstrated by attentional 
dysfunction, behavioural disinhibition, and at the highest dose, an increase in response 
latencies.  Acute PCP (2.0 – 2.5 mg/kg) resulted in a significant reduction in accuracy, percent 
correct responding and increased percent omissions.  These findings alone would suggest a 
generalised impairment in attentional capabilities, suggestive of an inability of the rat to 
sustain and divide attention (Robbins 2002).  However when the highest dose (2.5 mg/kg) 
was administered, the deficits in attentional measures were accompanied by a significant 
increase in all of the response latencies measured.  The effect on response latencies make 
interpretation difficult, as the inability to perform the task may have been the result of a 
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generalised performance deficit induced by motoric or motivational dysfunction (Robbins 
2002).  It should be noted that the treatment regimen followed a Latin square design and 
thus, each animal acted as its own control.  Whilst increasing the statistical power, this 
design is not truly acute administration as each animal received multiple injections of PCP.  
Consequently, the pronounced behavioural disrupted effects (discussed in detail in Chapter 
5) of a true acute dose of PCP may have been avoided as the treatment regimen used is 
technically repeated administration (Amitai and Markou, 2010).  Therefore, the motoric or 
motivational disruption may not have been apparent with the lower PCP doses. 
 
Acute PCP treatment, at all doses, produced an increase in the number of premature and 
perseverative responses suggestive of behavioural disinhibition.  This manifested as the 
inability of the rat to withhold from responding before the stimulus onset (premature 
response) or the inability of the rat to disengage from responding to a previously rewarded 
behaviour (increased perseverative responding).  Acute PCP treatment is reported to impair 
frontal cortical brain function (Verma and Moghaddam 1996; Jentsch and Roth 1999).  Acute 
exposure to ketamine has been shown to increase regional blood flow to the frontal areas of 
the brain, particularly the anterior cingulate and frontomedial cortical brain regions of 
normal humans and schizophrenia patients (Lahti et al. 1995; Breier et al. 1997; Vollenweider 
et al. 1997).  Therefore, it is possible that PCP, another NMDA receptor antagonist, also 
causes increased frontal cerebral blood flow that may result in over-activation of brain 
regions involved in behavioural inhibition, impairing inhibitory control following a non-
monotonic dose-response curve of activation necessary for optimal performance, commonly 
referred to as an inverted ‘U’ shaped response.  The inverted ‘U’ hypothesis, known as the 
Yerkes-Dodson principle (Yerkes and Dodson, 1908; Diamond et al. 2007), states that under-
activation of a brain region, or a reduced release of neurotransmitter, will result in reduced 
performance, as the specific brain region has not been sufficiently activated.  The same 
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applies for over-stimulation, whereby it is possible that receptors within the brain region are 
desensitised by the over-activation and cease to function properly, resulting in reduced 
activation of the brain region, and therefore impairment in behaviour. 
 
Acute treatment with amphetamine produced a much less pronounced effect on the 
attentional measures of the 5-choice task, only producing significant reduction in choice 
accuracy and percent correct at the highest dose (0.75 mg/kg).  The reduction in attentional 
measures was also accompanied by an increase in ML.  Therefore, it is reasonable to assume 
that the reduction in choice accuracy and percent correct responding was potentially 
mediated by a disruption in locomotor activity (e.g. hyperlocomotion) or reduced motivation 
of the animal to perform the task, as opposed to impairment in attentional functioning.  
Acute amphetamine administration had a more pronounced effect on impulse control or the 
ability to disengage from a response, compared to the effect on these measures from an 
acute challenge of PCP.  All three doses (0.25 – 0.75 mg/kg) increased in the number of 
premature and perseverative responding.  Response disinhibition following amphetamine 
administration has previously been described in the 5-CSRTT (van Gaalen et al. 2006).  These 
findings are possibly due to the fact that amphetamine mainly acts on the dopaminergic 
system, resulting in increased release of dopamine in cortical and limbic brain regions (Balla 
et al. 2002) possibly influencing regions of the brain that are involved with behavioural 
inhibition and impulse control such as the sub-regions of the PFC or the striatum (Dalley et al. 
2007b).  The increased release of dopamine within regions of the brain is likely to follow the 
same principle of the inverted ‘U’ hypothesis (described above) (Yerkes and Dodson 1908; 
Diamond et al. 2007).  Therefore the behavioural effects from the increased dopaminergic 
activity that results from a non-selective increase in dopamine release due to an acute 
challenge of amphetamine, is likely to result in impaired response inhibition, that manifests 
as increased premature and perseverative responding.  Amphetamine treatment also 
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significantly reduced the latency to make an incorrect response, without affecting the time 
taken to make a correct response.  The effect amphetamine had on behavioural inhibition 
and the increased number of premature responses likely causes this.  The reduction in IL is 
likely the result of the effect on impulse control, as some of the incorrect responses would 
have been made on the threshold of stimulus presentation.  The response would have been 
on the verge of being a premature response, but the animal made its ‘premature response’ 
just as the ITI elapsed, and the stimulus was presented.  It is more likely that the animal 
would make an incorrect response (4:5 chance) than a correct response (1:5 chance) and 
thus, the latency of this incorrect response would be a few milliseconds, significantly 
reducing the overall average of IL.  Therefore, a reduction in IL may provide additional 
information regarding impulse control in addition to premature responding. 
 The vast majority of previous investigations into rodent performance of the 5-choice task 
use male rats, from Long-Evans or Hooded-Lister strains (Stolerman et al. 2000;  Bari et al. 
2008; McNamara et al. 2010; Thomson et al. 2010) as both these strains have pigmented 
retinas and are suggested to have superior vision compared to non-pigmented species. 
However, some groups do use albino strains, such as Wistar or Sprague-Dawley (Le Pen et al. 
2003).  Auclair and colleagues (2009) compared a pigmented species (Long-Evans) with an 
albino species (Sprague-Dawley) in order to determine species-dependent variations in task 
acquisition, coupled with PCP sensitivity.  While Auclair and colleagues (2009) found little 
difference in task performance once rats were trained to criterion, they did report a 
difference in the effects of acute PCP administration.  The group reported that Sprague-
Dawley rats had a greater reduction of premature responding, whilst latency to make a 
correct response and levels of trials omitted were increased in response to PCP.  
Administration of PCP resulted in a reduction in premature responding in this study, in 
contrast to previous findings in the literature, which demonstrated that PCP treatment 
impaired behavioural inhibition (Amitai et al. 2007; Le Pen et al. 2003).  However, in the case 
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of Auclair et al (2009), in the paradigm used, premature responses were not punished, thus 
removing the incentive to withhold responding until the stimulus is presented.  The 
consequence of this is that basal levels of premature responses were elevated and were far 
higher than previous investigations reported.  This highlights the fact that subtle variations in 
task parameters between laboratories may result varying intra-laboratory results and 
therefore drawing meaningful conclusions does require careful consideration. 
 
As the vast majority of behavioural experimentation is carried out using male rats (Grottick 
and Higgins, 2000; Stolerman et al. 2000; Amitai et al. 2007; Bari et al. 2008) and the 
experiment conducted by Auclair and colleagues (2009) demonstrated differences in 
performance in the 5-CSRTT between strains of rat, it is therefore important to also consider 
gender differences and the impact they may have on task performance.  This consideration is 
of particular importance as all behavioural paradigms at University of Bradford use female 
hooded-Lister rats; with the current study no exception.  However, on the face of the present 
findings, there is no sex difference in general 5-CSRTT performance or the ability to acquire 
the task and so it appears that the ability to perform the basic task is not affected by gender.  
Moreover, previous investigations within our laboratory have demonstrated that cognitive 
performance is largely unaffected by different stages of the oestrous cycle (Sutcliffe et al. 
2007; McLean et al. 2009), further supporting the absence of a gender effect. 
 
These data have demonstrated that female hooded-Lister rats can be trained to perform in 
the 5-CSRTT, to predetermined criteria that is deemed sufficient by previous experiments 
and have a performance level well above the chance performance of 20% correct 
responding. It has also been shown that sub-chronic PCP treatment does not impair task 
performance when animals are tested using the standard training protocols.  However, when 
the animals’ performance was challenged, by manipulating task parameters sub-chronic PCP 
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treatment produced subtle deficits in task performance.  When psychotomimetic agents 
were acutely administered, there was a profound and pronounced impairment in task 
performance.  Acute PCP resulted in both attentional and inhibitory control impairments, 
whilst acute amphetamine primarily resulted in deficits in impulse control.  However, the 
potential for generalised response disruption cannot be ruled out.  This collection of 
experiments demonstrates that the 5-choice serial reaction time task is a valid behavioural 
paradigm for measuring various cognitive elements that are clinically affected in 
schizophrenia, and shows there is potential in pharmacologically inducing deficits that may 
model the cognitive dysfunction seen in the disorder.  Future experiments will further probe 
the possibility that the cognitive construct of attention is sensitive to pharmacological 
disruption using NMDA antagonists.  In order to do this, a modified version of the basic 5-
CSRTT will be utilised, which has recently been validated in mice (Young et al. 2009b), which 
may more accurately assess attention, specifically enabling quantification of vigilance in a 
manner consistent with human vigilance testing.  The following chapter will investigate the 
use of the 5-Choice Continuous Performance Test and the applicability of using rats in this 
paradigm. 
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4.1 Introduction 
As previously discussed, the 5-CSRTT is considered to share many of the features of the 
human CPT (Bari et al. 2008).  Despite this analogy with human CPTs, sub-chronic PCP 
treatment failed to induce convincing deficits (experimental chapter 3) in 5-CSRTT 
performance, perhaps limiting the applicability of this pharmacological model to replicate all 
of the cognitive impairment present in the disorder; or at least with the current preclinical 
model assessing the cognitive construct under investigation.  Schizophrenia patients perform 
poorly in multiple versions of the CPT, including the CPT-IP, chosen by the MATRICS initiative 
to assess attention in schizophrenia patients (Neuchterlein et al. 2008; Kern et al. 2008), 
indicating that impaired attention/vigilance is inherent to the disorder (Rosvold et al. 1956; 
Kornetsky and Mirsky, 1966; Wohlberg and Kornetsky, 1973; Cornblatt and Keilip, 1994; 
Kumar et al. 2010).  Impaired attention/vigilance, along with other cognitive deficits, 
deleteriously impact the patient’s quality of life (Cornblatt and Keilip, 1994; Marder and 
Fenton, 2004), relating to social problem solving and skill acquisition (Green et al. 1996).  
Despite the myriad versions of the CPT, (CPT) (Rosvold et al. 1956), CPT-Identical Pairs (CPT-
IP) (Cornblatt et al. 1988), AX-CPT (van den Bosch et al. 1996) or Conners CPT (Conner et al. 
2003) (described in chapter 1), each task has some consistency in that they include both 
target trials requiring a response and non-target trials requiring inhibition of a response, the 
key to successful task performance relies on successful discrimination between trial types. 
Depending on the trial presented, various response outcomes are possible in CPTs (hits, 
misses, correct rejections and false alarms – see table 4.1) and due to the generation of false 
alarms, signal detection theory (SDT) to be employed to further assess performance (See et 
al. 1995; Marston 1996; Steckler 2001).  SDT provides researchers additional insight into the 
response profile of the subject and can separate attentional or vigilance 
impairment/improvement from alterations in the response strategy or bias of the subject 
(Marston 1996; Robbins 1998; Young et al. 2009b).  Impairment or improvement in 
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sensitivity may be due to a reduced or increased ability to detect the signal, or alterations in 
the decision criteria of the subject; SDT enables the elucidation of the process behind task 
performance (Marston 1996).  Thus, the inclusion of SDT measures may provide an enhanced 
method of revealing or quantifying impairments in CPT performance that might not be 
evident using omission or commission errors alone (Lam and Beale 1991; Mass et al. 2000; 
Riccio et al. 2002) and as such, SDT is routinely utilised in the interpretation of CPT 
performance (Nestor et al. 1990). 
The premise behind SDT is that an individual is likely to develop a strategy to determine 
when it is appropriate to respond to a signal, depending on whether the salience of the signal 
corresponds to the individual’s internal criteria of what constitutes a signal that should elicit 
a response (Steckler 2001; Harvey 2003).  When SDT was in its infancy, researchers 
investigating the ability of individuals to correctly detect and report brief stimuli associated 
with radar scanning used statistical theory in order to aid the quantification of determining 
the probability of detection of brief, pulse-like signals in individuals using radar system 
technology (Marcum 1947).  The outcome of this technique led to development of the 
psychological theory behind SDT and formed the basis of the analytical theory by Wilson and 
Swets (1954) in which they evaluated the ability of an individual to detect a visual light 
stimulus from a background of uniformed light ‘noise’.  The ultimate aim of SDT is to utilise 
the available indices produced by the possible response outcomes (e.g. hit, miss, false alarm, 
correct rejection) in order to provide an enhanced level of interpretation of the performance 
ability of the individual in detecting a signal from noise, irrespective of other external 
parameters that may be influencing performance (Marston 1996).   
 Response Non - Response 
Signal Present (go trial) Hit Omission 
Signal Absent (no-go trial) False Alarm Correct Rejection 
Chapter 4     D1 agonism and the 5C-CPT 
90 
Table 4.1. A description of the possible response outcomes when animals are presented with signal or non-signal 
trials. Correct responses are in italics.  
 
Using the types of responses described in Table 4.1, along with the frequency that they are 
presented throughout the task session, SDT enables researchers to generate additional 
indices that may aid the interpretation of task performance.  CPT performance generates 
measures contained in table 4.1.  Thus, proficient performance requires the discrimination 
between signal (target trials) and noise (non-target trials), SDT can quantify this level of 
discrimination by producing the parametric index, D prime (d’).  The d’ index represents a 
measure of signal sensitivity or the ability to discriminate between target and non-target 
stimuli.  Therefore, a higher level of sensitivity results in a greater ability to correctly detect 
the signal stimuli and correctly ignore the non-target stimuli (Baerwald et al. 2005), and as a 
result the means of distribution between signal and noise events will be further apart (fig 
4.1).  Reduced sensitivity creates a greater overlap in the means of distribution, resulting in 
an area in which discrimination between signal and noise is impossible.  Therefore, the 
measure d’ can be interpreted as a measure of vigilance, as higher levels of vigilance in tasks 
such as the CPT, will generally result in a higher number of signals being detected, whilst 
keeping the number of false alarms to a minimum, increasing the discrimination index.  This 
measure of discrimination has been shown to be reduced in schizophrenia patients (Mussgay 
and Hertwig 1990), supporting the notion that impaired vigilance is associated with the 
disorder.  
Furthermore, also based on the measures summarised in table 4.1, SDT can generate a 
responsivity index known as β, which indicates the response strategy being utilised.  Bias in 
an individual may influence performance driven by other factors such as motivation, 
willingness to respond, or alterations in response strategy, factors that are not necessarily 
driven by vigilance or cognitively mediated measures (Marston 1996; Steckler 2001).  If the 
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value for β is high, it indicates that the subject is responding in a conservative fashion and 
will only respond if they are absolutely sure a signal has been presented.  This will ultimately 
result in a low false alarm rate, as incorrect responses to non-signals are less likely.  However, 
there is also the chance that actual signals will be missed, thus increasing the omission rate 
(number of misses).  Conversely, if the subject is responding in a liberal fashion, reporting the 
detection of anything that possibly may be construed as a signal, the omission level will be 
reduced but at the consequence of increasing the false alarm rate.  In this instance the value 
for β will be reduced.  The advantage of SDT is that it allows researchers to determine if 
pharmacological intervention is increasing performance by increasing the ability of the 
individual at discriminating the signal from background noise (increasing d’) or altering the 
response strategy of the individual (reflected by changes in β).  By using these additional 
measures it can be determined exactly how increases in task performance are achieved 
(Dudchenko et al. 1992). 
 
Fig 4.1. Depiction of the measures used in SDT, illustrating the means of distribution of signal and noise events 
and D demonstrates the discrimination of the two events. Additionally β is identified and provides information to 
the response strategy being used. D prime (d’) is equal to the mean signal minus mean noise divided by delta, 
which constitutes the standard deviation of distribution. Image was taken from http://sabometrics.com/?p=242  
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As mentioned, the indices d’ and β are parametric measures and as such, must conform to 
assumptions of normality, absence of skew and homogeneity of variance.  If these 
assumptions cannot be confirmed, it is appropriate to revert to a non-parametric approach 
to generate these indices.  Being non-parametric, fewer assumptions regarding the internal 
perceptions of the signal need to be made (Young et al. 2009b).  In respect to d’, the non-
parametric alternative utilised in the current chapter is the sensitivity index (SI), first 
described by Frey and Colliver (1973).  Moreover, the responsivity index (RI) also described 
by Frey and Colliver (1973) was used to represent the strategic bias used throughout the 
session. 
 
Although it has been suggested that the 5-CSRTT is analogous to the human CPT (Bari et al. 
2008), the 5-CSRTT only presents target trials of which there are only one of two possible 
response outcomes; a hit (correct or incorrect) or a miss.  That is to say, the animal responds 
to the stimulus or it fails to report the detection of the signal.  As the 5-CSRTT only presents 
target trials, it therefore can be implied that this task is not completely analogous to human 
CPTs (Young et al. 2009b) as the task lacks non-target stimuli that are present in all variants 
of human CPTs. The absence of trials that enable the generation of false alarms in the 5-
CSRTT prevents the use of signal detection analysis being accurately employed in the 
interpretation of behavioural performance.  
Furthermore, although the terms sustained attention and vigilance are often used 
interchangeably, there is a subtle difference between the two constructs (Robbins 1998).  
Vigilance reflects a cognitive construct described as the ability to remain alert towards 
incoming stimulus information (Collings 2003; Egeland et al. 2009), facilitating the state of 
readiness to detect and respond to unpredictable and rare events.  Thus, vigilance enables 
the discrimination between signal and noise (Mackworth 1957; Broadbent 1971; Robbins 
1998), whereas sustained attention enables an individual to focus attention over a prolonged 
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period enabling attentional goals to be maintained over time.  As such, it has been suggested 
that the current configuration of the 5-CSRTT restricts the ability to accurately evaluate 
vigilance (Robbins 1998) in a manner consistent with human CPTs, as in most vigilance 
experiments the critical signals for detection fall within a backdrop of non-signal events 
(Warm and Dember 1987), events that are absent in the original 5-CSRTT. 
A lever-based operant task developed by McGaughy and Sarter (1995) may accurately assess 
vigilance in preclinical testing, requiring animals to determine whether a visual cue appeared 
or not, prior to the presentation of the two levers (described in detail in chapter 1).  The SAT 
task records hits, misses, correct rejections and false alarms depending on the lever press 
during signal or non-signal trials.  However, in go/no-go paradigms (i.e. CPTs), false alarms 
typically constitute a failure to withhold from responding, resulting in an inappropriate 
response in contrast to a correct rejection that usually requires an inhibition of a response 
(Eagle et al. 2008).  As a result it could be maintained that the non-signal trial presented 
within the McGaughy and Sarter (1995) paradigm, of which a correct rejection requires an 
active response, may have limited analogy to the non-signal trials presented in human CPTs 
which in contrast, a correct rejection is comprised of an inhibition of an inappropriate 
response (Young et al. 2009b). This discrepancy may limit accurate parallels to be drawn 
between the clinical and preclinical tests of vigilance. 
Consequently, the 5-CSRTT has recently been modified to include not only target trials (light 
stimulus in one of the apertures) present in the original task, but also non-target trials (light 
stimulus in all the apertures) to generate a behavioural paradigm with enhanced analogy 
with human CPTs, called the 5-Choice Continuous Performance Test (5C-CPT) (Young et al. 
2009b).  Presentation of non-target trials in this task requires the animal to correctly inhibit a 
response, whereas a failure in action restraint, resulting in incorrect responding to the non-
target trial generates a false alarm.  Thus, this adaptation may improve the capability to 
assess vigilance in a preclinical model in a manner similar to human CPTs.  Additionally, as the 
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5C-CPT includes non-target trials generating correct rejections and false alarms, SDT can also 
be utilised to provide insight into the animals’ responsivity and give additional information on 
attentional performance in light of task or pharmacological manipulations (Dudchenko et al. 
1992). 
 
Previously discussed in chapter 1, various manipulations to basic 5-CSRTT protocols have 
been used to challenge performance by further taxing attentional or strategic performance 
(Carli et al. 1983; Stolerman et al. 2000; Grottick and Higgins, 2002; Hahn et al. 2002; 
Chudasama et al. 2003; Hahn et al. 2003; Winstanley et al. 2003), manipulations which 
include extending the duration between stimulus onset.  As such, similar parameter 
manipulations are likely to be an appropriate method to further tax performance in animals 
trained in the 5C-CPT.  However, caution must be exercised when employing such 
manipulations when the ultimate aim is pharmacologically attenuating deleterious 
performance.  Because months of training to a specific protocol is required for animals to 
perform operant tasks such as 5-CSRTT or the 5C-CPT, there is the potential confound, which 
requires consideration; drug treatment may facilitate an increased speed of learning or 
improved adaptation to the modified protocol.  This may weaken the interpretation of drug-
induced improvement in attentional function (Hahn et al. 2003; Young et al. 2009a).   
It has long been established that dopamine (DA) transmission is disrupted in the 
pathophysiology of schizophrenia; however, despite many years of research it is still not 
entirely clear how DA dysregulation and cognitive impairments in schizophrenia are 
connected (Cohen and Servan-Schreiber 1993).  Despite this uncertainty, it is evident that 
dopaminergic transmission in sub-cortical (Tomasi et al. 2010) and cortical brain regions 
(Sawaguchi and Goldman-Rakic 1991; Goldman-Rakic et al. 2004) is linked to various 
cognitive processes, including attentional functioning (Nieoullon 2002).  The DA D1 receptor 
has been identified as one of the most promising targets for developing pro-cognitive 
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therapeutics for schizophrenia (Hagen and Jones 2005; Tammaninga 2006), and there is 
some evidence that D1 agonists can improve sustained attention, shown by improved 
accuracy of responding in the 5-CSRTT in rats with poor baseline performance (Granon et al. 
2000).  However, enhancement of attentional performance via augmentation of the D1 
dopaminergic system in the 5C-CPT has yet to be determined.  Validation of the 5C-CPT has 
previously only been carried out in mice and therefore, the aims of the present chapter were 
to firstly identify whether rats could be trained to perform the 5C-CPT.  Secondly, the ability 
of a D1 agonist to improve performance at stable baseline and following behavioural 
challenge was investigated. 
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4.2. Methods 
4.2.1 Subjects 
Female hooded-Lister rats (n=35; Charles River; approx 250 + 10 g at the start of the 
experiment) were housed in groups of five on a 12 hour reversed light cycle (lights on at 
7:00pm) in a temperature (21 + 2oC) and humidity (55 + 5%) controlled environment.  For 
details regarding animal housing conditions, food restriction and eithical guidelines, please 
refer to the general methods section.   
 
4.2.2 Experimental Design 
4.2.2.1 Stable Baseline Task Performance 
The initial experiment investigated the effect of SKF 38393 on performance in the 5C-CPT 
under standard training conditions, which consisted of 1.5 s SD, 5 s TO period, 2 s LH, a 
variable ITI (4.0, 4.5, 5.5, and 6.0 s) which averaged 5 s, in a session consisting of 84 target 
trials and 36 non-target trials.  Following attainment of baseline stability (for details 
regarding the training, please see chapter 2 section 2.6.3), animals were randomly assigned 
to four treatment groups, whilst also ensuring no variability between groups based on 
behavioural performance existed prior to drug treatment. Animals then received vehicle 
(distilled H2O), 2.0, 4.0, or 6.0 mg/kg (n = 8 – 9) SKF 38393 30 minutes before behavioural 
testing.  
 
4.2.2.2 Reduced Event Rate Task Challenge 
The second experiment followed the same design in which animals were randomly assigned 
to four separate treatment groups, ensuring no variability between treatment groups and 
treated with either vehicle, 2.0, 4.0, or 6.0 mg/kg SKF 38393 (n = 8 – 9).  The rats were then 
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tested in the 5C-CPT.  The testing parameters were identical to the previous experiment, with 
the exception that the variable ITI was extended from the 5 s average used throughout 
training to an average of 10 s (8, 9, 11, and 12 s), thus reducing the event-rate of the task 
(Parasuraman, 1998).  One rat was excluded from analysis following the reduced event-rate 
challenge (6 mg/kg treatment group) due to malfunction of an operant chamber during 
testing. 
Baseline and challenge session were separated by two days, during which all animals 
received normal training sessions to ensure performance was maintained at a stable 
baseline, while also identifying possible lasting effects resulting from acute SKF 38393 
exposure. A between-subjects design was used rather than a within-subjects Latin square 
design (as used in chapter 3) in order to avoid the potential learning confound that may 
result from repeated exposure to the extended ITI challenge session. 
 
4.2.3 Drugs 
SKF 38393 (Sigma, UK) was dissolved in distilled H2O to give the appropriate doses (2.0, 4.0 
and 6.0 mg/kg) and was injected via the intraperitoneal (i.p.) route with a 30 minute pre-
treatment time at a dose volume of 1 ml/kg.  All drug doses were calculated as base 
equivalent weight.  The doses used in this study were chosen from previous behavioural 
experimentation conduced within our laboratory and others, which showed efficacy of SKF 
38393 within this dose range in behavioural tasks of cognition of relevance to schizophrenia 
(Hersi et al. 1995; McLean et al. 2009).  However, as previous pro-cognitive demonstrations 
following SKF 38393 administrations were not conducted in an attentional task, a wider dose-
response was used in the current study. 
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4.2.4 Data Analysis 
Performance for each behavioural measure in the 5C-CPT was displayed as mean + SEM. Data 
were analysed by a one-way between subjects ANOVA with drug as the between subjects 
factor, followed by Planned Comparisons on the predicted means back to control animals.  
Data presented over the duration of the session was displayed as mean + SEM and analysed 
using a repeated measures ANOVA (Treatment as fixed factor, Trial as repeated measure) 
followed by Planned Comparisons (Snedecor and Cochran, 1989) on the predicted means 
using Statistica v8.0 (Statsoft).  Planned Comparisons were utilised to test the hypothesis that 
drug treatment would, depending on test parameters, improve or impair performance.  
Comparison of means in order to determine whether rats were able to discriminate between 
trial types and the determination of the effect reducing the event-rate had on task 
performance were displayed as mean + SEM and analysed using a Student’s t test. 
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4.3 Results 
4.3.1 Discrimination between Trial Types 
In the initial part of training (approximately 1 month in), measures relating to the ‘go’ 
component suggest animals had acquired the ability to respond to the presentation of the 
target stimuli (accuracy, 94%; percent correct, 91%;  percent omissions, 5% - data not 
shown),  however it was evident that animals were not discriminating between the two trial 
types presented within the task.  This was exemplified by the high p[FA], coupled with the 
lack of difference between p[HR] and p[FA] (fig 4.2).  Additionally SDT measures further 
suggested that animals could not differentiate between trial type (SI = 0.04) and have 
adopted an extremely liberal response strategy (RI = 0.80) (data not shown).   
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Fig 4.2. Comparison of p[HR] and p[FA] during the initial phase of training indicating absence of discrimination 
between trial types. Data expressed as mean + SEM. 
 
Following continued training (with a greater emphasis placed on the no-go component, 
described in chapter 2 section 2.6.3), animals could successfully discriminate between the 
two trial types presented within the 5C-CPT.  There was a significant difference (t=7.31, 
p<0.001) between hit rate and false alarm rate (Fig 4.3A).  In addition, as a correct rejection 
and an omission both resulted from the same type of response, it was important to 
determine if rats were responding appropriately and treated the two trial types differently.  
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Analysis showed that there was a significant difference (t=9.97, p<0.001) when percent 
correct rejections was compared with percent omissions (Fig 4.3B). 
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Fig 4.3 Performance of vehicle treated animals under standard training conditions highlighting the ability to 
perform the 5C-CPT.  There was a significant difference between hit rate and false alarm rate (A) in addition to a 
significant difference between percent correct rejections and percent omissions (B).  Data are expressed as mean 
+ SEM, analysed by Students t-test. *** denotes p<0.001. 
 
4.3.2 SKF 38393 and Stable Baseline Task Performance 
Effects of the partial D1 receptor agonist on stable baseline performance of rats in the 5C-
CPT were examined.  Table 4.2 demonstrates there was no significant effect of drug 
treatment on accuracy, and SKF 38393 initially resulted in no effect on percent correct 
responding [F(3,31)=2.08, p=0.12], percent incorrect responding [F(3,31)=0.98, NS] or percent 
omissions [F(3,31)=1.95, p=0.14].  However, Planned Comparisons revealed a significant effect 
at the highest dose of SKF 38393 compared to control animals on both percent correct 
responding (decrease) (p<0.05) and percentage omissions (increase) (p<0.05).  SKF 38393 
treatment produced a significant increase in correct latency (CL) [F(3,31)=5.25, p<0.01].  
Planned Comparisons revealed that doses of 4 mg/kg and 6 mg/kg SKF 38393 resulted in a 
significant increase in correct latency time (p<0.05).  Statistical analysis showed no significant 
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change in incorrect latency (IL) [F>1, ns] or magazine latency (ML) [F(3,31)=1.47, p=0.24].  
When tested under standard conditions, SKF 38393 had no effect on impulsive or compulsive 
responding, demonstrated by no significant change in the number of premature [F>1, ns], 
although a slight trend towards a significant increase in perseverative [F(3,31)=2.04, p=0.12] 
responses was observed.  
 
Table 4.2 Effect of SKF 38393 on Stable Baseline Performance 
Measures Vehicle 2.0 mg/kg 4.0 mg/kg 6.0 mg/kg 
Accuracy (%) 
Percent Correct 
Percent Incorrect 
Percent Omission 
 
Correct Latency 
Incorrect Latency 
Magazine Latency 
 
Premature 
Perseverative 
94.35 + 1.58 
76.81 + 4.55 
4.28 + 1.03 
18.90 + 3.99 
 
0.71 + 0.06 
0.55 + 0.13 
1.26 + 0.06 
 
6.00 + 2.17 
10.67 + 3.36 
 96.40 + 0.94 
78.17 + 6.88 
2.64 + 0.71 
19.19 + 6.71 
 
0.65 + 0.03 
0.80 + 0.21 
1.29 + 0.07 
 
6.50 + 1.24 
10.75 + 2.25 
95.33 + 1.54 
71.28 + 4.70 
3.26 + 1.00 
25.46 + 4.34 
 
0.93 + 0.08 * 
1.03 + 0.27 
1.33 + 0.07 
 
5.56 + 2.24 
22.22 + 4.94 
91.41 + 1.75 
58.49 + 8.16 * 
4.57 + 0.74 
36.94 + 8.29 * 
 
0.90 + 0.05 * 
1.14 + 0.18 
1.46 + 0.10 
 
2.67 + 0.99 
20.89 + 5.76 
Measures are shown as mean + SEM.  Asterisks indicate statistically significant differences (*p<0.05) compared to 
the vehicle group (n = 8 – 9). Stable baseline parameters consisted of 1.5 s SD, 5 s TO period, 2 s LH, a variable ITI 
(4.0, 4.5, 5.5, and 6.0 s).  
 
Analysis of SKF 38393 treatment on p[HR] showed that there was no significant impairment 
in the proportion of hit rate, p[HR] [F(3,31)=2.08, p=0.12].  However Planned Comparisons of 
the means showed that the highest dose of SKF 38393 (6 mg/kg) resulted in a significant 
reduction in the proportion of target trials correctly reported (p<0.05, fig 4.4A).  Treatment 
with SKF 38393 had no significant effect on the remaining signal detection measures (p[FA], 
sensitivity index [SI] and responsivity index [RI]) (Fig 4.4B, C and D.) 
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Fig 4.4 Performance of animals in the 5C-CPT tested (n = 8 – 9) using standard conditions following SKF 38393 
treatment and analysed using signal detection theory.  Drug treatment produced a significant reduction in p[HR] 
(A).  There was no effect of SKF 38393 on p[FA] (B), Sensitivity Index (C) or Responsivity Index (D).  Data are 
expressed as mean + SEM and analysed by one-way ANOVA followed by Planned Comparisions on the predicted 
means. * denotes p<0.05 relative to the vehicle (Veh) group. 
 
4.3.3 Effect of a Reduced Event-Rate on Task Performance 
When the variable ITI was increased from an average of 5 s to 10 s, there was an impaired 
ability to correctly perform the 5C-CPT in a number of measures, displayed in table 4.3.  
There was no effect on accuracy (t=1.23, ns), but a significant reduction in percent correct 
(t=2.90, p<0.05) and increase in percent omission were observed (t=2.67, p<0.05).  Incorrect 
responding was unaffected, however (t=0.91, ns).  Correct latency and incorrect latency were 
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unaffected (t=0.93, ns and t=0.36, ns, respectively) but parameter manipulation resulted in a 
significant reduction in magazine latency (t=2.47, p<0.05).  Extending the ITI dramatically 
increased the number of premature responses made during a session (t=4.87, p<0.0001), 
whereas perseverative responding was unaffected (t=0.36, ns).  Reducing the event-rate had 
no effect on the ability to withhold a response when presented with a non-target trial 
(t=1.54, ns).  The p[HR] was significantly reduced when the ITI was extended (t=2.95, p<0.01), 
but the p[FA] was unchanged (t=1.16, ns).  As a result, there was a significant reduction in the 
sensitivity between target and non-target stimuli, characterised by a reduction in SI (t=2.82, 
p<0.05), which occurred without alterations in the responsivity index (t=1.05, ns). 
Table 4.3 Effect of a reduced event rate on 5C-CPT performance 
Measures Stable Baseline Reduced Event-rate 
Accuracy (%) 
Percent Correct 
Percent Incorrect 
Percent Omission 
Correct Latency 
Incorrect Latency 
Magazine Latency 
Premature 
Perseverative 
Correct Rejections (%) 
Hit Rate, p[HR] 
False Alarm Rate p[FA] 
Sensitivity Index 
Responsivity Index 
94.35 + 1.58 
76.81 + 4.55 
4.28 + 1.07 
18.90 + 3.99 
0.71 + 0.06 
0.55 + 0.13 
1.26 + 0.06 
6.00 + 2.17 
10.67 + 3.36 
66.11 + 5.56 
0.77 + 0.05 
0.34 + 0.06 
0.44 + 0.09 
0.15 + 0.06 
88.92 + 3.93 
56.41 + 5.27 * 
7.03 + 2.68 
37.69 + 5.60 * 
0.79 + 0.06 
0.69 + 0.14 
1.06 + 0.06 * 
36.50 + 5.59 *** 
9.40 + 1.51 
55.43 + 7.21 
0.56 + 0.05 ** 
0.45 + 0.07 
0.13 + 0.07 * 
0.01 + 0.11 
Effect of reducing the event-rate had on 5C-CPT performance in control animals (n = 9).  Measures are shown as 
mean + SEM.  Asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001) between 
reduced event-rate and stable baseline performance.  Stable baseline parameters consisted of 1.5 s SD, 5 s TO 
period, 2 s LH, a variable ITI (4.0, 4.5, 5.5, and 6.0 s), whereas the reduced event-rate had an extended variable ITI 
(8, 9, 11, 12 s)  
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4.3.4 SKF 38393 and Reduced Event Rate Task Performance 
SKF 38393 impaired performance when assessed during baseline level of performance.  This 
effect could have been as a result of ceiling effects (Granon et al. 2000) as animals were at 
their optimal level of performance.  One method used to challenge vigilance is to reduce the 
event rate where the period in which the animal must wait for a stimulus to appear is 
lengthened (Parasuraman, 1998).  Rats were challenged in the 5C-CPT using an extended 
variable ITI challenge (Table 4.4). Analysis showed that SKF 38393 treatment had no effect on 
accuracy [F3,30)=1.24, ns].  One-way ANOVA showed no significant difference in percent 
correct responding [F(3,30)=2.19, p=0.11] or percentage omissions [F(3,30)=1.72, p=0.18].  
However, Planned Comparison of the means revealed that 6 mg/kg of SKF 38393 resulted in 
a significant increase in the percentage of correct trials per session (p<0.05) and a significant 
reduction in the percentage of trials missed (p<0.05).  There was no treatment effect on the 
number of incorrect responses made throughout the reduced event-rate challenge 
[F(3,30)=1.01, ns].  Statistical analysis revealed no significant effect of SKF 38393 on correct 
latency [F(3,30)=0.2, ns], incorrect latency [F(3,30)=0.27, ns] or magazine latency [F(3,30)=1.41, ns].  
Although the baseline of premature responding was increased, compared to standard 
conditions, SKF 38393 had no significant effect on either premature [F(3,30)=0.59, ns] or 
perseverative responding [F(3,30)=1.37, ns] when the variable ITI was extended.  
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Table 4.4 Effect of SKF 38393 on Reduced Event Rate Performance 
Measures Vehicle 2.0 mg/kg 4.0 mg/kg 6.0 mg/kg 
Accuracy 
Percent Correct 
Percent Incorrect 
Percent Omission 
 
Correct Latency 
Incorrect Latency 
Magazine Latency 
 
Premature 
Perseverative 
88.92 + 3.93 
56.41 + 5.27 
7.03 + 2.68 
37.69 + 5.60 
 
0.79 + 0.06 
0.69 + 0.14 
1.06 + 0.06 
 
36.50 + 5.59 
9.40 + 1.51 
 
 
90.00 + 2.83 
63.04 + 8.88 
5.43 + 0.65 
30.90 + 7.39 
 
0.78 + 0.05 
0.52 + 0.10 
1.29 + 0.07 
 
33.14 + 6.05 
7.71 + 2.10 
94.74 + 1.55 
67.87 + 4.65 
3.46 + 0.84 
28.66 + 4.24 
 
0.78 + 0.06 
0.74 + 0.24 
1.34 + 0.22 
 
29.67 + 4.05 
6.44 + 1.41 
94.58 + 1.13 
76.14 + 4.11 * 
4.27 + 0.93 
19.59 + 3.95 * 
 
0.74 + 0.02 
0.73 + 0.19 
1.41 + 0.10 
 
27.38 + 5.62 
5.50 + 1.16 
Measures are shown as mean + SEM.  Asterisks indicate statistically significant differences (*p<0.05) compared to 
vehicle group (n = 8 – 9). 
 
Analysis showed that there was no significant effect on p[HR] as a result of SKF 38393 
treatment [F(3,30)=2.19, p=0.11], however Planned Comparisons showed a significant increase 
in p[HR] at the highest dose (6 mg/kg, p<0.05, fig 4.5A).  There was no significant effect of 
drug on the p[FA] (fig 4.5B) as a result of SKF 38393 treatment [F(3,30)=0.80, ns], however 
analysis revealed drug treatment produced a significant increase in the sensitivity index 
[F(3,30)=4.38, p<0.05] (fig 4.5C).  Planned Comparisons on the predicted means showed that 
both 4 mg/kg (p<0.05) and 6 mg/kg (p<0.01) SKF 38393 resulted in a significant increase in SI, 
while there was no significant effect of treatment compared to the control group for 
responsivity index [F(3,30)=0.42, ns] (fig 4.5D). 
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Fig 4.5 Effect of SKF 38393 on signal detection theory measures of performance in the 5C-CPT during a reduced 
event rate challenge (n = 8 – 9).   Drug treatment resulted in a significant increase in p[HR] (A).  No effect of drug 
was observed on p[FA] (B). SKF 38393 treatment resulted in a significant increase in the sensitivity index (C) 
without affecting the responsivity index of the animals (D).  Data are expressed as mean + SEM and analysed by 
one-way ANOVA followed by Planned Comparisions on the predicted means. * denotes p<0.05 and ** denotes 
p<0.01 relative to vehicle (Veh) group. 
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4.3.5 Reduced Event Rate Challenge – Performance across Session 
Altering the protocol of a task during testing requires the animal to adjust to that protocol.  
Thus drug effects on performance could affect vigilance or be confounded by affecting 
learning of the new protocol.  To assess for this learning confound, the effects of SKF 38393 
on animals within the session was examined in comparison to vehicle control animals.  
Analysis showed that SKF 38393 resulted in a significant increase in performance across the 
duration of the session as measured by the sensitivity index (SI). Analysis of drug effects 
indicated that there was a strong treand towards a significant difference in performance 
(F(3,30)=2.79, p=0.05). Following Planned Comparisons it was revealed that both 4.0 mg/kg 
(p<0.05) and 6.0 mg/kg (p<0.01) of SKF 38393 resulted in a significant increase in SI in the 
first trial bin and 6.0 mg/kg (p<0.01) SKF 38393 resulted in a significant increase in the second 
trial bin (Fig 4.6).  There was no significant interaction between dose and trial number 
(F(3,30)=0.17, p=0.91). 
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Fig 4.6 Effect of SKF 38393 treatment on performance in 5C-CPT across time in response to the reduced event rate 
challenge (n = 8 – 9).  Drug treatment (4.0 and 6.0 mg/kg i.p.) resulted in a significant increase in sensitivity index 
(SI) during trials 0 – 60 and trials 61 – 120 (6.0 mg/kg i.p.).  Data are expressed as mean + SEM and analysed by 
one-way repeated measures ANOVA with treatment as fixed factorand trial as repeated measure, followed by 
Planned Comparisons on the predicted means. # denotes p<0.05 (4.0 mg/kg) and * denotes p<0.05, ** denotes 
p<0.01 (6.0 mg/kg) compared to the vehicle group. 
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4.4. Discussion 
Firstly, these data demonstrate for the first time that rats can be successfully trained to 
respond to the target trials, whilst appropriately inhibiting a response when presented with 
the non-target trials that are presented in the 5C-CPT.  Previously, it has been shown that 
mice can be trained to discriminate between target and non-signal trials (Young et al. 2009b), 
however, this is the first time it has been demonstrated rats can perform the 5C-CPT.  
Secondly, these data confirm that activation of dopamine (DA) D1 receptors can improve or 
impair attention/vigilance in a baseline dependent manner, and thirdly supports the use of 
signal detection analysis as a means to quantify attentional performance and strategic bias. 
Rats use a temporally mediating strategy when performing the 5-CSRTT with constant ITIs 
and possibly respond to the cue in a semi-automatic manner.  This strategy was quantified 
following observations that rats responded 90% of the time following the ITI when acutely 
challenged with no presentation of stimuli (Spratt et al. 2000).  The current study has 
demonstrated however, that by utilising a variable ITI and a non-target stimulus during 
training, the development of a temporally mediated response strategy was minimised and 
rats could withhold from responding to non-target trials.  The start of training required a 
greater emphasis being placed on the proportion of non-target trials presented as initially 
animals responded to the majority of non-target trials, increasing the p[FA], suggesting they 
were treating both trial types identically. However, following continued training with the 
higher proportion of non-target trials, animals began to learn that a response to the non-
target trial did not result in a reward and thus modified their response to the non-target trial 
accordingly, demonstrated by the reduction in p[FA].  Once trained to withhold from 
responding, the discrimination of the two trial types was quantified by comparing p[HR] and 
p[FA], with the former being significantly greater than the latter. Additionally, percent 
correct rejections and percent omissions were compared.  In this instance, as both types of 
response essentially required the same action for target and non-target trials (i.e. a non 
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response); it was important to establish that performance is dependent on the type of trial 
presented to the animal (Young et al. 2009b).  Upon analysis, it was evident that there was a 
clear difference in non-responses dependent upon trial type (correct rejections > omissions), 
suggesting the rats could make a distinction between the two trial types and responded 
accordingly.  Thus, these data suggest that rats can be trained to differentiate and respond 
appropriately to two different stimulus types within the same task.  
The main finding that emerged from this chapter was that D1 receptor activation via systemic 
administration of the D1 partial agonist SKF 38393 improved attention/vigilance during a 
demanding task challenge.  These data support findings from previous studies that 
demonstrated D1 receptor activation enhanced sustained attentional performance, as 
assessed within the 5-CSRTT, a finding that was only evident in animals that had a lower 
baseline performance compared to the rest of the cohort (Granon et al. 2000).  The present 
findings demonstrate that, when the baseline performance is high (i.e. using standard task 
protocol), SKF 38393 did not improve attentional performance.  Activation of dopaminergic 
D1 receptors actually impaired performance under these conditions.  This finding was 
demonstrated by the reduction in percent correct trials and increased trials omitted during 
the session, along with an increase in the latency to make a correct response.  The slowed 
correct latency (CL) was unlikely to reflect general motoric impairment as incorrect latency 
and magazine latency were unaffected.  Thus SKF 38393-induced slowing of CL was likely to 
be the result of deficits in the speed of informational processing (Robbins 2002; Young et al. 
2009a).  In contrast, when performance was challenged with an extended variable ITI, thus 
reducing the event rate (Parasuraman et al. 1998), baseline performance was reduced, 
exemplified by the reduced ability to respond to the target stimulus, an increase in 
premature responding and reduction in the sensitivity to discriminate between signal and 
noise.  This reduction in performance, however, was attenuated by drug treatment.  
Augmentation of the dopaminergic D1 system, via systemic administration of SKF 38393, 
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increased the percentage of correct trials and reduced the number of trials missed.  As a 
result, the increase in vigilance, indicated by the increase in sensitivity index (SI), was likely 
driven by an increased p[HR] highlighting an increased capacity to detect and respond to the 
target stimulus.  Sarter and colleagues (2001) described signal sensitivity or detectability as a 
method of quantifying changes in vigilance levels.  Therefore, the increased SI produced by 
drug treatment, following the impaired performance following a reduced event rate, 
suggests that SKF 38393 administration increased the rats’ capability to detect and report the 
occurrence of signals, thus indicating an improved discriminability between signal (target 
trial) and noise (non-target trials), which is a hallmark of enhanced vigilance.  
No effect of SKF 38393 was observed on responsivity index (RI), therefore it is unlikely that 
performance in the task was altered due to a change in response bias or strategy, which 
implies that the improved SI was cognitive in nature (Marston 1996).  The ability of SDT to 
dissociate the SI and RI and reveal no change of RI in response to drug treatment indicates 
that improvements in performance may be specifically due to increases in attentional ability 
(Dudchenko et al. 1992) and not alterations in the animals willingness to respond (Steckler, 
2001).  Thus, this indicates that stimulation of the D1 dopaminergic system via systemic 
administration of SKF 38393 enhanced the attentional/vigilance performance of the animals 
only when task demands were increased.  
SKF 38393 treatment most likely elicited beneficial effects via activation of D1 receptors 
located in the medial prefrontal cortex (mPFC).  Previous work has demonstrated that lesions 
in this brain region impairs attentional function resulting in reduced choice accuracy in the 5-
CSRTT (Muir et al. 1996), thus highlighting the importance of the mPFC in this type of task 
performance.  In addition, previous studies have demonstrated that SKF 38393 improved 
attentional processing in the 5-CSRTT in animals with a reduced performance (Granon et al. 
2000; Fletcher et al. 2007), when administered by microinfusions directly into the mPFC.  
Furthermore, there is evidence to suggest that the DA D1 system is involved in other cognitive 
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processes besides attention and vigilance, including delayed working memory (Arnsten et al. 
1994; Sawaguchi and Goldman-Rakic 1994), spatial learning and memory (Hersi et al. 1995), 
visual learning and memory (Mclean et al. 2009) and reasoning and problem solving (Mclean 
et al. 2009) all of which have been shown to be dysfunctional in patients with schizophrenia 
(Young et al. 2009a), thus demonstrating the importance of this receptor system within 
frontal cortical brain regions in cognitive processes.  The D1 receptor has also been linked to 
motivation for reward (Young and Geyer 2010), which could have confounded the effects 
observed here.  The lack of effect on ML makes this interpretation unlikely, however 
(Robbins 2002).  These data therefore lend support to the hypothesis that activation of the 
D1 system may be a viable target for treating cognitive disruption in schizophrenia 
(Sawaguchi and Goldman-Rakic 1991; Sawaguchi and Goldman-Rakic 1994; Goldman-Rakic et 
al. 2004; Tamminga 2006) 
The reduced event-rate challenge used in the present study challenged the temporal strategy 
of animals, shown by the increased number of premature responses compared to baseline.  
Therefore, D1 agonist treatment-induced improvement in performance may have been 
facilitated by increased learning; enhancing the speed at which animals adjusted to the 
extended ITI and not by improving attention or vigilance per se (Young et al 2009a).  
However, there was no significant reduction in the number of premature responses made in 
the extended ITI challenge session following drug treatment, which would have occurred had 
the animals adapted to the increased duration between stimuli on-set.  These data therefore 
suggest that the improvement in performance was as a result of improved 
attention/vigilance and not due to improved temporal reintegration i.e. adjusting to the 
increase in ITI duration.  As a result, it is possible that augmentation of the dopaminergic D1 
system improved performance by heightening the rats’ ability to detect the signal, without 
enhancing within-session learning that has been demonstrated in previous studies using a 
reduced event-rate challenge (McGaughy and Sarter 1995; Hahn et al. 2002).  The absence of 
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within-session learning in the present study, unlike previous studies that reduced the event-
rate using a fixed ITI, was likely due to the fact that a variable ITI was utilised, thus minimising 
the development of a temporally-mediated strategy being implemented.  Further support for 
this interpretation can be seen when the performance is displayed over the course of the 
session.  An overall ‘trial-independent’ increase in SI following SKF 38393 treatment was 
observed throughout the duration of the session, whereas within-session learning would be 
exemplified by a performance increase as the session progressed.  Moreover, this is also 
supported by an improvement in performance that was seen immediately at the beginning of 
the session, further suggesting increased performance was the result of improved ability to 
detect target stimuli.  These data therefore suggest that activation of the D1 system improved 
vigilance throughout the session and did not simply increase the speed at which the animals 
learned to adapt to the reduced event-rate challenge.  
The impaired performance in the standard conditions in response to SKF 38393 treatment 
may have been as a result of an ‘inverted – U’ shaped dose response, whereby the level of 
DA stimulation is required to be at optimal levels for optimal performance.  Too much or too 
little DA stimulation will result in less than optimal performance as has been observed in 
spatial short-term memory in not only rats (Zahrt et al. 1997), but a variety of species e.g. 
primates and humans (Vijayraghavan et al. 2007).  This effect variation follows the concept of 
the Yerkes-Dodson principle and the link between the level of stress and arousal the 
relationship to behavioural performance (Yerkes and Dodson, 1908; Diamond et al. 2007).  
Thus, the effect SKF 38393 on task performance may depend on basal levels of DA and the 
optimal levels required depending on the nature of the task.  In the case of the standard 
baseline conditions, it is likely that DA utilisation is already at a maximum and therefore any 
further stimulation of the dopaminergic system will have a detrimental effect on task 
performance.  Lyon and Robbins (1975) suggested that in this case, excessive dopaminergic 
transmission impairs performance by progressively increasing the frequency of multiple, 
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concurrent behaviours and may lead to over-focused behaviour.  This suggestion may hold 
true as there was a trend towards an increase in perseverative responding, indicating the 
inability to disengage from a previously rewarded response; however this increase failed to 
achieve statistical significance in the present study.  In response to the increased ITI session, 
it is possible that the conditions of this task would demand an increase in catecholaminergic 
input, which resulted in the reduced baseline performance of rats treated with vehicle and, 
therefore, stimulation of the D1 system by SKF 38393 treatment exerted a beneficial effect on 
task performance.  As SKF 38393 is a partial agonist of the D1 DA receptor (Tirelli and Terry 
1993), future studies could investigate the effects of full DA D1 receptor agonists, such as (+)-
doxanthrine (Przybyla et al. 2009), and their effects on attention and vigilance.  Furthermore, 
the specificity of SKF 38393 should be noted as it has been shown to show affinity for the 5-
HT2c receptor (Briggs et al. 1991).  While involvement of the serotonergic system cannot be 
ruled out in the current study, previous demonstrations have indicated direct D1 involvement 
in cognitive processing (Granon et al. 2000; McLean et al. 2009), future investigation should 
investigate the precise role of SKF 38393 and attention/vigilance.  This would generate a 
more complete understanding of the involvement of DA D1 receptors in this particular 
cognitive domain.  Moreover, future studies could also investigate whether beneficial effects 
are mediated via D1 or D5 DA receptors given the fact that SKF 38393 acts equally on D5 
receptors also (Neumeyer et al. 2003; Qandil et al. 2003). 
These data presented within the current chapter fail to demonstrate a vigilance decrement, 
identified by absence of a reduction in SI as the session progressed in control animals.  In 
Mackworth’s (1950) investigation into vigilance, testing was conducted over relatively long 
periods, suggesting prolonged duration is necessary to induce vigilance decrements.  A 
vigilance decrement was observed in mice in the 5C-CPT, exemplified by a reduced SI when 
the session was extended from 120 to 250 trials (Young et al. 2009b).  A vigilance decrement 
was not observed in the current study, most likely due to the short session lengths used in 
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testing.  Future work could utilise additional task manipulations, such as reduced stimulus 
duration or extended session lengths, to additionally challenge attentional demands and 
further elucidate the mechanisms by which D1 augmentation improves task performance. 
Additionally, as this study was conducted in ‘normal’ animals, future studies could investigate 
the effect augmentation of the D1 system has on 5C-CPT performance when used in 
conjunction with an animal model of cognitive dysfunction present in schizophrenia patients 
(i.e. NMDA receptor antagonism) (Neill et al. 2010).  In addition to the potentially beneficial 
effects of D1 agonism, this would also investigate the potential to pharmacologically impair 
task performance in a manner consistent with CPT performance in a clinical setting.   
In conclusion, the findings of the present study demonstrate that rats can be trained to 
perform the 5C-CPT, a rodent analogue of the human CPT.  In addition, these findings 
support suggestions that activation of DA D1 receptors can improve attentional performance 
in animals that are not encumbered by ceiling effects and display a reduction in performance.  
Importantly, the present data suggest that these effects may be observed following systemic 
administration of the D1 agonists.  Thus D1 agonists may prove therapeutically beneficial in 
attenuating the attentional dysfunction that is evident in patients with schizophrenia.  Based 
on the findings that rats can be trained to perform the modified version of the 5-choice task, 
the following chapter (5) will investigate the effects PCP-treatment has on 5C-CPT 
performance. However, due to the paucity of impairments following a sub-chronic treatment 
regimen had on the original 5-CSRTT (chapter 3), a repeated PCP treatment schedule will be 
utilised instead of a sub-chronic treatment regimen, and animals will be tested while the 
drug is still in the system in the following experimental chapter. 
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5.1 Introduction 
As demonstrated in chapter 4, rats can be trained to respond to target trials requiring a 
response, and correctly withhold a response when presented with non-target trials.   
Therefore, it was demonstrated that rats can be trained to perform in the 5C-CPT, which is a 
task with enhanced analogy to the human CPT.  Experiments designed to assess the 
disruptive effects of PCP treatment in the 5C-CPT are reported in this chapter.  The aim of 
this work is to determine the potential of pharmacologically modelling the attentional 
disruption exhibited in schizophrenia patients, as demonstrated by impaired CPT 
performance. 
It has been widely demonstrated that acute administration of NMDA antagonists produces 
schizophrenia-like cognitive deficits in both rats and mice.  NMDA antagonism impairs the 
ability to successfully perform in the 5-CSRTT (Grottick and Higgins 2000; Higgins et al. 2003; 
Le Pen et al. 2003; Greco et al. 2005; Higgins et al. 2005; Amitai et al. 2007; Auclair et al. 
2009; Paine and Carlezon 2009; Chapter 3). NMDA receptor antagonism results in 
performance impairments that, amongst others, include a reduction in choice accuracy and 
percent correct responding.  These measures have been suggested to be mediated by 
attentional processing (Robbins 2002; Amitai and Markou 2010), therefore suggesting that 
blockade of the glutamatergic NMDA receptor impairs the attentional abilities of the animals, 
impeding their ability to correctly detect and report the occurrence of the visual stimulus 
within the task.  This impaired ability in stimulus detection will invariably lead to the reduced 
accuracy and/or percent correct responding observed and previously reported.   
Coupled with the attentional deficits, acute administration of NMDA antagonists (PCP, MK-
801) increase the number of premature responses during a 5-CSRTT session (Grottick and 
Higgins 2000; Le Pen et al. 2003; Greco et al. 2005).  Elevations in premature responding 
during the 5-CSRTT may represent higher levels of impulsivity or impaired impulse control 
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(Muir et al. 1996; Harrison et al. 1997; Dalley et al. 2008).  However, a single dose of PCP has 
also been demonstrated to produce a reduction in premature responding (Auclair et al. 
2009).  Consequently, Amitai and colleagues (2007) suggested that the reduction in 
premature responding may be attributed to the generalised response disruption induced by 
acute PCP treatment, rather than an effect on response inhibition per se.  Accordingly, Amitai 
et al. (2007) hypothesised that some of the performance impairments observed following 
acute exposure may be the result of a nonspecific response-suppressive effect, suggesting 
that deficits were the result of a generalised inability of the rat to perform in the task.  This 
observation is in contrast to the effects observed in chapter 3, where following an acute PCP 
challenge there was an increase in premature responding.  However, as discussed in chapter 
3, the treatment regimen utilised consisted of a Latin Square design with each animal acting 
as its own control, therefore receiving multiple PCP exposures.  As a result, the increase in 
premature responding observed in chapter 3 may not be the result of a true single acute 
exposure, and may be more akin to a repeated PCP treatment regimen (Amitai and Markou 
2010), perhaps accounting for the discrepancy in premature responding observed between 
studies.  Single acute administration of PCP (and other NMDA receptor antagonists) can 
result in profound behavioural deficits, including stereotypy, ataxia, sedation, paralysis of 
hind-limbs, locomototor impairment and/or motivational disruption (Castellani and Adams 
1981; Melnick et al. 2002; Daenen et al. 2003; Amitai et al. 2007).  These non-cognitive, non-
specific behavioural disturbances may impair performance of operant tasks.  Hence, non-
specific effects arising from single acute administration may confound the observation of 
cognitive disruption, obscuring the final interpretation and potentially mask the cognitive-
specific impairments. 
In an attempt to circumvent the generalised response disruption associated with acute PCP 
administration, a repeated PCP treatment regimen has been developed (Amitai et al. 2007; 
Amitai and Markou 2009; Amitai and Markou 2010).  Like acute treatment, animal 
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performance is assessed following a pre-treatment period.  However, in contrast to acute 
treatment, the drug is administered multiple times, over consecutive days.  The rationale for 
this pattern of drug exposure is that the initial behavioural disruptive effects arising from 
acute exposure dissipate following repeated administration, revealing a more selective 
cognitive-disruptive effect.  The effects of ataxia, stereotypy and locomotor impairment 
often observed with acute PCP treatment (Castellani and Adams 1981; Melnick et al. 2002; 
Daenen et al. 2003) are dramatically reduced or completely ameliorated following repeated 
PCP exposure (Amitai and Markou 2010).  Therefore, some of the more profound behavioural 
disturbances evident at the start of treatment, impairing the animals’ ability to perform 
complex tasks are reduced towards the end of the treatment regimen.  Hence a repeated 
administration facilitates the quantification of cognitive-specific impairments in behavioural 
paradigms, reducing the potential of interpretations being confounded by the non-specific 
behavioural effects of the drug.  Furthermore, the profound behavioural disturbance arising 
from acute PCP administration demonstrates considerable inter-animal variability, with some 
rats exhibiting a marked sensitivity to the stereotypy or ataxic effects, whilst others are 
considerably less affected (Amitai et al. 2007; personal communication; personal 
observations).  The initial exposure to PCP permits animals to be group-matched based on 
performance before and after the initial exposure to PCP.  The group-matching procedure 
enables an even distribution of animals highly sensitive to the PCP-induced generalised 
behavioural disruption  to be made throughout the treatment groups, avoiding the potential 
confound of unintentionally or randomly assigning all of the highly PCP-sensitive animals to 
the same treatment group.  This is a particularly important consideration in studies involving 
pharmacological attenuation of the PCP-induced performance impairment. 
A repeated PCP treatment regimen has been shown to impair choice accuracy and induce a 
reduction in the percent of correct responses in animals trained within the 5-CSRTT (Amitai 
et al. 2007; Amitai and Markou 2009; Amitai and Markou 2010), indicating impaired 
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attentional function (Robbins 2002).  Systemic PCP treatment may be disrupting the 
functioning of the frontal and prefrontal cortical regions, as these areas are densely 
populated with NMDA receptors (Cotman and Iversen 1987; Ulus et al. 1992) and suggested 
to be involved in attentional processing (Asplund et al. 2010; Bush 2010; Lesh et al. 2010).  
Furthermore, local infusion of NMDA antagonists within the medial PFC (mPFC) has been 
demonstrated to impair choice accuracy in the 5-CSRTT (Baviera et al. 2008).  Additionally, 
the initial response suppression which resulted in reduced premature responding (Amitai et 
al. 2007) was overcome following subsequent PCP exposure, resulting in impaired impulse 
control increasing  inappropriate responding during the ITI  (Amitai et al. 2007; Amitai and 
Markou 2009).  Premature responding has also been shown to be increased following local 
NMDA receptor blockade within the mPFC (Mirjana et al. 2004; Baviera et al. 2008), 
implicating this region’s involvement not only in attentional functioning, but also inhibitory 
control.  Additionally, the Markou group have also demonstrated that repeated exposure to 
PCP resulted in an increase in the latency to make a correct response, which was not 
accompanied by an increase in magazine latency.  As previously suggested (Robbins 2002; 
chapter 3), the increased time taken to respond to the target stimulus may be the result of 
PCP impairing the animal’s ability to processes incoming sensory information, consistent with 
previous studies (Grottick & Higgins, 2000; Le Pen et al. 2003; Auclair et al. 2009).  The 
elevation in time taken to respond to the stimulus cue is potentially mediated by a cognitive-
specific process, rather than motor or motivational impairment, as locomotor or motivational 
effects would also result in a concomitant increase in the time taken for the animals to 
retrieve the food reward, an effect which was not observed. 
Performance in another preclinical attentional task, the sustained attention task (SAT – 
described in detail in chapters 1 and 4), has been shown to be sensitive to disruption 
following NMDA antagonist administration (Rezvani and Levin 2003; Rezvani et al. 2008a, b; 
Rezvani et al. 2009).  Briefly, the SAT session is composed of two trial types and requires the 
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animal to report the detection of a visual signal (during the signal trial) or report the absence 
of the signal (during the non-signal trial) by pressing one of two response levers.  During the 
signal trial, lever presses result in either a hit (correct response) or a miss (incorrect 
response), thus generating a measure of response accuracy.  Conversely, in the non-signal 
trial, lever responses result in either correct rejections or false alarms, depending on correct 
or incorrect detection of the non-signal event prior to lever presentation (McGaughy and 
Sarter 1995).  The study conducted by Rezvani and colleagues (2003; 2008a, b) consisted of a 
session comprised of 300 trials, split into three blocks of 100 trials.  Following administration 
of MK-801, animals showed impaired ability to correctly report the detection of the signal 
trials (reduction in hit rate) in the latter two blocks of trials.  Furthermore, an increase in non-
signal trials incorrectly reported as signal trials (increase in false alarms) was evident across 
the entire session, following NMDA antagonism.  Taken together, the effect of MK-801 on 
signal and non-signal trials demonstrated by Rezvani and colleagues (2003; 2008a, b) provide 
supporting evidence to previous findings of attentional dysfunction following glutamatergic 
disruption. 
As previously discussed in chapters 1 and 4, cortical dopaminergic transmission is intrinsically 
linked to many of the cognitive domains playing a regulatory role (Goldman-Rakic et al. 
2004), and is suggested to be involved in modulating attentional functioning in humans 
(Nieoullon 2002) and schizophrenia patients (Cohen and Servan-Schreiber 1993).  As 
previously described (chapter 4), the effects of dopamine on cognition follow an ‘inverted-U’ 
shaped dose response curve i.e. the Yerkes-Dodson principle (Yerkes and Dodson 1908; 
Diamond et al. 2007; Vijayraghavan et al. 2009).  Therefore, attentional performance may be 
sensitive to impairment following alterations in dopamine efflux.  The dopaminergic system 
is closely linked with glutamatergic transmission.  Hirsch and colleagues (1996) have 
described that dendritic spines of glutamatergic pyramidal cells (located in the cortical layers) 
receive afferent innervations from dopaminergic neurons (Smiley et al. 1992).  Glutamate 
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receptors are located in the synapses of fibres arising from the nigrostriatal pathway (Roberts 
and Anderson 1979) and dopamine receptors are located in the synapses of glutamatergic 
projections arising from the striatum (Schwartz et al. 1978).  Furthermore, activation of 
NMDA receptors has been observed to alter the distribution of dopamine D1 receptors and D1 
activation increases the expression of NR1, NR2A and NR2B subunits of the NMDA receptor 
(Dunah et al. 2001; Cepeda et al. 2009).  These observations strongly suggest that a 
reciprocal relationship exists between dopaminergic and glutamatergic neurotransmitter 
systems (Carlsson 1995; Hirsch et al. 1996) and alterations in glutamatergic functioning may 
impact dopaminergic transmission, as a result influencing the cognitive processes mediated 
by the dopaminergic system.  
NMDA receptor antagonism has been shown to affect dopaminergic transmission; however it 
is highly dependent on the treatment regimen used.  Acute administration of PCP (and other 
NMDA receptor antagonists) is associated with a marked increase in dopaminergic 
transmission (Deutch et al. 1987; Hertel et al. 1996; Jentch et al. 1997c; Verma and 
Moghaddam 1997; Jentsch and Roth 1999; Jentsch et al. 2008) in both cortical (PFC) and sub-
cortical (ventral striatum i.e. nucleus accumbens) regions.  In contrast to acute 
administration, following sub-chronic PCP treatment, a reduction of dopamine turnover in 
the prefrontal cortex has been observed in both rats and monkeys (Jentsch et al. 1997a, b; 
Jentsch and Roth 1999; Noda et al. 2000).  After sub-chronic PCP exposure (in the drug-free 
state), a persistent reduction (at least 3 weeks) of around 75% of the basal dopamine levels 
were observed in prefrontal cortical regions, but not ventral or dorsal striatum (Jentsch et al. 
1997b; Jentsch et al. 1998).  The reduction in frontal cortical dopaminergic turnover was 
quantified by assessing the levels of dopaminergic metabolites (dihydroxy-O-phenyl-acetic 
acid [DOPAC]) in relation to dopamine.  Jentsch and Roth (1999) commented that the 
reduction in metabolite ratio (and thus utilisation levels) were not mediated by excessive 
neurotoxicity arising from sub-chronic PCP exposure, suggesting that the dopaminergic 
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abnormalities are specifically the result of abnormal levels of dopamine available.  
Furthermore, using autoradiography, it has been shown that sub-chronic PCP treatment 
reduces binding of a radioligand to dopamine D1 receptors in the basal ganglia (medial and 
lateral caudate-putamen) in rats (Choi et al. 2009).  These findings reveal that in contrast to 
acute administration, sub-chronic exposure to NMDA antagonists alters dopaminergic 
function, through a reduction in the ability of effective transmission; highlighting the 
dissociation of dopaminergic effects and various PCP treatment regimens.  However, the 
precise effects of dopaminergic transmission following repeated PCP treatment are still not 
entirely clear.  Dopamine levels may be increased, substantially or slightly, or reduced 
compared to basal levels.  However, the potential alterations in dopamine D1 function 
induced by repeated PCP treatment may be linked with the cognitive disruption observed.  
As a result, augmentation of the dopaminergic D1 system may prove fruitful in mediating 
cognitive enhancement in experimental animals or the compromised clinical populations 
(Goldman-Rakic et al. 2004; Hagen and Jones 2005; Tamminga 2006; Ibrahim and Tamminga 
2010). 
As the preceding chapter demonstrated that rats can be successfully trained to perform the 
modified version of the 5-CSRTT, the aim of the current chapter was to assess the disruptive 
effects of PCP within the 5C-CPT.  However, due to the paucity of effects observed using a 
sub-chronic treatment regimen in the 5-CSRTT (chapter 3); a repeated PCP treatment 
regimen (Amitai et al. 2007) was implemented in the current chapter.   Furthermore, in light 
of the reciprocal interaction between the glutamatergic and dopaminergic neurotransmitter 
systems, the putative abilities of systemic administration of the D1 partial agonist SKF 38393 
in attenuating a PCP-induced performance disruption was investigated.  The rational for this 
came from the observation that D1 augmentation improved 5C-CPT performance in a 
baseline-dependent manner (chapter 4). 
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5.2 Methods 
5.2.1 Subjects 
Female hooded-Lister rats (n=23; Charles River; approx 250 + 10 g at the start of the 
experiment) were housed on a 12 hour reversed light cycle (lights on at 7:00 pm) in a 
temperature (21 + 2oC) and humidity (55 + 5%) controlled environment.  For details regarding 
food restriction please refer to chapter 2. 
 
 5.2.2 Treatment Regimen 
The repeated PCP treatment regimen was adapted from that used by Amitai et al. (2007) 
(summarised in fig 5.1) and consisted of all animals being injected with vehicle (0.9% saline) 
for three days (days 1 – 3) followed by two days (days 4 and 5) where all animals received 
PCP (2.5 mg/kg i.p.).  Animals were then treated with vehicle for 5 consecutive days followed 
by 5 consecutive days of PCP treatment.  Animals were tested in the 5C-CPT on each day, 30 
minutes following drug administration.  During the second PCP treatment period (days 11 – 
15), animals were pre-treated 60 minutes before testing (30 minutes before PCP treatment) 
with either vehicle (0.9% saline, n = 11) or SKF 38393 (6.0 mg/kg i.p.;  the dose established as 
the most efficacious in chapter 4; n = 12).  This dosing regimen facilitated the investigation 
into whether pre-treatment with a D1 partial agonist can attenuate any disruptive effects in 
task performance that may arise from repeated PCP treatment.  Following the 15-day 
treatment regimen, performance was assessed for a further 3 days (day 16 – 18) following 
saline administration, assessing the potential long-term impact of repeated drug treatment 
on 5C-CPT performance, although this is not displayed on the schematic. 
 
 
Chapter 5                                                                                                Repeated PCP and the 5C-CPT 
124 
 
Fig 5.1 Diagram summarising the repeated PCP treatment regimen used. Arrows indicate PCP injection.  On days 
1-3 and 6 – 10, all animals received vehicle (0.9% saline) injections.  During the second period of PCP 
administration (days 11 – 15), animals were pre-treated with either vehicle or SKF 38393 prior to PCP 
administration. 
 
5.2.3 Group-Matching 
There is a great level of individual variability regarding sensitivity to PCP, resulting in some 
animals having a more profound reaction to PCP treatment than others (Amitai et al. 2007).  
This treatment regimen enabled animals to be group-matched depending on individual 
responsivity to both vehicle and PCP treatment.  On day 6, after all animals had been 
exposed to both saline (days 1 – 3) and PCP (days 4 and 5), animals were grouped into two 
treatment groups, based on their performance (based on several parameters) over the initial 
days of the treatment regimen.  Animals were balanced according to the following 
parameters, listed in the order of importance: accuracy, sensitivity index, premature 
responding, percent correct responding, correct rejections, percent omissions, responsivity 
index, correct latency and magazine latency.  The group-matching procedure ensured no 
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baseline differences in the initial response to PCP treatment existed between treatment 
groups, enabling a meaningful comparison of pharmacological attenuation of PCP-induced 
impairment to be made, without rats’ individual sensitivity to PCP confounding 
interpretation. 
 
5.2.4 Data Analysis 
5.2.4.1 Effect of PCP in 5C-CPT 
For each animal, the three measures from days 1 - 3 were used to produce an average 
baseline response per animal. An initial analysis was carried out, in the PCP treatment group 
that also received saline, facilitating a specific analysis investigating the effect of PCP 
treatment on 5C-CPT performance.  This was conducted using a one-way repeated measures 
analysis of variance (ANOVA) approach with Day of administration as the repeated factor.  All 
days of PCP administration (days 4 and 5 and days 11 – 15), along with the average baseline, 
were included in the analysis.  Individual performance following each dose of PCP was 
compared to baseline performance using within-animal Planned Comparisons.   The above 
analysis was repeated using animals pre-treated with SKF 38393 (days 11 – 15 only), with a 
repeated measures ANOVA comparing performance to the averaged baseline performance of 
days 1 – 3.  Planned Comparisons were again utilised to assess the within-animal alteration of 
baseline performance. 
 
5.2.4.2 Effect of SKF 38393 Treatment on PCP-induced Disruption 
To assess the effect of treatment, a second analysis was performed on days 11 to 15 data 
only.  Data were analysed using a two-way repeated measures analysis of covariance (RM-
ANCOVA) approach with Treatment as the fixed factor, Day of administration as the repeated 
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factor and average baseline performance of each animal as a covariate, compensating for 
between-animal variability which may have existed between the animals’ responses at 
baseline, therefore enhancing the statistical power of the approach.  Between-animal 
Planned Comparisons were then used to assess the effect of the SKF 38393 treated group 
compared to the saline group on days 11 – 15.  
 
5.2.4.3 Overall Performance 
To assess the overall effect of treatment across days 11-15, performance for each animal, on 
each day, was averaged.  Overall performance was displayed using an observed means with 
SEMs plot. Note: Saline and SKF 38393 are labelled on the figure to indicate future treatment 
as animals were only treated with saline during baseline testing.  Overall performance was 
assessed using unpaired Students t-test. 
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5.3 Results 
5.3.1 Effect of repeated PCP treatment on 5C-CPT performance 
Initially, the effect of PCP alone was analysed in order to specifically demonstrate the effect 
of repeated administration on task performance.  Analysis revealed that repeated PCP 
treatment resulted in a significant reduction in accuracy [F(7, 70) = 3.11, p<0.01] (fig 5.2A) and 
Planned Comparisons demonstrated a significant PCP-induced reduction in accuracy on day 4 
(p<0.05), day 5 (p<0.01), day 11 (p<0.05), day 12 (p<0.01), day 13 (p<0.05), day 14 (p<0.01), 
and day 15 (p<0.001).  Analysis also demonstrated an overall significant increase in the 
percentage of incorrect responses made during the 5C-CPT session, following PCP treatment 
[F(7,70)=2.72, p<0.05] (fig 5.2B).  A significant increase was evident on day 4 (p<0.05), day 5 
(p<0.05), day 11 (0.01), day 12 (p<0.01), day 13 (p<0.01), day 14 (p<0.05), and day 15 
(p<0.01). 
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Fig 5.2 Repeated PCP administration impaired performance, indicated by a significant reduction in response 
accuracy (A) and an increase in percent incorrect responding (B). Data are expressed as observed mean + SEM, n = 
11. * p<0.05, ** p<0.01 and *** p<0.001 significant difference compared to baseline performance. 
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Additionally, repeated PCP administration resulted in a significant reduction in the 
percentage of correct responses made throughout the session [F(7, 70) = 4.87 p<0.001] (fig 
5.3A).  This reduction was evident following PCP exposure on day 4 (p<0.05), day 5 (p<0.01), 
day 11 (p<0.01), day 12 (p<0.001), day 13 (p<0.05), day 14 (p<0.05) and day 15 (p<0.001).  
This effect was coupled with a significant increase in the percentage of omissions made 
during the session [F(7, 70) = 3.85, p<0.01] (fig 5.3B). Planned Comparisons demonstrated the 
increase in omissions was only evident on treatment day 5, 11, 12, and 15 (p<0.01). 
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Fig 5.3 Repeated PCP administration significantly reduced percent correct responding (A) and increased percent 
omissions. Data are expressed as observed mean + SEM, n = 11. * p<0.05, ** p<0.01 and *** p<0.001 significant 
difference compared to baseline performance. 
 
PCP treatment induced an increase in the latency to make a correct response [F(7, 70) = 2.55, p 
< 0.05] (fig 5.4A), which was evident on day 4 (p<0.01), day 5 (p<0.01), day 11 (p<0.05), day 
12 (p<0.01), and day 15 (p<0.01).  One-way repeated measures ANOVA demonstrated there 
was no overall significant effect of PCP treatment on magazine latency [F(7,70)=1.26, NS] (fig 
5.4B), however Planned Comparisons demonstrated a significant increase in ML on day 4, 5 
and 11 (p<0.05). 
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Fig 5.4 Repeated PCP administration impaired performance and significantly increased CL (A). While PCP 
treatment initially increased ML, any increase was not statistically significant after the third exposure to PCP (B). 
Data are expressed as observed mean + SEM, n = 11.  * p<0.05 and ** p<0.01 significant difference compared to 
baseline performance.  
 
Repeated PCP treatment resulted in an increase in perseverative responses [F(7, 70) = 4.31, 
p<0.001] (fig 5.5A) with Planned Comparisons demonstrating a significant increase in 
perseveration on day 11 (p<0.05), day 12 (p<0.01), day 13 (p<0.05), day 14 (p<0.01) and day 
15 (p<0.01).  Similarly, a significant increase in time out responding was observed following 
one-way repeated measures ANOVA [F(7,70)=5.14, p<0.001] (fig 5.5B), with Planned 
Comparisons demonstrating a significant increase on day 4 (p<0.01), day 5 (p<0.05), day 11 
(p<0.01), day 12 (p<0.05), day 13 (p<0.01), day 14 (p<0.01) and day 15 (p<0.01).  
Furthermore, there was a significant increase in inappropriate premature responding [F(7, 70) = 
4.48, p<0.001] (fig 5.5C), Planned Comparisons showed that the significant increase in 
premature responding was evident on day 11 (p<0.05), day 12 - 15 (p<0.01).  
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Fig 5.5.  Repeated PCP administration impaired performance shown as a significant increased in perseverative 
responding (A), time out responding (B) and premature responding (C).  Data are expressed as observed mean + 
SEM, n = 11.  * p<0.05 and ** p<0.01 significant difference compared to baseline performance.  
 
Additionally, repeated PCP administration induced an inability to withhold responding in the 
non-signal trials, exemplified by an overall significant reduction in correct rejections [F(7, 70) = 
3.22, p<0.01] (fig 5.6).  The reduction in percent correct rejections was evident on day 5 
(p<0.01), day 11 (p<0.05), day 13 (p<0.05), day 14 (p<0.05) and day 15 (p<0.001). 
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Fig 5.6  Repeated PCP administration impaired performance as significantly reduced correct rejections of non-
target trials.  Data are expressed as observed mean + SEM, n = 11.  * p<0.05, ** p<0.01 and *** p<0.001 
significant difference compared to baseline performance.  
 
PCP treatment also resulted in a significant reduction the hit rate when presented with target 
trials [F(7, 70) = 4.87, p<0.001] (fig 5.7A).  A significant reduction in HR was demonstrated on 
day 4 (p<0.05), day 5 (p<0.01), day 11 (p<0.01), day 12 (p<0.001), day 13 (p<0.05), day 14 
(p<0.05) and day 15 (p<0.001).  A significant increase in the false alarm rate was 
demonstrated following PCP treatment  [F(7, 70) = 3.22, p<0.01] (fig 5.7B), with a significant 
increase in incorrect responding to non-target trials evident on day 5 (p<0.01), day 11 
(p<0.05), day 13 (p<0.05), day 14 (p<0.05), and day 15 (p<0.001). 
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Fig 5.7  Repeated PCP administration impaired performance as significantly reduced hit rate of target trials (A) and 
increased the false alarm rate of non-target trials (B).  Data are are expressed as mean + SEM, n = 11. * p<0.05, ** 
p<0.01 and *** p<0.001 significant difference compared to baseline performance. 
 
Due to the significant reduction and increase in HR and FAR respectively, it was apparent that 
repeated PCP treatment induced a significant reduction in the sensitivity index [F(7, 70) = 7.65, 
p<0.001] (fig 5.8A).  This effect was demonstrated on day 4 (p<0.05), day 5 (p<0.001), day 11 
(p<0.01), day 12 (p<0.001), day 13 (p<0.01), day 14 (p<0.01) and day 15 (p<0.001).  The 
reduction in SI was independent of an overall alteration in the responsivity index, as this 
analysis showed no significant effect [F(7, 70) = 1.87, NS] (fig 5.8B).  Although there was no 
evidence of an overall alteration in RI, Planned Comparisons indicated a significant reduction 
on day 11 (p<0.05) and 12 (p<0.01), following PCP treatment. 
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Fig 5.8 Repeated PCP treatment significantly reduced the sensitivity index (A). Repeated PCP treatment reduced 
RI on treatment days 11 and 12 but following subsequent administration, alterations in RI were not significantly 
different to that of baseline (B).  Data are expressed as observed mean + SEM, n = 11. * p<0.05, ** p<0.01 and *** 
p<0.001 significant difference compared to baseline performance. 
 
Animals were tested on days 16 – 18 following saline administration, and performance 
analysed following one-way repeated measures ANOVA.  Performance for each behavioural 
measure returned to baseline, with no statistically significant differences between days 1-3 
and days 16 – 18 (data not shown).  
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5.3.2 Effects of SKF 38393 pre-treatment on the PCP-induced 5C-CPT disruption 
The following section demonstrates the effect of pre-treatment of either SKF 38393 or saline 
on the PCP-induced impairment in 5C-CPT performance.  The focus of the figures was to 
describe the between-subjects difference (two-way RM ANCOVA) during treatment days 11 – 
15 (greyed area).  As such, only these results are shown graphically.  The within-subjects 
differences (one-way ANOVA) of SKF 38393-treated animals following treatment compared 
to baseline performance, while conducted and reported within the text, were not graphically 
displayed in order to maintain clairity within the figure.  Furthermore, although the main 
focus of this section was to demonstrate the longitudinal effect of repeated drug treatment, 
the overall performance for both groups at baseline (days 1 – 3) and drug treatment (days 11 
– 15) are displayed as column charts. 
Investigation of the PCP animals pre-treated with SKF 38393 following one-way repeated 
measures ANOVA (Day as repeated factor) showed an overall significant effect [F(5,50)=10.89, 
p<0.001].  Within-subjects Planned Comparisons demonstrated that accuracy was reduced 
on days 11 (p<0.01), 12 (p<0.01), 14 (p<0.01), and 15 (p<0.05), compared to baseline 
accuracy (data not shown).  An overall significant effect was observed when percent 
incorrect responding was analysed by one-way repeated measures ANOVA [F(5,50)=2.66, 
p<0.05], with Planned Comparisons indicated a significant increase in incorrect responding 
was observed on day 11 only (p<0.05) (data not shown).  Two-way repeated measures 
analysis of covariance (ANCOVA) of the effect on accuracy demonstrated a strong trend 
towards an interaction between Treatment and Day [F(4,80)=2.22, p=0.07] (fig 5.9A), but 
Planned Comparisons between the two treatment groups indicated a significant increase in 
response accuracy in SKF 38393 treated animals on days 13 – 15 (p<0.05).  Although there 
was no significant Treatment*Day interaction for percent incorrect responding [F(4,80)=1.33, 
NS] (fig 5.9C), ANCOVA did indicate an overall SKF 38393 treatment effect [F(1,20)=14.47, 
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p<0.01].  Planned Comparisons between the two treatment groups showed SKF 38393 
treatment significantly reduced incorrect responses made during the session on days 13 – 15 
(p<0.01).  Students t-test indicated that SKF 38393 treatment significantly increased (t = 2.39, 
df = 110, p<0.05) the accuracy of PCP treated animals (fig 5.9B).  Furthermore, incorrect 
responding was also significantly (t = 4.86, df = 110, p<0.001) reduced in SKF 38393 treated 
animals (fig 5.9D). 
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Fig 5.9. Pre-treatment with SKF 38393 significantly attenuated the PCP-induced reduction in response accuracy 
(A) and percent incorrect responses (C) on days 13 – 15.  Overall response accuracy (B) and percent incorrect 
responding (D) was attenuated following SKF 38393 treatment.  Data are expressed as observed mean + SEM. 
Animals were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP administration. * denotes 
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p<0.05, ** denotes p<0.01 and *** denotes p<0.001 significant difference between treatment group.  Arrows 
represent PCP administration.  
An overall significant effect on percent correct responding following SKF 38393 and PCP 
treatment was observed [F(5,50)=12.75, p<0.001], with Planned Comparisons demonstrating a 
significant reduction on day 11 (p<0.01), day 12 (p<0.001), day 13, (p<0.05), day 14 (p<0.001) 
and day 15 (p<0.001) (data not shown).  Similarly, an overall significant effect was observed 
in animals treated with SKF 38393 and PCP on the number of omissions made [F(5,50)=11.65, 
p<0.001] and percent omissions was increased on day 11 (p<0.01), day 12 (p<0.001), day 13 
(p<0.05), day 14 (p<0.001) and day 15 (p<0.01) (data not shown).  Repeated measures 
ANCOVA showed SKF 38393 treatment had no between-subjects effect on the PCP-induced 
reduction of percent correct responding [F(4,80)=0.7, NS] (fig 5.10A), compared to the control 
(saline + PCP) group.  Analysis also demonstrated that SKF 38393 treatment had no effect on 
the PCP-induced increase in the number of trials omitted during the 5C-CPT session 
[F(4,80)=0.7, NS] (fig 5.10C).  There was no overall difference in percent correct responding (t = 
0.21, df = 110, NS) (fig 5.10B) or percent omissions (t = 1.09, df = 110, NS) (fig 5.10D) 
between treatment groups following Students t-test analysis. 
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Fig 5.10 Pre-treatment with SKF 38393 had no impact on the PCP-induced reduction of percent correct 
responding (A, B) or the PCP-induced increase in trials omissions (C, D). Data are expressed as observed mean + 
SEM. Animals were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP administration. Arrows 
represent PCP administration. 
 
One-way repeated measures ANOVA of SKF 38393 treated animals showed that drug 
treatment significantly increased the latency to make a correct response [F(5,50)=5.82, 
p<0.001], with Planned Comparisons indicating CL was increased on day 11 (p<0.01), day 12, 
(p<0.05), day 13 (p<0.01), day 14 (p<0.001), and day 15 (p<0.01) (data not shown).  
Additionally, analysis suggested there was an overall significant effect on latency to collect 
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the food reward [F(5,50)=3.03, p<0.05], but Planned Comparisons demonstrated the significant 
increase in ML was only evident on day 11 (p<0.01), day 12 (p<0.01), day 13 (p<0.001) and 
day 14 (0.001) (data not shown).  Any alteration of ML on day 15 was not significantly 
different from baseline.  ANCOVA analysis demonstrated SKF 38393 treatment had no 
significant effect on the PCP-induced increase in correct response latency [F(4,80)=0.5, NS] (fig 
5.11A) and there was no effect between treatment groups when the effect on magazine 
latency was assessed [F(4,80)=1.75, NS] (fig 5.11C).  Overall analysis also indicated no 
difference between treatment groups for CL (t = 0.3, df = 110, NS) (fig 5.11B) or ML (t = 0.11, 
df = 110, NS) (fig 5.11D). 
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Fig 5.11.  SKF 38393 treatment had no effect on the PCP-induced increase in CL (A, B). SKF 38393 treatment had 
no effect on the PCP-induced  ML effect (C, D). Data are expressed as observed mean + SEM. Animals were pre-
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treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP administration. Arrows represent PCP 
administration. 
Perseverative responding was also significantly increased following SKF 38393 and PCP 
treatment [F(5,50)=3.99, p<0.01] and Planned Comparisons indicated perseverative responding 
was increased compared to baseline on day 11 (p<0.01), day 13 (p<0.01), day 14 (p<0.05) and 
day 15 (p<0.05) (data not shown).  Additionally, there was a significant increase in 
inappropriate TO responding following SKF 38393 and PCP treatment [F(5,50)=5.47, p<0.001].  
Planned Comparisons demonstrated that TO responding was significantly increased on day 
11 (p<0.01), day 12 (p<0.05, day 13 (p<0.001), day 14 (p<0.001) and day 15 (p<0.001) (data 
not shown).  Likewise, there was no overall effect or treatment interaction when the effect 
on perseverative responding was analysed following RM ANCOVA [F(4,80)=0.2, NS] (fig 5.12A), 
but Planned Comparisons of performance means between the two treatment groups 
demonstrated a SKF 38393-induced reduction of perseverative responding on day 12 
(p<0.05).  ANCOVA analysis indicated no effect of drug treatment on the number of time out 
responses made between treatment groups [F(4,80)=1.56, NS] (fig 5.12C).  Students t-test 
indicated an overall significant reduction in perseverative responding in SKF 38393 treated 
animals (t = 2.61, df = 110, p<0.05) (fig 5.12B).  No overall difference was observed for TO 
responding, however a trend towards an SKF 38393-induced reduction was observed (t = 
1.93, df = 110, p<0.1) (fig 5.12D). 
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Fig 5.12. Pre-treatment with SKF 38393 significantly attenuated the PCP-induced increase in perseverative 
responding on day 12 (A) and resulted in an overall significant reduction (B), but had no significant effect on the 
PCP-induced elevation of inappropriate time out responding (C, D). Data are expressed as observed mean + SEM. 
Animals were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP administration. * p<0.05 
significant difference between treatment group.  Arrows represent PCP administration. 
 
Upon within-subjects analysis of SKF 38393 treated animals, there was a PCP-induced 
increase in premature responding [F(5,50)=4,97, p<0.001].  Planned Comparisons indicated the 
number of premature responses was increased on day 11 (p<0.01), day 13 (p<0.01), day 14 
(p<0.01) and day 15 (p<0.05), compared to baseline (data not shown).  Between-subjects 
ANCOVA analysis showed no effect of Treatment on the number of premature responses 
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made following PCP treatment and also showed no interaction between Treatment and Day 
[F(4,80)=0.12, NS] (fig 5.13A).  However, Planned Comparisons indicated that SKF 38393 
treatment on day 12 significantly reduced the number of PCP-induced premature responses.  
Overall analysis demonstrated that SKF 38393 pre-treatment significantly attenuated the 
PCP-induced increase in premature responding (t = 3.43, df 110, p<0.01) (fig 5.13B). 
1 2 3 4 5 6 7 8 9 101112131415
0
20
40
60
80
100
Saline
SKF 38393
*
A
Treatment Day
P
re
m
a
tu
re
Saline SKF Saline SKF
0
20
40
60
80
100
***
B
Baseline PCP
P
re
m
a
tu
re
Fig 5.13 SKF 38393-treatment significantly ameliorated the PCP-induced increase in inappropriate premature 
responding on treatment day 12 (A). Overall PCP-induced premature responding was attenuated in SKF 38393-
treated animals.  Data are expressed as observed mean + SEM. Animals were pre-treated with ether saline (n=11) 
or SKF 38393 (n=12) prior to PCP administration.  * p<0.05 and *** p<0.01 significant difference between 
treatment group. Arrows represent PCP administration. 
 
Within-subjects analysis indicated an overall significant effect on correct rejections, resulting 
from SKF 38393 and PCP treatment [F(5,50)=2.70, p<0.05].  However, within-subject Planned 
Comparisons demonstrated that a significant reduction in correct rejections, compared to 
baseline performance, was only evident on day 11 (p<0.01) (data not shown).  Between-
subjects ANCOVA analysis indicated there was no significant interaction between Treatment 
and Day [F(4,80)=1.91, NS] (fig 5.14A), but Planned Comparisons demonstrated there was a 
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significant SKF 38393-induced attenuation of the PCP-induced reduction of correct rejections.  
The SKF 38393-induced significant increase in correct rejections occurred on treatment day 
15 only (p<0.01).  However, overall Students t-test indicated a significant increase in correct 
rejections in PCP animals pre-treated with SKF 38393 (t = 2.58, df = 110, p<0.05) (fig 5.14B). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
40
50
60
70
80
90
Saline
SKF 38393
**
A
Treatment Day
C
o
rr
e
c
t 
R
e
je
c
ti
o
n
 (
%
)
Saline SKF Saline SKF
0
10
20
30
40
50
60
70
80
90
B
Baseline PCP
*
C
o
rr
e
c
t 
R
e
je
c
tio
n
 (
%
)
Fig 5.14 SKF 38393 treatment significantly attenuated the PCP-induced reduction in correct rejections on 
treatment day 15 (A).  Overall correct rejections were increased in SKF 38393 treated animals (B).  Data are 
expressed as observed mean + SEM. Animals were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior 
to PCP administration. * p<0.05 and ** p<0.01 significant difference between treatment groups. Arrows represent 
PCP administration. 
One-way repeated measures ANOVA indicated that the hit rate of SKF 38393 treated animals 
was significantly reduced [F(5,50)=12.75, p<0.001].  Planned Comparisons indicated that HR 
was significantly reduced on day 11 (p<0.01), day 12 (p<0.001), day 13 (p<0.05), day 14 
(p<0.001), and day 15 (p<0.01) (data not shown).  Within-subject analysis also demonstrated 
a significant increase in false alarms following SKF 38393 and PCP treatment [F(5,50)=2.71, 
p<0.05], but the only day where p[FA] was significantly elevated was day 11 (p<0.01) (data 
not shown).  Between-subjects ANCOVA analysis indicated no effect of SKF 38393 treatment 
on the PCP-induced reduction of hit rate [F(4,80)=0.7, NS] (fig 5.15A).  In a similar manner to 
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the effect on correct rejections, there was no overall effect of SKF 38393 treatment on the 
PCP-induced increase in false alarms [F(4,80)=191, NS] (fig 5.15C).  However, Planned 
Comparisons demonstrated a between-subjects reduction in false alarms, showing that SKF 
38393 treatment significantly reduced incorrect responding to non-target trials on day 15 
(p<0.01).  No overall effect was observed between treatment groups for hit rate (t = 0.21, df 
= 110, NS) (fig 5.15B).  In contrast, an overall significant reduction in false alarms was 
observed in the SKF 38393 treatment group (t = 2.58, df = 110, p<0.01) (fig 5.15D). 
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Fig 5.15. SKF 38393 treatment did not significantly attenuate the PCP-induced reduction in hit rate (A, B) but did 
significantly reduce the PCP-induced increase in false alarms on day 15 (C).  Overall analysis also indicated a SKF 
38393-induced significant reduction in false alarms (D).  Data are expressed as observed mean + SEM. Animals 
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were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP administration. ** p<0.01 significant 
difference between treatment group. Arrows represent PCP administration. 
 
Analysis demonstrated there was a significant within-subject reduction in SI following SKF 
38393 and PCP treatment [F(5,50)=11.06, p<0.001].  Planned Comparisons indicated this 
reduction of SI was evident on day 11 (p<0.001), day 12 (p<0.001), day 13 (p<0.05), day 14 
(p<0.001) and day 15 (p<0.01) (data not shown).  This was coupled with a significant 
alteration in RI [F(5,50)=7.12, p<0.001], but Planned Comparisons attributed this significant 
effect to a reduction on day 12 (p<0.001) and day 15 (p<0.05) (data not shown).  Between-
subjects ANCOVA analysis of the PCP-induced effect on SI demonstrated no overall significant 
Treatment*Day interaction [F(4,80)=1.54, NS] (fig 5.16A), however Planned Comparisons 
demonstrated a significant between-subjects increase in SI following SKF 38393 treatment on 
day 15 (p<0.05).  Although there was also no significant effect of drug treatment or day on 
the responsivity index of animals [F(4,80)=1.09, NS] (fig 5.16C), the significant increase in SI on 
day 15 was also accompanied by a significant SKF 38393-induced reduction of RI on day 15 
(p<0.05).  Students t-test indicated a significant increase in SI in the SKF 38393 treated 
animals (t = 2.12, df = 110, p<0.05) (fig 5.16B), independent of alterations in RI (t = 1.28, df = 
110, NS) (fig 5.16D). 
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Fig 5.16 Pre-treatment with SKF 38393 significantly increased the PCP-induced reduction in sensitivity index on 
day 15 (A), which was coupled with a significant reduction in responsivity index on day 15 (C).  However, overall SI 
was increased in SKF 38393-treated animals (B) independent of alterations in RI (D). Data are expressed as 
observed mean + SEM. Animals were pre-treated with ether saline (n=11) or SKF 38393 (n=12) prior to PCP 
administration. * p<0.05 significant difference between treatment group. Arrows represent PCP administration. 
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5.4 Discussion 
Firstly, these data demonstrate that repeated administration of PCP induced robust 
disruption of 5C-CPT performance.  These findings are in agreement with previous 
investigations of repeated PCP treatment and impaired 5-CSRTT performance (Amitai et al. 
2007; Amitai and Markou 2009; Amitai and Markou 2010).    Cognitive-specific effects and 
not generalised behavioural disruption, which is often associated with acute PCP 
administration, mediated impaired performance.  These findings, however, expand on those 
demonstrated by the Markou group as PCP treatment was shown to also impair performance 
during non-target trials, exemplified by the reduced ability to correctly withhold responding.  
Additionally, these data demonstrate that the PCP-induced impairment is susceptible to 
attenuation, at least partially, following augmentation of the D1 dopaminergic system.  When 
PCP-treatment was preceded by SKF 38393 administration there was an attenuation of the 
PCP-induced disruption of 5C-CPT performance on a number of behavioural parameters 
measured. 
 
5.4.1 Effect of Repeated PCP treatment on 5C-CPT performance 
The response to PCP was analysed separately in order to specifically assess the effect 
repeated administration of the NMDA receptor antagonist had on performance in the 5C-
CPT.  Repeated PCP administration significantly reduced choice accuracy (mediated by 
reduced correct responding and increased incorrect responding), percent correct and 
increased the number of omissions, indicative of impaired sustained attentional processing 
(Robbins 2002; Dalley et al. 2004; Amitai and Markou 2010).  Exposure to PCP also increased 
the time taken to make a correct response (CL), suggesting PCP exposure reduced the speed 
of information processing.  This was coupled with an initial increase of magazine latency 
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(ML), indicating locomotor impairment or a reduced motivation to perform the task may 
have induced the increased time taken to respond.  However, this effect dissipated following 
subsequent doses of PCP.  This attenuation of the elevated ML following repeated PCP 
exposure suggested that putative locomotor or motivational impairments were not 
responsible for the increased CL observed towards the latter stages of the treatment 
regimen.  These data indicated PCP treatment induced a specific impairment in the speed of 
information processing, an effect observed in schizophrenia patients (Nelson et al. 1990).  
Additionally, the lack of a concomitant increase in ML following repeated treatment 
suggested that the increased number of trials omitted was likely the result of cognitive-
specific attentional dysfunction. 
PCP treatment produced an increase in the number of inappropriate responses made 
throughout the 5C-CPT session, demonstrated by an increase in perseveration and a 
subsequent increase in inappropriate time out responses.  Increases in both of these 
measures suggest that PCP treatment produced a reduced ability to disengage from a 
behaviour once initiated, indicative of increased compulsivity or cognitive inflexibility (Amitai 
and Markou 2010).  Increased perseveration has also been demonstrated following PCP 
administration in the 5-CSRTT (Auclair et al. 2009).  Studies conducted by the Markou group 
did not find a PCP-induced increase in perseverative responding (Amitai et al. 2007; Amitai et 
al. 2008; Amitai and Markou 2009), however the first perseverative response initiated a time 
out, thus only one perseverative response could be made per trial.  However, the Markou 
group demonstrated the number of time out responses was significantly elevated following 
PCP treatment, suggesting increased compulsive-like behaviour.  Similarly though, the first 
perseverative response in the current study also initiated a time out, but in contrast to the 
findings demonstrated by the Markou group, PCP-treatment significantly increased not only 
time out responding, but also perseverative responding.  This may highlight a gender-specific 
difference as females were used in this instance, cf male subjects used in all studies from the 
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Markou group.  This may suggest females may have enhanced sensitivity to the PCP-induced 
failure to disengage from a response once initiated.  Aspects of this type of dysfunctional 
behaviour have also been demonstrated in schizophrenia patients (Goldberg et al. 1988; 
Morice 1990).  PCP-induced impairments in cognitive flexibility are not unique to the 5C-CPT 
(or the 5-CSRTT in previous cases), as impairments in a reversal-learning paradigm have also 
been demonstrated (Abdul-Monim et al. 2003; Idris et al. 2005; McLean et al. 2009).  
Although these studies utilised acute or sub-chronic PCP treatment regimens, they highlight 
the susceptibility of cognitive flexibility to NMDA antagonist disruption.  Impairments in this 
task are only evident in the reversal phase, with performance in the initial phase being left 
intact, symptomatic of impaired cognitive flexibility as animals have a reduced capability to 
switch their response behaviour once the reward contingency has been reversed.  
PCP treatment also resulted in deficits in impulse control, exemplified by the increased 
number of premature responses made throughout the session.  Premature responses within 
the 5-CSRTT (or in this case, the 5C-CPT) are a well characterised measure of impulsivity 
(Puumala and Sitvio 1998; Evenden 1999; Robbins 2000; Amitai and Markou 2010; Besson et 
al. 2010) and represents a reduced ability to withhold, or a failure of the animal to inhibit, a 
response.  Consequently, this failure of inhibitory control elevates the frequency of 
inappropriate responding during the ITI, before the stimulus cue has been presented.  
Schizophrenia patients also demonstrate increased impulsivity characterised by deficits in 
behavioural inhibition, resulting in an increased frequency of inappropriate responding in 
situations requiring the inhibition of a response (Kiehl et al. 2000; Weibrod et al. 2000; 
Wykes et al. 2000).  PCP treatment has been shown on a number of occasions to increase the 
frequency of premature responding, suggesting a deficit in impulse control (Le Pen et al. 
2003; Amitai et al. 2007).   
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Premature responding in the 5-CSRTT and 5C-CPT, however, reflect an inappropriate 
response before a stimulus has been presented. Consequently, premature responses may 
demonstrate limited analogy to the increased impulsivity exhibited by schizophrenia 
patients.  As described, impulsivity is often assessed by inappropriate responding when 
presented with irrelevant stimuli that require inhibition of a response, characteristic of 
behavioural disinhibition demonstrated in schizophrenia patients (Green 1997).  Therefore, 
the increased premature responding induced through repeated PCP treatment is perhaps 
more likely to embody a form of motoric impulsivity as opposed to behavioural disinhibition 
(Evenden 1999).  However, the 5C-CPT also encompasses non-target trials and the correct 
action when presented with these trials is to inhibit a response.  Coupled with the elevation 
in premature responding, it was demonstrated that PCP treatment also increased the 
number of inappropriate responses when presented with non-target trials.  This resulted in a 
reduction in the number of correct rejections increasing the number of false alarms made 
throughout the session.  As false alarms constitutes a failure to inhibit a response when the 
animal was presented with inappropriate stimuli, an increase in false alarms has enhanced 
analogy to behavioural disinhibition observed in schizophrenia patients (Kiehl et al. 2000; 
Weibrod et al. 2000; Wykes et al. 2000) over the traditional 5-CSRTT measure of impulsivity – 
premature responding.  Taken together however, the effect of increased premature 
responding and increased false alarms suggests that PCP treatment induced a form of 
behavioural disinhibition, not just motoric impulsivity, of relevance to that observed in 
schizophrenia patients.  NMDA receptor antagonism has previously been shown to reduce 
the number of correct rejections (ergo increased false alarms) in animals performing the 
sustained attention task (SAT – Rezvani and Levin 2003; Rezvani et al. 2008a, b) a task 
developed by McGaughy and Sarter (1995), reflecting increased inappropriate responding to 
non-signal stimuli.  However, as discussed in chapters 1 and 4, both false alarms and correct 
rejections within this task require an active response.  Therefore, the correct rejections 
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cannot be fully analogous to correct rejections in human CPTs.  As the contrary measure of a 
correct rejection is a false alarm, the NMDA-induced increase in false alarms within the SAT 
(Rezvani et al. 2003; 2008a, b), may not fully encompass the behavioural disinhibition 
demonstrated by schizophrenia patients performing go/no-go tasks or CPTs (Cornblatt and 
Malhotra 2001; Neuchterlein et al. 2008).  However, as previously described, the non-target 
trials within the 5C-CPT require the animal to withhold a response when presented with non-
target trials.  Therefore, the PCP-induced increase in false alarms within the 5C-CPT is 
representative of a failure in action restraint (Eagle et al. 2008; Young et al. 2009b), perhaps 
providing greater analogy than other preclinical paradigms to the clinical observations of 
behavioural disinhibition exhibited by schizophrenia patients. 
As previously described, PCP treatment reduced target trials correctly detected (reduction in 
hit rate) whilst simultaneously reducing non-target trials correctly rejected (increase in false 
alarm rate).  These effects suggested that repeated PCP administration completely abolished 
the animal’s ability to discriminate between trial types presented within the 5C-CPT.  This 
abolition of target discrimination was quantified by the reduction in the sensitivity index (SI).  
As the SI has been implemented as a means of quantifying vigilance performance in a 
manner consistent with human attention/vigilance assessment utilising one of the myriad 
CPTs (Young et al. 2009b), it can therefore be inferred that PCP treatment impaired signal 
discriminability, manifesting as impairment in vigilance.  The 5C-CPT also generates an index 
of responsivity (RI), enabling the characterisation of cognitive impairment to be dissociated 
from alterations in strategic bias of the animal.  It was evident that PCP treatment 
significantly reduced RI (days 11 and 12), suggesting that impaired performance may 
potentially be mediated by alterations in the decision criteria, shifting to a more conservative 
response strategy, rather than a truly cognitive mechanism (Davies and Parasuraman 1982; 
Parasuraman et al. 1998).  However, following repeated administration of PCP, the reduction 
in the responsivity index returned to that of baseline, whilst reductions in target 
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discrimination persisted.  These findings suggest that PCP treatment impaired the ability of 
the animal to detect and respond to target stimuli and increased the response to non-target 
stimuli, independently of alterations in the strategy being employed, indicating impairments 
being driven by cognitive mechanisms (Marston 1996; Parasuraman et al. 1998). 
 
5.4.2 Effects of SKF 38393 on PCP-induced 5C-CPT impairment 
When animals were treated with SKF 38393 prior to PCP treatment there was a partial 
amelioration of the PCP-induced cognitive disruption.  SKF 38393 pre-treatment significantly 
increased the PCP-induced reduction in response accuracy.  The SKF 38393-induced 
attenuation was not immediate, however.  In the initial two days of PCP/SKF 38393 
treatment there was no difference to the animals treated with PCP/saline.  However, 
following the initial two days (days 13 – 15), there was a significant increase in response 
accuracy, when a between-subjects comparison was conducted.  Upon inspection of the 
treatment effect on percent correct responding, analysis demonstrated that there was no 
significant effect of SKF 38393-treatment on the PCP-induced reduction in target trials 
correctly detected.  Following analysis of percent incorrect responding it was evident that 
SKF 38393 pre-treatment completely attenuated the PCP-induced increase in incorrect 
responding after treatment day 12.  These findings suggest that augmentation of the 
dopaminergic D1 system attenuated the PCP-induced impairment in response accuracy, 
mediated by a specific amelioration of the number of incorrect responses made following 
PCP treatment.  It is well established that acute and repeated NMDA antagonism elevates 
acetylcholine release in the PFC (Kim et al. 1999; Nelson et al. 2002).  Additionally, cortical 
deafferation has been shown to impair target detection in the SAT, suggesting cholinergic 
transmission is involved in stimulus detection (McGaughy et al. 1996; McGaughy and Sarter 
1998; McGaughy et al. 2002), and NMDA antagonism impairs target detection in the SAT 
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(Rezvani et al. 2003; 2008a, b).  These findings potentially suggest that disrupted cholinergic 
transmission may be involved with the PCP-induced reduction in correct responding. 
There was a significant attenuation of incorrect responding in the SKF 38393-treated animals.  
This suggests that aberrant dopaminergic transmission may mediate the generation of 
incorrect responding following PCP treatment.  Augmentation of the D1 system therefore 
would attenuate the PCP-induced increase in incorrect responding, mediating the partial 
attenuation of the response accuracy impairment.  Unfortunately, a general theme within 5-
CSRTT literature is to only report the effects on response accuracy or percent correct 
responding.  It is therefore not possible to determine whether any impairment in response 
accuracy was driven by a reduction in correct responding, increased incorrect responding, or 
a combination of the two.  An exception to this rule is the study published by Amitai and 
colleagues (2007) who demonstrated that repeated PCP treatment increased incorrect 
responses.  Furthermore, the group demonstrated that the PCP-induced increase in incorrect 
responses was attenuated by chronic clozapine treatment (4.0 mg/kg/day), which may have 
accounted for the clozapine-induced partial attenuation of the PCP-induced reduction in 
response accuracy demonstrated by Amitai and colleagues (2007).  It has been suggested 
that clozapine provides therapeutic efficacy by normalising prefrontal dopamine levels 
following PCP treatment (Elsworth et al. 2008).  The beneficial effects in the SKF 38393 
treated animals may be mediated by a similar process following clozapine treatment; 
normalisation of frontal cortical dopamine levels, restoring cognitive function.  In addition to 
the lack of attenuation of the PCP-induced reduction in percent correct responding, pre-
treatment with SKF 38393 had no impact on the increase in omissions following PCP 
treatment.   
There was no difference between groups on any of the treatment days when the measures of 
correct latency or magazine latency (ML) were assessed.  It should be noted, however, that 
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the effect of drug treatment (SKF 38393 + PCP) on ML followed a similar trend to PCP alone 
when analysed separately; while there may have been an initial significant increase in ML 
compared to baseline performance, any alterations in ML by the end of the treatment 
regimen were not statistically significant from baseline performance.  This confirms that any 
behavioural effects observed following SKF 38393 and PCP treatment were not mediated by 
putative alterations in locomotor abilities or reduced motivation to perform the task.  SKF 
38393 treatment had a partial effect on the PCP-induced increase in perseverative 
responding.  Analysis of performance on individual days indicated a significant SKF 38393-
induced reduction in perseverative responding on day 12 only, but, comparison of the overall 
means between the treatment groups suggest at least a partial attenuation of the PCP-
induced increase in perseverative responding.  However, no effect was observed on the PCP-
induced increase in time out responding.  A similar effect was observed for premature 
responding; analysis of performance over individual treatment days indicated a significant 
reduction on day 12 only, whilst a comparison of the overall performance means indicated 
that SKF 38393 treatment induced a partial attenuation of the PCP-induced increase in 
premature responding. 
It was revealed that SKF 38393 pre-treatment significantly attenuated the PCP-induced 
reduction of correct rejections.  Between-subjects comparison indicated this effect was only 
evident on treatment day 15.  As correct rejections reflect the inhibition of a response the 
measure is obviously sensitive to confounding effects of locomotor impairment.  However, 
the significant SKF 38393-induced attenuation of correct rejections occurred on day 15, when 
there was no significant effect on ML suggesting the effect was not attributed to a 
generalised inability to respond thus ruling out the potential confound of locomotor 
impairment.  The SKF 38393-induced partial amelioration of premature responding, along 
with the attenuation of the PCP-induced reduction in correct rejections suggests aberrant 
dopaminergic transmission is involved with PCP-induced impairment in behavioural 
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inhibition.  While it has been demonstrated that chronic clozapine attenuates the increase in 
premature responding in the 5-CSRTT (Amitai et al. 2007), clozapine treatment had no effect 
on the reduction in correct rejections when MK-801 was administered to animals performing 
the SAT (Rezvani et al. 2008b).  These findings suggest that perhaps NMDA antagonism 
impairs behavioural inhibition, increasing premature responding and reducing correct 
rejections.  The amelioration of premature responding by clozapine may be due to 
clozapine’s effect on prefrontal dopamine transmission.  This could explain the effects 
observed in the current chapter.  However, this does not account for the SKF 38393-induced 
attenuation of correct rejections observed (day 15) and the lack of effect demonstrated by 
Rezvani and colleagues (2008b).  If the beneficial effects of SKF 38393 on correct rejections 
are to be attributed to normalization of prefrontal dopamine levels following PCP treatment, 
it would be expected that clozapine treatment (which also normalises cortical dopamine 
levels) would produce similar effects.  However, a number of differences exist between the 
Rezvani study (2008b) and data shown in the current chapter; firstly MK-801 is used and not 
PCP.  Whilst both are primarily NMDA antagonists, they may have subtle differences in 
pharmacology accounting for differing behavioural impairments.  Secondly, MK-801 was 
administered acutely (although it can be argued that a repeated treatment regimen was used 
as a Latin square design was implemented).  Thirdly and perhaps most importantly, clozapine 
was administered acutely.  The efficacious effects of clozapine on PCP-induced premature 
responding were observed following chronic administration (Amitai et al. 2007).  SKF 38393 
was administered repeatedly over 5 days in the current chapter, with amelioration of correct 
rejections observed on the last treatment day only.  Additionally, when clozapine was 
demonstrated to normalize prefrontal cortical dopamine levels following PCP treatment, it 
was also administered repeatedly (Elsworth et al. 2008).  These observations could account 
for the SKF 38393-induced amelioration of correct rejections in the current chapter, whilst 
clozapine (which normalises PFC DA levels) failed to attenuate NMDA-induced reduction in 
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correct rejections in the SAT (Rezvani et al. 2008b).  These findings attest to aberrant 
dopaminergic transmission involvement in behavioural disinhibition following PCP treatment. 
PCP-treatment significantly reduced the hit rate, an effect that was not sensitive to SKF 
38393-treatment. However, SKF 38393 pre-treatment significantly ameliorated the PCP-
induced increase in false alarms on treatment day 15.  Taken together, this effect led to a 
complete abolition of signal discrimination, an impairment that was significantly attenuated 
by SKF 38393 treatment.  However, the PCP effect on SI was only partially attenuated by SKF 
38393 treatment.  This was not suprising as SKF 38393 treatment had no beneficial impact on 
the hit rate and so the SKF 38393-induced attenuation of SI was driven solely by the effect on 
the false alarm rate.  As such, the SKF 38393-induced increase in SI only became apparent on 
day 15.  While there was no overall significant effect observed between treatment groups, 
the SKF 38393-induced increase of the PCP-induced reduction in SI on day 15 was 
accompanied by a significant reduction in the responsivity index.  This finding suggests that 
partial attenuation of SI may not have been mediated by enhanced discrimination of trial 
types, which would be attributed to enhanced cognitive abilities.  However, the increase in SI 
was potentially driven by enhanced behavioural inhibition, reflected by a more conservative 
response strategy being utilised and therefore a reduced RI. 
These data demonstrate that 5C-CPT performance is robustly disrupted following repeated 
PCP administration in a cognitive-specific manner, impairments that are not precluded by 
generalised-response disruption.  The PCP-induced impairment was partially ameliorated if 
PCP administration is preceded by treatment with a D1 receptor partial agonist.  These 
findings suggest that the PCP-induced impairment observed may be mediated, at least in 
part, by aberrant dopaminergic transmission.  However, as previously mentioned, it is still 
not entirely clear the effect that a repeated PCP treatment regimen has on cortical DA 
turnover.  A single acute injection of PCP considerably increases PFC DA release (Jentsch et 
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al. 2008), while in contrast, during the drug-free state following sub-chronic PCP treatment 
there is a marked decrease in DA utilisation in the PFC (Jentsch et al. 1997a, b; Jentsch and 
Roth 1999; Noda et al. 2000).  It has been demonstrated that glutamate is release is 
increased following a single acute injection of PCP (Adams and Moghaddam 2001) and 
evidence has recently emerged that following repeated PCP administration, glutamate is 
elevated above basal levels, albeit blunted compared to acute administration (Amitai et al. 
2011).  Although the precise effect is unclear, it is likely that the effects are similar for 
dopamine following repeated PCP treatment; increased above basal levels, but blunted 
compared to the increase elicited following a single acute dose.  In this scenario, beneficial 
effects following dopamine D1 partial agonism are likely mediated by SKF 38393 competing 
with DA for the D1 receptor.   SKF 38393 would activate the D1 second messenger system 
(adenylate cyclase), but due to lower intrinsic activity of the compound, activation would be 
to a lesser extent than a full agonist (e.g. DA) (Stahl 2008a; Strange 2008).  Thus, this would 
achieve the net effect of reducing the effect of elevated DA release following PCP 
administration, potentially attenuating cognitive function mediated by this region.  
Alternatively, there is the possibility that dopamine levels are reduced following repeated 
PCP treatment, at least during the later exposures of the drug.  This has been demonstrated 
following sub-chronic PCP administration, in the drug-free state (Jentsch et al. 1997a, b; 
Jentsch and Roth 1999; Noda et al. 2000).  Reduced prefrontal DA transmission would have 
clinical face validity as prefrontal hypdopaminergia has been shown in schizophrenia (Abi-
Dargham and Moore 2003).  If there is indeed a reduction in frontal DA levels following 
repeated PCP treatment, cognitive improvement arising from SKF 38393 treatment would be 
derived from the compound acting as an agonist of the DA D1 receptor compensating for the 
PCP-induced reduction in DA transmission.  This could explain why an immediate SKF 38393-
induced attenuation was not observed.  However, the scenario of a blunted increase in DA 
efflux following repeated PCP treatment is more likely, as Jentsch et al. (1998) has firstly 
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demonstrated PFC DA levels are reduced in the drug-free state following sub-chronic PCP 
treatment, but there is a blunted increase in DA release when animals are re-challenged with 
an acute systemic dose of PCP.  
As these data demonstrate, the 5C-CPT task is sensitive to disruption following PCP 
treatment; the aim of the next chapter was to assess the capability of a sub-chronic PCP 
treatment regimen to induce performance disruptions.  Previous investigations within our 
laboratory utilise a sub-chronic pattern of exposure, assessing cognitive performance in the 
drug-free state.  As a result, the potential of inducing persistent attentional impairments 
following this treatment regimen was to be explored in chapter 6. 
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6.1 Introduction 
 
As demonstrated in chapter 5, performance within the 5C-CPT is sensitive to disruption 
following repeated PCP administration.  Disrupted performance was the result of a cognitive-
specific impairment, at least following repeated administration with impairment not being 
confounded by generalised behavioural disruption.  Although these findings demonstrate 
that the 5C-CPT is sensitive to cognitive disruption following PCP treatment, impaired 
performance was observed whilst animals were acutely intoxicated, with cognitive testing 
conducted  30 minutes following PCP administration. 
Previous investigations within our laboratory have demonstrated that a sub-chronic PCP 
treatment regimen induces persistent cognitive disruption, even in the drug-free state, in 
several behavioural paradigms that show relevance to cognitive disruption exhibited in 
schizophrenia. In conjunction, sub-chronic PCP treatment also induces neuropathological 
disturbances that are associated with the disorder (see Neill et al. 2010 for full review).  
Impairment has been demonstrated in tasks that assess recognition memory, cognitive 
flexibility, executive functioning and social behaviour.  These tasks are suggested to reflect a 
battery of preclinical tasks that effectively probe areas of cognition (Young et al. 2009a) that 
are affected in schizophrenia (Neuchterlein et al. 2004).  Novel object recognition (NOR) 
involves a task consisting of two distinct trials; in the first the animal is presented with two 
identical objects (acquisition phase) which they are allowed to explore and interact with.  In 
the second trial (retention phase) one of the objects is replaced, allowing the animal to 
explore and interact with one familiar object and a novel one.  The NOR task is a non-
rewarded, ethologically valid task that exploits the rodents’ natural exploratory behaviour 
originally described by Ennaceur and Delacour (1988).  It has been demonstrated a number 
of times within our laboratory that control animals spend significantly more time exploring 
the novel object than the familiar one in the retention phase.  Conversely, animals sub-
chronically treated with PCP (2 mg/kg, 7-days bi-daily followed by at least 7 day washout) 
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spend an equal amount of time exploring novel and familiar objects in the retention phase 
(Grayson et al. 2007; McLean et al. 2009; Idris et al. 2010), suggesting that recognition 
memory is impaired.  Levels of exploration in either trial were unaffected by PCP treatment, 
ruling out impaired motivation impairing task performance.  Thus, from these observations it 
is suggested PCP treatment induced impairment in recognition memory in the retention 
phase of the NOR task.  Similarly, sub-chronic PCP treatment impairs performance in an 
operant reversal learning (RL) task (Abdul-Monim et al. 2006, 2007; McLean et al. 2009; Idris 
et al. 2010).  The RL task also involves two distinct trials; the initial phase requires animals to 
lever press depending on a previously learned reward contingency.  In the reversal phase, the 
reward contingency is reversed; animals are required to inhibit the previously rewarded 
strategy and modify their behaviour to facilitate the acquisition of the new reward strategy.  
PCP induced no impairment in the initial phase suggesting no overt inability to perform the 
task.  However, when the reward contingency was switched PCP treatment resulted in a 
reduced ability to inhibit the previously rewarded behaviour, inducing selective impairments 
in the reversal phase of the task.  Successful performance of the RL task requires the 
prefrontal cortex to be fully functioning.  Select lesion studies have implicated the orbital 
frontal cortex (OFC) involvement in the successful inhibition of previously rewarded 
behaviour, with impairment observed in the reversal phase, when a previously rewarded 
behaviour was to be inhibited (Bohn et al. 2003; McAlonan and Brown 2003; Boulougouris et 
al. 2007; Tait and Brown 2007).  Schizophrenia patients have shown deficits in the Wisconsin 
Card Sorting Task (WCST) (Haut et al. 1996), in which patients show a reduced 
conceptualisation of the task and demonstrate a higher incidence of perseverative errors and 
impaired shifting of an attentional set.  Furthermore, it was described that patients with 
frontal tumours had comparable WCST performance deficits (Haut et al. 2006).  This 
observation suggests frontal cortical abnormalities in schizophrenia may mediate impaired 
performance within this task.   A rodent analogue of the WCST was developed by Birrell and 
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Brown (2000) and is known as the attentional set—shifting task (ASST).  An attentional set is 
formed when the animal discriminates and responds to a stimulus based on the features of 
that stimulus (e.g. digging medium).  The attentional set enhances the efficiency of 
informational processing of the stimulus features.  The ASST involves 7 discriminations; 
simple discrimination (SD), compound discrimination (CD), reversal 1 (R1), intra-dimensional 
shift (IDS), reversal 2 (R2), extra-dimensional shift (EDS) and reversal 3 (R3) (Birrell and Brown 
2000).  The ASST assesses the ability of the animal to form an attentional set within the same 
sorting category (intra-dimensional shift –IDS).  Additionally, the task investigates the ability 
to shift an attentional set between different sorting categories (extra-dimensional shift – 
EDS).  Birrell and Brown (2000) showed that medial prefrontal cortical lesion resulted in a 
specific impairment in the ability of the animal to shift attentional set between sorting 
categories (EDS impairment).  These findings suggest that the frontal cortical region is 
involved in successful task performance, facilitating the ability of the animal to switch 
attentional sets between stimuli.  Sub-chronic PCP treatment has been shown to impair ASST 
performance that was also specific to impaired EDS (Rodefer et al. 2005; McLean et al. 2009).  
Impairment in social interaction has also been observed following sub-chronic PCP treatment 
(Snigdha and Neill 2008).  Whist social interaction is not strictly a form of cognition, social 
cognitive deficits involving the evaluation and appropriate responding to cues have been 
observed in schizophrenia (Penn et al. 2002) and described by the MATRICS initiative as one 
of the cognitive domains putatively affected in schizophrenia (Nuechterlein et al. 2004).  The 
task involves the assessment of interactive behaviours of two unfamiliar rats placed in an 
open-field test arena.  PCP treatment has been shown to significantly reduce interaction 
behaviours, whilst increasing the active avoidance of social contact (Snigdha and Neill 2008) 
up to at least 6-weeks following PCP treatment. 
These observations demonstrate that PCP treatment (2 mg/kg) administered twice a day for 
a period of 7-days, followed by at least one week washout, induced persistent cognitive 
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disruption in a number of task of relevance to the cognitive deficits observed in 
schizophrenia.  Due to the persistence of impairments (up to 12 months in some cases – 
Grayson, unpublished observations), it is clear that impaired performance is not due to the 
transient drug effects arising from PCP treatment.  Moreover, in addition to the cognitive 
disruption, it is evident that sub-chronic PCP treatment induces a number of long-term 
neuropathological changes in the brain, many of which are reminiscent of those 
demonstrated in schizophrenia patients. 
Notably, GABAergic dysfunction has been observed in schizophrenia patients, originally 
proposed by Roberts in 1972, confirmed following examination of post-mortem tissue 
demonstrating deficits in schizophrenia patients within interneuron populations that mediate 
GABAergic transmission (Blum and Mann 2002).  Deficits in parvalbumin (PV) containing 
interneurons in the PFC (Beasley and Reynolds, 1997; Beasley et al. 2002) and the 
hippocampus (Zhang and Reynolds, 2002) have also been identified in schizophrenia 
patients.  Coupled with the defects in GABAergic containing interneurons in schizophrenia 
patients, there is also a consistent reduction in the expression of the mRNA and protein for 
glutamic acid decarboxylase67 (GAD67), a synthesizing enzyme for GABA in the prefrontal 
cortex of schizophrenia patients (Guidotti et al. 2000; Volk et al. 2000; reviewed in Neill et al. 
2010).  Furthermore, it has been demonstrated that mRNA expression for GAD67 along with 
GAT1 (GABA transporter) is impaired in schizophrenia and are selective for PV-
immunoreactive (ir) containing neurons within the PFC (Hashimoto et al. 2003).  These 
findings clearly implicate a dysfunctional GABAergic system is involved in the pathogenesis of 
schizophrenia, and due to their location, deficits that may contribute to the development of 
cognitive dysfunction associated with the disorder (Lewis et al. 2005), potentially mediating 
the fractionated thought and cognitive impairment demonstrated in schizophrenia patients. 
A similar dysfunction has been observed following repeated exposure to NMDA antagonists 
(Abdul-Monim et al. 2007; Jenkins et al. 2008), with reduction in parvalbumin containing 
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neurons in the hippocampus and prefrontal cortex.  Additionally, reductions in the 
expression of GAD67 mRNA have also been observed in rats treated with NMDA antagonists, 
suggesting a reduction in the GABA synthesising enzyme (Behrens et al. 2007; Bullock et al. 
2009).  These data suggest that repeated glutamatergic blockade induces GABAergic 
dysfunction in experimental animals that is similar to the pathological observations of 
GABAergic dysfunction observed in schizophrenia patients, supporting the face validity of this 
pharmacological model for investigating schizophrenia-like behaviours. 
In addition to the findings centred on GABAergic dysfunction, sub-chronic PCP treatment has 
also been shown to induce other pathological changes observed in schizophrenia.  Studies 
have identified that brain-derived neurotrophic factor (BDNF) is altered in schizophrenia 
(Thompson et al. 2011). Reduced BDNF levels have also been observed in female rat 
following sub-chronic PCP treatment (Snigdha et al. 2010), which were associated with 
impaired cognitive performance exemplified by impaired EDS in the ASST.  Additionally, sub-
chronic PCP has been shown to significantly reduce the number of dendritic spine synapses in 
the PFC (Hajszan et al. 2006).  As this region is heavily implicated in multiple domains of 
cognition, reduced dendritic function may contribute to the cognitive impairment observed 
following sub-chronic PCP exposure.  Dendritic spine density of prefrontal pyramidal neurons 
has been shown to be reduced in schizophrenia patients (Glantz and Lewis 2000), suggestive 
of dysfunctional prefrontal cortex function potentially mediated by loss of spine synapses.   
Furthermore, sub-chronic PCP treatment induces neurochemical alterations mirroring the 
clinical deficits, which are not clearly evident following acute or repeated PCP administration.  
In the drug-free state following sub-chronic PCP treatment, significant reductions in basal 
levels of glutamate and dopamine have been observed within the prefrontal cortex (Jentsch 
et al. 1997a, b; Murai et al. 2007).  Elevations of the expression of a glutamate transporter 
have been observed following sub-chronic PCP treatment (Fattorini et al. 2008), potentially 
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accounting for the reduction in cortical glutamate levels observed in the drug-free state.  
While dopamine hyperactivity is associated with schizophrenia (Howes and Kapur 2009), 
hyperactivity is largely restricted to sub-cortical regions (striatum) and implicated in 
psychotic symptoms.  Cortical dopaminergic hypofunction, however, is hypothesised mediate 
certain cognitive deficits (Davis et al. 1991; Sawaguchi and Goldman-Rakic 1991; Arnsten et 
al. 1994; Knable and Weinberger 1997; Goldman-Rakic et al. 2004) and is observed in 
schizophrenia patients (Egan et al. 2001; Guo et al. 2003).  These observations provide 
further justification and enhance the validity of a sub-chronic treatment regimen in contrast 
to acute treatment, which increases prefrontal dopamine levels as a reduction in basal 
cortical dopamine levels are observed in the drug-free state, following sub-chronic PCP 
administration (Verma and Moghaddam 1997; Jentsch and Roth 1999). 
The findings described above provide a considerable level of evidence to suggest that chronic 
exposure to NMDA antagonists replicates not only cognitive dysfunction observed in 
schizophrenia, but also some of the neurochemical, neuropathological and morphological 
findings that are also evident.  Furthermore, these findings display persistence, suggesting 
long-term neuropathological changes are induced, mimicking those observed clinically in 
schizophrenia patients. 
In addition to the cognitive disruption described above, NMDA receptor antagonism has 
been shown to disrupt attentional processing, demonstrated when animals were acutely 
(Chapter 3) or repeatedly administered PCP (Amitai et al. 2007; Amitai and Markou, 2009; 
Chapter 5).  Additionally, intra-medial prefrontal cortical (mPFC) infusion of the competitive 
NMDA antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP) also disrupts 5-
CSRTT performance (Murphy et al. 2005; Baviera et al. 2008).  These data further highlight 
the involvement of the NMDA receptor in attentional function and furthermore, implicate 
mPFC involvement in attentional processing.  However, to date, previous studies have only 
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shown disrupted attentional performance (assessed using the 5-CSRTT) while animals were 
‘acutely’ intoxicated with NMDA antagonists (Le Pen et al. 2003; Amitai et al. 2007; Amitai 
and Markou, 2009; Auclair et al. 2009; Chapter 3) and not following a significant washout 
period.  Due to the paucity of information on the effect of a sub-chronic PCP regimen on 5-
CSRTT performance, there is clearly a need to understand the enduring effect of long-term 
NMDA antagonism on attention/vigilance.  Thus, the aim of the presented within this chapter 
was to determine the effect of sub-chronic PCP treatment, following a substantial washout 
period, on performance in the 5C-CPT at baseline.  However, due to the lack of PCP-induced 
impairment observed in chapter 3 within the 5-CSRTT, a higher dose was used in the current 
chapter in addition to the use of behavioural challenges designed to further tax attentional 
processing. 
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6.2 Methods 
6.2.1 Subjects 
Female hooded-Lister rats (n=35; Charles River; approx 250 + 10 g at the start of the 
experiment) were housed in groups of five on a 12 hour reversed light cycle (lights on at 
7:00pm) in a temperature (21 + 2oC) and humidity (55 + 5%) controlled environment.  Further 
information regarding housing conditions, food deprivation and ethical guidelines can be 
found in chapter 2.  
 
6.2.2 Drug Treatment Regimen 
Rats were divided into three treatment groups, matched for baseline performance (the 
group-matching procedure and measures that are balanced is described in chapter 5).  
Following group-matching, rats were sub-chronically administered PCP (2.5 mg/kg, n = 11 or 
5.0 mg/kg, n = 10 i.p.) or vehicle (0.9% saline, n = 11) twice daily (9am and 5pm) for 7-days, 
followed by a 7-day washout period, after which behavioural testing commenced.  Animals 
were not trained or tested during drug treatment.  Rats that failed to reach a stable baseline 
at the desired criteria were excluded from the study (n = 3). 
 
6.2.3 Experimental Design 
6.2.3.1 Stable Baseline Performance 
Rats were tested following sub-chronic PCP administration (8-days post PCP) using standard 
training parameters that consisted of a 1 s SD, variable ITI which had a mean of 5 s (4.0, 4.5, 
5.5, and 6.0 s), a 5 s TO period and a 2 s LH.  The animals were presented with 84 target trials 
and 36 non-target trials in a session lasting no more than 30 minutes. 
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6.2.3.2 Variable Stimulus Duration 
Rats performance was challenged (9-days post PCP regimen) within a single session that 
presented a variable SD (0.25, 0.5, 0.75, and 1 s).  All other parameters (TO, LH, target/non-
target ratio) were as before (section 6.2.6.1) with the exception of the variable ITI.  Due to a 
programming limitation, which would have attributed one specific SD value to a specific ITI 
value, the vITI was switched to a fixed ITI (5 s). 
 
6.2.3.3 Extended Session 
Rats were exposed to an extended session (11-days post PCP regimen) to further challenge 
vigilance performance.  The session consisted of 256 trials, of which 160 were target (40 x 4 
ITIs) and 96 non-target trials (24 x 4 ITIs) and lasted no longer then 60 minutes.  Test 
parameters were the same as standard training conditions i.e. 1 s SD, variable ITI (4.0, 4.5, 
5.5, and 6.0 s), 5 s TO and 2 s LH. 
All animals received a normal training session on day 10, between the vSD and extended 
session protocol manipulations to ensure performance was maintained at a stable baseline. 
 
6.2.4 Data Analysis 
All data are displayed as observed mean + SEM. Overall performance was analysed by one-
way between-subjects ANOVA followed by Planned Comparisons.  Analysis of the 
performance across the duration of the session was carried out by two-way repeated 
measures ANOVA (Treatment as a fixed factor and Trial as a repeated measures factor – 
session was divided into trial bins, each composed of 40 trials for the 120 trial sessions or 64 
trials for the extended session).  Planned Comparisons (Snedecor and Cochran, 1989) 
compared PCP animals to control animals in each of the separate trial bins.  Assessment of 
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the effect of a variable SD on task performance was conducted by two-way repeated (SD as 
within-subjects factor and Treatment as between-subjects factor) measures ANOVA, 
followed by Planned Comparisons. Assessment of vSD on performance of control animals’ 
was conducted by one-way repeated measures ANOVA (SD as within-subjects factor).  
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6.3Results 
6.3.1 Stable Baseline Performance 
A one-way ANOVA analysis revealed that sub-chronic PCP treatment had no significant effect 
on baseline performance for any measure, suggesting that treatment induced no impairment 
in the animals ability to perform the 5C-CPT when standard testing parameters were used 
(table 6.1). 
 
Table 6.1Effect of Sub-Chronic PCP on overall performance in 5C-CPT with stable baseline 
Measure Vehicle 2.5 mg/kg PCP 5.0 mg/kg PCP 
Accuracy (%) 94.52 + 1.41 93.68 + 1.13 93.56 + 1.49 
Percent Correct 78.63 + 3.40 74.56 + 3.07 73.78 + 3.56 
Percent Incorrect 4.33 + 1.03 4.88 + 0.86 4.90 + 1.00 
Percent Omission 17.03 + 2.84 20.56 + 2.71 21.32 + 3.26 
Correct Latency 0.67 + 0.04 0.64 + 0.03 0.68 + 0.05 
Incorrect Latency 0.82 + 0.12 0.86 + 0.14 0.91 + 0.10 
Magazine Latency 1.22 + 0.08 1.17 + 0.05 1.26 + 0.06 
Perseverative Response  1.82 + 0.85 2.00 + 0.66 4.60 + 2.12 
Premature Response 6.55 + 1.86 10.09 + 1.80 11.90 + 2.49 
Time Out Response 8.18 + 1.62 11.00 + 3.10 14.40 + 4.14 
p[HR] 0.79 + 0.03 0.75 + .0.03 0.74 + 0.04 
p[FA] 0.26 + 0.04 0.31 + 0.05 0.34 + 0.06 
Sensitivity Index 0.54 + 0.06 0.45 + 0.04 0.42 + 0.06 
Responsivity Index 0.06 + 0.07 0.06 + 0.08 0.06 + 0.09 
Measures are shown as observed mean + SEM. PCP treatment resulted in no significant effect under these 
conditions.  Veh (n=11), 2.5 mg/kg PCP (n=11) and 5.0 mg/kg PCP (n=10). 
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A two-way repeated measures analysis of the baselines also revealed the performance did 
not alter with session (data not shown).  No significant Dose*Trial interaction were observed 
for any measure. 
 
6.3.2 Variable Stimulus Duration (vSD) 
6.3.2.1 Overall Performance 
A vSD was then used to challenge performance (table 6.2).  Statistical analysis revealed no 
significant difference in accuracy between treatments [F(2,29)=2.01, NS], however, Planned 
Comparisons analysis demonstrated that there was a trend towards reduced accuracy in the 
5 mg/kg PCP treatment group (p=0.06) when compared to the vehicle group.  A significant 
effect of treatment on percent correct responding [F(2,29)=5.85, p<0.01] was observed and 
PCP (5 mg/kg) significantly reduced percent correct responses (p<0.01).  No effect was 
observed when percent incorrect responding [F(2,29)=1.02, NS] was assessed, however.  A 
strong trend toward a significant PCP effect was observed for percent omissions [F(2,29)=3.16, 
p=0.057], with Planned Comparisons showing that PCP at 5 mg/kg significantly increased 
percent omissions (p<0.05).   
There was no significant overall PCP treatment effect on latency to respond (CL, IL, or ML) or 
perseverative responses although significantly increased TO responses [F(2,29)=4.12, p<0.05] 
were observed at 5 mg/kg of PCP, when compared with vehicle (p<0.01).  There was no 
significant effect on the number of premature responses [F(2, 29)=2.36, NS], although Planned 
Comparisons demonstrated a trend towards a significant effect at the highest dose (p=0.07).   
PCP treatment significantly reduced p[HR] [F(2,29)=5.85, p<0.01] with Planned Comparisons 
revealing that 5 mg/kg PCP significantly reduced p[HR] when compared with vehicle 
treatment (p<0.01).  There was a trend towards an increase in the p[FA] [F(2,29)=2.78, p=0.07] 
with the highest dose of PCP significantly increasing p[FA] (p<0.05).  Sub-chronic PCP 
treatment significantly decreased the SI [F(2,29)=6.83, p<0.01] with both 2.5 mg/kg and 5 
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mg/kg PCP significantly reducing signal discrimination (p<0.05 and p<0.001 respectively), 
while there was no significant effect on the RI [F<1, NS].   
 
Table 6.2 Effect of Sub-Chronic PCP on overall performance in 5C-CPT using a variable SD 
Measure Vehicle 2.5 mg/kg PCP 5.0 mg/kg PCP 
Accuracy (%) 88.15 + 1.57 85.23 + 2.79 81.43 + 2.55 
Percent Correct 67.42 + 2.93 62.55 + 2.72 53.79 + 2.79 ** 
Percent Incorrect 9.00 + 1.24 10.80 + 2.06 12.66 + 2.01 
Percent Omission 23.58 + 2.86 26.65 + 2.04 33.79 + 2.79 * 
Correct Latency 0.68 + 0.03 0.58 + 0.04 0.63 + 0.06 
Incorrect Latency 0.93 + 0.07 0.81 + 0.06 0.99 + 0.11 
Magazine Latency 1.18 + 0.06 1.14 + 0.06 1.26 + 0.08 
Perseverative Response 1.00 + 0.54 2.27 + 1.23 3.50 + 1.59 
Premature Response 3.82 + 0.98 7.27 + 1.52 9.60 + 2.86 
Time Out Response 8.09 + 1.33 12.00 + 2.28 16.70 + 2.58 * 
p[HR] 0.67 + 0.03 0.63 + 0.03 0.54 + 0.03 ** 
p[FA] 0.18 + 0.04 0.27 + 0.03 0.32 + 0.06 * 
Sensitivity Index 0.52 + 0.05 0.36 + 0.04* 0.24 + 0.07 *** 
Responsivity Index -0.21 + 0.07 -0.12 + 0.05 -0.17 + 0.07 
Measures are shown as observed mean + SEM. Asterisks indicate statistically significant differences (*p<0.05, 
**p<0.01) compared to the vehicle group. 
 
6.3.2.2 Within-Session Performance 
Within-session analysis of performance from the vSD challenge revealed some more specific 
effects of sub-chronic PCP compared to overall performance.  Repeated measures ANOVA 
revealed a Dose*Trial interaction on accuracy [F(4,58)=3.45, p<0.05] (fig 6.1A).  Planned 
Chapter 6      Sub-chronic PCP and the 5C-CPT 
172 
Comparisons revealed that 2.5 mg/kg PCP reduced accuracy in trial bin 1 (p<0.05), while 5 
mg/kg PCP reduced accuracy in trial bin 3 (p<0.05), when compared to vehicle treated 
animals. PCP treatment resulted in no Trial effect [F(2,58)=2.21, NS] and no Trial*Treatment 
interaction [F(4,58)=0.28, NS] on percent omission.  However, Planned Comparisons 
demonstrated 5 mg/kg significantly increased omissions, compared to control animals, in the 
first trial bin (p<0.05) (fig 6.1B). 
PCP treatment reduced p[HR] [Treatment: F(2,29)=5.71, p<0.01, Treatment*Trial: F4,58=1.75, 
NS].  Planned Comparisons demonstrated that 2.5 mg/kg and 5 mg/kg significantly reduced 
the p[HR] during the first trial bin (p<0.05) (fig 6.1C).  The highest dose of PCP (5 mg/kg) 
produced a trend towards a significant reduction in p[HR] in the trials bin 2 (p=0.058) but 
resulted in a significant reduction in p[HR] in the trial bin 3 (p<0.05).  PCP treatment resulted 
in a trend toward increased p[FA] [Dose: F(2,29)=2.84, p=0.07, Dose*Trial: F4,58=1.26, NS].  
Planned Comparisons showed that PCP (both 2.5 & 5 mg/kg) significantly elevated p[FA] in 
the last trial bin (p<0.05 and p<0.01, respectively) (fig 6.1D).  In light of the effect on p[HR] 
and p[FA], it was clear that PCP produced a significant Trial*Dose interaction for SI 
[F(4,58)=2.80, p<0.05], with Planned Comparisons indicating that 5 mg/kg PCP significantly 
reduced SI in the first two trial bins (p<0.05), with a more substantial reduction observed in 
the last group of trials when compared with vehicle treatment (p<0.001) (fig 6.1E). PCP 
treatment had no significant effect on the RI [F4,58)=1.38, NS] (fig 6.1F). 
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Fig 6.1 Performance displayed over the duration of the session following an acute behavioural challenge 
consisting of introducing a variable SD. T1 – T3 refers to the trial bin, each consisting of 40 trials.  Data were 
expressed as observed mean + SEM and analysed by two-way repeated measures ANOVA (Trial as within-subjects 
factor and Treatment as between-subjects factor) followed by Planned Comparisons on the predicted means. # 
p<0.05 significant difference in Trial bin between PCP (2.5 mg/kg, n=11) and vehicle animals (n=11).  * p<0.05, ** 
p<0.01, and *** p < 0.001 significant difference in Trial bin between PCP (5.0 mg/kg, n=10) and vehicle animals.   
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While there was no significant difference between treatment groups in RI for each trial bin, a 
significant reduction of RI in vehicle treated rats was observed as the session progressed 
[F(2,29)=4.08, p<0.05].  A significant reduction was observed when the RI of trials bin1 was 
compared to trial bin 3 (p<0.01).  This progressive reduction in RI was not evident in PCP 
treated animals (Table 6.3).   
 
Table 6.3 Within-session alteration of strategy in control animals following vSD challenge 
Trial Bin T1 T2 T3 
Responsivity Index -0.11 + 0.09 -0.24 + 0.09 -0.37 + 0.08 ** 
Measures are shown as mean + SEM.  A more conservative response strategy was adopted in control animals as 
the session progressed, an effect that was absent in PCP treated animals. ** denotes p<0.01 when compared to 
trial bin 1 
 
6.3.2.3 Effect of vSD on performance 
There was a significant main effect of SD on response accuracy [F(3,87)=56.39, p<0.001] and 
percent omissions [F(3,87)=29.23, p<0.001] when a vSD was introduced, without a significant 
interaction between SD and Dose for accuracy [F(6,87)=0.3, NS] or percent omissions 
[F(6,87)=0.4, NS]. There was a main effect of SD on p[HR] [F(3,87)=84.44, p<0.001], but no 
significant interaction between SD and Treatment [F(6,87)=0.2, NS].  No significant effect of SD 
was observed on p[FA] [F(3,87)=0.8, NS] although there was a slight trend towards a 
SD*Treatment interaction [F(6,87)=1.86, p=0.09] (data not shown). There was a significant 
main effect of SD on SI [F(3,87)=23.32, p<0.001], along with a significant SD*Treatment 
interaction [F(6,87)=2.48, p<0.05], with Planned Comparisons demonstrating a significant PCP-
induced reduction in SI following 1 s SD (5 mg/kg, p<0.05), 0.75 s SD (2.5 and 5 mg/kg, 
p<0.05) and 0.25 s SD (2.5 mg/kg, p<0.05; 5 mg/kg, p<0.001).  No effect on SI was observed 
when the SD was 0.5 s.  Additionally, when the effect of SD on SI was analysed specifically for 
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control animals, a main effect was observed [F(3,30)=4.95, p<0.01], with Planned Comparisons 
showing that SI following 0.25 s SD was significantly reduced compared with SI following 1 s 
SD (p<0.05) (fig 6.2).  There was significant main effect on the responsivity for SD 
[F(3,87)=26.38, p<0.001], but no interaction of SD*Dose [F(6,87)=0.9, ns] (data not shown). 
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Fig 6.2 Sensitivity Index displayed for each individual stimulus duration presented throughout the session. Data 
are displayed as observed mean + SEM and analysed by two-way repeated measures ANOVA (SD as within-
subjects factor and Treatment as between-subjects factor) followed by Planned Comparisons on the predicted 
means. The effect of SD on SI was analysed specifically for control animals via one-way repeated measures 
ANOVA (SD as within-subjects factor) followed by Planned Comparisons. * p<0.05 reduction in SI for 0.25 s SD 
compared to 1 s SD in control animals.  
 
6.3.3 Normal Baseline Performance 
Following the vSD challenge, but prior to the extended session challenge (day 10), 
performance was assessed when protocols were returned to that of baseline. Animal 
performance returned to baseline with no significant differences existing between treatment 
groups in any of the behavioural measures assessed (data not shown). 
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6.3.4 Extended Session 
6.3.4.1 Overall Performance 
The extended session challenge (table 6.4), revealed varying effects of PCP treatment.  There 
was no overall effect on accuracy [F(2,29)=1.38, NS], percent correct [F(2,29)=1.41, NS], percent 
incorrect [F(2,29)=071, NS] or percent omissions [F(2,29)=1.05, NS].  A trend toward significance 
was observed for CL [F(2,29)=3.17, p=0.056], with Planned Comparisons indicating that 2.5 
mg/kg PCP reduced CL (p<0.05).  No significant effect was observed for ML [F(2,29)=1.93, NS] 
or IL [F(2,29)=1.2, NS] 
There was a trend towards a significant increase in perseverative responding [F(2,29)=2.68, 
p=0.08], with Planned Comparisons revealing that 5 mg/kg PCP significantly increased 
perseveration (p<0.05).  Additionally, there was also a significant increase in TO responses 
[F(2,29)=3.74, p<0.05) and Planned Comparisons indicated that 5 mg/kg PCP significantly 
increased TO responding (p<0.05).  No effect on premature responses were observed 
[F(229)=2.40, NS].  
Sub-chronic PCP produced no significant effect on p[HR] [F(2,29)=1.41, NS], but increased p[FA] 
[F(2,29)=3.57, p<0.05], by both doses of PCP following Planned Comparisons analysis (p<0.05).  
There was an overall reduction in the SI [F(2,29)=6.84, p<0.01] with Planned Comparisons 
indicating that both 2.5 and 5 mg/kg decreased discriminability (p<0.05 and p<0.01, 
respectively).  No effect of PCP was observed for RI [F(2,29)=1.00, NS]. 
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Table 6.4 Effect of Sub-Chronic PCP on overall performance in 5C-CPT following an extended 
session 
Measure Vehicle 2.5 mg/kg PCP 5.0 mg/kg PCP 
Accuracy (%) 93.85 + 1.13 92.03 + 1.45 90.38 + 1.82 
Percent Correct 70.17 + 3.81 68.69 + 3.14 61.50 + 4.57 
Percent Incorrect 4.55 + 0.89 5.80 + 1.02 6.33 + 1.34 
Percent Omission 25.28 + 3.87 25.51 + 2.86 32.18 + 4.49 
Correct Latency 0.71 + 0.03 0.59 + 0.03 * 0.63 + 0.04 
Incorrect Latency 1.13 + 0.08 1.12 + 0.12 1.27 + 0.12 
Magazine Latency 1.17 + 0.05 1.13 + 0.05  1.28 + 0.07 
Perseverative Response 2.00 + 0.56 5.45 + 1.71 7.10 + 2.16 * 
Premature Response 6.73 + 1.44 13.55 + 2.80 16.90 + 5.10 
Time Out Response 12.45 + 1.29 20.55 + 3.49 32.30 + 8.51 * 
p[HR] 0.70 + 0.04 0.69 + 0.03 0.61 + 0.05 
p[FA] 0.16 + 0.04 0.28 + 0.03 * 0.28 + 0.04 * 
Sensitivity Index 0.57 + 0.04 0.42 + 0.03 * 0.36 + 0.06 ** 
Responsivity Index -0.19 + 0.10 -0.04 + 0.06 -0.12 + 0.07 
Measures are shown as observed mean + SEM.  Asterisks indicate statistically significant differences (*p<0.05, 
**p<0.01) compared to the vehicle group. 
 
6.3.4.2 Within-Session Performance 
In a within-session analysis of the extended session challenge on performance repeated 
measures ANOVA revealed no Treatment*Trial interaction for accuracy [F(6, 87)=1.1, NS]. A 
Trial effect was observed [F(3,87)=3.09, p<0.05]. A Trial effect was observed for percent 
omissions [F(3,87)=13.03, p<0.001], attributed to an increase in omissions in trial bin 4 
(p<0.001).  This occurred indendent of a Treatment*Trial interaction [F(6,87)=1.13, NS] (data 
Chapter 6      Sub-chronic PCP and the 5C-CPT 
178 
not shown).  A Trial effect was observed for p[HR] [F(3,87)=14.51, p<0.001], but this occurred 
without a Treatment*Trial interaction [F(6,87)=1.51, NS] (fig 6.3A).  A Treatment*Trial 
interaction was observed for p[FA] [F(6,87)=2.90, p<0.05], however (fig 6.3B).  The significant 
increase in p[FA] was associated with 2.5 and 5 mg/kg PCP during the first trial bin (p<0.01 
and p<0.05, respectively) and 5 mg/kg PCP in the second trial bin (p<0.01).  PCP did not 
increase p[FA] in remaining  trial bins.  Although there was no Treatment*Trial interaction 
[F(6,87)=1.47, NS], there was an overall Trial effect on SI [F(3,87)=8.73, p<0.001] (fig 6.3C).  
ANOVA initially demonstrated no Drug effect in RI [F(2,29)=2.40, NS].  There was a Trial 
[F3,87)=10.41, p<0.001] and a Trial*Treatment interaction on RI [F(6,87) =2.57, p<0.05] and 
Planned Comparisons revealed 2.5 mg/kg and 5 mg/kg PCP increased RI in trial bin 1 only 
(p<0.01 and p<0.05, respectively) (fig 6.3D). 
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Fig 6.3 Performance displayed over the duration of the session that was extended to 256 trials.  T1 – T4 refers to 
the trial bins each consisting of 64 trials.  Effect of extended session on hit rate (A), false alarm rate (B), sensitivity 
index (SI) and responsivity index (D) are displayed.  # p<0.05 and ## p<0.01 significant difference in Trial bin 
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between PCP (2.5 mg/kg, n=11) and vehicle animals (n=11). * denotes p<0.05 and ** denotes p<0.01 significant 
difference in Trial bin between PCP (5 mg/kg, n=10) and vehicle animals. 
 
6.3.4.3 Vigilance Decrement 
Analysis of the control animals’ performance demonstrated a trend towards a main effect 
when SI was analysed by repeated measures (trial as within-subjects factor) ANOVA 
[F(3,30)=2.58, p = 0.07], with Planned Comparisons indicating that Trial bin 4 was significantly 
reduced (p<0.05) when compared with Trial bin 2 (fig 6.4). 
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Fig 6.4 Sensitivity Index (SI) of control animals (n=11) following the extended session challenge.  T1 – T4 refers to 
the trial bins each consisting of 64 trials. Data were expressed as observed mean + SEM and analysed by one-way 
repeated measures (Trial as within-subjects factor) ANOVA followed by Planned Comparisons. * p<0.05 Trial bin 4 
(trials 193 – 256) significantly reduced compared to Trial bin 2 (trials 65 – 128). 
 
 
 
 
 
 
Chapter 6      Sub-chronic PCP and the 5C-CPT 
180 
6.4 Discussion 
The present study supports the hypothesis that sub-chronic PCP treatment impairs 
performance in rats, in a manner consistent with impaired vigilance seen in patients with 
schizophrenia, up to 11 days after cessation of treatment.  These data suggest that PCP 
treatment induces persistent cognitive disruption, resulting in impaired 5C-CPT performance.  
However, these data also indicate that elucidation of these deficits requires animals’ 
performance to be challenged beyond that of baseline.  Hence, in some cases, sub-chronic 
PCP-induced deficits only became evident when the performance was displayed in discrete 
time bins throughout the session.  To our knowledge, this is the first time that sub-chronic 
PCP-induced impairments in the drug-free state in the pre-clinical test of vigilance, the 5C-
CPT have been demonstrated in rats. 
Successful performance of the 5C-CPT requires animals to be thoroughly trained with a highly 
pre-potent response necessary for task completion.  While acute or repeated PCP treatment 
resulted 5-CSRTT deficits at baseline (Amitai et al. 2007; Amitai and Markou, 2009; Chapter 
5), the lack of impairment on baseline performance in the present study suggests that a sub-
chronic PCP dosing regimen does not lead to task disruption, when performance was 
assessed at a baseline level of attentional demands.  Although this is in contrast to previous 
investigations, a major methodological difference exists as previous studies were conducted 
when animals were under the influence of PCP treatment (Le Pen et al. 2003; Amitai et al. 
2007; Amitai and Markou, 2009; Auclair et al. 2009) and not in the drug-free state.  The 
complete absence of performance impairment during baseline testing is similar to the lack of 
effect observed in chapter 3, using the 5-CSRTT even though a higher dose of PCP was used 
in the current chapter.  Sub-chronic PCP treatment results in a number of persistent 
neuropathological abnormalities (Jentsch et al. 1997a; Jentsch et al. 1997b; Cochran et al. 
2003; Hajszan et al. 2006; Abdul-Monim et al. 2007; Jenkins et al. 2008; Snigdha et al. 2010).   
However, it could be that none of these neurochemical, morphological or metabolic 
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disturbances contribute to attentional disruption under normal task demands.  Normal 
baseline performance in the 5-CSRTT following dorsal noradrenergic bundle lesions (Carli et 
al. 1983; Cole and Robbins, 1992) or dopamine depletion of the dorsal striatum (Baunez and 
Robbins, 1999), have been observed previously with deficits only apparent during increasing 
task demands, which included reducing stimulus intensity, stimulus duration, event-rate, or 
interpolating bursts of distracting white noise (see Robbins, 2002).  These findings, along with 
the trend towards impairment in chapter 3 following parameter manipulations, prompted 
the use of behavioural challenges within the 5C-CPT in order to determine if performance 
deficits induced by sub-chronic PCP treatment could be elucidated. 
By manipulating the test parameters to further tax attentional demands, it was 
demonstrated that PCP treated animals had a reduced ability to perform the 5C-CPT, 
compared to control animals.  The variable SD (vSD) task challenge was chosen specifically 
because it does not fundamentally alter the protocol the animal is responding to.  Alterations 
in the fundamental task parameters (i.e. extending the ITI) can lead to adaptation or 
modification of performance strategy.  Thus changes in performance following a vSD 
challenge are less likely to reflect within-session learning, as has been observed elsewhere 
(Hahn et al. 2002; see Young et al. 2009a).  When a vSD was introduced, so increasing the 
attentional demands of the task (McGaughy and Sarter, 1995; Jones et al. 1995; Mirza and 
Stolerman, 1998; Parasuraman, 1998), animals treated with PCP exhibited a reduced 
performance consistent with attentional dysfunction.  Although there was no significant 
effect on response accuracy, a strong trend towards a PCP-induced reduction was observed.  
When the effect of PCP-treatment and accuracy was assessed in discrete trial bins, across the 
duration of the session, significant impairments were observed.  Animals treated with the 
lower dose of PCP had an initial reduction in accuracy, but this effect disappeared as the 
session progressed.  Conversely, the initial response accuracy of animals treated with 5 
mg/kg PCP was no different to control animals.  However, as the session progressed the 
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response accuracy reduced, being significantly lower in the last group of trials.  As response 
accuracy is a well described measure of sustained attention (Muir 1996; Robbins 2002), these 
findings suggest that PCP-treatment is inducing deficits in attentional processing.  In contrast 
to the effects observed following repeated PCP treatment (chapter 5), the number of 
incorrect responses made following sub-chronic PCP remained unaffected.  The lack of an 
effect on incorrect responding indicated that a ‘guessing strategy’ was not utilised following 
failed target detection, demonstrating the differential attentional response profile following 
repeated or sub-chronic PCP treatment.  Furthermore, this suggested that the reduction in 
accuracy was mediated solely by impaired target detection, exemplified by the reduction in 
correct responses.  In light of this effect, an overall reduction in percent correct responding 
was observed.  This was coupled with an increase in trials omitted, consistent with previous 
reports using the standard 5-CSRTT (Amitai and Markou, 2010).  Like the reduction in 
response accuracy, it has been suggested that these findings represent impaired attentional 
functioning, as long as a concomitant increase in response latencies is not observed.  An 
increase in response latencies would potentially suggest locomotor impairment or reduced 
motivation resulting in a reduction in responding (hence decreased % correct and increased 
% omissions).  As there were no PCP-induced effects on the response latencies, particularly 
the magazine latency, these confounding effects can be ruled out, supporting the notion of a 
PCP-induced attentional deficit following the vSD challenge.   
There was no significant increase in perseverative responding in PCP-treated animals, but 
there was an increase in time out (TO).  TO responding is an under-reported and under-
studied measure in 5-CSRTT/5C-CPT testing but, along with preservative responding, TO 
responding is suggested to represent compulsive-like behaviour or cognitive inflexibility 
(Dalley et al. 2002; Amitai and Markou 2010).  Thus, an increase in TO responding may 
suggest that PCP-treated animals showed impaired cognitive flexibility, inappropriately 
responding during a TO period resulting from deficits in response inhibition.  This suggestion 
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is supported by previous findings in our laboratory in which PCP-treatment induced deficits in 
reversal learning impairing performance during the reversal phase, when inhibition of a 
previously rewarded response was required (Abdul-Monim et al. 2006, 2007; McLean et al. 
2009; Idris et al. 2010).  However, deficits in response inhibition appear to be selective for 
inappropriate responding during the TO period; PCP-treatment did not increase premature 
responding.  While there was a trend towards an increase in premature responding with the 
higher PCP dose, the increase lacked statistical significance.  The lack of a significant increase 
in ITI responses indicates that sub-chronic PCP treatment does not result in deficits in 
impulse control, in contrast to acute or repeated PCP treatment which dramatically increases 
premature responding (Chapter 3; Chapter 5).  This suggests that while NMDA antagonism 
induces pronounced deficits in behavioural inhibition while the drug is in the system, long-
term abnormalities resulting from sub-chronic PCP treatment are not associated with 
motoric impulsivity, as assessed by premature responding in the 5C-CPT.  This is supported 
by the absence of alterations in premature responding in chapter 3, when the effect of sub-
chronic PCP treatment was assessed in the 5-CSRTT.  
The addition of non-target stimuli in the 5C-CPT provides a method to further assess this 
deficit, however, by a method not available in 5-CSRTT testing.  In comparison with control 
animals, PCP treatment reduced the rats’ ability to withhold a response when presented with 
non-target stimuli, therefore suggesting impairment in action restraint (Eagle et al. 2008).  
There was an overall reduction in correct rejections (thus, increased false alarms).  However, 
assessment of performance across the session indicates inappropriate responding to non-
target trials is only elevated in the latter stages of the session.  It appears as if control animals 
are improving their performance when presented with non-target trials (reducing p[FA]) as 
the session progresses, an action that is inhibited by PCP-treatment.  Therefore PCP-
treatment is perhaps not increasing inappropriate responding but impairing the reduction of 
inappropriate responding, an effect which occurs in control animals. 
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The differential findings regarding premature responding and false alarms perhaps suggests a 
fractionation of the PCP-induced deficit in impulse control; motoric impulsivity assessed by 
premature responding is unaffected, while behavioural disinhibition assessed by false alarms 
is compromised.  These findings correlate with clinical observations.  Schizophrenia patients 
show dysfunction when presented with stimuli requiring response inhibition, increasing 
inappropriate responding compared to control subjects (Kiehl et al. 2000; Weibrod et al. 
2000; Wykes et al. 2000).  However, it would be pertinent to investigate the precise nature of 
this deficit.  Does schizophrenia increase behavioural disinhibition, increasing inappropriate 
responding or does schizophrenia impair the development of behavioural inhibition, 
preventing the reduction of inappropriate responding? So far, clinical reports only 
demonstrate the overall effect and not the performance throughout the course of a session.  
Therefore, a full and direct comparison between PCP treated animals and schizophrenia 
patients cannot be accurately substantiated. 
The PCP-induced reduction in correct detection of target stimuli, coupled with the increased 
frequency of incorrect responding to non-target stimuli ultimately results in a reduction in 
signal sensitivity, quantified by the PCP-induced reduction in the sensitivity index (SI).  The SI 
has been implemented as a non-parametric method of displaying d’ commonly used in 
human CPTs to assess performance, reflecting a measure of vigilance.  D’ is consistently 
reduced in schizophrenia patients, indicating stimuli discrimination deficits are inherent to 
the disorder (Nestor et al. 1990; Parasuraman, 1998; Mass et al. 2000; Baerwald et al. 2005; 
Wang et al. 2007; Park et al. 2010).  The PCP-induced reduction of SI, following the vSD 
challenge, is consistent with the impaired performance of patients with schizophrenia in 
human CPTs.  Furthermore, while PCP induced an overall significant reduction in SI, 
assessment of performance across the session demonstrates that the PCP-induced reduction 
was more substantial in the latter phase of the session compared to control animals.  The 
reduction in SI was initially driven by the reduction in hit rate (T1 and T2); however in the last 
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trial bin, the SI reduction was mediated both by the reduction in hit rate and the increased 
false alarm rate.  These data suggest that PCP treatment induced an element of cognitive 
fatigue, resulting in increasing deficits in signal discrimination as the session progressed, an 
effect that was absent in control animals.  Additionally, it has been observed that healthy 
volunteers infused with ketamine demonstrated impairment in CPT performance, 
exemplified by a decreased hit rate, increased false alarm rate and impaired signal sensitivity 
(Krystal et al. 1994; Umbricht et al. 2000; Heekeren et al. 2008).  These findings are similar 
not only to those observed in schizophrenia patients, but also to the PCP-induced 
impairment demonstrated within the current chapter.  However, these studies involved 
acute ketamine exposure, and did not investigate the enduring effects of chronic ketamine 
use on CPT performance.  This type of investigation is inherently difficult however, given the 
ethical considerations concerning the repeated administration of ketamine to healthy 
volunteers.  
The presence of target and non-target stimuli in the 5C-CPT also provides the ability to assess 
response strategy (bias).  Changes in SI (as described above) are less likely to reflect deficits 
of the construct being measured (vigilance) if the change was due to alterations in bias 
(Marston, 1996).  The reduction in SI in the present study was not accompanied by 
alterations in the responsivity index measure of bias (RI) between treatment groups, 
however, suggesting that impairment in signal sensitivity were mediate by cognitive 
mechanisms (Marston, 1996; Steckler, 2001).  Thus, it is likely that PCP treatment truly 
resulted in impaired vigilance, manifested as a reduced ability of animals to discriminate 
between signal and noise, consistent with reduced d’ exhibited by schizophrenia patients in 
human CPTs (Nestor et al. 1990; Parasuraman, 1998; Mass et al. 2000; Baerwald et al. 2005; 
Wang et al. 2007; Park et al. 2010).   
There were no significant differences between the RI and treatment groups, when assessed 
over the whole session or within individual trial bins.  However, it was apparent that the RI of 
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control animals significantly reduced as the session progressed, suggesting that animals were 
modifying their strategy in light of the increased cognitive demands of the challenge.  This 
modification of strategy was absent in PCP treated animals.  These data, therefore, suggest 
that PCP treatment may have reduced the ability of animals to adapt to the increased 
attentional load of the task, which may account for the reduced performance when 
challenged with a vSD.  As discussed previously, the p[FA] of animals treated with saline 
progressively reduced as the session progressed, possibly as a result of adaptation to the 
challenge of varying SDs or consistent, and therefore more predictable ITIs, which was 
reflective of their more conservative bias over time.  Varying the SD in mice while 
maintaining a variable ITI does not result in improved performance over the session (J. Young 
Personal Communication) suggesting that, in the present studies, control animals may be 
honing a temporally-mediating strategy (Spratt et al. 2000) within the session, consistent 
with previous reports when using extended ITI challenges (Hahn et al. 2002).  Noradrenergic 
depletion also impairs rats’ ability to adapt to variable ITI challenges (when trained with a 
constant ITI) in the 5-CSRTT (Cole and Robbins, 1992), while noradrenaline levels as 
measured by microdialysis only increase during such challenges (Dalley et al. 2001).  Thus 
PCP-induced deficits in the vSD challenge are possibly the result of the inhibition of the 
adaptation of the better strategy, evidenced by the absences of alterations in RI.  These 
effects may reflect alterations in noradrenergic levels following PCP treatment.  
Dopaminergic transmission has also been implicated in the formation and execution of 
strategy (Robbins and Roberts 2007).  Moreover, it is well established cortical dopaminergic 
levels are sensitive to sub-chronic PCP treatment, showing persistent reductions following 
treatment (Jentsch et al. 1997a, b; Elsworth et al. 2008).  This, along with potential NAergic 
dysfunction, may impair the development of a more conservative response strategy being 
implemented during the vSD challenge, accounting for disrupted performance. 
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Vigilant performance was further challenged by extending the session duration.  The most 
robust finding was a PCP-induced reduction in SI primarily mediated by an increased p[FA]  
indicative of response disinhibition.  During the start of the session (trials 0 – 64) this was 
coupled with increased RI, indicating a more liberal strategy than vehicle treated animals and 
the PCP-treated animals may simply have been increasing their responding to all signals.  The 
initial impairment in performance therefore may have been due to a shift in the animals’ 
decision criteria as opposed to alterations in cognitive processing per se.  However, the 
increase in RI disappeared as the session progressed while p[FA] remained high.  Moreover 
the p[HR] was unaffected, suggesting that the animals were not simply hyper-responsive to 
all stimuli.  Furthermore, the PCP-induced SI decrement was only evident in the middle part 
of the session (trials 65 – 192), independent of changes in RI, indicative of reduced 
performance resulting from cognitive dysfunction (Dudchenko, 1992; Marston, 1996).  While 
the PCP-induced impairment in SI was absent in the latter part of the session (trials 193 – 
256), this was primarily due to a reduction in SI in the vehicle treated animals.  This is likely 
due to cognitive fatigue in control animals.  There was a significant reduction in SI (from T2 to 
T4) in control animals, suggesting a reduction in signal sensitivity even in the control group.  
This is suggestive of a vigilance decrement, consistent with that observed in human CPTs 
(Parasuraman, 1998; Riccio et al. 2002) and also in mice in the extended session 5C-CPT 
challenge (Young et al. 2009b).  Studies assessing vigilance in humans traditionally utilise 
relatively long-term performance sessions, typically extending from 30 minutes to several 
hours (Parasuraman et al. 1998).  The seminal studies conducted by Mackworth (1950) 
involved subjects observing a clock face for periods of up to 2-hours.  Subjects had to report 
the occurrence of rare and unpredictable double-jumps of the clock hand (signal) from the 
frequent and predictable single jumps (noise).  Mackworth (1950) reported that correct 
signal detection fell dramatically as the session progressed, comparing performance in the 
first 30 minutes to the next 30 minutes. The decline in performance is a phenomenon 
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referred to as vigilance decrement (Parasuraman et al. 1998; Grottick and Higgins 2002; 
Young et al. 2009b).  There is the danger that impaired performance towards the latter part 
of the session may have been induced by excessive satiety.  The increased volume of reward 
pellets dispensed during the extended session may have resulted in reduced motivation to 
perform the task.  However, the lack of alterations in reward latency throughout the session 
suggested that motivation remained consistent (Robbins, 2002).  Therefore, satiation is 
unlikely, further supporting the hypothesis that a vigilance decrement was observed.  The 
vigilance decrement observed in control animals’ following the extended session challenge is 
in contrast to improved performance over time in the vSD challenge, supporting the use of 
an extended session challenge to further probe vigilance.  Although the short session used in 
the vSD challenge may not have been sufficient to induce a vigilance decrement in control 
animals.  However the reduction in SI in PCP-treated animals may suggest that drug 
treatment reduced the threshold for decrements in vigilance to become evident.  Vigilance 
decrements have been observed in aged rats performing an extended version of the 5-CSRTT 
(Grottick and Higgins 2002), characterised by a reduction in response accuracy as the session 
progressed.  Additionally, a vigilance decrement has been observed in mice, utilising an 
extended session in the 5C-CPT (Young et al. 2009b).  Impaired performance in this instance 
was demonstrated by a progressive reduction in SI throughout the session, independent of 
alterations in RI.  These findings reveal that experimental animals are sensitive to 
deterioration of performance consistent with the vigilance decrement observed in human 
attentional studies, enhancing the validity of such testing. 
The extended session challenge also revealed that sub-chronic PCP-induced a reduction in 
correct latency (CL), without affecting reward or incorrect latencies.  These findings suggest 
that sub-chronic PCP results in a specific enhancement of the speed of information 
processing resulting in a quicker correct response to target stimuli.  This is in contrast to PCP-
induced slowing of responding observed following acute administration or repeated PCP 
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treatment (chapter 3; chapter 5), although the effects following acute treatment were likely 
to be non-specific motoric effects as other latency measures were also slowed (Le Pen et al. 
2003; Amitai et al. 2007).  One study has demonstrated that acute MK-801 reduced CL in the 
5-CSRTT (Grottick and Higgins, 2000).  The MK-801-induced reduction in CL appeared to be 
dose-specific and only evident following low-dose administration and not following a higher 
dose.   These effects resemble those observed in the current chapter as the sub-chronic PCP-
induced reduction in CL was only evident in the group treated with the lower PCP dose.  In 
addition to the findings in the current chapter, the MK-801-induced reduction in CL occurred 
without alterations in the reward latency, indicating a specific cognitive effect as it was not 
the result of a generalised response-hyperactivity.  Thus, NMDA antagonism (either acute or 
sub-chronic) may reduce CL in a dose specific manner.  
In summary, these data demonstrate that a sub-chronic PCP treatment regimen can induce 
persistent deficits that result in attentional impairment in the 5C-CPT.  However, disrupted 
performance was only detected following increased attentional demands.  These data 
therefore suggest that the cognitive domain of attention/vigilance, although susceptible, may 
be less sensitive to the disruptive effects of sub-chronic PCP in rats compared with acute or 
repeated PCP treatment.  This conclusion is drawn from the observation that other cognitive 
domains (such as episodic memory, cognitive flexibility, social cognition and executive 
functioning), are disrupted following sub-chronic PCP treatment, without the need for 
further task challenge (see Neill et al. 2010 for a full review).  It may be that PCP-induced 
deficits in these tasks are mediated via a different mechanism to those observed in the 
current study, although further experiments will be required to test this hypothesis.  As there 
are, however, impairments in performance that were evident some 11 days following the 
cessation of drug treatment, this indicates that persistent changes are associated with this 
PCP-treatment regimen.  As described above, GABAergic dysfunction is observed following 
sub-chronic PCP treatment, along with morphological abnormalities.  Coupled with cognitive 
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impairment, neurochemical and morphological abnormalities appear to be enduring, 
persisting at least for several weeks.  The enduring morphological effects and their relation to 
attentional disruption following a sub-chronic PCP treatment regimen (using a dose of 5 
mg/kg) were to be investigated in the next chapter, utilising structural magnetic resonance 
imaging (MRI) in combination with the 5-CSRTT and PPI. 
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7.1 Introduction 
Coupled with the profound psychotic, behavioural and cognitive disturbances associated with 
schizophrenia, there appears to be a number of structural and functional brain abnormalities 
associated with the disorder.  Extensive work in schizophrenia patients has demonstrated a 
reduction in grey matter, white matter and overall brain volume, in addition to an 
enlargement in the volume of the ventricles (Meyer-Lindernberg, 2010).  Studies have 
reported a widespread reduction in cortical thickness associated with the disease (Kuperberg 
et al. 2003; Goldman et al. 2009; Rimol et al. 2010).  Furthermore, Rimol et al. (2010) also 
demonstrated substantial sub-cortical volume reductions and, consistent with previous 
findings (Shenton et al. 2001), also demonstrated that ventricular enlargement was present 
in patients with schizophrenia.  In fact, enlargement of the ventricular system has been one 
of the most consistent and reproducible findings that has emerged from neuroimaging 
studies in schizophrenia.  Moreover, magnetic resonance imaging (MRI) studies have 
demonstrated there is typically a 2% reduction in total brain tissue volume in schizophrenia 
patients (Wright et al. 2000), highlighting the gross structural abnormalities associated with 
the disease pathology.  A recent multimodal study, utilising functional and structural imaging, 
has indentified the medial prefrontal cortex (mPFC) as a region of the brain with prominent 
abnormalities in schizophrenia, coupled with dysfunction in the dorsal lateral prefrontal 
cortex (DLPFC) (Pomarol-Clotet et al. 2010), characterised by volumetric reductions, white 
matter abnormalities and hyperactivation or a failure of deactivation.  Yoon et al. (2008) 
conducted a study investigating the functional relationship between brain activation and 
performance in the CPT-AX, one of the many variants of the human attentional task, the 
continuous performance test (CPT). It was determined that impaired performance in this task 
by schizophrenia patients was related to a reduced level of activation in the dorsal lateral 
prefrontal cortex, thus highlighting the correlation between cognitive functioning and 
specific neuronal regions, and implicating the frontal cortex in attentional processing. 
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Antagonism of the glutamatergic NMDA receptor has been suggested to be a valid means of 
pharmacologically modelling aspects of schizophrenia neuropathology (Olney and Farber, 
1995; Coyle, 2006).  Chronic blockade of the glutamatergic NMDA receptor produces a 
number of cognitive (Neill et al. 2010; Chapter 6), metabolic (Cochran et al. 2003), 
morphological (Hajszan et al. 2006), and pathophysiological and neurochemical (Abdul-
Monim et al. 2006; Jenkins et al. 2008; Snigdha et al. 2010) abnormalities that are also 
observed in schizophrenia patients.  Therefore, the use of NMDA antagonists in 
neuroimaging studies provides a means of assessing the functional, structural and cognitive 
consequences of glutamatergic disruption in humans, and may provide a means of 
determining the validity of this pharmacological method of investigating schizophrenia.  
Investigation of white matter using diffusion tensor imaging (DTI) in chronic ketamine users 
identified bilateral frontal and left temporoparietal abnormalities consisting of reduced 
fractional anisotropy, changes that were correlated to the level of consumption of ketamine 
(Liao et al. 2010).  In addition, the decreased fractional anisotropy located in the medial 
frontal cortex seen in ketamine users showed striking consistency with that demonstrated in 
schizophrenia patients (Pomarol-Clotet et al. 2010).   Examination of chronic ketamine users 
also revealed structural abnormalities, as assessed by voxel based morphometry (VBM), 
characterised by reductions in grey matter density (Liao et al. 2011).  These findings 
demonstrated that chronic blockade of NMDA receptors produced a reduction in frontal grey 
matter density, specifically located in the left superior frontal gyrus and right middle frontal 
gyrus.  Grey matter abnormalities within the mPFC and DLPFC regions also have been 
demonstrated in individuals with schizophrenia (Pomarol-Clotet et al. 2010).  The findings 
demonstrated by Liao and colleagues (2010; 2011) revealed, for the first time, that chronic 
exposure to a glutamatergic antagonist induces persistent structural changes in humans that 
are reminiscent to the alterations in brain morphometry present within the clinical 
population.  However, human NMDA antagonist abusers are likely to be poly-drug users.  
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Thus, it is difficult to determine whether these effects were specifically mediated by 
ketamine, another psychoactive drug or a combination of both influences.  Due to ethical 
considerations, human imaging studies in controlled settings are not permitted to chronically 
administer NMDA antagonists to volunteers, only acute.  Therefore, the use of preclinical 
imaging studies utilising experimental animals can be implemented facilitating the 
elucidation of the effects of NMDA antagonism within the brain. 
The use of preclinical experimental model enables researchers to draw conclusions on causal 
mechanisms underlying neurocognitive impairment associated with chronic NMDA receptor 
blockade. Furthermore, preclinical studies facilitate a level of sample control that cannot be 
achieved in a clinical setting.  Chronic intermittent administration of PCP has been identified 
to induce metabolic hypofunction within prefrontal cortical regions.  The imaging technique 
2-deoxyglucose autoradiography (2-DG) has indicated a reduction in glucose utilisation 
within a number of cortical regions.  PCP treatment induced a regionally specific reduction in 
local cerebral glucose utilization, including the medial orbital cortex and throughout all layers 
of the prelimbic cortex.  In addition to cortical metabolic hypofunction, it was demonstrated 
PCP treatment was associated with reduced glucose metabolism within sub-cortical 
structures such as the lateral lemniscus and reticular nucleus of the thalamus (Cochran et al. 
2003).  Prefrontal glucose utilisation has been shown to be correlated with not only the 
presence, but also the severity of cognitive and negative symptoms of schizophrenia 
(Buchsbaum and Hazlett 1998; Hazlett et al. 2000; Cochran et al. 2003).  Furthermore, 
dysfunctional neuronal metabolism within the temporal lobes has been linked to the 
development of psychotic symptoms and thought disorder (Buchsbaum and Hazlett 1998).  
These findings demonstrate that effective neuronal metabolism is essential for normal brain 
activity and erroneous glucose utilisation may be intrinsically involved with schizophrenia 
symptomatology.  Moreover, the findings reported by Cochran and colleagues (2003) 
indicate that chronic NMDA receptor antagonism may induce functional impairment in brain 
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regions that share functional homology with impairments present in human PCP abusers 
performing frontally controlled tasks (Wu et al. 1991) as well as schizophrenia patients 
(Wolkin et al. 1992; Tamminga et al. 1992), as assessed by positron emission tomography.   
Impaired functioning of cortical regions demonstrated in schizophrenia patients and human 
PCP users and now experimental animals following PCP administration may mediate the 
cognitive impairments observed.  Prefrontal cortical regions have been extensively 
associated with the involvement in higher-order cognitive processing (Volz et al. 1998; 
Hazlett et al. 2000; Miller and Cohen 2001; Lesh et al. 2010) and therefore abnormal 
neuronal activity may lead to cognitive dysfunction.  Additionally, it has also been 
demonstrated that acute administration of PCP produced altered relative cerebral blood 
volume (rCBV) in distinct corticolimbic-thalamic structures, including medial prefrontal, 
cingulate, orbitofrontal and retrospenial cortices (Gozzi et al. 2008), in a pharmacological MRI 
(phMRI) study.  These findings demonstrate that systemic administration of PCP results in 
hypofrontality of cortical brain regions implicated in cognition relative to schizophrenia.  
Thus, these findings further enhance the cross-species translational validity of utilising NMDA 
antagonists to pharmacologically induce abnormal neuronal functioning of cortical brain 
regions. 
Schizophrenia is associated with impairments in cognition across a number of domains 
(Marder et al. 2004; Neuchterlein et al. 2004; Ibrahim and Tamminga, 2010), many of which 
can be modelled in experimental animals (Young et al. 2009a) and are susceptible to 
enduring disruption following sub-chronic NMDA receptor antagonism (Neill et al. 2010).  
Previous experiments have demonstrated that attentional processing is impaired following 
repeated PCP treatment (Amitai and Markou 2010; chapter 5) or in the drug-free state 
following sub-chronic PCP treatment (chapter 6).  In addition to voluntary attentional 
processing (sustained, divided, selective), sensorimotor gating reflects passive or ‘automatic’ 
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attentional processing and involves the pre-processing of incoming sensory information 
(Graham, 1975).  Sensorimotor gating is usually assessed using pre-pulse inhibition (PPI) of a 
startle response (Braff and Geyer 1990).  When a startling stimulus is preceded by a non-
startling ‘prepulse’, the startle reflex elicited has a diminished intensity.  This phenomenon is 
observed in all mammalian species (Braff et al. 2001).  PPI deficits are evident in 
schizophrenia patients (Braff et al. 1978, 1992; Swerdlow et al. 1994) and have been 
suggested to be associated with cognitive fragmentation and the generation of thought 
disorders (Perry and Braff et al. 1994).  Inhibition of a startle reflex has been shown to be 
disrupted in rats following administration of psychostimulants, including NMDA receptor 
antagonists (Mansbach and Geyer 1989, 1991).  These findings suggest that glutamatergic 
disruption results in deficits in sensorimotor gating which is consistent with that observed in 
schizophrenia patients. 
As described above, in addition to the cognitive disruption induced by NMDA antagonism, 
blockade of the glutamatergic system also results in a number of functional, 
neurophysiological and neurochemical abnormalities that are present in schizophrenia 
patients.  While the metabolic abnormalities and neuropathalogical commonalities are well 
characterised following NMDA receptor antagonism, there is a distinct lack of preclinical data 
characterising the structural abnormalities following sub-chronic PCP administration.  This is 
especially true of studies that were not limited to a region of interest approach.   Therefore, 
the aim of this experimental chapter was (1) to confirm whether sub-chronic PCP treatment 
induces attentional disruption, characterised by attentional impairment on the 5-CSRTT; (2) 
whether PCP treatment affects startle reactivity; (3) whether sub-chronic PCP treatment is 
associated with enduring structural brain abnormalities.   
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7.2 Methods 
7.2.1 Subjects 
Male Lister-hooded rats (n=20; Charles River; weighing approx 350 + 10 g at the start of the 
experiment) were housed in groups of four on a 12 hour reversed light cycle (lights on at 
7:00pm).  Details regarding the environmental conditions, food restriction and ethical 
considerations can be found in the general methods section (chapter 2).  
7.2.2 Behavioural Assessment 
Behavioural assessment was conducted both before and after sub-chronic PCP treatment.  
This enabled the longitudinal assessment of cognitive performance, enabling within-subjects 
assessment of performance alterations following PCP treatment to be made. 
7.2.3 5-Choice Serial Reaction Time Task 
Animals were trained to perform the 5-CSRTT as described in chapter 2.  Additionally, the 
equipment used during the experimental procedures is also described within the general 
methods chapter.  The following 5-CSRTT testing conditions were conducted before and after 
sub-chronic PCP treatment.  Details regarding the duration between PCP treatment and 
behavioural challenge is described in the experimental design section. 
7.2.3.1 Stable Baseline Performance 
Performance was assessed using the protocols designated in Training Stage 7, which 
consisted of a 1 s SD, 5 s ITI, 5 s TO period and a 5 s LH.  Animals were presented with 100 
trials in a session lasting no longer than 30 minutes.  Pre-treatment assessment of stable 
baseline performance was conducted when animals performed consistently to the criteria 
described in the general methods section. 
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7.2.3.2 Variable Stimulus Duration (vSD) 
Rat performance was challenged within a single session that presented a variable SD (0.25, 
0.5, 0.75, and 1 s) as opposed to a fixed SD (1 s).  Every SD was presented pseudo-randomly, 
25 times each in a session consisting of 100 trials.  All other parameters (TO, LH and ITI) were 
as before. 
7.2.3.3 Variable Inter-trial Interval (vITI) 
Rats were exposed to a variable ITI session as a further behavioural challenge.  The fixed ITI 
of 5 s now consisted of a variable ITI (2, 4, 6, and 8 s), which was presented in a pseudo-
random order throughout the session (25 times for each individual ITI).  Other testing 
parameters were identical to standard training conditions i.e. 100 trials, 1 s SD, 5 s TO and 5 s 
LH. 
Both challenge sessions were interspersed with standard training sessions, before and after 
PCP treatment ensuring stable performance was maintained throughout the experimental 
procedure.   
7.2.4 Pre-pulse Inhibition 
Following 5-CSRTT testing, (stable baseline performance and behavioural challenges) all 
animals were tested in startle chambers (Kinder Scientific, USA), investigating the 
attenuation of startle reflex by the presentation of a non-startling pre-pulse.  Pre-pulse 
inhibition (PPI) testing was conducted both before and after sub-chronic PCP treatment. 
7.2.4.1 Description of PPI Paradigm 
No training was required for startle experiments.  The session was configured following the 
protocols described within the training manual published by Geyer and Swerdlow (2001).  
The session began with a 5 min habituation period during which a background noise (white 
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noise) was presented with an intensity of 65 dB.  The session consisted of 36 trials comprised 
of either pulse only trials (120 dB) or trials containing a pre-pulse (3, 6, or 12 dB above 
background noise; Swerdlow and Geyer 2001).  Trials were separated by variable inter-trial 
intervals (ITI; 8 – 23 s) which averaged 15 s.  The initial part of the session, following the 
habituation period, was composed of 6 consecutive pulse only trials, which was followed by 
25 trials consisting of pulse only and three individual pre-pulse trials, presented in a 
randomised order, which was then followed by 5 consecutive pulse only trials.  Testing was 
conducted in three startle chambers and data collection was conducted by (Startle Monitor, 
Kinder Scientific) software and analysed in Excel (Microsoft).  Each chamber was calibrated 
for intra-chamber consistency, thus enabling the accelerometer used to quantify the startle 
response to assess a reaction up to a force of 15 Newton’s (N). 
7.2.4.2 Description of Startle Stimulus 
The pre-pulse trials were constructed as follows; the noise level increased above background 
noise (3, 6, or 12 dB) for a period of 20 msec, after which the noise level was reduced back to 
65 dB. After a period of 80 msec the software began recording the startle response 
(recording window of 250 msec) and a pulse was delivered (120 dB), which had a rise time of 
< 2 msec and a duration of 40 msec.  After the pulse, the noise level reduced to background 
level and the trial ended, initiating the ITI.  Pulse only trials were constructed in the same 
manner, only without the 20 msec pre-pulse. Each of the various pulse or pre-pulse trials 
were interspersed by variable ITIs and the session lasted for approximately 10 minutes. 
7.2.4.3 Calculation of Pre-pulse Inhibition 
The level of pre-pulse inhibition was expressed as a percentage of the full startle response.  
This enabled differing amplitudes of startle response to be normalised.  The inhibition of the 
startle response was calculated for each individual animal and averaged, indicating the level 
Chapter 7             Structural MRI and PCP 
200 
of startle inhibition for each pre-pulse trial.  The following calculation was used to calculate 
the percentage of pre-pulse inhibition of the startle response when the stimulus was 
preceded by a non-startling pre-pulse: 
PPI = 100 x {[pulse only units – (prepulse + pulse units)] / (pulse only units)} 
7.2.5 Sub-chronic PCP Treatment Regimen 
Animals were treated with saline (0.9% saline, n = 10) or PCP (5 mg/kg, n = 10) via the 
interperitoneal (i.p.) route.  The sub-chronic PCP treatment regimen consisted of 7 twice-
daily (approximately 9am and 5pm) injections followed by a 7-day washout period.  During 
this treatment regimen and washout duration animals received no behavioural training or 
testing and were kept in home cages.  Food restriction continued throughout the 
experiment.  
7.2.6 Induction and Maintenance of General Anaesthesia 
Animals were anaesthetised during the MRI procedure.  Animals were placed into the 
induction chamber and anaesthesia was induced using 5% isofluorane in 02 (2L/min) for a 
period of 3 – 5 minutes.  Once animals’ paw-pinch reflex was absent, animals were removed 
from the induction chamber and transferred to the MRI bed.  Anaesthesia was maintained 
with a flow-rate of 2 – 2.5% isofluorane in 02 (2L/min) throughout the duration of the 
scanning procedure.  Animals were fixed in a stereotaxic head frame.  Respiration rate, core 
temperature and blood oxygenation level were monitored throughout the scanning 
procedure.  Upon completion of the scanning procedure, animals were removed and placed 
in a recovery chamber and monitored throughout recovery, after which they were returned 
to an isolation cage within the holding room until the following morning. 
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7.2.7 Structural Magnetic Resonance Imaging 
Once the animal was fixed in the MRI bed, the cradle was inserted into the bore of the 4.7 
tesla MRI magnet (Bruker BioSpec 47/40 System).  Following the alignment of the scanning 
region, the scan sequence was initiated; firstly diffusion tensor images were acquired 
followed by high resolution structural images.  Total scan time was approximately 1 hr 45 
mins and yielded an image resolution of 160 µm.  Images were analysed in SPM5 with the 
SPM Mouse plug-in (Wellcome Department of Clinical Neurology, London 
(http://www.fil.ion.ucl.ac.uk). 
7.2.8 Experimental Design 
Once trained, all 20 animals were tested in the 5-CSRTT using standard training conditions 
and then exposed to two behavioural challenges.  Figure 7.1 summarises the experimental 
design used.  Following the 5-CSRTT baseline and challenge sessions, baseline PPI 
performance was recorded in all 20 animals.  Upon completion of baseline behavioural 
testing, baseline MRI scanning was conducted utilising VBM and DTI techniques.  Following 
the completion of baseline behaviour and structural imaging, animals were then dosed with 
either PCP or saline following a sub-chronic dosing schedule.  To determine treatment 
groups, animals were group-matched based on 5-CSRTT performance before and after 
behavioural challenges, along with PPI startle responsivity, in order to create two treatment 
groups with no significant variation between behavioural measures.  The group-matching 
procedure used was identical to that that described in chapter 5 and 6.  In addition to the 
group-matching procedure, animals were ranked depending on baseline 5-CSRTT 
performance and based on the rank and treatment group, the order in which they were 
scanned was determined.  This ensured there was no variability or bias throughout the 
scanning procedure.  Animals were then treated according to the sub-chronic PCP regimen, 
outlined above.  The dosing schedule was staggered to ensure all animals received identical 
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durations between drug washout, post-dose behavioural testing and MRI scanning.  
Following the wash-out period, animals were re-tested in the 5-CSRTT, using stable baseline 
conditions (8-days post-PCP) and the acute behavioural challenges (variable SD and variable 
ITI; 10 – 13 days post-PCP), PPI (14 days post-PCP) and finally animals were re-scanned 
following the same procedure used previously (15 days post-PCP).  On the day following MRI 
scanning (16 days post-PCP), brains were removed, snap-frozen and stored at -80oC, enabling 
ex-vivo analysis to be conducted. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.1 A schematic diagram showing an overview of the experimental design used. Sub-chronic treatment 
consisted of 7-day twice daily administration, followed by 7-day washout period. 5-CSRTT testing includes 
baseline attentional load and two challenge sessions. 
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7.2.9 Data Analysis 
To analyse the longitudinal, within-subjects effect of sub-chronic PCP treatment before and 
after treatment, a two-way repeated measures analysis of variance (ANOVA) was utilised.  
‘Day’ (before or after treatment) was the repeated measure and ‘Treatment’ (saline or PCP) 
was the fixed between-subjects factor.  Repeated measure ANOVA was used to assess 
performance for standard parameters session and following the vSD and vITI challenge 
sessions.  Planned Comparisons (Snedecor and Cochran 1989) were used to assess post-dose 
performance differences compared to pre-dose performance.  To specifically address the 
post-dose between-subjects differences of the treatment groups, a one-way analysis of 
covariance (ANCOVA) was carried out with Treatment as the fixed factor.  Pre-treatment 
performance was used as a covariate, compensating for between-animal variability that may 
have existed among the animals response prior to drug treatment, therefore enhancing the 
statistical power of the approach.  Again, ANCOVA analysis was used to assess performance 
following standard parameters session, and the vSD and vITI challenge sessions.  Assessment 
of performance when presented with individual SD (1, 0.75, 0.5, 0.25 s) or ITI (8, 6, 4, 2 s) was 
conducted by two-way repeated measures ANOVA.  The between-subjects factor was 
Treatment, and repeated measure was SD or ITI.  Additionally, a two-way repeated measures 
ANOVA was also used to determine performance across the session.  The 5-CSRTT session 
was split into trial bins, each containing 50 trials (T1 and T2).  Treatment group was the 
between-subjects factor and trial bin the repeated measure.  
A two-way repeated measures ANOVA was used to analyse startle reactivity, before and after 
PCP treatment.  The repeated measure was the pre-pulse amplitude and the fixed factor was 
the treatment group.  Planned Comparisons were used to compare startle response of each 
pre-pulse to each other.  Pre and post-treatment conditions were analysed individually and 
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like 5-CSRTT figure, saline and PCP labels within the pre-treatment groups indicates future 
treatment. 
Structural MR images were processed using SPM5 following a standard VBM paradigm for 
animal imaging (Sawiak et al. 2009).  Following manual alignment, brains were segmented 
into grey and white matter maps using the SPM Mouse toolbox 
(www.wbic.cam.ac.uk/~sjs80/spmmouse.html) and DARTEL (Ashburner and Friston 2000).  
Modulated GM maps were prepared for each subject scan pre- and post-administration and 
smoothed with an 800µm isotropic Gaussian smoothing kernel.  Voxel-wise paired Student’s 
t-tests were performed two-tailed at each voxel to identify group differences.  To control for 
multiple comparisons, an adjusted p-value of p<0.005 in combination with an extent 
threshold of 100 voxels was used.  Additionally, a family-wise error (FWE) correction was 
applied. 
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7.3  Results 
7.3.1 Voxel-Based Morphometry 
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Fig 7.3 Overview of regional GM score differences in rats administered either saline (n=10) or PCP (n=10). Regions 
include prelimbic cortex (Prl), dorsal presubiculum (DS) and dorsal endopiriform cortex (DEn).  Colour gradient 
indicates two-tailed t-test F-score with 18 degrees of freedom. 
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Fig 7.2 displays rostral to caudal coronal brain slices showing significant differences in GM 
class between saline and PCP-treated animals.  A FDR and FWE threshold of p=0.005 for 
controlling the type 1 error was applied.  The PCP-induced morphological abnormality within 
prelimbic cortex (PrL) survived correction for multiple comparisons (FWE or FDR) when small 
volume correction was applied to the frontal cortex (p<0.05).  Voxel clusters within the 
hippocampal formation/dorsal presubiculum (DS) and dorsal endopiriform cortex (DEn) 
survived a weak correction for multiple comparisons.  However, when more stringent 
controls (FDR, FWE) are applied the effect lost statistical significance.  Fig 7.3 represents an 
overview of brain morphology, showing coronal, sagittal and horizontal slices.  Colour 
gradient represents F-scores (2/18 degrees of freedom) indicating intensity of MRI signal.  
Table 7.1 summarises the MRI results, displaying corrected and uncorrected p values, F-
scores and region. 
Table 7.1 Description of sub-chronic PCP induced structural changes 
Extent (voxels) p value uncorrected p value FWE corrected F-score Region 
191 0.00035 <0.05 19.3 Prelimbic 
296 0.00047 = 18.2 Dorsal Endopiriform 
119 0.00008 = 25.9 Presubiculum 
Summary of the PCP-induced effect on brain morphology.  Cluster region determined from Paxinos and Watson 
(2004) rat brain atlas 
 
7.3.2 5-CSRTT - Stable Baseline Performance 
The following describes the effect of sub-chronic PCP treatment on 5-CSRTT performance.  As 
discussed in section 7.2.9, a repeated measure ANOVA was used to analyse the longitudinal 
effect, assessing performance before and after sub-chronic PCP treatment.  Conversely, a 
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one-way ANCOVA analysis was used to determine the post-treatment between-subject 
effect.  Performance in the 5-CSRTT when animals were tested using standard training 
parameters was analysed.  Two-way repeated measures ANOVA demonstrated no Treatment 
effect [F(1,18)=0.83, NS] or Treatment*Day interaction [F(1,18)=1.29, NS] for response accuracy 
under standard training parameters (fig 7.4A).  Additionally, one-way ANCOVA demonstrated 
no significant between-subjects effect following sub-chronic PCP treatment [F(1,17)=1.59, NS]. 
Analysis of the percent correct responding in PCP treated animals’ indicated an overall 
significant effect for Day [F(1,18)=6.11, p<0.05], without an effect on Treatment [F(1,18)=0.39, 
NS] or a Treatment*Day interaction [F(1,18)=2.93, NS].  Planned Comparisons revealed the 
significant Day effect was mediated by a significant reduction in percent correct responding 
following PCP treatment (p<0.01), an effect that was absent in control animals (fig 7.4B).  
While the effect lacked statistical significance, the one-way ANCOVA demonstrated a trend 
towards a PCP-induced reduction in percent correct responding following drug treatment 
[F(1,17)= 3.12, p<0.1]. 
There was no Treatment effect [F(1,18)=0.81, NS] or Treatment*Day interaction [F(1,18)=0.88, 
NS] when the longitudinal effect on incorrect responses was analysed (fig 7.4C).  Similarly, 
there was no between-subjects effect following ANCOVA analysis [F(1,17)=1.21, NS]. 
Analysis of percent omissions demonstrated a significant Day effect [F(1,18)=6.17, p<0.05], 
which occurred independently of a Treatment effect [F(1,18)=0.00, NS] or Treatment*Day 
interaction [F(1,18)=1.63, NS].  Planned Comparisons demonstrated that PCP treatment 
resulted in a significant increase in omissions following sub-chronic treatment (p<0.05).  This 
effect was not evident in control animals (fig 7.4D).  Between-subjects comparisons revealed 
no significant difference in omissions between treatment groups following treatment 
[F(1,17)=1.19, NS]. 
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Fig 7.4. Performance before and after sub-chronic PCP treatment in the 5-CSRTT using standard parameters.  
Measures displayed include response accuracy (A), percent correct responding (B), percent incorrect responding 
(C) and percent of omissions (D). **denotes p<0.01 following between-subjects analysis of the saline (n=10) and 
PCP (n=10) treatment groups, post-dose. # denotes p<0.05 and ## p<0.01 within-subjects difference in PCP-
treated animals when compared with pre-treatment performance. 
 
PCP treatment had no significant effect on perseverative responding, indicated by the 
absence of a Treatment effect [F(1,18)=2.26, NS] or Treatment * Day interaction [F(1,18)=2.30, 
NS]. Furthermore, no effect between saline and PCP treated animals was observed 
[F(1,17)=0.82, NS].  Likewise, sub-chronic PCP treatment had a non-significant within-subjects 
effect on premature responding, demonstrated by the lack of Treatment effect [F(1,18)=0.68, 
NS] or Treatment*Day interaction [F(1,18)=0.06, NS] (table 7.2).  This was accompanied by no 
significant effect following one-way ANCOVA analysis [F(1,17)=0.00, NS] (table 7.3). 
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Table 7.2 Effect of PCP treatment on baseline performance in the 5-CSRTT 
Parameter Pre-Treatment Post-Treatment 
Perseverative (n) 157.80 + 28.01 161.80 + 26.86 
Premature (%) 5.90 + 1.30 9.55 + 3.31 
Correct Latency (s) 0.69 + 0.04 0.76 + 0.05 * 
Magazine Latency (s) 1.39 + 0.06 1.29 + 0.06 * 
Within-subjects comparison of standard 5-CSRTT performance before and after PCP treatment 
Investigation of the effect on correct latency (CL) revealed a significant Treatment*Day 
interaction [F(1,18)=6.95, p<0.05].  Planned Comparisons attributed this interaction to a PCP-
induced increase in CL (p<0.05), with no effect observed in control animals (table 7.2).  
Analysis of the between-subjects effect demonstrated a significant PCP-induced increase in 
CL [F(1,17)=6.86, p<0.05] (table 7.3). 
Analysis of the longitudinal effect on magazine latency demonstrated no effect of Treatment 
[F(1,18)=0.29, NS] or a Treatment*Day interaction [F(1,18)=0.34, NS] but did reveal a significant 
Day effect [F(1,18)=7.39, p<0.05].  Planned Comparisons indicated that the ML was significantly 
reduced in PCP treated animals following treatment (p<0.05), without an effect in saline 
treated animals (table 7.2).  However, there was no significant difference between treatment 
groups following ANCOVA analysis [F(1,17)=0.5, NS] (table 7.3). 
These analyses demonstrate that post-treatment comparisons between vehicle and PCP 
treated animals reveal no significant difference in the attentional measures assessed, when 
animals were assessed under a low attentional load.  However, an increase in CL was 
observed.  Upon assessment of the pre vs post within-subject effect of PCP treatment, subtle 
deficits were observed.  Correct responding was reduced and the number of omissions was 
increased.  Furthermore, CL was increased and this was coupled with a reduction in ML. 
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Table 7.3. Baseline 5-CSRTT performance following sub-chronic PCP treatment 
Parameter Saline PCP 
Perseverative (n) 131.20 + 11.39 161.80 + 26.86 
Premature (%) 11.21 + 1.79 9.55 + 3.31 
Correct Latency (s) 0.68 + 0.05 0.76 + 0.05 *  
Magazine Latency (s) 1.36 + 0.09 1.29 + 0.06 
Between-subjects comparison of treatment groups during standard 5-CSRTT parameters following sub-chronic 
treatment 
7.3.3 Variable Stimulus Duration (vSD) Challenge Session 
Based on previous observations (chapters 3 and 6) that baseline performance is generally 
unaffected following sub-chronic PCP treatment, a vSD challenge session was implemented 
to further tax attentional processing.  Two-way repeated measures ANOVA demonstrated a 
significant longitudinal Treatment effect [F(1,18)=5.04, p<0.05] and a Treatment*Day 
interaction [F(1,18)=7.79, p<0.05] for response accuracy.  Planned Comparisons demonstrated 
the significant effect was attributed to a PCP-specific reduction in accuracy following 
treatment (p<0.01).  One-way ANOCVA analysis of the between-subject post-dose 
performance also demonstrated a significant difference between treatment groups 
[F(1,17)=9.85, p<0.01] (fig 7.5A). 
The effect on percent correct responding demonstrated a significant Day effect [F(1,18)=4.58, 
p<0.05] a strong trend towards a Treatment effect [F(1,18)=4.07, p=0.058], but no 
Treatment*Day interaction [F(1,18)=2.75, NS].  Planned Comparisons demonstrated a 
significant within-subjects reduction in percent correct for PCP treated animals (p<0.05) but 
not saline treated animals.  A strong trend towards a significant between-subjects effect was 
observed following one-way ANCOVA analysis [F(1,17)=4.17, p=0.057] (fig 7.5B). 
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Repeated measures ANOVA showed a significant Treatment*Day interaction when the 
number of incorrect responses was analysed [F(1,18)=8.67, p<0.01].  A trend towards a 
Treatment effect [F(1,18)=3.11, p<0.1] was also observed.  Planned Comparisons indicated this 
effect was mediated by a within-subjects PCP-induced increase in incorrect responding 
(p<0.01).  ANCOVA analysis revealed a significant between-subject effect [F(1,17)=9.67, p<0.01] 
when saline and PCP-treated animals’ were compared following drug treatment (fig 7.5C). No 
Treatment effect [F(1,18)=0.4, NS] or Treatment*Day interaction [F(1,18)=0.00, NS] was observed 
when the number of omissions was analysed.  Similarly, no between-subjects effect was 
observed following ANCOVA analysis [F(1,17)=0.03, NS] (fig 7.5D). 
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Fig 7.5 Effect of a variable stimulus duration (vSD) challenge session on performance, before and after sub-chronic 
PCP treatment.  Measures displayed include response accuracy (A), percent correct responding (B), percent 
incorrect responding (C) and percent of omissions (D). **denotes p<0.01 following between-subjects analysis of 
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the saline (n=10) and PCP (n=10) treatment groups, post-dose. # denotes p<0.05 and ## p<0.01 within-subjects 
difference in PCP-treated animals when compared with pre-treatment performance. 
Two-way ANOVA of perseverative responding demonstrated no Treatment [F(1,18)=1.08, NS] 
or a Day effect [F(1,18)=1.89, NS] or a Treatment*Day interaction [F(1,18)=0.27, NS] (table 7.3).  
Furthermore, no difference existed between control and PCP groups following ANCOVA 
analysis [F(1,17)=0.00, NS] (table 7.4).  Within-subjects analysis of the PCP-induced effect on 
premature responding demonstrated a significant Day effect [F(1,18)=6.04, p<0.05], 
independent of a Treatment effect [F(1,18)=0.14, NS] (table 7.3).  However, a trend towards a 
Treatment*Day interaction was observed [F(1,18)=3.94, p=0.06].  Planned Comparisons 
demonstrated a significant within-subjects reduction in premature responding in saline 
treated animals (p<0.01, data not shown).  No effect was observed in PCP-treated animals 
(table 7.4).  Despite the significant within-subjects reduction in saline treated animals, 
between-subjects analysis following sub-chronic treatment demonstrated no significant 
difference [F(1,17)=2.15, NS] (table 7.5). 
 
Table 7.4 Effect of PCP treatment on 5-CSRTT performance following a vSD challenge 
Parameter Pre-Treatment Post-Treatment 
Perseverative (n) 167.40 + 32.48 149.50 + 30.16 
Premature (%) 6.90 + 1.39 6.33 + 2.38 
Correct Latency (s) 0.71 + 0.03 0.76 + 0.05 
Magazine Latency (s) 1.37 + 0.04 1.36 + 0.07 
Within-subjects comparison of performance before and after PCP treatment during vSD challenge 
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No significant within-subjects Treatment effect [F(1,18)=0.41, NS] or Treatment*Day 
interaction [F(1,18)=0.45, NS] were observed when correct latency was analysed (table 7.4).  
Likewise, no significant effect was observed following one-way ANCOVA analysis [F(1,17)=0.64, 
NS] (table 7.5). 
Additionally, no significant within-subjects Treatment effect [F(1,18)=0.00, NS] or 
Treatment*Day interaction [F(1,18)=0.09, NS] was  observed when magazine latency was 
analysed (table 7.4).  This lack of effect was accompanied by no significant difference 
between treatment groups following drug treatment [F(1,17)=0.08, NS] (table 7.5). 
 
Table 7.5  5-CSRTT performance during vSD challenge session following sub-chronic PCP 
treatment 
Parameter Saline PCP 
Perseverative (n) 120.00 + 12.36  149.50 + 30.16 
Premature (%) 4.79 + 1.02 6.33 + 2.38 
Correct Latency (s) 0.71 + 0.05 0.76 + 0.05 
Magazine Latency (s) 1.36 + 0.09 1.36 + 0.06 
Between-subjects comparison of treatment groups during vSD challenge session 
In contrast to the paucity of effects during baseline conditions, when performance was 
challenged using a vSD session PCP treated animals exhibited substantial attentional 
impairment.  This was exemplified by a PCP-induced reduction in response accuracy and 
percent correct responding, which was coupled with an increase in the number of incorrect 
responses made.  The number of omissions throughout the session was unaffected.  These 
effects displayed remarkable behavioural specificity as no other parameters were sensitive to 
impairment.  
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7.3.3.1  Effect of Stimulus Duration 
As substantial effects were observed following the vSD challenge but not duringthe baseline 
session, it was important to assess the effect as function of SD.  Repeated measure ANOVA 
demonstrated a significant Treatment effect [F(1,18)=9.22, p<0.001] and a significant SD effect 
[F(3,54)=12.47, p<0.001] for response accuracy (fig 7.6A).  Analysis failed to detect a significant 
Treatment*SD interaction [F(3,54)=0.69, NS].  Pair-wise comparisons demonstrated PCP 
treatment reduced accuracy when animals were presented with a 1 s (p<0.05) and 0.75 s SD 
(p<0.05).  A trend towards a significant PCP-induced reduction in accuracy was observed for 
0.5 s SD (p = 0.06).   
Similarly, a significant Treatment effect [F(1,18)=5.06, p<0.05] and SD effect [F(3,54)=20.27, 
p<0.001] was observed when percent correct responding was assessed (fig 7.6B).  While 
lacking statistical significance, a strong trend towards a significant Treatment*SD interaction 
was observed [F(3,54)=2.74, p = 0.052].  PCP treatment significantly reduced percent correct 
responding during 1 s (p<0.05) and 0.75 s SD (p<0.05).   
Additionally, a Treatment effect [F(1,18)=7.75, p<0.05] and a SD effect [F(,3,54)=10.48, p<0.001] 
was observed when percent incorrect responding was analysed (fig 7.6C).  No significant 
Treatment*SD interaction was evident [F(3,54)=0.73, NS].   A significant PCP-induced increase 
in incorrect responding was observed during 1 s (p<0.05) and 0.5 s SD (p<0.05), with a strong 
trend towards a significant increase when presented with a 0.75 s SD (p = 0.06).   
When percent omissions were analysed, no Treatment effect [F(1,18)=0.15, NS] was observed 
(fig 7.6D).  A slight trend towards a SD effect [F(3,54)=2.19, p<0.1] was evident, without a 
significant Treatment*SD interaction [F(3,54)=0.97,NS].   
The vSD challenge increased the attentional load, evidenced by the reduction in performance 
as the SD is shortened, even in control animals.  PCP treatment reduced performance, which 
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resulted in significant impairment compared to control animals at the longer SDs only.  A 
PCP-induced performance reduction was not evident at the shorter SD as even control 
animals displayed impaired ability to correctly perform the task.  Measures affected include 
response accuracy, percent correct responding and incorrect responding.  Omissions were 
not susceptible to a PCP-induced impairment.  
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Fig 7.6 Effect of stimulus duration on 5-CSRTT performance.  Measures displayed include response accuracy (A), 
percent correct responding (B), percent incorrect responding (C) and percent omissions (D). * denotes significant 
difference (p<0.05) between saline (n=10) and PCP (n=10) animals when presented various SDs  
 
7.3.3.2 Performance Throughout vSD Challenge Session 
To determine the potential of PCP treatment to induce a performance decrement, the ability 
to conduct the task throughout the session was assessed.  Analysis of session performance 
revealed a significant Treatment effect [F(1,18)=10.21, p<0.01] for response accuracy (fig 7.7A).  
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This occurred independently of an overall Trial effect [F(1,18)=2.69, NS], but was coupled with 
a significant Treatment*Trial interaction [F(1,18)=5.96, p<0.05].  Within-session comparisons 
demonstrated a significant PCP-induced reduction in T2 compared with T1 (p<0.01).  
Additionally, a PCP-induced reduction in accuracy was observed in T2 when compared to 
control animals (p<0.01).   
A significant Treatment effect [F(1,18)=4.91, p<0.05] was observed when percent correct 
responding was analysed (fig 7.7B).  Although lacking statistical significance, a trend towards 
a significant Trial effect [F(1,18)=3.06, p<0.1] and a strong trend towards a Treatment*Trial 
interaction [F(1,18)=3.82, p=0.06] was observed.  PCP treatment induced a within-subjects 
(p<0.05) and between-subjects (p<0.05) reduction in T2.  
 Analyses of percent incorrect responding revealed a significant Treatment effect [F(1,18)=7.67, 
p<0.05] and a Treatment*Trial interaction [F(1,18)=4.97, p<0.05] (fig 7.7C).  An overall 
significant Trial effect was not observed, however [F(1,18)=1.09, NS].  These effects were 
attributed to a significant PCP-induced within-subjects (p<0.01) and between-subjects 
(p<0.05) increase in incorrect responding in T2.   
No Treatment [F(1,18)=0.53, NS] or Trial effect [F(1,18)=1.35, NS] was observed for omissions 
across the session (fig 7.7D).  Furthermore, no Trial*Treatment interaction was evident 
[F(1,18)=0.18, NS]. 
Again, it was evident that PCP treatment selectively impaired overall response accuracy, 
percent correct responding and incorrect responding.  Interestingly, the performance deficit 
was localised to the second trial bin, indicating a PCP-induced reduction in the ability to 
sustain performance throughout the duration of the session. 
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Fig 7.7  5-CSRTT session performance during the vSD challenge.  Measures displayed include response accuracy 
(A), percent correct responding (B), percent incorrect responding (C) and percent omissions (D). T1 reflects the 
first 50 trials of the session and T2 the last 50 trials. # and ## denotes within-subjects difference (p<0.05 and 
p<0.01, respectively) in PCP treated animals from T1 and T2. * and ** denotes significant difference (p<0.05 and 
p<0.01, respectively) between saline (n=10) and PCP (n=10) treated animals in T2.  
 
7.3.4 Variable ITI Challenge Session (vITI) 
In a similar manner to the vSD challenge, 5-CSRTT performance was further taxed by 
exposing animals to a single session consisting of a vITI.  Repeated measures ANOVA 
demonstrated a strong trend towards a significant Treatment effect [F(1,18)=3.76, p=0.06] but 
no Treatment*Day interaction [F(1,18)=2.66, NS] for response accuracy.  Planned Comparisons 
however demonstrated a significant PCP-induced reduction in response accuracy (p<0.05), 
compared to pre-treatment performance. No effect was observed for saline treated animals.  
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A between-subjects ANCOVA reported a significant treatment effect [F(1,17)=5.89, p<0.05], 
indicating a significant reduction of response accuracy in PCP-treated animal (fig 7.8A). 
The effect on response accuracy was not mediated by erroneous correct responding.  
Percent correct responding was reduced in PCP-treated animals, but the effect was non-
significant.  Analysis demonstrated no significant Treatment effect [F(1,18)=2.49, NS] and no 
Treatment*Day interaction [F(1,18)=0.35, NS] (fig 7.8B).  Additionally, no significant between-
subjects Treatment effect [F(1,17)=1.79, NS] was observed following drug treatment.  
Thus, the PCP-induced effect on response accuracy was likely the result of increased 
incorrect responding.  Hence, ANOVA analysis demonstrated that there was no significant 
within-subjects Treatment effect [F(1,18)=2.71, NS] or a Treatment*Day interaction 
[F(1,18)=2.53, NS] for the number of incorrect responses made.  However, following one-way 
ANCOVA analysis a significant Treatment effect [F(1,17)=6.09, p<0.05] was demonstrated, 
indicating a significant PCP-induced increase in the number of incorrect responses made 
throughout the session (fig 7.8C).  
Comparable with the effect following the vSD challenge, analysis of the within-subject effect 
on omissions revealed no significant Treatment effect [F(1,18)=0.55, NS] or a Treatment*Day 
interaction [F(1,18)=0.16, NS].  This was coupled with no significant Treatment effect following 
one-way ANCOVA analysis [F(1,17)=0.01, NS] (fig 7.8D). 
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Fig 7.8 Effect of a variable ITI challenge session on performance before and after sub-chronic PCP treatment.  
Measures displayed include response accuracy (A), percent correct responding (B), percent incorrect responding 
(C) and percent of omissions (D). *denotes p<0.05 following between-subjects analysis of the saline (n=10) and 
(n=10) PCP treatment groups, post-dose. # denotes p<0.05 difference following within-subject analysis of PCP-
treated animals when compared with pre-treatment performance. 
 
The number of perseverative responding was unchanged following PCP treatment.  No 
Treatment [F(1,18)=1.14, NS] or Day effect [F(1,18)=0.72, NS], or a Treatment*Day interaction 
[F(1,18)=0.03, NS] were observed (table 7.6).  Additionally, ANCOVA analysis between control 
and PCP animals also revealed no difference between treatment groups [F(1,17)=0.26, NS] 
(table 7.7). 
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Table 7.6 Effect of PCP treatment on 5-CSRTT performance following a vITI challenge 
Parameter Pre-Treatment Post-Treatment 
Perseverative (n) 181.00 + 36.39 171.70 + 35.47 
Premature (%) 21.66 + 2.93 28.55 + 2.68  
Correct Latency (s) 0.83 + 0.06 0.98 + 0.09 * 
Magazine Latency (s) 1.34 + 0.04 1.29 + 0.05 
Within-subjects comparison of performance before and after PCP treatment during vITI challenge 
Following repeated measures ANOVA on premature responding made during the sessions, a 
Treatment*Day interaction was observed [F(1,18)=6.42, p<0.05].  Planned Comparisons 
demonstrated a strong PCP-induced trend towards a significant increase in premature 
responding (p=0.07), compared to pre-treatment performance (table 7.6).  No effect was 
observed for control animals.  Between-subjects analysis demonstrated no significant 
Treatment effect [F(1,17)=2.92, NS] existed following sub-chronic PCP treatment for premature 
responding (table 7.7). 
No within-subject Treatment effect [F(1,18)=0.65, NS] or a Treatment*Day interaction 
[F(1,18)=2.76, NS] was observed when correct latency (CL) was analysed (table 7.6).  However, 
Planned Comparisons indicated a significant increase in CL in PCP treated animals (p<0.05), 
when CL was compared to pre-treatment performance.  No between-subject Treatment 
effect [F(1,17)=2.59, NS] was observed following ANCOVA analysis on CL (table 7.7). 
No Treatment [F(1,18)=0.08, NS] or Treatment*Day interaction [F(1,18)= 0.9, NS] was observed 
when the magazine latency was analysed (table 7.6).  Additionally, there was no significant 
between subjects effect on ML, post-treatment [F(1,17)=1.01, NS] (table 7.7).  
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Table 7.7. 5-CSRTT performance during vITI challenge session following sub-chronic PCP 
treatment 
Parameter Saline PCP 
Perseverative (n) 130.20 + 16.59 171.70 + 35.47 
Premature (%) 24.26 + 2.80 28.55 + 2.68 
Correct Latency (s) 0.84 + 0.07 0.98 + 0.09 
Magazine Latency (s) 1.34 + 0.09 1.29 + 0.05 
Between-subjects comparison of treatment groups during vITI challenge session following sub-chronic treatment 
 
These results show that while a PCP-induced impairment was evident following a vITI 
challenge, it appears as if the deficit was not as substantial as that which followed the vSD 
challenge.  A PCP-induced reduction in response accuracy was observed, specifically 
mediated by an increase in incorrect responding.  The attentional impairment was coupled 
with a between-subject slowing of CL.  Although these effects are perhaps less substantial 
than those observed during the vSD challenge, there is consistency in that the effects again 
display a high level of behavioural specificity.  
 
7.3.4.1 Effect of Inter-Trial Interval 
Comparable with the vSD challenge, it was important to display the effect that each ITI 
duration had on task performance.  Repeated measures ANOVA of response accuracy 
indicated a significant Treatment effect [F(1,18)=4.90, p<0.05] and a significant ITI effect 
[F(3,54)=8.58, p<0.001] (fig 7.9A).  No Treatment*ITI interaction was observed [F(3,54)=1.08, NS].  
Planned Comparisons demonstrated PCP reduced response accuracy when animals were 
presented with a 2 s ITI only (p<0.05).   
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There was no Treatment effect [F(1,18)=2.48, NS] when percent correct responding was 
assessed (fig 7.9B).  A significant ITI effect [F(3,54)=26.22, p<0.001] was observed without a 
significant Treatment*ITI interaction [F(3,54)=0.47, NS].  
However, a significant Treatment effect [F(1,18)=5.09, p<0.05] was evident for percent 
incorrect responding (fig 7.9C).  This occurred independently of an ITI effect [F(3,54)=1.92, NS] 
or a Treatment*ITI interaction [F(3,54)=1.15, NS].  Planned Comparisons demonstrated that 
PCP treatment significantly increased incorrect responding compared to control animals, an 
effect only evident during the 2 s ITI (p<0.05).   
There was no Treatment effect [F(1,18)=0.16, NS] when the effect on omissions was analysed 
(fig 7.9D).  An ITI effect was evident [F(3,54)=17.56, p<0.001], without a Treatment*ITI 
interaction [F(3,54)=0.3, NS].  
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Fig 7.9. – 5-CSRTT performance displayed as function of inter-trial interval.  Measures displayed include response 
accuracy (A), percent correct responding (B), percent incorrect responding (C) and percent omissions (D). * 
denotes significant difference (p<0.05) between saline (n=10) and PCP (n=10) animals when presented various ITIs  
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These results demonstrate that, during the vITI challenge session, PCP-induced performance 
impairment was evident only during the shortest ITI.  This may explain why the the overall 
performance deficit was less substantial than that observed following this vSD challenge 
session.  Extreme deviations from the norm (5 s ITI) resulted in impaired performance in both 
control and PCP animals (e.g. reduction in percent correct and increased omissions).  
Incorrect responding was only affected in PCP-treated animals at the shortest ITI and so a 
PCP-induced reduction in response accuracy was only evident following the 2 s ITI. 
 
7.3.4.2 Performance Throughout vITI Challenge Session 
Finally, the performance following the vITI challenge was assessed across the session, spilt 
into two trial bins.  A Treatment effect [F(1,16)=11.38, p<0.01] was observed when response 
accuracy was assessed across the session (fig 7.10A).  This occurred independently of a Trial 
effect [F(1,16)=1.05, NS] or a Treatment*Trial interaction [F(1,16)=2.35, NS].  A trend towards a 
PCP-induced within-subjects reduction in accuracy in T2 was observed (p<0.1), but a 
significant reduction in T2 was observed between PCP and control animals (p<0.01).  
A strong trend towards a Treatment effect [F(1,16)=4.22, p = 0.056] was observed when 
percent correct responding was assessed.  No Trial effect [F(1,16)=0.04, NS] or Treatment*Trial 
interaction [F(1,16)=2.20, NS] was observed (fig 7.10B).  Comparisons demonstrated that no 
significant within-subjects effect was evident, but a significant effect between control and 
PCP animals was evident in T2 (p<0.05). 
When the effect on incorrect responses was analysed, a significant Treatment effect 
[F(1,16)=10.23, p<0.01] was observed (fig 7.10C).  This occurred without a Trial effect 
[F(1,16)=1.12, NS] or a Treatment*Trial interaction [F(1,16)=1.13, NS].  Consistent with the 
response accuracy and correct responding impairment, a significant effect was only observed 
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in T2 between control and PCP animals (p<0.01).  No within-subject effect was observed in 
either control or PCP animals, comparing T1 with T2 performance.  Again, despite the PCP-
induced attentional defict observed following the vITI challenge, omissions were unaffected. 
No significant Treatment [F(1,16)=0.33, NS] or Trial effect [F(1,16)=0.27, NS] were revealed when 
the number of omissions were analysed (fig 7.10D).  Additionally, there was no significant 
Treatment*Trial interaction [F(1,16)=1.28, NS]. 
Thus, in a similar manner to that observed following the vSD challenge, a PCP-induced deficit 
was only evident in the second trial bin.  Along with response accuracy and incorrect 
responding deficits, a PCP-induced reduction in correct responding was also observed.  The 
lack of an effect in this measure when overall performance was displayed may be the result 
of the subtlety of this reduction, which was masked when the overall performance was 
displayed. 
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Fig 7.10.  5-CSRTT session performance following vITI challenge.  Measures displayed include response accuracy 
(A), percent correct responding (B), percent incorrect responding (C) and percent omissions (D). T1 reflects first 50 
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trials of the session and T2 the last 50 trials.. * and ** denotes a significant difference (p<0.05 and p<0.01, 
respectively) between saline (n=10) and PCP (n=10) treated animals in T2.  
 
7.3.5 Pre-pulse Inhibition 
Analysis of startle reactivitly indicate no difference in PPI between treatment groups 
[F(1,18)=2.18, NS] and no Group*PPI interaction [F(2,36)=0.66, NS].  However, a significant PPI 
effect was observed [F(2,26)=22.57, p<0.001].  Planned Comparisons indicated that a pre-pulse 
of 12 dB significantly inhibited the startle response (fig 7.11A).  This effect was evident in 
both animals that were to receive saline (p<0.001) and those that were to receieve PCP 
(p<0.01).  Following sub-chronic PCP treatment there was no significant Treatment effect 
[F(1,18)=0.12, NS] or a Treatment*PPI interaction [F(2,36)=0.58, NS].  Consistent with pre-
treatment startle assesment, a significant PPI effect was observed [F(2,36)=29.35, p<0.001].  
This was attributed to a significant attenuation of the startle response following a 12 dB pre-
pulse in both saline (p<0.001) and PCP (p<0.001) treated animals (fig 7.11B).  A pre-pulse of a 
lower magnitude had no significant effect on inhibition of the startle response. 
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Fig 7.11. Pre-pulse inhibition of the startle response before animals underwent sub-chronic treatment (A) and 
following drug treatment (B).  The level of PPI was demonstrated by percent inhibition. *** denotes p<0.001 in 
saline (n=10) animals and ## denotes p<0.01 and ### denotes p<0.001 in PCP (n=10) animals (12 dB compared 
with 3dB). 
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7.4 Discussion  
These data demonstrate that morphological abnormalities are evident in rats treated sub-
chronically with PCP.  Structural MRI revealed an increase in MRI signal in discrete cortical 
and sub-cortical brain regions following sub-chronic PCP treatment.  In addition to structural 
abnormalities, a persistent attentional disruption was observed.  In the drug-free state at 
least 13 days after cessation of treatment, 5-CSRTT performance was impaired in a manner 
characteristic of disrupted sustained attention.  The PCP-induced attentional deficit was 
exemplified by a reduced ability to sustain performance throughout the whole session, when 
the attentional load had been increased.  In contrast, startle responsivity and the inhibition 
of the startle response was unaffected following PCP treatment.  These findings reveal, for 
the first time, that sub-chronic PCP treatment produces structural abnormalities in brain 
regions associated with attentional performance, abnormalities that are evidently sensitive 
to detection with MRI imaging.  These structural abnormalities may contribute to the 
observed sustained attentional impairment, but importantly, appear to be dissociable from 
deficits in passive attentional pre-processing.     
Structural MRI identified regional abnormalities following systemic PCP treatment, localised 
to the prelimbic cortex, sub regions of the hippocampus and presubicular structures, and the 
dorsal endopiriform cortex.  These findings suggest that PCP treatment results in regionally 
specific, morphological aberrations.  The hippocampus has been suggested to play an 
important role in cognitive processes, and is intrinsically involved in aspects of memory 
(Kesner and Dakis 1993; Eichenbaum 2004; Gimbel and Brewer 2011).  As such, structural 
deficits localised within the hippocampal formation, bordering with the subicular regions, 
may contribute to the persistent performance impairments in the novel object recognition 
task (NOR) observed following sub-chronic PCP treatment (Grayson et al. 2007; McLean et al. 
2009; Idris et al. 2010).  With respect to the attentional disruption observed, structural 
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abnormalities within the medial prefrontal cortex (specifically, the prelimbic cortex sub-
region) were evident.  The mPFC cortex has been hypothesised to be involved in the PCP-
induced attentional disruption.  Indeed, the mPFC has been suggested to play a pivotal role in 
many aspects of cognition in rats, humans and schizophrenia patients (Miller 2000; Uylings et 
al. 2003; Lesh et al. 2010).  Therefore, PCP-induced structural abnormalities within the 
prelimbic cortex may be central to the persistent cognitive deficits that follow sub-chronic 
PCP administration (Neill et al. 2010).   
Voxel-based morphometry (VBM) is an incredibly powerful tool, enabling the assessment and 
evaluation of neurological disease in vivo.  It allows whole brain morphology to be assessed, 
without being bound by a region of interest approach (Job et al. 2002).  MRI can be 
conducted as a recovery procedure, facilitating the visualisation of structural morphology in 
live animals.  Alternative approaches, such as confocal microscopy, histological techniques or 
electron microscopy, are all terminal procedures.  Animals are culled, brains harvested and 
treated, prepared and the procedure conducted.  Consequently, MRI is the only imaging 
technique that enables volumetric differences, following drug treatment, to be assessed 
within a longitudinal design. 
However, a number of potential caveats or pitfalls exist potentially limiting its application 
and between-study comparison (Whitwell 2009), limitations that warrant further discussion.  
These restrictions are particularly pertinent when comparing clinical and preclinical findings.  
VBM involves a number of processing steps in order to generate and analyse the images 
acquired, which include registering, segmenting and smoothing the images.  Registering the 
images ensures all the voxels from each subject are aligned to the same sterotaxic position, 
known as spatial normalisation.  This produces a template image, matching all images used in 
the study, accounting for regional volume variability between subjects within the sample.  
Voxels are then segmentated into differing tissue compartments, depending on whether the 
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voxel contained grey matter, white matter, or CSF.  The images are then smoothed.  The 
smoothing process ensures that data conforms to the Gaussian field model of variance.  
Smoothing the images increases the sensitivity of detecting a change by reducing the 
variance between subjects (Ashburner and Friston 2000; Whitwell 2009).  While these 
processing steps are essential for the construction and analysis of VBM images, one or all of 
these steps can vary slightly between studies, introducing potential confounds that may 
hinder accurate comparisons (Whitwell and Jack 2005).  In addition, there is no conventional 
threshold for significance.  The final interpretation of a study may depend on the p value 
assigned to each analysis, or what method was used to correct for multiple comparisons.  
Due to the extraordinarily high number of comparisons made (comparison of millions of 
voxels), safeguards to protect against type 1 error are necessary.  Two common approaches 
used are the family-wise error (FWE) or false discovery rate (FDR).  However, Whitwell (2009) 
demonstrated that depending on the statistical threshold and method used to correct for 
multiple comparisons, even within the same subjects, differing conclusions could be drawn.  
The FWE is a conservative approach, whereas the FDR is more lenient and therefore 
depending on the approach used, different patterns of grey matter changes could be 
observed.  The increase in MRI signal demonstrated in the current study survived a weak 
correction for multiple comparisons, but not when a more stringent approach was used if the 
whole brain was used.  However, alterations in the prelimbic cortex did survive more 
stringent corrections (p<0.05 following FDR or FWE) when a small correction volume was 
applied to the frontal cortex.  The small volume correction is appropriate, given the priori 
hypothesis that changes would be evident within the frontal cortex.  However, it was not 
appropriate to apply a small volume correction to the sub-cortical regions given the absence 
of a priori hypothesis for alterations within these regions, and therefore they may reflect a 
type 1 error. 
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Furthermore, in addition to differences in how the data are compiled and analysed, giving 
rise to potential confounds in human studies, differences in the subjects selected can also 
contribute to a source of heterogeneity amongst studies (Whitwell 2009).  Factors such as 
sample size, age, gender, IQ scores, and handedness in either the control or disease 
population can introduce subtle differences within the morphology of the sample, altering 
the homogeneity of the cohort under investigation.  Moreover, aspects such as disease stage 
(chronic Vs first episode psychosis), treatment history, substance abuse, traumatic head 
injury or pathological comorbidity may also play a pivotal role in the final interpretation of 
imaging studies.  While the factors regarding sample selection may provide a source of 
variability, they can also be carefully guarded against with a comprehensive selection 
criterion and matching process.  Nevertheless, they may, along with methodological 
differences, potentially contribute to the inconsistencies demonstrated within the clinical 
imaging literature (Honea et al. 2005).  An advantage of preclinical investigations is the high 
control of subject factors, enabling a level of homogeneity within the subject sample that 
would be difficult to rival in a clinical setting.  Hence, influences of previous exposure to 
antipsychotic medication, poly drug abuse or disease stage can be eliminated as a source of 
variance within the current study.  The level of homogeneity coupled with the control of 
confounding factors within preclinical research has exciting potential.  For the first time, the 
ability of a drug to alter brain morphology and induce persistent cognitive deficits has been 
demonstrated in a longitudinal manner.  This enabled the precise elucidation of regional 
specific structural deficits and the development of cognitive disturbances to be visualised, in 
vivo.  
The prefrontal cortex (PFC) receives afferent connections from multiple areas and also 
projects efferent fibres to a number of cortical and sub-cortical structures (Groenewegen et 
al. 1990).  The prelimbic cortex, a subdivision of the PFC, has been suggested to innervate a 
number of structures located within the limbic system, generating circuitry that is involved in 
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the mediation of cognitive processes (Vertes 2004).  Some controversy exists regarding trans-
species homology of the frontal cortex (Kolb 1990; Preuss 1995), questioning the existence of 
comparable primate dorsolateral prefrontal cortical structures in non-primate species.  
However, due to reciprocal connections and more importantly, the functionality of the rat 
PFC (including the prelimbic sub-region), it has been suggested that this region shares 
analogy with the DLPFC in primates (Ongur and Price 2000; Brown and Bowman 2002; Vertes 
2004).  The DLPFC is suggested play a crucial role in human cognitive control (Miller and 
Cohen 2001; Lesh et al. 2010).  Moreover, the DLPFC has consistently been implicated in 
cognitive disturbances in schizophrenia (Callicott et al. 2000; Cannon et al. 2005; Yoon et al. 
2008; Lesh et al. 2010), and attentional performance (MacDonald and Carter 2003).  With 
respect to the findings in the current chapter, the prelimbic cortex in rats has previously been 
demonstrated to be intrinsically involved in attentional processing.  Various pharmacological 
or lesion studies have indicated this regions’ involvement in performance of visuospatial 
attentional tasks, indicating prelimbic mediation of sustained attention (Granon et al. 1998; 
Broesrsen and Uylings 1999; Granon et al. 2000). 
PCP treatment may have induced regional specific structural abnormalities within the 
prelimbic cortex due to specific disinhibition of the GABAergic interneurons located within 
this region.  This population of interneurons provide local inhibitory tone to the excitatory 
pyramidal cells (Lopez-Gil et al. 2007).  Extensive GABAergic deficits have been observed 
following PCP treatment (Abdul-Monim et al. 2007; Jenkins et al. 2008; Amitai et al. 2011).  
Excitatory disinhibition may contribute to morphological abnormalities observed following 
NMDA antagonism (discussed in detail in chapter 8).  Additionally, neuroimaging studies in 
human volunteers have demonstrated specific neuronal activation of the PFC following 
systemic ketamine infusion (Breier et al. 1997), but no significant effect on metabolic activity 
in other regions.  These findings suggested that systemic ketamine administration results in a 
focalized activation of the prefrontal cortex in humans.  Investigation of the effect systemic 
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PCP treatment has on neuronal activity in experimental animals’ revealed dramatic activation 
of prefrontal cortical neurons.  The vast majority of cortical neuronal activation, 
demonstrated by increased c-fos expression or extracellular electrophysiology recordings, 
was contained within the prelimbic cortex (Kargieman et al. 2008).  Furthermore, 
neurotoxicity arising from high concentrations of NMDA antagonists was restricted to 
corticolimbic structures (Olney et al. 1989).  This apparent regional selectivity following 
systemic PCP administration may provide an explanation to why cortical structural 
abnormalities were localised to the prelimbic cortex, despite the ubiquitous distribution of 
NMDA receptors (Petralia et al. 1994).  It should be noted, however, it is possible that 
structural abnormalities were evident in additional regions, but were below the conservative 
statistical threshold of detection used within this study.   
Sub-chronic PCP treatment resulted in enduring performance deficits within the 5-CSRTT.   
For the first time, a subtle impairment in 5-CSRTT functioning was described when animals 
were tested using baseline attentional demands.  In this instance, PCP treatment resulted in 
a reduction in percent correct and an increase in the number of omissions.  These effects 
were coupled with an increase in correct latency, but a reduction in magazine latency.  These 
findings could suggest that animals had impaired attentional functioning, which manifested 
as target trials not being detected, and therefore omitted.  The effect on response latencies 
suggested impaired speed of cognitive processing.  As the time taken to collect the food 
reward was in fact reduced, impaired locomotor or reduced motivation was unlikely.  As 
impaired locomotor abilities or sedation was ruled out, increased omissions (and consequent 
reduced correct responding) was likely mediated by attentional deficits.  However, these 
effects were subtle and only detected following within-subjects analysis.  Repeated measures 
analyses are generally more sensitive than a between-subjects approach as it eliminates 
intra-animal variability, therefore enhancing the statistical power of the design (Lambdin and 
Shaffer 2009).  Previous investigations in this thesis utilising a sub-chronic PCP treatment 
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regimen (chapters 3 and chapter 6) assessing attentional performance were designed using a 
between-subjects approach.  This may account for the lack of statistical significance when 
attentional performance was investigated previously – even when a comparable PCP dose 
was used (chapter 6).  The only effect that was evident following a between-subjects 
approach when animals were tested using the standard parameters was an increased latency 
to make a correct response.  Again, this was not evident in previous investigations, but this 
may have again been due to the current experimental design utilised.  The design enabled an 
analysis of covariance to be conducted taking previous animal performance into 
consideration, which also enhanced the statistical power of the between-subjects 
comparisons (S Bate, Personal Communication).  The increased CL may indicate a 
speed/accuracy trade off (Robbins 2002; Young et al. 2009a), whereby the animals may have 
been sacrificing the speed of responding to ensure a higher accuracy facilitating maximum 
reward.  This was also supported by the lack of incorrect responding.  Although, it should be 
noted, as these effects represent performance immediately following sub-chronic treatment 
(during which animals received no training or testing), they may reflect subtle alterations in 
the ability to resume a previously learned task.  As such, although some significant effects 
were observed, caution should be exercised when drawing conclusions about their meaning. 
Task-related interventions are an accepted technique of further taxing attentional demands, 
depending on the parameter manipulation utilised.  When the stimulus duration was variably 
shortened (vSD), more robust performance impairments were revealed.  PCP treatment 
induced a significant reduction in response accuracy, percent correct responding and 
significantly increased incorrect responding.  As PCP treatment had no adverse effects on 
response latencies (particularly ML), elements of motor impairment or impaired motivation 
did not contribute to erroneous responding.  Thus, sub-chronic PCP treatment resulted in a 
robust impairment in 5-CSRTT performance indicating attentional disruption.  It has 
previously been suggested that animals trained with a constant ITI utilise a temporally 
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mediated strategy to respond to stimuli within the 5-CSRTT (Spratt et al. 2000).  Therefore, in 
the event of failed target detection, the animal was likely to exploit a guessing strategy.  This 
type of responding could explain the increased incorrect responding and the lack of PCP-
induced increase in omissions.  Once the ITI had elapsed (and the animal had missed the 
stimulus presentation), a guessed response was more likely to be incorrect than correct.  
Therefore responding when the stimulus was not detected increased incorrect responding 
and reduced correct responding and response accuracy.  These effects are consistent with 
attentional impairment (Robbins 2002).   
Performance displayed as a function of SD demonstrates performance was impaired, even in 
control animals, as the SD was reduced.  This supports the notion of utilising the vSD 
challenge as a means to tax attentional processing.  PCP-induced performance impairment 
was restricted to the longer SD only.  Response accuracy and percent correct responding was 
significantly reduced, compared to saline animals, when the animals were presented with the 
1 and 0.75 s SD.  PCP-treatment increased the number of incorrect responses made during 1, 
(a strong trend with 0.75 s) and 0.5 s SDs.  The lack of effect at the shorter SDs can be 
attributed to the impaired performance in control animals.  Previous experiments have 
shown performance was reduced not only in lesioned rats, but also in control animals when 
the SD was reduced to 0.25 s (Muir et al. 1996).  While the performance of PCP-treated 
animals is impaired as the SD is shortened, the effect is more substantial in control animals.  
It is possible that when faced with the vSD challenge, PCP-treatment resulted in a 
performance deficit regardless of the SD.  With the longer SD, the duration was sufficient for 
control animals to successfully detect their presentation whilst PCP treated animals could 
not, and therefore a significant difference emerged.  However, when the SD was reduced, 
control animals’ performance was impaired to that of PCP-treated animals; hence no 
performance deficit was detected. 
Chapter 7             Structural MRI and PCP 
235 
When performance was assessed over the duration of the session, PCP-induced impairments 
were restricted to the latter half of the session.  Response accuracy, percent correct 
responding and percent incorrect responding were all impaired following PCP treatment, in 
trial bin two.  These data suggest that PCP treatment induced a performance decrement, 
resulting in the inability to sustain attention for the duration of the session.  This observation 
may explain why performance was robustly disrupted at the longer SD during this challenge 
session, but not during the standard parameter session (also 1 s SD).  Initial performance of 
PCP animals during the vSD challenge session was no different to control animals.  However, 
the vSD challenge would increase the overall attentional load of the task, as the shorter SDs 
would require a higher level of attention to detect (Bushnell 1998).  PCP treatment may 
result in animals being more sensitive to cognitive fatigue when attentional demands are 
elevated.  Thus, PCP-treated animals began to display attentional impairments as the session 
progressed, consistent with a reduced ability to maintain sustained attentional abilities 
throughout the entirety of the session.  This effect was absent in control animals, suggesting 
that although performance was impaired following the vSD challenge, the control animals’ 
could maintain attentional processing throughout the duration of the session. 
Previous investigations utilising neurotoxic lesions of the prelimbic cortex that assessed 
attentional performance reveal encouraging findings (Muir et al. 1996; Broersen and Uylings 
1999 Chudasama and Muir 2001).  Although lesion effects on response accuracy were 
absent, an increase in omissions was observed without concomitant alterations in magazine 
latency, therefore suggesting attentional disruption (Chudasama and Muir 2001).  The effect 
of prelimbic lesions was also assessed in the sustained attention task (SAT).  The authors had 
implemented non-parametric signal detection analysis as a means to assess vigilance, which 
demonstrated reductions in signal sensitivity following prelimbic cortex lesion when the 
stimulus duration of the target signal was reduced (Chudasama and Muir 2001).  This not 
only indicates that the prelimbic cortex is involved in attentional performance, but further 
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highlights the need in some cases of increasing attentional demands to elucidate impaired 
performance.  While neurotoxic lesion studies implicate the prelimbic cortex in attentional 
performance, pharmacological investigation has demonstrated the importance of not only 
the prelimbic cortex, but also dopaminergic transmission and attentional performance 
(Granon et al. 2000).  Therefore, enduring abnormalities in the prelimbic cortex following 
sub-chronic PCP treatment may mediate the robust disruption of performance when the 
attentional load was increased in the vSD challenge session.  Moreover, reductions in 
prefrontal basal dopamine levels following sub-chronic PCP treatment (Jentsch et al. 1997b) 
may also contribute to the cognitive impairment observed in the current chapter.   
Perseverative responding was not affected within the current study, which is in contrast to 
increased perseveration following neurotoxic lesion to the prelimbic cortex (Chudasama and 
Muir 2001).  However, perseverative responses were not punished in the current study and 
merely recorded.  Previously, studies have demonstrated that when premature responding 
was monitored without consequence the baseline was exceptionally high (Auclair et al. 
2009).  As there was no TO period following an inappropriate premature response, it 
removes the incentive to withhold inappropriate responses.  This, therefore, changes the 
nature of the response making direct comparisons with studies that do punish inappropriate 
responding difficult (Amitai and Markou 2010).  The lack of PCP-induced perseverative 
responding in the current study may be due to a similar effect observed by Auclair and 
colleagues (2009).  The high baseline level of perseverative responding within the current 
experiment demonstrates that the incentive to withhold from inappropriate perseveration 
had been removed.   
In support of the attentional disruption observed following a vSD challenge session, impaired 
performance was also demonstrated following a vITI challenge session.  PCP-treated animals 
exhibited reduced response accuracy.  Impaired accuracy was primarily mediated by an 
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increase in the number of incorrect responses made throughout the session.  While the 
reduction of percent correct responding in PCP-treated animals lacked statistical significance, 
there was a trend towards a treatment-induced reduction which would have contributed to 
the reduction in response accuracy.  Again, these effects occurred without any alteration in 
the number of omissions made throughout the session.  Like the vSD challenge, the lack of an 
effect on omissions, coupled with the increase in incorrect responding suggests animals were 
utilising a guessing strategy following failed stimulus detection (Spratt et al. 2000).  In 
addition to the disruption of attentional measures of the 5-CSRTT, sub-chronic PCP treatment 
also significantly increased the CL following within-subjects analysis.  As this increase in time 
taken to initiate a response occurred independent of impairments in motivation or sedation, 
increased CL was likely mediated by impaired speed of informational processing (Amitai and 
Markou 2010). 
When performance was assessed for each of the four ITI durations used, a PCP-induced 
impairment was only evident during the 2 s ITI.  When presented with a 2 s ITI, response 
accuracy was reduced, a reduction mediated by increased incorrect responding.  In a similar 
fashion to the vSD challenge, the vITI challenge impaired performance that was restricted to 
the second trial bin.  In addition to the reduced accuracy and increased incorrect responding, 
a PCP-induced reduction in percent correct responding was also revealed in T2.  The lack of 
impairment in this measure when displayed as overall session performance was possibly due 
to the PCP-induced effect being more subtle that that observed in response accuracy and 
incorrect responding.  When the overall performance was displayed, the effect on correct 
responding was masked, something not observed with response accuracy or incorrect 
responding.  Thus, a PCP-induced deficit in correct responding emerged during the second 
trial bin.  These findings further suggest that PCP treatment induced a reduced ability of 
sustaining attention throughout the whole session, consistent with the vSD challenge 
session.  Moreover, no effect on omissions was observed providing further evidence for the 
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utilisation of a temporal strategy being implemented.  Furthermore, these findings support 
the need for assessing performance across the session in order to reveal subtle performance 
deficits.  The observation of impaired performance during the high event-rate condition (2 s 
ITI) and performance decrement are in agreement with those demonstrated by Dalley and 
colleagues (2004b).  The group revealed that mPFC cholinergic lesion (which included the 
ventral prelimbic cortex) resulted in 5-CSRTT performance impairment, which was 
particularly evident not only during conditions of an increased attentional load, but also as 
the session progressed, with performance deficits only apparent in the latter stage of the 
session.  These findings further support the notion that the prefrontal cortex is involved with 
the mediation of sustained attentional performance throughout the whole session and the 
adaptation to increased attentional demands.  PCP-induced abnormalities within the 
prelimbic cortex are likely to contribute to the inability to sustain accurate performance for 
the required duration during attentionally challenging sessions. 
While an enduring impairment was observed in the 5-CSRTT, there was no treatment effect 
on inhibition of a startle response.  Pre-pulse inhibition (PPI) of an acoustic startle response is 
a measure of sensorimotor gating and is consistently shown to be impaired in schizophrenia 
patients, as well as their non-symptomatic relatives (Weike et al. 2000; Braff et al. 2001).  
NMDA antagonism has been shown to impair the pre-pulse inhibition (Geyer et al. 2001; 
Scwabe et al. 2005), impairing the diminution of the startle response when the full stimulus is 
preceded by a non-startling pre-pulse.  However, PPI disruption is absent in animals following 
long-term exposure to PCP (in the drug-free state), despite persistent neuropathological 
changes following repeated exposure (Martinez et al. 1999).   While PPI impairment were 
observed 24 hours following chronic PCP treatment, impairment dissipated by 48 hours, 
despite persistent cognitive impairment being observed in the form of impaired extra-
dimensional shift (EDS) in the attentional set-shifting task (Egerton et al. 2008).  These 
findings, along with the lack of PPI impairment in the current chapter, suggest that sub-
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chronic PCP treatment does not result in persistent functional, structural or 
neuropathological abnormalities that underpin sensorimotor gating deficits.  The enduring 
cognitive effects observed by Egerton and colleagues (2008) however, may be the result of 
PCP acting on the prelimbic cortex.  Lesion of the mPFC, (including the prelimbic cortex) 
produced impairments in EDS in animals assessed in the attentional set-shifting task (Birrell 
and Brown 2000).  The susceptibility of prelimbic cortex to PCP-induced structural 
abnormalities may also contribute to the persistent impairment in attentional set-shifting 
observed. 
The observation in the current chapter that sub-chronic PCP treatment impairs 5-CSRTT 
performance upon an increased attentional load (sustained divided attention), along with the 
previous demonstration that EDS impairment is evident (selective attentional shifts) (Egerton 
et al. 2008; McLean et al. 2008), but not PPI deficits suggests a dissociation in PCP-induced 
attentional disruption.  PPI is an involuntary process describing passive attentional pre-
processing, filtering incoming sensory information.  In contrast, the attentional modalities 
susceptible to PCP-induced disruption reflect higher-order cognitive processes.  As such, 
morphological abnormalities within the prelimbic cortex may impede the ability to conduct 
these voluntary processes, without affecting the ability to actively attend to or filter incoming 
sensory information.  Moreover, sub-chronic PCP-induced deficits, when observed, are only 
evident during attentionally challenging aspects of a task.  Deficits in attentional set-shifting 
occur only during the EDS phase, and not during the intra-dimensional shift (IDS) (McLean et 
al. 2008).  Additionally, sustained attention deficits are only revealed when the attentional 
load of the task is increased, and are particularly evident as the session progresses.  Thus, as 
PPI is an involuntary pre-processing measure and PCP-induced deficits are only apparent 
during demanding challenges, this may account for the distinction in passive and spatial 
sustained attentional deficits observed in the current chapter.  Startle responsivity was 
assessed in the drug-free state, confirming this treatment regimen is not suitable for 
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investigating PPI deficits.  In contrast, NMDA antagonism does result in robust PPI deficits, 
whilst animals are under the influence of the drug.  This is elegantly demonstrated by 
Martinez and colleagues (1999) who report chronic PCP treatment produced PPI impairment 
only immediately following administration (10 minutes), but not following a substantial delay 
(6 hours).  While the absence of a PPI deficit after 6 hours is in contrast to that observed by 
Egerton and co-workers (2008) who demonstrated impaired PPI up to 24 hours post-
treatment, a different PCP treatment regimen was utilised in the two studies, which may 
have differentially altered dopaminergic transmission thus accounting for discrepancies in 
the duration of PPI deficits.  It is well documented that acute exposure to NMDA antagonism 
induces pronounced increase in dopaminergic efflux (Moghaddam et al. 1997).  Thus, 
excessive dopaminergic activity may be one mechanism pivotal to disrupted inhibition of 
startle reactivity.  In support, it has previously been demonstrated that dopaminergic 
agonists, or drugs that promote dopaminergic transmission, (e.g. amphetamine, cocaine, and 
apomorphine) disrupt startle inhibition (see Geyer et al. 2001 for full review).  In contrast to 
acute NMDA antagonism, a pronounced reduction in basal cortical dopamine levels following 
sub-chronic PCP treatment is seen (Jentsch et al. 1997a).  This reduction in basal dopamine 
transmission may explain the lack of PPI deficit observed in the current chapter.  However, 
decreased cortical dopaminergic activity, coupled with prelimbic cortical abnormalities, may 
contribute to the 5-CSRTT deficits observed following an increased attentional load. 
In summary, these data demonstrate, for the first time, that sub-chronic PCP treatment 
induces regional-specific morphological brain abnormalities.  These structural abnormalities 
were accompanied by selective, dissociable attentional impairments; sustained attention was 
disrupted following a task-related intervention yet passive attentional pre-processing was 
unaffected.  These findings revealed that sub-chronic PCP treatment impairs cognitive 
processing, and more importantly, displays regional selectivity for brain areas associated with 
schizophrenia pathophysiology. 
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8.1 Introduction 
Results presented in this thesis show that sustained visual attention is susceptible to 
disruption by treatment with the NMDA receptor antagonist PCP.  Attentional disturbances 
are suggested to be core symptoms of schizophrenia, to underlie higher-order cognitive 
impairment, and to precede episodes of psychosis and are evident in non-symptomatic 
relatives (Chen and Faraone 2000).  Therefore, improved understanding of the biological 
mechanisms that underpin attentional performance is paramount.  There is a major clinical 
unmet need with regards to cognitive deficits, resulting in a lack of effective cognitive 
remediation (Goldberg and Gold 1995; Marder et al. 2004).  Attenuation of the attentional 
disruption associated with schizophrenia may play an important role in improving the long-
term outcome of the patient and facilitate improved social and occupational reintegration.   
While these findings demonstrate attentional impairment following PCP treatment, the 
profile of PCP-induced attentional impairment is highly dependent on the treatment regimen 
utilised; acute administration induced a performance impairment that was coupled with a 
generalised response disruption, potentially precluding the interpretation of cognitive 
impairment.  Repeated treatment resulted in a selective and substantial performance deficit, 
without concomitant motivational deficits, and therefore was most likely mediated by 
specific cognitive disruption.  Performance following these treatment regimens was assessed 
shortly after PCP administration, while animals were under the influence of PCP.  Therefore, 
the more pronounced effects may have been attributed to the transient effects of drug 
treatment.  In contrast, sub-chronic PCP treatment assessed performance in the drug-free 
state, following a substantial washout period.  While attentional processing was sensitive to 
disruption, the impairment observed was less pronounced and required the attentional load 
of the task to be increased to elucidate performance deficits. 
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8.2 Experimental Overview 
Attentional performance was initially assessed using the 5-choice serial reaction time task (5-
CSRTT), a well characterised and validated task assessing several aspects of the multifaceted 
construct of attention; namely sustained and divided attention (Robbins 2002). The 
experiments in chapter 3 demonstrated that sub-chronic PCP treatment had little effect on 
the animals’ ability to conduct the visuospatial attentional task, in the drug-free state.  The 
treatment regimen (2 mg/kg twice daily for 7-days) was chosen because of the long-standing 
demonstration that pronounced and persistent impairment in a variety of cognitive 
paradigms are produced (see Neill et al. 2010).  Following various task-related interventions, 
subtle PCP-induced performance impairments were observed, indicating the potential of 
revealing attentional impairment in the drug-free state.  The demonstration of at least a 
subtle performance deficit prompted the full characterisation of PCP-induced attentional 
disruption, utilising various treatment regimens.  The outcomes of this investigation into the 
nature of PCP-induced attentional disruption are discussed below.  
Firstly, these findings demonstrated that rats can be trained to perform a modified version of 
the 5-CSRTT.  The modification resulted in a task that consisted of target and non-target 
trials, known as the 5-choice continuous performance test (5C-CPT).  Despite the myriad of 
continuous performance tests (CPTs) used in human attentional assessments, each version 
conforms to the basic premise of target trials requiring a response, and non-target trials 
requiring the inhibition of a response.  Robbins (1998) suggested that the current 5-CSRTT 
configuration may limit its application to accurately probe vigilance, which has been 
described as the ability to remain alert to incoming sensory information, discriminating 
salient information amongst a backdrop of irrelevant stimuli (Warm and Dember 1987; 
Collings 2003; Egeland et al. 2009).  As such, the 5C-CPT may allow the construct of not only 
sustained attention, but also vigilance to be more accurately assessed in a preclinical setting, 
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in a manner more consistent with human studies.  Schizophrenia patients consistently 
demonstrate impairments when performing the CPT.  Patients display reduced hit rates, 
increased false alarm rates and thus exhibit reduced signal sensitivity (Nestor et al. 1990; 
Chen and Faraone 2000).  PCP treatment was shown to impair signal discrimination, 
comparable with the impaired CPT performance exhibited by schizophrenia patients.  
Depending on the treatment regimen utilised, PCP treatment impaired signal discrimination, 
mediated by either a reduction in hit rate, increase in false alarm rate, or a combination of 
the two. 
In addition, it was demonstrated that dopamine transmission, specifically D1 dopaminergic 
transmission, was involved in attentional processing.  Previous investigations have implicated 
the D1 dopaminergic system and cognitive processing – however this work largely focused on 
the domain of memory (Sawaguchi and Goldman-Rakic 1991; Goldman-Rakic et al. 2004).  
The findings described in chapter 4 expand on previous findings that augmentation of the D1 
system improves attentional performance, in a baseline dependent manner (Granon et al. 
2000).  The use of the 5C-CPT enable the demonstration that D1 receptor activation by the 
D1-like specific partial agonist, SKF 38393, improved performance as a result of enhanced 
signal sensitivity.  Moreover, improvement was only evident in animals whose performance 
had been impaired following increased attentional demands.  Furthermore, this experiment 
also demonstrated impaired attentional performance during baseline attentional demands.  
These findings emphasise the principle of an ‘inverted-U’ shaped dose-response of the 
dopaminergic system (Vijayraghavan et al. 2007).  During low attentional demands, D1 
receptor activation increased omissions and impaired speed of processing; suggesting that 
increased dopaminergic D1 transmission reduced attentional abilities, under baseline 
conditions.  In contrast, when attentional demands had been increased, reducing baseline 
performance, D1 activation enhanced target detection via a reduction in omissions.  This led 
to enhanced signal sensitivity, an effect that occurred independent of alterations in 
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responsivity or strategic bias.  Hence, when the demands of the task were increased, 
activation of the dopaminergic system increased the readiness to respond, improving overall 
performance.  The baseline-dependent improvement of 5C-CPT performance is largely in 
agreement with findings reported by Granon and colleagues (2000), although differences do 
exist.  The main discrepancy in findings within chapter 4 is the absence of an improvement in 
response accuracy.  This may be the result of methodological differences; a longer SD was 
used in the current study, as was a variable ITI (instead of the fixed ITI used in the Granon 
study).  These differences may have changed the response strategy of the animals, and 
improved attentional performance was displayed with slight variation as a result.  Moreover, 
SKF 38393 was systemically administered in the current investigations, whereas Granon and 
colleagues (2000) utilised local prelimbic cortical infusions.  Furthermore, Granon and co-
workers (2000) demonstrated a baseline-dependent improvement in poor performing 
animals.  In contrast, chapter 4 revealed an improvement following a behavioural challenge.  
Encouragingly, however, the reduction in omissions observed following SKF 38393 treatment 
is consistent between studies, suggesting that DA transmission within the prelimbic cortex 
exerts some control of attentional performance.  Another aspect of consistency between the 
two studies is the relative specificity of the behavioural effects.  Of the common parameters 
that are assessed in both the 5C-CPT and 5-CSRTT, only omissions were improved.  While 
accuracy was increased in the Granon study (2000), the effect on correct responding was not 
reported.  Given the effect on omissions, it is likely that prelimbic infusion of SKF 38393 
increased correct responding (thus increasing accuracy).  While in the current investigation 
(chapter 4) accuracy was not improved, correct responding was increased; an effect 
mediated by a reduction in omissions, suggesting that SKF 38393 treatment improved 5C-CPT 
performance with a high level of behavioural specificity, primarily enhancing the attentional 
measures.   
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Following the successful demonstration that rats can be trained to perform the 5C-CPT, the 
disruptive effect of PCP treatment was investigated.  For the first time, it was revealed that 
repeated PCP treatment disrupts 5C-CPT performance (chapter 5).  These findings were in 
agreement with those demonstrated by Amitai and colleagues (2007), who reported 
disrupted 5-CSRTT performance following a repeated PCP treatment regimen.  PCP treatment 
significantly reduced response accuracy, indicating impaired attentional functionality.  This 
was coupled with response disinhibition, elevating the number of premature responses.  The 
use of the 5C-CPT not only supported the observations of Amitai and colleagues (2007), but 
also expanded on them; demonstrating the attentional disruption was characterised by a 
pronounced impairment in signal sensitivity.  Reductions in sensitivity index (SI) were 
mediated by a combination of impaired target detection (reduced hit rate) and behavioural 
disinhibition (increased false alarm rate).  This is in agreement with the consistent clinical 
observation that schizophrenia patients exhibit impaired CPT performance, exemplified by 
disrupted signal discrimination (Nestor et al. 1990; Parasuraman, 1998; Mass et al. 2000; 
Baerwald et al. 2005; Wang et al. 2007; Park et al. 2010).  These findings suggest that PCP 
treatment abolished the ability of successful discrimination between target and non-target 
stimuli, effects that were not confounded by alterations in motivation or strategic bias.  
Dysregulation of the glutamatergic system, or the consequential downstream effects, may 
therefore be central to the impairment in attention/vigilance observed in schizophrenia 
patients.   
Furthermore, chapter 5 revealed that the performances deficit following repeated PCP 
treatment was subject to a partial reversal following D1 receptor activation.  These findings 
suggest that augmentation of the dopaminergic D1 system partially attenuated the PCP-
induced impairment in response accuracy, mediated by a specific amelioration of the number 
of incorrect responses made following PCP treatment.  It has been suggested that target 
detection, defined as “the entry of information concerning the presence of a signal in a 
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system that allows the subject to report the existence of the signal by an arbitrary response 
indicated by the experimenter” (Postner et al. 1980) is controlled, at least partially, by 
cholinergic transmission (McGaughy et al. 1996; McGaughy and Sarter 1998; McGaughy et al. 
2002).  Therefore, the PCP-induced reduction in percent correct responding observed may be 
attributed to excessive cortical cholinergic transmission.  Acute and repeated NMDA 
antagonism has been shown to elevate acetylcholine release in the prefrontal cortex (Kim et 
al. 1999; Nelson et al. 2002).  This could account for the insensitivity of the PCP-induced 
reduction in percent correct responding following administration of a dopaminergic D1 partial 
agonist.  However, aberrant dopaminergic transmission may be involved in the generation of 
incorrect responses in the 5C-CPT; PCP treatment has profound effects on cortical 
dopaminergic transmission (Jentsch and Roth 1999; Jentsch et al. 2008).  This effect may 
account for not only the PCP-induced increase, but also the SKF 38393-induced attenuation 
in incorrect responding.  The dissociation of effects on correct and incorrect responding 
highlights the importance of fully describing the behavioural consequence of drug 
administration on task performance.  Unfortunately, a general theme within 5-CSRTT 
literature is to only report the effects on response accuracy.  It is therefore difficult to 
determine whether effects on response accuracy are driven by alterations in correct 
responding, increased incorrect responding, or a combination of the two.  An exception to 
this rule is the study published by Amitai and colleagues (2007), who demonstrated that 
repeated PCP treatment increased incorrect responses, contributing to the PCP-induced 
accuracy deficit.  Furthermore, the group demonstrated that the increase in incorrect 
responses was attenuated by chronic clozapine treatment (4.0 mg/kg/day), which may have 
accounted for the clozapine-induced partial attenuation of the PCP-induced reduction in 
response accuracy (Amitai et al. 2007).  It has been suggested that clozapine may provide 
therapeutic efficacy by normalising prefrontal dopamine levels following PCP treatment 
(Elsworth et al. 2008).  The beneficial effects in the SKF 38393 treated animals may be 
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mediated by a similar process as that induced by clozapine treatment; normalisation of PFC 
dopamine levels, thus restoring cognitive functioning.  However, clozapine has a remarkably 
complex pharmacology (Coward 1992), and additional mechanisms involved in the 
attenuation of PCP-induced cognitive impairment cannot be ruled out.  In addition to the lack 
of effect on the PCP-induced reduction in percent correct responding, SKF 38393 treatment 
had no impact on the increased omissions, suggesting these measures were mediated and 
impaired by another mechanism.  The SKF 38393-induced improvement of the PCP-induced 
5C-CPT attentional disruption may in fact be mediated by enhanced behavioural inhibition.  
The PCP-induced deficits in accuracy and SI (both quantitative measures of attentional 
performance) were only partially ameliorated in the SKF 38393 treated animals.  Response 
accuracy and SI were improved following the reduction of incorrect responding and false 
alarms, respectively.  The inability to correctly detect and report the occurrence of the target 
stimulus was unaffected in SKF 38393 treated animals.  Thus, D1 receptor activation may 
improve the PCP-induced attentional disruption specifically through behavioural inhibition 
and not improved target detection, enhancing attentional performance by reducing 
inappropriate responding.  Interestingly, there was a delayed onset of the beneficial effects 
of SKF 38393 pre-treatment, with attenuation emerging after the third injection.  Further 
work is required to elucidate the precise nature of the delayed onset of action.   
Investigation into the enduring disruptive effects of PCP treatment demonstrated, for the 
first time, that 5C-CPT performance is sensitive to impairment in the drug-free state 
following a sub-chronic PCP treatment regimen (chapter 6).  In contrast to the attentional 
disruption observed in chapter 5, baseline performance was unaffected in chapter 6; a 
behavioural challenge that increased the attentional load was required to elucidate the 
attentional deficit.  A variable SD was implemented, reducing the SD than the one presented 
during baseline.  Bushnell (1998) argued that if the duration of stimulus presentation is 
reduced, a greater level of attention is required in order to detect its occurrence.  This was 
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exemplified by the reduction in vigilant performance as the SD was reduced, even in control 
animals.  However, this effect was exacerbated in animals treated with PCP, demonstrated by 
the reduction in SI that was more pronounced as the SD was reduced.  Interestingly, when 
the stimulus duration was variably shortened there were no differences between PCP treated 
(5 mg/kg) and control animals in the initial part of the session.  However, control animals 
could generally sustain attentional performance throughout the entirety of the session, 
despite the increased attentional load.  This ability was abolished in PCP treated animals and 
the PCP-induced deleterious performance emerged as the session progressed.  These 
observations indicate that sub-chronic PCP treatment introduced an element of cognitive 
fatigue that was not evident in control animals, impairing the ability to sustain accurate 
performance throughout the duration of a session of increased attentional load.  This effect 
was illustrated by the reduction in response accuracy and the amplified reduction in SI within 
the last trial bin.  The effect of sub-chronic PCP treatment displayed behavioural specificity; 
attentional measures were impaired, but aspects of impulsivity were dissociated.  Premature 
responding was unaffected yet false alarms were elevated, an effect that was also restricted 
to the final trial bin.  The increase in false alarms was attributed to the inhibition of a 
reduction in erroneous responding; control animals progressively improved their 
performance when presented with non-target trials, whereas PCP treated animals did not.  
Therefore, the sub-chronic PCP treatment regimen did not induce behavioural disinhibition, 
but rather appeared to inhibit the development of behavioural inhibition.  However, the 
effect on behavioural disinhibition was further dissociated as time out (TO) responding was 
increased.  This reflects an inability to withhold inappropriate repeat responses.  Thus, while 
premature responding was unaffected and false alarms were increased due to the reduced 
ability to implement a better strategy, TO responses were significantly increased following 
PCP treatment. 
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Extending the 5C-CPT demonstrated a vigilance decrement in control animals, indicated by 
the reduction of SI as the session progressed.  This enhances the validity of the 5C-CPT for 
assessing the sub-division of attention.  This decline in attentional performance is evident not 
only in mice performing the 5C-CPT (Young et al. 2009b), but is also a feature of human 
attentional testing (Parasuraman, 1998; Riccio et al. 2002).  PCP-induced performance 
impairments were evident, but less pronounced than those observed during the vSD 
challenge session.  This is most likely the result of the basic task configuration being similar to 
that of baseline testing, and so the initial attentional load was reduced.  As a result the PCP-
induced reductions in accuracy were absent, but increased perseverative and TO responding 
were evident.  Additionally, alterations in the number or frequency of non-target trials 
presented initially increased the number of false alarms, reducing the SI.  Importantly 
though, these findings demonstrated that control animals are sensitive to deteriorations in 
performance, consistent with the vigilance decrement observed in human studies 
(Mackworth 1950), thus enhancing the validity of the 5C-CPT and the assessment of vigilance 
in rats. 
Sub-chronic PCP-induced attentional impairments were not restricted to the 5C-CPT; chapter 
7 also for the first time demonstrated disruptions in 5-CSRTT performance following sub-
chronic PCP treatment.  Consistent with previous observations, impaired attentional function 
was only evident following an increase in the attentional load.  As a result, challenge sessions 
consisting of a variable SD or variable ITI were implemented, increasing the demands of the 
task and elucidating a PCP-induced performance deficit.  Consistent with chapter 6, PCP-
treatment appeared to introduce cognitive fatigue, reducing the ability to maintain 
performance throughout a session of increased attentional demands.  As such, the PCP-
induced performance impairment was restricted to the second trial bin.  Yet again, the PCP-
induced performance impairment displayed remarkable behavioural specificity; attentional 
deficits were the most pronounced effects with aspects of behavioural inhibition left intact.  
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In contrast to chapter 6, inappropriate repeat responses were unaffected, even during 
challenge sessions.  However, as discussed in chapter 7, perseverative responses while 
recorded, did not induce a TO period.  Thus, the nature of the response was altered and the 
incentive to withhold responding removed. As such, a PCP-induced increase was not 
observed.  Comparable with that observed in chapter 6, the vSD challenge session increased 
attentional load as a higher level of attention was required to detect and respond to the 
target stimulus, resulting in a reduction in performance of control animals.  PCP treatment 
impaired performance during the longer SDs, with the absence of impairment at the shortest 
SD, attributable to the reduced performance of the control animals.  Following the vITI 
challenge session, a PCP-induced impairment was only detected during conditions of a high 
event-rate, with an ITI of 2 s.  This aspect of the challenge session impairs performance due 
to the continuous allocation of finite attentional resources (Dalley et al. 2004a).   
Although the findings in chapter 7 demonstrate a PCP-induced performance deficit was 
baseline dependent, the profile of impairment differed to that indicated in chapter 6.  The 
impaired performance in chapter 7 was primarily driven by an increase in incorrect 
responding, in contrast to the increase in omissions observed in chapter 6.   This discrepancy 
in effects may have been the result of fundamental methodological differences between the 
two experiments.  Firstly, male rats were used in chapter 7 and not females.  It is possible 
that the PCP-induced attentional disruption manifests with subtle differences depending on 
gender.  Secondly, and perhaps more importantly, a fixed ITI was used, in contrast to the vITI 
in chapter 6.  It has been highlighted that rats’ tend to utilise a temporally-mediated strategy 
within the 5-CSRTT when trained with a fixed ITI (Spratt et al. 2000), responding semi-
automatically.  As such, upon failed target detection it is more likely that the animal 
implemented a guessing strategy, which in turn is likely to increase the frequency of incorrect 
responses.  This is supported by the paucity of alterations in omissions observed within 
chapter 7.  When animals were trained using a variable ITI, thus minimising the development 
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of a temporal strategy (chapter 6), sub-chronic PCP treatment tended to increase omissions 
rather than incorrect responses during effortful conditions.  Both measures can be the 
consequence of inattentiveness, but emphasise the effect basic protocol configuration may 
have on the ultimate impairment profile observed.  Interestingly, sub-chronic PCP treatment 
reduced correct responding irrespective of the response strategy being employed, supporting 
the conclusion of attentional impairment despite methodological differences. 
Importantly, in addition to 5-CSRTT performance impairments, chapter 7 indicated for the 
first time that sub-chronic PCP treatment can induce structural brain abnormalities that are 
identifiable using in-vivo MRI.  The integrity of the prelimbic cortex, a sub-region of the mPFC 
suggested to be functionally analogous to the DLPFC in primates (Brown and Bowman 2002), 
was altered following sub-chronic PCP treatment.  This effect, coupled with the baseline-
dependent performance deficits suggests the prelimbic cortex may be essential in optimizing 
and maintaining behavioural output specifically during more effortful conditions.  
Furthermore, the PCP-induced attentional impairment observed in chapter 7 was dissociable 
between voluntary and passive pre-attentional performance; 5-CSRTT deficits were evident 
yet PPI was intact.  With focus to sustained attention/vigilance, sub-regions of the PFC may 
have dissociable specificity, and mediate behavioural control that is dependent on the level 
of attention required.  As a result, elements of sustained attention under effortful conditions 
are susceptible to sub-chronic PCP-induced performance deficits, whereas automatic 
attentional pre-processing is unaffected in the drug-free state. 
 
8.3 Underlying Mechanisms 
The investigations contained within this thesis demonstrate that sustained 
attention/vigilance is sensitive to disruption following PCP treatment, when assessed after a 
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substantial washout-period.  However, these findings do not fully elucidate the mechanism 
involved, and therefore the precise neurobiological process underpinning the dysfunctional 
performance observed is still unclear.  What is clear, however, is that an additional challenge 
is necessary to reveal the performance impairment and the prelimbic cortex is sensitive to 
PCP-induced morphological disturbances.  While further work is needed to fully understand 
the mechanisms involved, based on the current findings coupled with existing evidence I will 
propose a working hypothesis that will attempt to explain the PCP-induced deficit in 
sustained attention.  
Evidence suggests that the prefrontal cortex is implicated in attentional function (Dalley et al. 
2004; Brennan and Arnsten 2008).  The rodent medial PFC can be divided into three sub-
regions; anterior cingulate cortex, prelimbic cortex and the infralimbic cortex, with 
neurotoxic lesion studies demonstrating regional specificity regarding the mediation of 
attentional performance (Muir et al. 1996; Chudasama et al. 2001; Passetti et al. 2002).  A 
robust deficit in response accuracy is evident following neurotoxic lesion of the mPFC that 
includes the anterior cingulate cortex, even during baseline attentional demands (Muir et al. 
1996).  Conversely, lesions of the infralimbic cortex tended to increase premature 
responding, suggesting this sub-region is involved in the mediation of impulse control.  
Interestingly, lesions of the prelimbic cortex have been shown to robustly increase 
perseverative responding, with attentional functioning remaining intact.  The effects 
described above demonstrate a dissociation of the functional aspects of the 5-CSRTT 
suggesting they are, at least in part, mediated by specific sub-regions of the PFC.  However, 
this fractionation of performance deficits was evident when animals were assessed during 
baseline conditions and not following an increased attentional load.  The structural brain 
abnormality indicated in chapter 7 was regional specific, with the prelimbic cortex the only 
sub-division of the mPFC subject to morphological aberration.  Furthermore, the attentional 
deficit was baseline dependent, evident only following an increase in the attentional load.  
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The prelimbic cortex may therefore mediate more effortful attentional performance, being 
recruited specifically during attentionally demanding challenges, providing ‘top-down’ 
optimization of limited attentional resources and coordinating the maintenance of 
attentional goals in challenging situations.  If during low attentional demands, the prelimbic 
cortex does not mediate attentional function, but provides the necessary input during more 
effortful, novel conditions (e.g. shortened SD, unpredictable stimulus presentation), this may 
accommodate the PCP-induced performance deficit that was only revealed upon behavioural 
challenge.  With the structural integrity of the prelimbic cortex compromised following PCP 
treatment, the necessary input to coordinate behaviour was lost.  However, during low 
attentional demands, input of the prelimbic cortex is not required for attentional output and 
so PCP-induced performance impairment is not evident. 
A neurotoxic lesion of the prelimbic cortex impairs attentional performance in the sustained 
attention task (SAT) (Chudasama and Muir 2001).  Importantly, the deficit was baseline 
dependent; signal sensitivity was unaffected during a longer SD, yet impaired when the SD 
was shortened.  This suggests that the prelimbic cortex mediates attentional functionality in 
an attentional load-dependent manner, with increasing attentional demands revealing 
lesion-induced performance impairment.  Additionally, following lesion of the prelimbic 
cortex and assessment in the 5-CSRTT, there was no attentional impairment when animals 
were tested during baseline conditions (Chudasama and Muir 2001).  The lack of 5-CSRTT 
impairment following prelimbic cortex lesion supports the hypothesis that the prelimbic 
cortex is not critical in the mediation of performance during low attentional demands.  When 
Chudasama and Muir (2001) increased the attentional load, by reducing the SD, the prelimbic 
cortex lesion group exhibited an increase in omissions.  While lesions of the prelimbic cortex 
had no effect on response accuracy in this instance, as discussed previously, an increase in 
omissions can be interpreted as attentional impairment. 
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Conversely, Passetti and colleagues (2002) demonstrated baseline attentional impairment 
(reduced accuracy) following lesion of the ventral mPFC, which included the prelimbic and 
infralimbic cortex in the 5-CSRTT.  However, the SD used by Passetti and co-workers was 
considerably shorter (0.35 s) than the current investigations, and consequently may account 
for the discrepancy between observations as the attentional load under ‘baseline’ was 
already increased.  Moreover, following a further increase of attentional load (reducing the 
SD by half) animals with ventral mPFC lesion were more sensitive to attentional impairment, 
highlighting this regions importance in performance during demanding conditions.  Muir and 
colleagues (1996) assessed 5-CSRTT performance at baseline and following a challenge of the 
attentional load.  Lesions of the medial frontal cortex (which included the prelimbic cortex) 
produced a performance deficit during baseline conditions.  Similar to that observed by 
Passetti and colleagues (2002), the baseline deficit could be attributed to the inclusion of 
regions other than the prelimbic cortex in the lesion area.  When the demands of the task 
were increased, there was a trend towards an exaggeration of the lesion-induced deficit.  
These findings point towards the involvement of the prelimbic cortex and the mediation of 5-
CSRTT performance during situations of increased attentional load.  However, non-specific 
lesion or differing protocol configurations make direct comparisons with existing literature 
difficult. 
The evidence discussed above supports a role of the rat prelimbic cortex in attentional 
processing, demonstrating involvement in 5-CSRTT and SAT performance in a baseline-
dependent manner.  Further evidence to suggest the prelimbic cortex may be involved in 
effortful attention comes from the indication that this region may be central to performance 
of the attentional set-shifting task (ASST).  Lesion of the mPFC increased the number of trials 
to criterion in the extra-dimensional shift discrimination (Birrell and Brown 2000).  Other 
aspects of the ASST, such as discriminations based on the same perceptual stimuli (intra-
dimensional shift, IDS) or reversal learning, were not affected, suggesting the medial frontal 
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cortex lesion (centred around the prelimbic and infralimbic cortices) impairs the ability to 
shift attentional-sets.  Further evidence implicating the mPFC and maintenance of effortful 
performance arises from lesion of the ascending dorsal noradrenergic bundle (DNAB) fibres.  
A consequence of DNAB lesion is depletion of NA within the mPFC (including the prelimbic 
cortex) that resulted in selective EDS deficits (Tait et al. 2007).  While DNAB lesions also 
result in noradrenaline (NA) depletion of other mPFC regions, it implicates not only the 
prelimbic cortex, but also NA in effortful processing.  The effects observed by Tait and 
colleagues are reminiscent of those demonstrated by Carli and co-workers (1983) who also 
showed that DNAB lesions deplete cortical NA levels.  Carli and colleagues (1983) then 
demonstrated that 5-CSRTT performance was initially unaffected following DNAB lesion, yet 
impaired following distractions or parameter manipulations.  Additional work is required to 
fully understand the involvement of sub-regions of the mPFC and the role of NA and 
attentional processes, but taken together, these findings suggest cortical NA levels and 
effortful attentional processing may be linked.  Another aspect that warrants further 
investigation is the role of cortical dopaminergic transmission and attentional processing.  As 
Granon and colleagues (2000) demonstrated, DA within the prelimbic cortex is involved in 
sustained attention in a baseline dependent manner.  Furthermore, sub-chronic PCP 
treatment has been shown to reduce cortical DA (Jentsch et al. 1998), and sustained 
attentional deficits following sub-chronic PCP treatment are also baseline dependent 
(chapters 6 and 7).  Thus, morphological abnormalities within the prelimbic cortex, coupled 
with PCP-induced DA reductions may impair sustained attention during conditions of 
increasing attentional load.  Figure 8.1 summarises the involvement of the mPFC and 
attentional output, during baseline and increased attentional demands.  Based on my 
findings, coupled with previous investigations, it was hypothesised that the susceptibility of 
the prelimbic cortex to structural abnormalities following sub-chronic PCP treatment impairs 
the optimization or modification of strategy when faced with increasing attentional 
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demands, impairing behavioural output specifically during these conditions.  During low 
attentional demands, attentional performance is primarily mediated through regions other 
than the prelimbic cortex (e.g. anterior cingulate cortex).  Therefore despite the structural 
abnormalities following PCP treatment, attentional performance is not affected.  However, 
during conditions of increased attentional load, the prelimbic cortex is recruited to 
coordinate behavioural output and maintain finite attentional resources; with task 
performance less reliant on other regions of the mPFC.  PCP-induced structural abnormalities 
under these conditions result in a reduction in attentional performance. 
 
Fig 8.1 Diagram hypothesising the potential mechanism involved in the baseline-dependent PCP-induced 
attentional impairment.  During low attentional demands attentional performance is mediated by regions other 
sub-regions of the mPFC along with reciprocal connections with sub-cortical regions.  Despite morphological 
abnormalities within the prelimbic cortex following PCP treatment, differential regional recruitment maintains 
attentional performance.  When the attentional load is increased, the prelimbic cortex is recruited to maintain 
finite attentional resources and sustain performance.  During conditions of increased attentional load, a structural 
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abnormality within the prelimbic cortex impairs the ability to maintain behavioural coordination and deficits in 
sustained attention are observed.  ACC indicates the anterior cingulate cortex. PrL represents the prelimbic cortex 
and IL the infralimbic cortex, which collectively form the medial prefrontal cortex (mPFC).  Dashed red lines 
indicated compromised structural integrity leading to an attentional-load dependent deficit. 
This work has established persistent attentional impairments following sub-chronic PCP 
treatment, in the drug-free state, which were coupled with structural abnormalities.  
However, translational aspects were a consistent consideration throughout this work and an 
obvious limitation has been highlighted; a discrepancy exists between the morphological 
abnormalities induced by sub-chronic PCP treatment and that observed in chronic ketamine 
users and schizophrenia patients.  The current findings indicate an increase in MRI signal, 
whereas a reduction of grey and white matter density is observed in chronic ketamine users 
(Liao et al. 2010, 2011) and also schizophrenia patients (Pomarol-Clotet et al. 2010).  It has 
been suggested that schizophrenia is a neurodevelopmental disorder, with the individual 
susceptible to abnormal neurodevelopment in their formative years leading to aberrant 
neuronal morphology.  Because of this, Insel (2010) suggested that the onset of psychosis 
and the emergence of schizophrenia symptomatology may in fact be the late stages of the 
disorder, and not the onset.  Additionally, reductions in grey and white matter densities 
observed in chronic ketamine users were apparent following several years of escalating 
abuse and level of consumption also correlated with the level of grey/white matter reduction 
(Liao et al. 2010, 2011).  The treatment regimen used in chapter 7, while demonstrated 
previously to induce enduring cognitive and neuropathological disruptions (see Neill et al. 
2010), did not replicate morphological changes observed in the clinic.  However, while the 
treatment regimen utilised is known as ‘sub-chronic’ PCP administration, it is comparatively 
short; schizophrenia is a chronic disorder and the structural changes demonstrated in human 
ketamine abusers were observed over a prolonged period (mean usage ~2 years).  These 
observations may account for the inconsistency in morphological findings between clinical 
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and preclinical studies.  While sub-chronic PCP treatment provides an excellent method to 
model many of the cognitive, neurochemical and neuropathological features of 
schizophrenia, it is just a model and will never replicate the disorder in its entirety.  
Furthermore, as schizophrenia is very much a neurodevelopmental disorder, with clinical 
symptomatology emerging in early adulthood, grey matter changes are not linear (Pantelis et 
al. 2005; Theberge et al. 2007).  However, the morphological findings do indicate NMDA 
receptor antagonism produces structural deficits that are detectable in experimental animals 
using MRI.  Furthermore morphological alterations are located within a region that has 
important implications in schizophrenia.  For future considerations, it would be interesting to 
determine the longevity of these structural abnormalities.   
Although the findings indicate an increase in MRI signal, in contrast to that observed in 
schizophrenia patients and human ketamine users, the potential mechanism of this increase 
MRI signal may provide important insight into the neurobiological processes that mediate the 
effects observed following sub-chronic PCP treatment.  The treatment regimen used has 
previously been shown to induce a 40% reduction in dendrite spine synapse in the medial 
prefrontal cortex, regions that included the prelimbic cortex (Hajszan et al. 2006).  The PCP-
induced reduction in dendrite spine synapses mimics that observed in schizophrenia patients 
in which prefrontal pyramidal cell dendrite spine density is reduced (Glantz and Lewis 1997; 
Glantz and Lewis 2000).  Dendritic spine loss in schizophrenia is not restricted to frontal 
cortical regions as abnormal spine formation has been observed in the hippocampus and 
dorsal thalamus (Harrison 2004; Lewis 2004; Owen et al. 2005).  As the approach used by 
Hajszan and colleagues (2006) was restricted by a ROI, the effect of PCP and dendritic spines 
in other regions was not determined.  The susceptibility of additional brain regions and PCP-
induced dendritic spine loss should be further explored. 
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It is well established that sub-chronic PCP treatment induces a robust reduction in basal 
cortical DA levels in both rats and monkeys in the drug-free state (Jentsch et al. 1997a, b; 
Jentsch et al. 1998; Jentsch and Roth 1999; Elsworth et al. 2008), in regions that include the 
prelimbic cortex.  DA depletion of the ventral tegmental area following 6-OHDA lesion has 
also been shown to reduce dendritic length and spine density of layer V pyramidal cells in the 
prelimbic cortex (Wang and Deutch 2008).  In contrast, but supporting this observation, 
elevations of cortical DA levels following chronic psychostimulant administration has been 
shown to increase PFC pyramidal dendritic length and spine density (Robinson and Kolb 
1997, 1999).  These findings indicate that PCP-induced reductions in cortical DA levels may 
mediate the PCP-induced reduction in dendritic spine synapses.  It has been suggested that 
reductions in dendritic spine synapses may contribute to the persistent cognitive impairment 
observed following sub-chronic PCP administration (Hajszan et al. 2006).  However, whilst 
dendritic reductions may play a role in the cognitive impairment observed, it is unlikely to 
account for the increased MRI signal demonstrated. 
Crucially, Hajszan and colleagues (2006) demonstrated that the reduction of dendrite spine 
synapses was accompanied by a 60% increase in the density of astroglial branches, leaving 
the actual number of astrocytes unchanged.  While the reduction in dendritic connections 
may contribute to the persistent cognitive impairment present in the drug-free state, a PCP-
induced increase in astrocyte process formation may account for the increased MRI signal 
observed in chapter 7.  Hajszan and colleagues (2006) initially suggested that the increased 
proliferation of astrocytes may have been the result of PCP-induced neurotoxicity, however 
signs of neurotoxicity (e.g. cellular degeneration) were not observed following electron 
microscopic inspection.  In fact, the dose used in the current study is well below that 
demonstrated to induce aspects of neuronal toxicity (Olney et al. 1989; Nakki et al. 1995).  
Hajszan and colleagues (2006) went on to suggest that the increased astrocyte branching was 
simply to “occupy the cleared out space” which resulted from the reduction in dendritic 
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spine density.  However, it is possible that astroglial density is increased in response to PCP 
exposure as a neuroprotective mechanism, with evidence emerging supporting this 
hypothesis.  Astrocytes contain glutamate transporters and mediate homeostasis by 
absorbing and recycling excess glutamate via excitatory amino-acid transporters (Gluck et al. 
2002; Katsel et al. 2011).  It has been described that astrocytic processes orient towards 
regions where extrasynaptic glutamate concentration is elevated (Witcher et al. 2007; Eroglu 
and Barres 2010).  Acute NMDA antagonism results in a dramatic increase in glutamate 
release (Moghaddam et al. 1997) in the prefrontal cortex.  Excessive glutamate can result in 
calcium overload and induce excitotoxic cell death (Mark et al. 2001).  Therefore, the 
proliferation of astroglial processes may occur in response to increased glutamate levels, 
facilitating the necessary glutamate uptake to prevent neuronal toxicity.  An increase in 
astroglial branching arising as a protective mechanism may also account for the blunted 
increase (compared to single acute) in glutamate levels following repeated PCP 
administration (Amitai et al. 2011).  In support of this, it has also been demonstrated that 
sub-chronic PCP treatment (albeit a different treatment regimen than the one used within 
this thesis) increased the expression of the cortical astrocytic glutamate transporters GLT-
1/EAAT2 (Fattorini et al. 2008).  Fattorini and colleagues (2008) also investigated the effect of 
PCP treatment on proteins that mediate vesicular packaging and release of glutamate.  The 
absence of PCP-induced reductions in the proteins mediating glutamate release suggested 
that increased expression of a cortical glutamatergic transporter accounted for the 
decreased basal glutamate levels seen following sub-chronic PCP treatment.   
Eroglu and Barres (2010) argued that it is functionally important that astroglial processes do 
not fully encapsulate neuronal synapses.  As neuronal connections are three-dimensional, 
activation of neighbouring neurons may be important for functional efficiency.  It has been 
demonstrated that in hippocampal formations, there are regions of the synapse that are free 
of astrocytes, enabling the escape of neurotransmitters from the synaptic cleft facilitating 
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trans-synaptic activation (Ventura and Harris 1999).  It has also been observed that increased 
perisynaptic astrocytic processes can obstruct synaptic junctions and impede trans-synaptic 
neurotransmission (Witcher et al. 2010).  These findings, along with the increased astroglial 
process density and glutamate transporter expression following sub-chronic PCP treatment 
(Hajzsan et al. 2006; Fattorini et al. 2008) suggest that abnormal morphology may result in 
disrupted cognitive processes.  As it has been described that astroglial processes orient 
towards areas where glutamate concentration is elevated (Witcher et al. 2007; Eroglu and 
Barres 2010), glutamate releases is increased in the mPFC following NMDA antagonism 
(Katayama et al. 2007), and astroglial density is increased in the medial PFC following sub-
chronic PCP treatment (Hajzsans et al. 2006), the increased prelimbic MRI signal observed in 
chapter 7 may be the result of increased astrocytic proliferation.  This, along with the 
presence of neurochemical and neuropathological effects arising from sub-chronic PCP 
treatment, may contribute to the persistent cognitive impairment observed.   
 
8.4 Future Experimental Direction 
While the 5C-CPT represents a preclinical task that is analogous to the human CPT, it is not 
without its limitations.  Human CPTs are generally experimenter-paced; that is the stimulus 
cues (akin to each trial) are presented to the subject independent of the subject’s action.  
The 5C-CPT (along with the 5-CSRTT), however, is self-paced; the animal initiates each trial in 
the form of food reward collection.  While efforts to limit the animal-paced aspect of the task 
can be implemented (e.g. stimulus onset-asynchrony), the animal still initiates each trial and 
so can be argued to still be self-paced.   Operant task performance is mediated by the desire 
to earn food reinforcement.  As such, it would be impossible to have a preclinical task that 
assesses performance over consecutive trials which is completely experimenter-paced, as the 
motivation to perform the task would be eliminated.  However, it would be feasible to 
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further enhance the translational qualities of the 5C-CPT by introducing at least an element 
of experimenter-paced protocol into the execution of the task.  Theoretically, it would be 
possible to train animals to perform the task with reward pellets only being dispensed 
following an extended number of completed or correct trials, instead of each successful trial.  
Obviously, validation work to determine the break point of the animal would need to be 
conducted.  Furthermore, in the event of pharmacological manipulations (e.g. PCP 
administration), it would need to be ascertained that drug treatment was not altering the 
break point or motivation to perform the task, which could be misinterpreted as attentional 
disruption.  This adaptation would at least remove the complete self-paced nature of the 
task.  Although, it should be noted that in addition to schizophrenia inducing disruptions in 
classic experimenter-paced CPTs, impaired performance has also been observed in self-paced 
CPTs (J Young, Personal Communication).  Furthermore, impaired vigilance has also been 
demonstrated in hyperactive children using a self-paced task assessing visual attention, 
characterised by a reduction in hits and an increase in false alarms (Goldberg and 
Konstantareas, 1981).  Thus, the use of a self-paced paradigm for human or animal studies 
may not be completely invalid.  Another potential issue is the obvious spatial component of 
the 5-CSRTT and 5C-CPT, the animals must scan a horizontal array in order to detect the 
presentation of the visual stimulus.  In contrast, visual stimuli are presented in one location 
in human CPTs.  A human version of the 5C-CPT has recently been developed.  Consistent 
with traditional human CPTs, schizophrenia patients’ exhibit reduced signal sensitivity, 
mediated by reduced hit rate that occurred independently of strategic bias alterations (J. 
Young, Personal Communication).  While there was a trend towards an increased false alarm 
rate, it suggests impaired signal sensitivity was primarily mediated by reduced target 
detection.  These observations suggest that the spatial component of the 5C-CPT may not 
confound the translational qualities of the task. 
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The experiment in chapter 7 demonstrated structural abnormalities following PCP treatment.  
MRI does not provide insight into the causality of the structural abnormality, only the 
presence of morphological alterations and the location.  Furture investigations should 
determine the origin of the increased MRI signal.  Discussed above, evidence suggests that a 
potential consequence of sub-chronic PCP treatment is astrocytic proliferation, which may 
account for the increased MRI signal observed.  Firstly, it would be important to confirm an 
increase in astrocyte proliferation was evident following sub-chronic PCP treatment.  
Secondly, the impact of this proliferation could be explored.  Of particular interest is an 
endogenous α7 nicotinic antagonist synthesised exclusively in astrocytes, known as kynurenic 
acid (KYNA).  Fluctuations in KYNA levels can impair or enhance cognitive processing 
(Zmarowski 2008; Potter et al. 2010), modulate extracellular glutamate and DA levels in 
various brain regions, including the mPFC (Carpenedo et al. 2001; Wu et al. 2006) and 
modulate basal and evoked PFC Ach release (Zmarowski et al. 2009).  Importantly, increased 
KYNA levels have been observed in schizophrenia patients (Erhardt et al. 2001; Schwarcz et 
al. 2001).  A PCP-induced increase in KYNA levels, along with dendritic spine reductions and 
GABAergic deficits, may contribute to persistent impairments in cognition. 
In summary, these findings highlight that attention/vigilance is sensitive to a PCP-induced 
disruption.  Profound cognitive deficits are observed while the animal is under the influence 
of PCP but importantly, impairment is also demonstrated in the drug-free state following a 
sub-chronic treatment regimen.  The performance deficit following sub-chronic PCP 
treatment is also dissociable between effortful and passive attentional processing.  
Furthermore, in addition to the apparent cognitive impairment, sub-chronic PCP treatment 
produces morphological abnormalities that may, along with the neurochemical and 
neuropathological disturbances, contribute to the cognitive impairment demonstrated.  
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